DANMAP 2017 - Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark by Borck Høg, Birgitte et al.
 
 
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright 
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
 Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
 You may not further distribute the material or use it for any profit-making activity or commercial gain 
 You may freely distribute the URL identifying the publication in the public portal 
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
  
 
   
 
 
Downloaded from orbit.dtu.dk on: Mar 29, 2019
DANMAP 2017 - Use of antimicrobial agents and occurrence of antimicrobial
resistance in bacteria from food animals, food and humans in Denmark
Borck Høg, Birgitte; Bager, Flemming; Korsgaard, Helle Bisgaard; Ellis-Iversen, Johanne; Pedersen,
Karl; Jensen, Lars Bogø; Hendriksen, Rene S.; Bortolaia, Valeria; Rhod Larsen, Anders; Petersen,
Andreas; Hammerich, Anette M.; Nielsen, Eva Møller; Slotved, Hans-Christian; Hasman, Henrik; Boel,
Jeppe; Skov Jensen, Jørgen; Skjold Selle Pedersen, Karoline; Roer, Louise; Torpdahl, Mia; Skovgaard,
Sissel; Hoffmann, Steen; Schytte Olsen, Stefan; Dalby, Tine; Wolff Sönksen, Ute; Vorobieva, Veronika
Publication date:
2018
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Borck Høg, B., Bager, F., Korsgaard, H. B., Ellis-Iversen, J., Pedersen, K., Jensen, L. B., ... Vorobieva, V.
(2018). DANMAP 2017 - Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from
food animals, food and humans in Denmark. Copenhagen: Statens Serum Institut, National Veterinary Institute,
Technical University of Denmark National Food Institute, Technical University of Denmark.
DANMAP
 2017
DANMAP 2017 - Use of antimicrobial agents and occurrence 
of antimicrobial resistance in bacteria from food animals, 
food and humans in Denmark
Statens Serum Institut
National Veterinary Institute, Technical University of Denmark
National Food Institute, Technical University of Denmark
This report is issued by DANMAP - The Danish Integrated Antimicrobial Resistance Monitoring and Research 
Programme. It presents the results of monitoring the antimicrobial use and antimicrobial resistance in food animals, 
food and humans in 2017. The report is produced in collaboration between the National Food Institute, Technical 
University of Denmark and Statens Serum Institut. The DANMAP programme is funded jointly by the Ministry of Health, 
the Ministry of Environment and Food and the Ministry of Higher Education and Science.
DANMAP 2017
Editors:
Birgitte Borck Høg (bibo@food.dtu.dk) 
Johanne Ellis-Iversen (joell@food.dtu.dk)
Ute Wolff Sönksen (uws@ssi.dk) 
Editing group:
Helle Korsgaard 
Anna Emilie Henius
Karoline Skjold Selle Pedersen
Authors:
National Food Institute
Birgitte Borck Høg, Flemming Bager, 
Helle Korsgaard, Johanne Ellis-Iversen, 
Karl Pedersen, Lars Bogø Jensen,   
Rene S. Hendriksen, Valeria Bortolaia
Statens Serum Institut
Anders Rhod Larsen, Andreas Petersen, Anette M. Hammerum,  
Eva Møller Nielsen, Hans-Christian Slotved, Henrik Hasman, Jeppe Boel,  
Jørgen Skov Jensen, Karoline Skjold Selle Pedersen, Louise Roer,  
Mia Torpdahl, Sissel Skovgaard, Steen Hoffmann,  Stefan Schytte Olsen, Tine Dalby, 
Ute Wolff Sönksen, Veronika Vorobieva Solholm Jensen
DANMAP board: 
National Food Institute: Flemming Bager, Johanne Ellis-Iversen
National Veterinary Institute: Karl Pedersen
Statens Serum Institut: Anders Rhod Larsen, Ute Wolff Sönksen
Layout: Daniella Pilegaard, STEP
Photos: Colourbox and Mikkel Adsbøl 
Printing: STEP
Contact:
National Food Institute,
Technical University of Denmark 
Kemitorvet, Building 202, DK-2800 Kgs. Lyngby
Microbiology and Infection Control, 
Statens Serum Institut
Artillerivej 5, DK-2300 Copenhagen
DANMAP 2017 – October 2018 – ISSN 1600-2032
Text and tables may be cited and reprinted only with reference to this report: DANMAP 2017
- Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food 
animals, food and humans in Denmark. ISSN 1600-2032
The report is available from www.danmap.org
DANMAP 
 2017
DANMAP 2017 - Use of antimicrobial agents and occurrence 
of antimicrobial resistance in bacteria from food animals, 
food and humans in Denmark
DANMAP 20174
TABLE OF CONTENTS
Table of contents
1. Editorial  7
Acknowledgements 8
2. Summary 9
3.  Introduction to DANMAP 15
3.1 Background 16
3.2 Antimicrobial surveillance in Denmark 17
4.  Antimicrobial consumption in animals 21
 Highlights 22
4.1 Introduction  22
4.2 Total antimicrobial consumption in animals 25
4.3 Antimicrobial consumption by animal species 27
Textbox 4.1 Political agreement on the veterinary strategy, 2018-2021 33
Textbox 4.2 Effects of the differentiated Yellow Card initiative from 2016 34
5.  Antimicrobial consumption in humans 35
 Highlights 36
5.1 Introduction  37
5.2 Total consumption (Primary Health Care and Hospital Care Sectors) 38
5.3 Primary Health Care  38
Textbox 5.1  University of Copenhagen Research Centre for Control of Antibiotic Resistance (UC-CARE) 
 – a multidisciplinary One Health approach 48
5.4 Hospital Care 50
Textbox 5.2  Consumption of antifungal compounds and resistance patterns of  
human invasive isolates of Candida  57
  Consumption of antifungal compounds and resistance patterns of  
human invasive isolates of Aspergillus 60
Textbox 5.3 Antimicrobial resistance and consumption of antimicrobials in the Faroe Islands 64
6.  Resistance in zoonotic bacteria  67
 Highlights 68
6.1 Introduction 68
6.2 Salmonella 69
6.3 Campylobacter 73
Textbox 6.1 Resistance in bacteria from diagnostic submissions from pigs 77
Textbox 6.2 MRSA contamination of human volunteers after short time visit in MRSA positive pig farms  79
7.  Resistance in indicator bacteria  81
 Highlights  82
7.1 Introduction 82
7.2 Enterococci 83
7.3 Indicator Escherichia coli 84
7.4 Extended spectrum beta-lactamase (ESBL)-/AmpC- and carbapenemase-producing E. coli  87
Textbox 7.1   ESBL/AmpC-producing Escherichia coli – comparison of isolates of animal  
origin with isolates obtained from human bloodstream infections 91
Textbox 7.2   Whole genome sequence (WGS)-based prediction of antimicrobial  
resistance in clinical Escherichia coli from one day in Denmark 93
5DANMAP 2017
TABLE OF CONTENTS
8.  Resistance in human clinical bacteria 95
 Highlights 96
8.0 Introduction 97
8.1 Escherichia coli 99
8.2 Klebsiella pneumoniae 103
8.3 Pseudomonas aeruginosa 106
8.4 Acinetobacter species 107
Textbox 8.1  Characterization of ESBL/pAmpC- and carbapenemase producing E. coli  
from bloodstream infections, 2017 Denmark 108
Textbox 8.2 Carbapenemase producing bacteria in Denmark, 2017 111
8.5 Enterococci 113
Textbox 8.3 Emergence of clinical vanA E. faecium in Denmark, 2017 115
 Vancomycin-variable enterococci (VVE) 117
8.6 Streptococci 118
Textbox 8.4 Surveillance of invasive isolates of Haemophilus influenzae 121
8.7 Staphylococcus aureus 124
Textbox 8.5 Incidence of multiresistant bacteria in Greenland 128
8.8 Neisseria gonorrhoeae 130
Textbox 8.6 Mycoplasma genitalium  132
9.  Materials and Methods  135
9.1 General information   136
9.2 Data on antimicrobial consumption in animals  136
9.3 Collection of bacterial isolates – animals and meat  138
9.4 Microbiological methods – isolates from animals and meat  139
9.5 Susceptibility testing - isolates from animals and meat  140
9.6 Whole genome sequencing - isolates from animals and meat  140
9.7 Data handling - isolates from animals and meat  140
9.8 Data on antimicrobial consumption in humans  142
9.9 Salmonella and Campylobacter in humans  143
9.10 Staphylococcus aureus including MRSA in humans  143
9.11 Invasive Streptococcus pneumonia in humans  143
9.12 Invasive Beta-haemolytic streptococci 
 (Group A, B, C and G Streptococci) in humans  144
9.13 E. coli, K. pneumoniae, P. aeruginosa, Acinetobacter spp., E. faecium  
 and E. faecalis in humans  144
9.14 ESBL-producing bacteria in human patients  144
9.15 CPO in human patients  145
9.16 VRE in human patients  145
9.17 Statistical tests for human data   145
 
10.  Terminology 147
List of abbreviations 148
Glossary 149
DANMAP 20176
7DANMAP 2017
1.EDITORIAL
1. Editorial
It has been 22 years, since DANMAP was established.  Since 
then, the need for an integrated approach to control antimicro-
bial resistance has only become more apparent.
Published estimations for the global burden of antimicrobial 
resistance (AMR) show that by 2050, 10 million people will 
die each year due to infection with bacteria that are resistant 
to antimicrobials. That is 2 million more than estimated to die 
from cancer. Furthermore, routine surgical interventions will 
be associated with an increased risk of serious complications. 
Although there is the need for data to improve the parameters 
and estimates in such reports, there is no doubt that increas-
ing levels of AMR are a considerable health threat worldwide 
and must be addressed. Yet, in 2013, it was also estimated 
that about 5.7 million people, particularly in low and middle in-
come countries, die each year, because they don’t have access 
to antibiotics. Providing such access, without exacerbating the 
AMR situation, represents a significant challenge.
In the agricultural domain, very large quantities of antimicrobi-
als are used in food animals for treatment, to prevent disease 
or to promote growth, as well as in plant production against 
pests. Sick animals need treatment with antimicrobials, which 
is justified by both an animal welfare perspective and the need 
to ensure worldwide food security. However, using antimicrobi-
als as a cheap alternative to good animal husbandry is difficult 
to support these days. The AMR threat also includes environ-
mental issues, as polluted water for drinking and for irrigation 
of ready-to-eat crops represents a source of AMR. However, 
pointing fingers and passing blame will be counterproductive 
in the face of the current crisis; instead all sectors need to 
unite to address the threat of AMR. 
Apart from restricting and improving the use of antimicrobi-
als, we also need a change of the worldwide perception of 
antimicrobials. Instead of perceiving antimicrobials as common 
goods, safety net or replacement for hygiene, they need to be 
regarded as precious agents that should be used sparingly in 
quantities that are just adequate to safeguard health. 
Surveillance is paramount to understanding the situation. To 
enable intervention, there is a strong need for good qual-
ity data on consumption of antimicrobials and knowledge of 
trends in AMR in as much detail as possible. The historical 
DANMAP has demonstrated that curbing the use of one spe-
cific antimicrobial can result in the reduction of the resis-
tance phenotype to very low levels. However, a more typical 
outcome will often be a mere stabilising of resistance levels, 
because of co-selection by other antimicrobials. Thus, the ef-
fort may primarily result in preventing further rise in resistance 
rather than actually lowering the number. This illustrates that 
comprehensive and detailed surveillance of AMR does not al-
ways give the answer as to whether an intervention has been 
efficient. However, information on resistance levels in relevant 
reservoirs is still desirable and so is the ability to spot new or 
emerging resistances in new reservoirs, if the aim is to control. 
In Denmark, DANMAP 2017 shows – again – that the level of 
acquired carbapenemase producing microorganisms in humans 
continues to increase, despite a highly restricted use of car-
bapenems in Denmark. It is clear that AMR represents a global 
public health challenge that can be tackled only by all sectors 
and countries working together. The threat from antimicrobial 
resistance has been acknowledged internationally and the 
united work of WHO, FAO and OIE are good examples of a way 
forward. DANMAP has been mentioned in these fora as one of 
the initiatives demonstrating that One Health surveillance is 
possible and can make a change. 
While the integrated approach to monitoring remains valid, 
the details deserve scrutiny. Better use of available data and 
future access to more comprehensive data are areas, where 
DANMAP works to expand. Whole genome sequencing and 
increased data analyses are also opening new doors to further 
understanding and lead the way towards development, expan-
sion and increased relevance of the DANMAP surveillance. 
DANMAP Steering Committee
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2. Summary
The Danish integrated Antimicrobial Resistance Monitoring 
and Research Programme (DANMAP) was founded in 1995, 
providing a unique One Health platform for the continuous 
surveillance and research of antimicrobial consumption and 
resistance. A key objective of the DANMAP programme is to 
provide an evidence base for decision-making and to further 
understand the associations between antimicrobial usage 
(AMU) and the occurrence of antimicrobial resistance (AMR). 
In Denmark, antibiotic treatment - of both humans and animals 
- is available by prescription only, and all prescriptions are re-
corded in national databases (MEDSTAT and VetStat). Through 
many years, Denmark has maintained a strong focus on trans-
mission of AMR from production animals to humans. Prescrip-
tion and treatment guidelines for human and animal use have 
ensured effective treatments even with very restrictive use 
of critically important antimicrobials. In hospital settings, effec-
tive control measures have been initiated, whereas ongoing 
research is trying to find the most effective ways to minimise 
the public health risks in the community. 
The report DANMAP 2017 summarises the results of sus-
ceptibility testing of isolates obtained by hospitals, general 
practice, veterinary practice and the National Food and Vet-
erinary Authority; as well as records of the types and amount 
of antimicrobials prescribed by physicians and veterinarians in 
Denmark during 2017. 
Human isolates cover all bacteremias caused by the most 
important pathogenic bacteria, based on reporting of the first 
isolate per species per patient per year representing complete 
data from all Denmark. Also included are a representative num-
ber of isolates from urinary tract infections at hospitals and 
in the community. Statens Serum Institut collate and interpret 
data from the human sectors. 
Samples from production animals and meat are collected and 
analysed in accordance with the EU harmonised monitoring of 
antimicrobial resistance [Decision 2013/652/EU]. AMR data 
from additional surveys conducted by the Danish Veterinary 
and Food Administration and zoonotic bacteria from national 
control programmes are also included. DTU Technical Univer-
sity of Denmark collate and interpret data from the food and 
animals sectors.
Antimicrobial consumption in animals
The overall use of antimicrobials for animals decreased for the 
fourth consecutive year and has since 2013 been reduced by 
more than 16 tonnes. From 2016 to 2017, the antimicrobial 
consumption decreased by approximately 3%. 
The decrease was driven by the use of antimicrobials for pigs, 
which was approximately 4% (3.4 tonnes active compound) less 
than the year before, with a total of 74.8 tonnes. In 2017, the 
export of weaner pigs continued to increase, while the total num-
ber of pigs produced remained at approximately the same level. 
The use of tetracyclines for pigs has been reduced significantly 
and almost consistently since 2009. From 2016 to 2017 the use 
of tetracyclines was further reduced by approximately one third 
(7.2 tonnes), following the revision of the differentiated "Yellow 
Card" initiative, where the use of tetracyclines is multiplied with 
a factor 1.5. The differentiated "Yellow Card" initiative has also 
resulted in a close to zero use of colistin after the first quarter of 
2017. However, the decrease in the use of tetracylines and colis-
tin, was mirrored by less marked but clear increases in the use of 
macrolides, pleuromutilines and aminoglycosides. 
To take into account changes in prescription patterns, changes 
in production, and differences between age groups, the antimi-
crobial use in pigs was also calculated as treatment intensity 
(DAPD). Thus, on any given day in 2017, approximately 2% of 
sows and piglets, 1-2% of finisher pigs and 10% of weaner 
pigs were treated with antimicrobials. Also measured in DAPD, 
the antimicrobial use in pigs was 4% lower compared with 
2016 and 29% lower than in 2009, when adjusted for export.
Both the poultry and the aquaculture industry saw further de-
creases in the use of antimicrobials from 2016 to 2017. In poultry, 
there was a decrease from 1,560 kg in 2016 to 1,488 kg in 2017. 
In the aquaculture industry, the antimicrobial consumption was 
the lowest ever recorded in VetStat at 1,697 kg (2,303 kg in 
2016). The decreasing trend in aquaculture is likely to be positive 
effects of favourable weather conditions i.e. low summer tempera-
tures combined with the implemented vaccination strategies
The fur animal industry continued to increase their antimi-
crobial use with a total use of 6,134 kg, corresponding to an 
increase of 15% compared with 2016. However, in 2017 there 
was no apparent increase in diagnostic submissions to provide 
an explanation for the increased use.
The estimated use of antimicrobials for companion animals 
was 1,296 kg in 2017. The use of critically important antimi-
crobials is still relatively high compared with other species. 
Almost all fluoroquinolones (87%, equivalent to 13 kg) and 
more than half of the cephalosporins (62%, equivalent to 111 
kg) used for animals are prescribed for dogs and cats. Despite 
a small increase in use from 2015 to 2016, there has been an 
overall decreasing trend in the use of antimicrobials for dogs 
and cats since 2011. The shift in the use of antimicrobials con-
tinued in 2017 with a marked reduction in the relative use of 
cephalosporins and an increase in the use of aminopenicillins.
Antimicrobial consumption in humans
In 2017, the total consumption of antimicrobials in humans 
was 17.55 defined daily doses per 1000 inhabitants per day 
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(DID), lower than the consumption in 2016 (18.44 DID) and 
a decade ago in 2008 (18.09 DID). Overall, the consumption 
of antimicrobials increased from its first registrations in the 
DANMAP report 1996 (13.60 DID) until 2011 (19.80 DID) and 
has since levelled off. 
Decreases in the past ten years were observed for all age 
groups (excluding the eldest > 80 years) and for both gen-
ders, regardless of the indicators used. The biggest decrease 
was observed in the youngest (0 to 4 year olds), where the 
number of treated patients per 1000 inhabitants decreased 
with 30%. In 2017, there were 298 per 1000 treated 0 to 4 
year olds corresponding to 507 prescriptions redeemed per 
1000 inhabitants.
In women, the number of treated patients per 1000 inhabit-
ants decreased with 16% and in men with 20%. In 2017, the 
average number of patients treated (regardless of age and 
gender) was 255 per 1000 inhabitants corresponding to 489 
prescriptions redeemed per 1000 inhabitants. 
The total antimicrobial consumption at hospitals was mea-
sured at 110.28 defined daily doses per bed-days (DBD) 
and 323.53 defined daily doses per 100 admissions (DAD), 
respectively, a rise from 104.21 DBD and 310.68 DAD the 
previous year. From 2008 to 2017, the total consumption at 
hospitals increased with 43% and 2.8%, when measured in 
DBD and DAD, respectively.
Penicillins remained the most frequently used antimicrobial 
agents in both primary health care (67%) and in hospital care 
(53%), but the changes in consumption observed within this 
drug group in the last decade continued. Thus in 2008, beta-
lactamase sensitive penicillins constituted 53% of all penicil-
lins consumed in primary health care (5.31 DID of 9.99 DID), 
while in 2017 this had decreased to 38% (3.88 DID of 10.29 
DID), a decrease of close to 27%. Simultaneously, consumption 
of combination penicillins increased markedly in both sectors 
for that decade. Thus in 2017, combination penicillins consti-
tuted 7.7% of the antimicrobial consumption in primary health 
care and 16% of the consumption in hospital care. Together 
with the penicillins with extended spectrum, combination 
penicillins were in 2017 the largest antimicrobial drug group 
consumed at hospitals. 
In Denmark, fluoroquinolones, cephalosporins and carbapen-
ems are defined as antimicrobials of critical interest and 
cephalosporins and carbapenems are only used at hospitals. 
In 2017, the consumption of the three drug classes consti-
tuted altogether 23% of the consumption at hospitals, a slight 
increase from 22% observed the year before, but a decrease 
from 31% in 2008. The increase in 2017 was observed for all 
five regions of Denmark and was mainly driven by an increase 
in the use of cephalosporins from 10.58 DBD to 12.49 DBD 
(18 %) and a slighter increase in the use of carbapenems from 
4.06 DBD to 4.26 DBD (6.0%). These increases are probably 
linked to a long-term shortage in supply of piperacillin with 
tazobactam, where the consumption fell from 9.32 DBD to 
7.75 DBD (- 17%). 
Fluoroquinolones continued the decreasing trend observed 
since 2010, but with more pronounced reductions for the 
last two years. In 2016, fluoroquinolones accounted for a 
consumption of 8.37 DBD, corresponding to 8.2% of the total 
consumption at hospital.  In 2017, this had decreased to 8.06 
DBD, corresponding to 7.3% of the consumption at hospitals. In 
primary care, fluoroquinolones accounted for 0.44 DID equal to 
2.9% of the total consumption. 
Resistance in zoonotic- and indicator bacteria
Salmonella
Salmonella isolates from Danish pigs and domestically-pro-
duced pork were included in the DANMAP 2017, and Salmo-
nella Typhimurium remained the most prevalent serotype. The 
resistance profiles were dominated by the large proportion 
of monophasic Salmonella Typhimurium isolates, exhibiting 
resistance to tetracycline, ampicillin and sulfonamides. The 
trend in resistance to these three antibiotics has been increas-
ing steadily with approximately 30% increase since 2010. 
This steady increase was mirrored in the domestically acquired 
human isolates. Resistance to ciprofloxacin and 3rd generation 
cephalosporins was present in low levels in human isolates, 
but not found pigs or domestically-produced pork. 
Campylobacter
Campylobacter isolates from humans (domestically acquired), 
broilers and cattle exhibited similar resistance patterns. Cipro-
floxacin resistance was the most prevalent resistance, despite 
very limited veterinary use of quinolones. Tetracycline resis-
tance also occurred in similar levels in all three populations. 
Isolates from travel-associated human cases were much more 
likely to be resistant than the domestically acquired isolates.  
Enterococcus
In 2017, resistance to erythromycin and tetracycline was ob-
served in 55% and 78% of the Enterococcus faecalis isolates 
from Danish pigs, respectively. A few gentamicin-resistant 
isolates (non-HLGR) were found, but no resistance to other 
antimicrobial agents critical to human medicine was detected.
Indicator E. coli
The proportion of fully susceptible indicator E. coli increased 
slightly in poultry and pigs, and decreased slightly in cattle in 
2017 compared to 2016. Resistance patterns and levels in in-
dicator E. coli from poultry, pigs and cattle were overall similar 
to previous years and no resistance to colistin, meropenem and 
tigecycline was detected.
ESBL/AmpC-producing E. coli
ESBL/AmpC-producing E. coli were recovered from 25% and 7% 
of the samples from Danish pigs and cattle, from 1% and 4% 
of the samples from domestically produced pork and beef, and 
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from 14% and 3% of the samples from imported pork and beef. 
The ESBL/AmpC occurrence in E. coli from the sources monitored 
in 2017 was comparable to the level observed in 2015. ESBL/
AmpC genotypes were determined for isolates from meat and 
CTX-M-1 was the most common ESBL in E. coli from domesti-
cally produced pork and imported pork and beef. CTX-M-14, 
CTX-M-15, and CTX-M-1 were equally prevalent in domestically 
produced beef isolates. No plasmid-mediated AmpCs such as 
CMY was detected in the samples of pork and beef.
Resistance in human clinical bacteria
Since the beginning of DANMAP and especially during the 
past decade, the number of human invasive infections has 
increased remarkably. 
Escherichia coli
For Escherichia coli, which causes approximately 50% of the 
monitored infections, the number of invasive isolates from 
hospital patients has increased continuously and almost 
doubled throughout the past decade, reaching a total of 5114 
individual cases in 2017. Until 2016, the resistance trends 
were slightly decreasing, despite the increasing number of 
submitted isolates. However, the resistance trends for inva-
sive E. coli reversed from 2016 to 2017 and showed slight 
increases for almost all drugs tested. In 2017, the following 
resistance percentages were observed: ampicillin 46%, mecil-
linam 14%, piperacillin/tazobactam 4.5%, gentamicin 6.0%, 
cefuroxime 9.7%, third-generation cephalosporins 6.7% and 
carbapenems < 1%. 
In addition, the number of reported isolates from urinary 
tract infections increased markedly during the past decade 
and trends in resistance rates in these followed the trends 
observed in invasive isolates.
Klebsiella pneumoniae
In 2017, the total number of invasive Klebsiella pneumoniae 
isolates continued the worrying increase, reaching 1183 indi-
vidual cases. As for E.coli, increases were also observed in the 
number of reported isolates from urinary tract infection. Eye-
catching increases in resistance to mecillinam and sulphon-
amide were observed in urinary samples from 2016 to 2017, 
from 10% to 16% and from 18% to 26%, respectively. Despite 
these trends, a general tendency of decrease regarding criti-
cally important antimicrobials was observed for K. pneumoniae 
for the last decade. In 2017, the following resistances were 
noted in invasive isolates: mecillinam 19%, piperacillin/tazo-
bactam 7.4%, gentamicin 3.2%, cefuroxime 11%, third-genera-
tion cephalosporins 7% and carbapenems < 1%.
Staphylococcus aureus
As for other invasive infections, the number of bloodstream 
infections with Staphylococcus aureus increased, reaching a 
total of 1996 individual cases in 2017, while the percentage 
of MRSA among all invasive S. aureus isolates has kept stable, 
between 0-3% throughout the years. 
Still, attention has been drawn towards methicillin-resistant 
Staphylococcus aureus (MRSA), which, in number of incident 
cases, has grown by 420% (from 853 to 3,579 cases) from 
2008 to 2017. This may partly be a result of changes in 
sampling methods due to extended guidelines, but also an 
increase in community-acquired infections was observed.
Carbapenemase-producing organisms (CPO)
During 2017, all carbapenemase-producing organisms (CPO) 
found in either clinical or screenings samples were sent to SSI 
for characterization based on whole genome sequencing. Al-
together 123 CPO were detected from 115 patients compared 
with 115 CPO from 99 patients in 2016, leading to a 6% over-
all increase of submitted CPO isolates compared to 2016. More 
than one isolate from the same patient were included in the 
reporting, if the isolates belonged to different bacterial species 
and/or if the isolates harboured different carbapenemases. 
The 123 CPO consisted of 104 CPE (mainly E.coli, 
K.pneumoniae and Citrobacter freundii), 15 Acinetobacter spp 
and 4 Pseudomonas spp. For 40 of the cases with CPE a travel 
history could be obtained – 27 of the patients reported of 
travelling outside the Nordic countries, while 13 had not trav-
elled. Nine of the persons with Acinetobacter spp reported of 
travelling and one of the patients with Pseudomonas spp. For 
several of the CPE and two of the Acinetobacter spp spread 
within hospital setting was reported.
Vancomycin-resistant Enterococcus faecium (VRE)
Since 2005, Danish Departments of Clinical Microbiology 
(DCM) have voluntarily submitted VRE for species identifi-
cation, genotyping and surveillance to SSI. Since 2013, an 
increase in clinical VRE isolates has been observed, mainly 
driven by increases observed in the Capital Region. For the 
report 2017, the number of submitted isolates was supple-
mented with the number of VRE registered in the Danish mi-
crobiological database (MiBa), resulting in a total of 508 VRE, 
a slight decrease compared to 515 VRE in 2016. For 66 of 
the patients, bloodstream infection was reported. While this 
is the first time in the observation period without an increase 
in the number, the geographical dispersing to other regions 
continued, which is worrisome.
Other key findings in 2017
Besides the mentioned bacteria, DANMAP 2017 presents 
AMR findings in: Enterococcus faecalis and faecium, Strepto-
coccus pneumoniae, beta-haemolytic streptococci, Pseudo-
monas aeruginosa, Acinetobacter spp., and for the first time, 
Haemophilus influenza from invasive infections in humans 
(textbox 8.4). It also includes resistance findings in sexually 
acquired Neisseria gonorrhoeae and Mycoplasma genitalium 
(textbox 8.6).
Also for the first time the report introduces reporting on con-
sumption of antifungals and development of resistance in human 
clinical isolates of Candida and Aspergillus (textbox 5.2).
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Textbox 6.1 describes resistance in clinical isolates from animals 
for E.coli, Streptococcus suis and Actinobacillus pleuropneumonia. 
Finally, the report provides updates on control initiatives and 
presents some research study outcomes. 
Future improvements and developments
DANMAP demonstrates that a well-established surveillance 
program is important to understand the development of AMR 
and where prudent use of antimicrobials is necessary. 
The general use of antibiotics in humans and food animals is 
relatively low in Denmark compared to EU and the rest of the 
world. Even so, we observe an increasing number of multi-
resistant organisms in farm animals and humans. International 
travel and trade are considered an important factor in introduc-
ing new bacteria and resistance traits that may be maintained 
and spread in the Danish populations. Once introduced, high 
levels of consumed antimicrobials in subpopulations of humans 
or animals may maintain these resistance traits and even 
contribute to their dispersion. Monitoring of multi-resistance 
pathogenic bacteria as MRSA, ESBL, CPE and VRE in all rel-
evant reservoirs provides essential information on when and 
where control measures are needed. 
DANMAP 2017 provides a solid foundation for the Danish 
surveillance and methods to monitor the antimicrobial resis-
tance situation over time. Moreover, the report reveals some 
gaps and areas that need further improvements to improve our 
understanding.    
DANMAP 201714
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3. Introduction to DANMAP
3.1 Background
DANMAP was established in 1995 at initiative of the Danish 
Ministry of Health and the Danish Ministry of Food, Agricul-
ture and Fisheries. Participants of the programme count: the 
National Food Institute and the National Veterinary Institute 
(both situated at Technical University of Denmark (DTU)) as 
well as Statens Serum Institut (SSI). The DANMAP programme 
is funded jointly by the Ministry of Health, the Ministry of 
Higher Education and Science, and the Ministry of Environment 
and Food.
A main purpose of DANMAP, has been to implement a One 
Health approach, comprising the entire chain from farm to fork 
to sickbed, since 1995. The organisation and collection of DAN-
MAP data is presented in Figure 3.1. The diagram shows the in-
terdisciplinarity and close cooperation between the participants.
The key objectives of DANMAP are:
• To monitor the consumption of antimicrobial agents in food 
animals and humans
• To monitor the occurrence of antimicrobial resistance in bac-
teria isolated from food animals, food of animal origin (e.g. 
meat) and humans
• To study associations between antimicrobial consumption 
and antimicrobial resistance
• To identify routes of transmission and areas for further 
research studies
A major part of the report concerns antimicrobial resistance in 
different contexts. The monitoring of resistance is based on 
three categories of bacteria:
• Human and animal pathogens that cause infections and are 
thought to reflect resistance caused by use of antimicrobial 
agents in their respective reservoirs
• Zoonotic bacteria capable of developing resistance in the 
animal reservoir, which may subsequently compromise treat-
ment outcome when causing infection in humans
• Indicator bacteria (enterococci and E. coli) due to their ubiq-
uitous nature in animals, food and humans, and their ability 
to readily develop or transfer antimicrobial resistance in 
response to selective pressure in both reservoirs
All pathogens may be considered reservoirs of resistance de-
terminants – genes – that may be disseminated independently 
of the bacterial hosts.
A web annex presenting minimum inhibitory concentration 
(MIC) distributions, detailed tables of antimicrobial consump-
tion and other additional data are available for download at 
www.danmap.org. Current and previous DANMAP reports are 
also available at the website (PDF versions).
Public health risks
Bacteria can be inherent resistant or become resistant either by spontaneous mutation or by transfer of resistance genes from 
other bacteria. Resistant strains are favoured when use of antimicrobial agents provide a selective pressure. This occurs in hu-
mans as well as in animals undergoing antimicrobial treatment. Resistant bacteria can spread between humans in the community, 
at healthcare centres and at hospitals. Furthermore, resistant bacteria from animals can be transmitted to humans either through 
direct contact with animals and their environment or through ingestion of contaminated food or other contaminated vehicles.
Antimicrobial treatment failure may occur if the ingested resistant bacteria are a direct cause of disease, or if resistance determi-
nants are transferred to pathogenic bacteria causing the disease. Bacteria may be resistant to several – sometimes all – antimicrobial 
agents available for treatment, increasing the risk of treatment failure.
Currently there is only a limited number of antimicrobial agents, with novel modes of actions, under development by the pharmaceu-
tical industry. Therefore, it is vital for public health organisations to ensure the continued effectiveness of compounds considered 
critically important to human treatment by ensuring prudent use for both humans and animals.
Prudent use should include considerations on possible restrictions of critical antimicrobial agents, so these can be reserved for use in 
humans primarily, to consider the introduction of new compounds for use in one sector only, as well as to eliminate all overuse. Only 
humans and animals suffering from an infection responsive to antimicrobial treatment should be exposed to antimicrobial agents.
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3.2 Antimicrobial surveillance in Denmark
The following sections present some general information about 
the human population in Denmark in 2017, the production 
of food animals and the amount of meat available for human 
consumption in Denmark through the past decade. It also pro-
vides an overview of the antimicrobial agents for systemic and 
intramammary therapeutic use in humans and animals in 2017.
3.2.1 Populations and productions
During the past two decades, the human population in Den-
mark has increased from approximately 5.2 million inhabit-
ants in 1995 to almost 5.8 million in 2017 (www.dst.dk).The 
population, which could potentially have received antimicro-
bial treatment in 2017, is shown as regional distribution in 
Figure 3.2. The five healthcare regions and the 10 Depart-
ments of Clinical Microbiology (DCM) in Denmark are pictured 
as well.
The production of food animals and the production of meat 
and milk are presented in Table 3.1. In 2017, the number of 
pigs produced was approximately the same as in 2016, but 
the number of exported fattening pigs (15–50 kg) continued to 
increase by approximately 7%. Since 2004, the total exports of 
fattening pigs have increased more than seven-fold. 
From 2016 to 2017, the number of cattle slaughtered de-
creased, while the number of dairy cows remained at the same 
level as in 2016, and the amount of milk produced increased 
by approximately 2%.
The number of broilers produced decreased and approximately 
16% of the broilers produced in Denmark in 2017 were exported 
for slaughter. The production of turkeys has fluctuated consider-
ably over the past decade. Since 2006, more than 99% of the tur-
keys produced have been exported for slaughter, thus the majority 
of turkey meat available for sale in Denmark is listed as imported.
3.2.2 Registered antimicrobial agents
Table 3.2 shows the antimicrobial agents registered to treat 
bacterial infections in humans and animals respectively. Some 
of these are listed on the highest priority list of critically im-
portant antimicrobial agents for the treatment of bacterial in-
fections in humans, according to definitions made by a working 
group under the World Health Organization [AGISAR, 5.revision, 
WHO 2017]. In order to be considered critically important, an 
antimicrobial must be the only- or one of a limited number of 
compounds available to treat serious human disease. Critically 
important antimicrobial agents are also used to treat diseases 
in food animals and pets, so the reservoir of resistance-poten-
tial bacteria is not restricted to humans only. Since bacteria 
may be transmitted from animals to humans, and bacteria 
that cause human disease are capable of acquiring resistance 
genes from bacteria of animal origin, resistance against the 
critically important antimicrobials can be spread widely.
Figure 3.1 Organisation of DANMAP DANMAP 2017
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In the newest revision from 2017, five drug classes were con-
sidered to be critically important:  fluoroquinolones, 3rd, 4th 
and 5th generation cephalosporins, macrolides, glycopeptides 
and polymyxins. In Denmark, in food animals the use of these 
drug classes has in general been low or been reduced through 
either voluntary or legislative restrictions, see chapter 4 for 
more information. For trends and traditions in the antimicrobial 
treatment of humans and informations on recent national ac-
tion plans see chapter 5.
Growth promoters (no longer used for animals in Denmark) are 
shown in parentheses in Table 3.2. Most of these influenced 
Gram-positive bacteria. Since 1995, the indicator enterococci 
from animals and meat (and in some years from healthy 
humans) have been used as a measure of resistance towards 
growth promoters.
Figure 3.2 The five Danish healthcare regions and their respective population distributions. In addition,  
the 10 DCM are marked by black squares. The grey square indicates the reference laboratory situated at SSI. DANMAP 2017
 
■
DCM ODENSE
■ DCM ESBJERG
DCM AARHUS
■
■
DCM SØNDERBORG
■ 
REF LAB SSI
■
Nykøbing F.
■
Slagelse
■
DCM AALBORG
DCM VEJLE
■ DCM HVIDOVRE ■
DCM REGION
ZEALAND
Region 
Zealand
Region of 
Southern Denmark
Central Denmark 
Region
North Denmark 
Region
The Capital Region 
of Denmark
Bornholm
  
 DCM HERLEV ■
DCM RIGS-
HOSPITALET 
■
North Denmark Region
No. of inhabitants 587,335
No. of inhabitants/km2 75
No. of inhabitants/GP 1,938
 
Central Denmark Region
No. of inhabitants 1,304,253 
No. of inhabitants/km2 100
No. of inhabitants/GP 1,608 
Capital Region of Denmark
No. of inhabitants 1,807,404
No. of inhabitants/km2 706
No. of inhabitants/GP 1,713
Region Zealand
No. of inhabitants 832,553 
No. of inhabitants/km2 115 
No. of inhabitants/GP 1,727
Region of Southern Denmark
No. of inhabitants 1,217,224 
No. of inhabitants/km2 99
No. of inhabitants/GP 1,550
GP = general practitioner. 
Source: Statistics Denmark (www.dst.
dk) and the Danish Medical Association 
(www.laeger.dk) 
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Year Broilers Turkeys Cattle 
(slaughtered)
Dairy cows Pigs  Farmed fish(a) 
Fresh 
water
Marine
1,000 
heads 
mill. 
kg(b)
1,000 
heads
mill. kg 1,000 
heads
mill. kg 1,000 
heads
mill. kg 
milk
1,000 
heads
Export 
1,000 
heads(c)
mill. kg mill. kg mill. kg
1990 94560 116 571 2,5 789 219 753 4542 16425 - 1260 - -
1992 107188 137 761 5,4 862 236 712 4405 18442 - 1442 35 7
1994 116036 152 1091 8,6 813 210 700 4442 20651 - 1604 35 7
1996 107895 149 961 9,3 789 198 701 4494 20424 - 1592 32 8
1998 126063 168 1124 11,6 732 179 669 4468 22738 - 1770 32 7
2000 133987 181 1042 10,3 691 171 636 4520 22414 - 1748 32 7
2001 136603 192 1086 13,2 653 169 623 4418 23199 - 1836 31 8
2002 136350 190 1073 12,8 668 169 611 4455 24203 - 1892 32 8
2003 129861 197 777 11,2 625 161 596 4540 24434 - 1898 34 8
2004 130674 198 1086 19,6 632 165 569 4434 25141 1712 1967 34 9
2005 122179 183 1237 17,4 549 145 559 4449 25758 2720 1988 31 8
2006 106182 161 785 11,3 509 140 556 4492 25763 3204 1957 29 8
2007 107952 163 1009 14,4 512 141 545 4515 26311 3522 2046 31 10
2008 107595 163 1068 12,3 509 138 559 4585 27078 4943 1985 30 10
2009 108851 165 1175 11,1 507 137 569 4734 27603 6642 1898 29 11
2010 117653 178 1184 14,0 519 142 574 4830 28505 7074 1974 28 10
2011 115454 175 960 9,4 551 145 575 4801 29399 7632 2008 28 11
2012 111080 168 1103 12,4 539 138 580 4928 29047 8794 1902 28 13
2013 117315 177 692 8,3 551 140 574 5025 28996 9318 1896 28 12
2014 115497 174 595 8,8 556 143 563 5113 29926 10517 1924 30 11
2015 114238 172 598 8,8 513 135 561 5270 30874 12133 1954 32 12
2016 120685 182 834 9,9 540 142 571 5276 31660 13280 1943 33 12
2017 117602 178 601 7,3 509 135 570 5478 31662 14173 1896 32 12
Table 3.1 Production of food animals and the production of meat and milk, Denmark DANMAP 2017
Source: Statistics Denmark (www.dst.dk) and The Danish AgriFish Agency. Production data for farmed fish was not available for 2017. Live 
animals exported prior to slaughter are included in number of animals and amount of meat produced. Export data for poultry from Statistics 
Denmark (personal communication) and export of 15-50 kg live pigs from the Danish Agriculture and Food Council 
a) The numbers for 2017 are not final. The production of farmed fish includes fish transferred from one production facility to another
b) Assume a final slaughtered weight of 1.51 kg per broiler produced (Danish Agriculture and Food, 2013)  
c) Export of 15-50 kg live pigs. These are included in total number of heads, but antimicrobial use after export until slaughter is not registered as 
it takes place outside of Denmark
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Table 3.2  Antimicrobial agents registered for systemic and veterinary intramammary  
therapeutic use in animals and humans, Denmark DANMAP 2017
ATC / ATCvet codes (a) Therapeutic group Antimicrobial agents within the therapeutic groups
Animals Humans
J01AA / QJ01AA,QJ51AA Tetracyclines Chlortetracycline, doxycycline, 
oxytetracycline
Doxycycline, lymecycline, 
tetracycline, tigecycline
QJ01BA Amphenicols Florfenicol
J01CA / QJ01CA Penicillins with extended 
spectrum
Ampicillin, amoxicillin Ampicillin, pivampicillin, amoxicillin, 
pivmecillinam, mecillinam
J01CE / QJ01CE Beta-lactamase sensitive 
penicillins
Benzylpenicillin, 
phenoxymethylpenicillin, 
procaine penicillin, 
penethamate hydroiodide
Benzylpenicillin, 
phenoxymethylpenicillin
J01CF / QJ51CF Beta-lactamase resistant 
penicillins
Cloxacillin, nafcillin Dicloxacillin, flucloxacillin
J01CR / QJ01CR Comb. of penicillins and beta-
lactamase inhibitors
Amoxicillin/clavulanate Amoxicillin/clavulanic acid, 
piperacillin/tazobactam
J01DB / QJ01DB,QJ51DB 1st generation cephalosporins Cefalexin, cefadroxil, cefapirin Cefalexin, cefazolin
J01DC 2nd generation cephalosporins Cefuroxime
J01DD / QJ01DD,QJ51DD 3rd generation cephalosporins 
incl. comb. with beta-lactamase 
inhibitors
Cefoperazone, ceftiofur, 
cefovecin
Cefotaxime, ceftazidime, 
ceftriaxone, ceftazidime/avibactam
J01DE / QJ51DE 4th generation cephalosporins Cefquinome Cefepime
J01DF Monobactams Aztreonam
J01DH Carbapenems Meropenem, ertapenem
J01DI 5th generation cephalosporins 
incl. comb. with beta-lactamase 
inhibitors
Ceftaroline fasamil, ceftolozan/
tazobactam, ceftobiprol
J01EA Trimethoprim and derivatives Trimethoprim
J01EB / QJ01EQ Short-acting sulfonamides Sulfadimidine Sulfamethizole
J01EE / QJ01EW Comb.of sulfonamides and 
trimethoprim, incl. derivatives
Sulfadiazine/trimethoprim, 
sulfadoxine/trimethoprim,
sulfamethoxasol/trimethoprim  
Sulfamethoxazole/trimethoprim
J01FA / QJ01FA Macrolides Spiramycin, tylosin, tilmicosin, 
tylvalosintartrat, tulathromycin, 
gamithromycin, tildiprocin 
Erythromycine, roxithromycine, 
clarithromycine, azithromycine, 
telithromycine
J01FF / QJ01FF Lincosamides Clindamycin, lincomycin Clindamycin
QJ01XX (b) Streptogramins (Virginiamycin)
J01GB / QJ01RA,QA07AA Aminoglycosides Streptomycin, 
dihydrostreptomycin, 
gentamicin, neomycin, 
apramycin
Tobramycin, gentamicin
J01MA / QJ01MA Fluoroquinolones Enrofloxacin, marbofloxacin, 
difloxacin, ibafloxacin, 
pradofloxacin
Ciprofloxacin, levofloxacin, 
moxifloxacin
QJ01MB Other quinolones Oxolinic acid
QJ01MQ (b) Quinoxalines (Carbadox, olaquindox)
J01XA,A07AA / Not in ATCvet 
(b,c)
Glycopeptides (Avoparcin) Vancomycin, teicoplanin, 
dalbavancin, oritavancin
J01XB / QA07AA (b) Polypeptides (incl. polymyxins) Colistin, bacitracin Colistin
J01XC Steroid antibacterials Fusidic acid 
J01XD,P01AB (c) Imidazole derivatives Metronidazole
J01XE Nitrofurane derivatives Nitrofurantoin 
J01XX / QJ01FF Other antibacterials Spectinomycin Methenamine, linezolid, daptomycin, 
tedizolide, fosfomycin
QJ01XQ Pleuromutilins Tiamulin, valnemulin
QP51AG04 Antiprotozoals, sulfonamides Sulfaclozine
Not in ATCvet (b) Oligosaccharides (Avilamycin)
Not in ATCvet (b) Flavofosfolipols (Flavomycin)
a) ATCvet codes start with a Q 
b) Animal growth promoters used before 1999 are listed in parentheses 
c) Intestinal antiinfectives (A07AA) and imidazole derivatives for protozoal diseases (P01AB) were, for the first time, included in DANMAP 2014, 
since their widespread use in the treatment of Clostridium difficile infections makes them belong to the most used antibiotics in human infections 
in Denmark
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4. Antimicrobial consumption in animals
4.1 Introduction
The use of antimicrobial agents in humans and animals has 
been monitored by the DANMAP programme since 1995. Since 
the early 1990s, there has been both political and public focus 
on the use of antimicrobial agents in the Danish animal produc-
tion. This resulted in discontinued use of antimicrobial agents 
for growth promotion from 1994-1999, and more recently, in 
a voluntary ban of use of cephalosporins in the pig and dairy 
cattle production, as well as in regulatory legislation regarding 
therapeutic use [DANMAP 2010].
Figure 4.1 shows the total use of antimicrobials for animals 
and humans since 1994 and 1997, respectively. Changes in 
the antimicrobial consumption patterns for animals can be ex-
plained in part by an increase in pig production over the years, 
but risk management measures to reduce consumption have 
also played a role. In addition, the downward trend in consump-
tion in animals has been affected by increasing export of live 
pigs at 30-40 kg live weight in recent years.
The prescription patterns for animals have clearly been influ-
enced by risk management decisions during the period. For ex-
ample, the decrease in antimicrobial consumption after 1994 
was likely the result of 1) limitation of veterinary practitioners’ 
profit from sales of medicine, 2) implementation of preven-
tive veterinary strategies with Veterinary Advisory Service 
contracts (VASCs) and regular visits from the veterinarian in 
order to promote preventive veterinary strategies and optimize 
antimicrobial use, and 3) enforcement of the so called “cascade 
rule” [Order (DK) 142/1993], which limits the use of (cheaper) 
    Highlights: The overall use of antimicrobials for animals decreased for the fourth consecu-
tive year and has since 2013 been reduced by more than 16 tonnes. From 2016 to 2017, 
the antimicrobial consumption decreased by approximately 3%. 
  The decrease was driven by the use of antimicrobials for pigs, which was approximately 
4% (3.4 tonnes) less than the year before. In 2017 the export of weaner pigs continued to 
increase, while the total number of pigs produced remained at approximately at the same 
level. The use of tetracyclines for pigs has been reduced significantly and almost consis-
tently since 2009, and in particular from 2016 to 2017, following the implementation of the 
differentiated “Yellow Card”. The differentiated “Yellow Card” initiative has also resulted in 
a close to zero use of colistin after the first quarter of 2017. However, the decrease in the 
use of tetracylines and colistin, was mirrored by less marked but clear increases in the use of 
macrolides, pleuromutilines and aminoglycosides. 
  Both the poultry and aquaculture industry further decreased their use of antimicrobials from 
2016 to 2017. Use of antimicrobials in the aquaculture industry was the lowest ever recorded 
in VetStat. The decreasing trend is likely to be positive effects of favourable weather condi-
tions i.e low summer temperatures combined with the implemented vaccination strategies.
  The fur animal industry continued to increase their antimicrobial use, which increased by 
15% in 2017, equivalent to approximately 800 kg. There was no apparent increase in diag-
nostic submissions that could provide an explanation for the increased use.
  In companion animals, the use of critically important antimicrobials is still relatively high 
compared with other species. Almost all fluoroquinolones and more than half of the cepha-
losporins used for animals are used for dogs and cats. Despite a small increase in use from 
2015 to 2016, there has been an overall decreasing trend in the use of antimicrobials for 
dogs and cats since 2011. The shift in the use of antimicrobials continued in 2017 with a 
marked reduction in the relative use of cephalosporins and an increase in the use of amino-
penicillins.
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extemporaneously produced medicines. The latter particularly 
affected the use of tetracyclines from 1994. Another impor-
tant intervention was the restriction on the use of fluoroqui-
nolones in production animals through legislation implemented 
in 2002 and 2003. Furthermore, in July 2010, the pig industry 
imposed a voluntary ban on the use of cephalosporins. This 
was followed by a similar initiative by the cattle industry in 
July 2014.
From 2010 to 2011, consumption decreased following the 
introduction of threshold values for antimicrobial consump-
tion adopted within the “Yellow Card Initiative”. This enforces 
legal actions on pig farmers with high antimicrobial use per 
pig [DANMAP 2010]. The “Yellow Card” was revised in 2016 
and further adjusted in 2017 and the latest adjustments are 
described in Textbox 4.2 Effects from other parts of the legis-
lation may be less obvious, but are also likely to have affected 
prescription patterns. For example, the rules for group medica-
tion in pig herds were tightened in 2014, requiring intensive 
laboratory diagnoses and frequent veterinary visits when 
antimicrobials are prescribed for groups of pigs.
Official guidelines regarding the selection of antimicrobial 
agents for pigs and cattle have been available since 1996. 
The guidelines provide specific recommendations for selec-
tion of the appropriate antimicrobial treatment of all common 
indications in the major production animal species. Initially, 
guidelines were developed by the National Veterinary 
Laboratory (presently, DTU National Veterinary Institute). 
Since 2005, the guidelines have been updated by the Danish 
Veterinary and Food Administration (DVFA) in collaboration 
with stakeholders and university experts. The guidelines 
were updated in 2010, when new dynamic evidence based 
treatment guidelines for pigs were launched [DANMAP 2010, 
www.fvst.dk], and were further revised in 2017 and the new 
version published in April 2018. In 2012, the Danish Veteri-
nary Association published treatment guidelines to promote 
prudent use of antimicrobials in dogs and cats. The guidelines 
were prepared by clinical specialists and expert scientists 
from the Faculty of Health and Medical Sciences at the Uni-
versity of Copenhagen and DTU National Food Institute. The 
treatment guidelines for dogs and cats was under revision in 
2017. Similarly, the Danish Veterinary Association have also 
published treatment guidelines for use of antimicrobials in 
horses.
4.1.1 Data sources
Data on antimicrobial use at the product level have been collect-
ed in Denmark since 1996, including historical data back to 1990. 
In Denmark, antimicrobials are available by prescription only.
Since 2001, data on all medicine prescribed for use in animals, 
including vaccines, antimicrobial growth promoters (no longer 
permitted) and coccidiostatic agents (non-prescription) have 
Figure 4.1 Prescribed antimicrobial agents for humans, and for all animal species, Denmark   DANMAP 2017
Sources: Human therapeutics: The Danish Medicines Agency. Antimicrobials for animals: Until 2001, data are based on reports from the 
pharmaceutical industry of total annual sales from the Federation of Danish pig producers and slaughterhouses (1994-1995) and Danish     
Medicines Agency and Danish Plant Directorate (1996–2000). Data from 2004–2017 are based on data extracted from VetStat. Data for 
DANMAP 2017 was  extracted from VetStat 6th August 2018. This figure includes all antimicrobial agents registered for use in animals.
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been recorded in the national database VetStat. The VetStat 
database is hosted and maintained by Danish Veterinary and 
Food Administration (DVFA). Data in VetStat are validated by 
the DVFA.
The data presented in this report were extracted from VetStat 
on 6th of August 2018. Data have been summarized for DAN-
MAP by DTU National Food Institute.
4.1.2 Methods
Metrics of antimicrobial consumption are numerous, each with 
its own advantages and limitations. Therefore, the selection 
of metrics used for monitoring must depend on the monitoring 
objective and the information available.
The overall amount of antimicrobial agents is measured in kg 
active compound and is used in Section 4.2 for the purpose of 
Table 4.1 Antimicrobial agents sold (kg active compound) by animal species and age group, Denmark DANMAP 2017
Note: Data for 2016 and 2017 were extracted from VetStat 6 August 2018. Only the ATCvet group contributing mostly to the antimicrobial group is 
mentioned. Combination drugs are divided into active compounds
a) Penicillins with extended spectrum and combination penicilins, incl. b-lactamase inhibitors
b) Since DANMAP 2016, new principles have been used to estimate the antimicrobial use for companion animals, see section 4.3.4
c) Approximately 242 kg of the sulfonamides and trimethoprim registered for pets are products (oral paste) typically used for horses
d) This includes data on sheep and goats (13 kg), data where the animal species has not been defined or where the age group does apply to the 
designated animal species 
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Pigs 6240 381 <1 <1 2100 11584 315 0 15910 8733 7669 6615 15212 78150 74758
Sows and piglets 1709 279 <1 <1 433 427 34 0 8447 3580 694 4739 1272 22300 21616
Weaners 4328 95 <1 0 937 7928 276 0 1869 4373 2986 1661 9337 34450 33791
Finishers 203 7 <1 0 729 3228 4 0 5594 780 3989 214 4603 21401 19352
Cattle 723 737 63 <1 5 235 4 0 7421 742 0 922 1514 12948 12366
Intramammaries 40 0 53 0 4 0 <1 0 301 102 0 2 0 498 503
Cows and bulls excl. 
intramammaries
213 15 9 <1 <1 98 <1 0 6520 491 0 791 922 9656 9060
Calves <12 months 444 706 <1 <1 <1 131 4 0 448 139 0 118 556 2562 2547
Heifers and steers 26 16 <1 0 <1 5 <1 0 151 10 0 10 36 233 256
Poultry 65 5 0 <1 32 205 0 0 321 292 <1 85 483 1560 1488
All poultry excl. turkeys 47 1 0 <1 23 96 0 0 234 164 <1 85 198 942 848
Turkeys 18 4 0 0 9 109 0 0 87 128 0 0 285 619 640
Other production 
animal species
429 350 0 <1 134 932 <1 637 <1 2799 0 1587 962 7648 7831
Aquaculture 0 350 0 <1 <1 0 <1 637 0 31 0 679 <1 2303 1697
Fur animals 429 <1 0 <1 134 932 <1 0 <1 2768 0 908 962 5345 6134
Companion animals(b) 19 1 111 13 67 2 29 0 28 718 <1 1452 40 2458 2481
Pets(estimated)(c) 18 1 111 13 67 2 29 0 19 718 <1 280 38 1326 1296
Horses (estimated) <1 <1 <1 <1 0 <1 <1 0 9 <1 0 1172 3 1131 1184
Other(d) 234 7 4 2 10 240 3 4 865 147 6 293 153 1622 1967
Total 7709 1482 178 15 2347 13198 351 640 24544 13431 7676 10953 18364 104387 100890
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an overall crude comparison of antimicrobial use in the veteri-
nary and human sectors (Figure 4.1).
Since 2012, we have further presented ‘defined animal daily 
dose’ (DADD) and ‘proportion of population in treatment per 
day’ (DAPD) to monitor trends in antimicrobial consumption. 
These metrics are defined below, and for additional informa-
tion on methodology, please refer to Chapter 9 and the web 
annex [www.Danmap.org].
DADD - Defined animal daily dose.
DADD is the average maintenance dose per day for the main 
indication of a drug in the appropriate animal species. The 
DADD is not defined at product level but for each antimicrobial 
agent, administration route and animal species; and when 
appropriate, also age group. The DADDs have been specifi-
cally defined for use in DANMAP based on current knowledge 
(Chapter 9, Materials and Methods) and may vary from the 
prescribed daily dose or the recommended dosage in the 
Summaries of Product Characteristics (SPC) or in the VetStat 
database (Web Annex).
DAPD - proportion of population in treatment per day 
Trends in antimicrobial usage for pigs are presented in DAPD, 
because this measure allows for comparison between sec-
tors. DAPD=DADD per 1000 animals per day, where ‘animals’ 
are represented by their live biomass and adjusted for life-
span. The estimated live biomass is expressed as the number 
of standard animals with an estimated average weight on a 
given day. This may also be referred to as the ‘standard-ani-
mals-at-risk’. This metric allows comparison between species 
with large differences in body-mass and life-span, but for 
DANMAP 2017, we have calculated treatment proportions for 
pigs only.
The estimated treatment proportion, DAPD, is a statistical 
measure that provides a rough estimate of the proportion of 
animals treated daily with a particular antimicrobial agent. For 
example, 10 DAPDs means that an estimated 1% of the pig 
population, on average, receives a certain treatment on a given 
day (Chapter 9, Materials and Methods). In principle, DAPD also 
allows comparisons with the antimicrobial consumption in the 
human sector, which is measured in defined daily dose per 
1,000 inhabitants per day (DID), see Chapter 9 for a descrip-
tion of DID.
4.2 Total antimicrobial consumption in animals
Measured in kg active compound, the total use of antimicrobial 
agents used for all animals, amounted to 100.9 tonnes active 
compound, representing an overall 3% decrease compared with 
2016, Figure 4.1 and Table 4.1.
In 2017, the antimicrobial use for pigs, cattle, fur animals 
and poultry comprised approximately 74%, and 12%, 6% 
and 1% of the total antimicrobial consumption for animals, 
respectively (Figure 4.2). The overall decrease in antimicro-
bial use for animals was mainly attributed to a 4% decrease 
in the amount used in the pig industry, which is the main 
driver of antimicrobial usage in animals in Denmark, due to 
the size of the production. Cattle and pigs comprise almost 
equal proportions of live biomass. However, the vast propor-
tion of cattle biomass consists of dairy cows, which have 
very low consumption of antimicrobial agents compared 
with growing animals.
Pigs, 74%
All cattle, 12%
Horses, 1%
Poultry, 1%
Fur Animals, 6%
Pet animals, 1%
Other, 2%
Aquaculture, 2%
Kg active compound
Pigs, 41%
Cattle>1 year, 38%
Cattle<1 year, 7%
Horses, 5%
Poultry, 1%
Fur animals, 5%
Pet animals, 1%
Aquaculture, 2%
Live biomass
Figure 4.2 Live biomass (mill. kg) and antimicrobial consumption (kg) in main animal species, Denmark DANMAP 2017
Note: The live biomass is estimated from census data (pigs, cattle and pet animals) and production data (poultry, fur animals and aquaculture). 
For poultry: the figures comprise only the biomass for the main production types (turkeys and broilers). The live biomass estimates for poultry, 
aquaculture and pet animals are based on 2012 data. The estimation procedures are described in Chapter 9, Materials and Methods.
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Figure 4.3 Change in antimicrobial use (kg active compound) in pigs, cattle, fur animals and pets (dogs and cats) 2013 – 2017, Denmark
Note: The figure includes the antimicrobial agents registered for use in the particular animal species. Note the different scale on the x-axis. The use 
of antimicrobial agents for pets (dogs and cats) has been estimated as described in section 4.2.2. Poultry has not been included in the figure, since 
several serious disease outbreaks in 2014 and 2015 have caused considerable fluctuations in the use of antimicrobials during these years.
a) Penicillins with extended spectrum: amoxicillin/clavulanic acid, and also, ampicillin, amoxicillin and cloxacillin
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Historically, the overall consumption, measured as kg active 
compound, was 51% lower in 2017 compared with 1994. ). A 
major part of the decrease in consumption can be explained by 
the discontinued use of growth promoters from 1994 to 1999.
In contrast, the total meat production increased by 12% during 
this period (Table 3.1 and Figure 4.1).
Between 2000 (start of VetStat) and 2009, when consump-
tion was at its highest, the amount of kg active compound 
increased by 62% (Figure 4.1). This increase was driven 
mainly by consumption in pigs, and during this period the 
number of pigs produced went up by 23% (Table 3.1). At the 
same time, the proportion of exported live pigs (at approx. 30 
kg) increased and thus resulted in a decrease in the overall 
biomass of the pig population. Since then, the proportions of 
exported live pigs has continued to increase. Overall, there 
has been a gradual decreasing trend in the use of antimicro-
bials for animals and in 2017 it was approximately 23% lower 
than in 2009.
Figure 4.3 illustrates the changes in antimicrobial usage in 
pigs, cattle, fur animals and pets over the past five years (in 
kg active compound). With the exception of fur animals, the 
changes in the antimicrobial use within the different animal 
species have been clearly affected by the different initiatives 
to reduce not only the total use of antimicrobials, but also the 
use of particular antimicrobial classes. Particularly, the use 
of tetracyclines for pigs has been reduced significantly over 
the past five years. The usage patterns in cattle has shifted 
towards more penicillins and less sulfonamides and trime-
thoprim, amphenicols and cephalosporins. In dogs and cats, the 
use has shifted away from the cephalosporins. For both pigs 
and cattle there has been an increase in the use of aminogly-
cosides and macrolides over the last five years.
4.3 Antimicrobial consumption by animal species
4.3.1 Antimicrobial consumption in pigs
For this issue of DANMAP, updated data from 2016 and 2017 
were extracted from VetStat and measures for the antimicro-
bial usage in pigs were calculated for 2016 and 2017, using 
the updated dataset.
In 2017, the total antimicrobial consumption in pigs (sows and 
piglets, weaners, finishers) was 74.8 tonnes active compound 
(Table 4.1), a decrease of 3.4 tonnes (4%) compared with 
2016. The treatment proportions (DAPD) in the pig popula-
tion overall and by age group are presented in Figure 4.4 and 
Figure 4.5 and the DADD’s are shown in the in the web annex 
(Table A4.1 and in the DADD description). 
The treatment proportion (DAPD) of the total population reflects 
the trends in selection pressure within the population. However, 
the treatment intensity is much higher in the weaning pigs than 
in finishers and sows (Figure 4.4). Furthermore, the biomass of 
the weaning pigs is also very small (7.5- 30 kg, 4 weeks), com-
pared with the finishers (31-107 kg, 12 weeks) and the sows. 
The large differences in DAPDs between age groups affects 
the DAPD of the total population and trends are influenced by 
changes in population structure. Thus, export or productivity 
need to be accounted for, before interpreting the antimicrobial 
consumption patterns and selection pressure in the pig produc-
tion. As an example, increased export of live pigs right after 
weaning could lead to an increase in DAPD for the remaining 
population, since the exported pigs were only in the country, 
when the treatment proportion was highest.
Historically, the treatment proportion (DAPD) increased from 
2004 to 2009, followed by a decrease in 2010 and 2011, 
which is considered a result of the “Yellow Card Initiative” (See 
DANMAP 2010). 
In 2017, the antimicrobial consumption in pigs, measured in 
DAPD, decreased from approximately 25 DAPD to 24 DAPD 
(Figure 4.4) when adjusted for export. The number of exported 
live pigs continued to increase in 2017, while the total number 
of pigs slaughtered remained at approximately the same level 
(Table 3.1). Within the different age groups, the treatment pro-
portions decreased slightly for sows and piglets and finishers, 
but increased for weaners (Figure 4.4). Thus, on a given day in 
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a) The DAPD is calculated as the number of standard doses for one kg 
animal divided by the estimated live biomass in the age group of the 
total population (in tonnes)
Figure 4.4 Antimicrobial consumption (a) in the pig production, 
and the distribution on age groups, Denmark 
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Figure 4.5 Antimicrobial consumption(a) in the total pig production(b), and in finishers, weaners, sows and piglets, Denmark 
DANMAP 2017
Note: Amphenicols, colistin, fluoroquinolones, intramammaries, gynecologicals and topical drugs are not included in the figure.
a)  The DAPD is calculated as the number of standard doses for one kg animal divided by the estimated live biomass in the age group or 
the total population (in tonnes)
b) The total is adjusted for the increasing export of pigs at 30 kg (see text). “Sows” includes treatment in boars and piglets pre-weaning
c) Lincosamide/spectinomycin combinations comprise 56% of this group
d) Beta-lactamase sensitive penicillins
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2017, approximately 2% of sows and piglets, 1-2% of finisher 
pigs and 10% of weaner pigs were treated with antimicrobials. 
Also measured in DAPD, the antimicrobial use in pigs was 29% 
lower in 2017 than in 2009, when adjusted for changes in 
export (Figure 4.4).
Changes to the yellow card initiative were implemented during 
2017, i.e. multiplication factors of 1.5 and 10 were applied to 
the use of tetracyclines and colistin, respectively, to promote 
further reduction (see Textbox 4.1). 
The National MRSA Action plan aims to reduce the antimicro-
bial use in pigs by 15% in 2018, compared to 2014. In 2017, 
the overall use in the pig production was reduced by approxi-
mately 13%, both when measured in kg active compound and 
when measured in DAPD (adjusted for export).
Tetracyclines has been one of the most commonly used 
antimicrobials in the Danish pig production for more than a 
decade. It is almost exclusively administered orally, and is 
especially used for treatment of gastrointestinal disease in 
weaning pigs and finishers. The overall use of tetracyclines 
has decreased since 2013 and 2016 saw the lowest DAPD 
levels since 2005. In 2017, the use of tetracyclines was 
further sharply reduced, following the implementation of 
the higher multiplication factor in the Yellow Card Initiative. 
Measured in DAPD, the use of tetracyclines, for all age groups 
was reduced by 32% from 2016 to 2017 and has decreased 
55% since 2009. The proportion of weaner pigs treated with 
tetracyclines on any given day has decreased from approxi-
mately 5% in 2009, to approximately 2% in 2017.In contrast, 
the use of other antimicrobials has increased, particularly the 
use of aminoglycosides (mainly neomycin), macrolides and 
pleuromutilins, see Figure 4.4
The use of colistin for pigs increased more than two-fold from 
403 kg in 2009 to 864 kg in 2016, of which 752 kg were used 
for weaners. Since the implementation of a multiplication fac-
tor of 10 in the "Yellow Card" Initiative April 2017, the use of 
colistin has been close to zero (Textbox 4.2). 
Use of the critically important antimicrobial agents, fluoroqui-
nolones and cephalosporins was close to zero in 2017.
Use of medical zinc in pigs
In the latest issues of DANMAP, we have presented the use 
of medical zinc for pigs (Figure 4.6). This is relevant in the 
context of DANMAP, because its use may select for antimicro-
bial resistance in some bacteria, including MRSA. Medical zinc, 
in the form of zinc oxide, is fed to piglets after weaning to 
prevent or treat diarrhoea. 
For more than a decade the use of zinc for pigs increased 
steadily, reaching a peak in 2015 and has since then fluctu-
ated between approximately 527 and 548 tonnes. In 2017, 
the European Commission announced an EU wide ban on 
the use of medical zinc for pigs from June 2022. In February 
2016, the Danish pig industry launched an action plan to help 
the pig producers reduce the use of medical zinc. The action 
plan, focusses on correct use/reduction of medical zinc and 
investigates alternative methods for preventing diarrhoea in 
weaner pigs. 
Use of colistin and neomycin 
In Denmark, almost all the colistin prescribed for animals (882 
kg in 2016 and 321 kg in 2017) is used in the pig production 
for treating gastrointestinal infections in weaners. Only small-
er amounts are used for cattle and poultry. In 2010, colistin 
was introduced as one of the “first choice” antimicrobial agents 
for the treatment of gastroenteritis in the official treatment 
guidelines for pigs. Furthermore, in 2014, the Danish pig pro-
ducers committed themselves to reduce the consumption of 
tetracyclines by 50% and the steep increase in colistin use in 
2014 and 2015 was probably a result of this. Since then, the 
policy has changed because of the emergence of new colistin 
resistance. As part of the differentiated ‘Yellow Card’ in April 
2016, a multiplication factor of 10 was applied to colistin (see 
Textbox 4.2) and as a consequence, the use of colistin dropped 
significantly in 2017. An overview of colistin consumption in 
production animals 2004-2016 is shown in Figure 4.7.
As the use colistin has been phased out, the use of neomycin has 
been introduced. In VetStat only very little or zero use of neomycin 
has been recorded since 2008. In 2017, a new neomycin product 
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zinc (Zn) in the pig production, Denmark  DANMAP 2017
Note: The most commonly used product is zinc oxide (ZnO) which 
contains 80% zinc and which is largely insoluble in water
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registered for pigs was introduced on the market and subsequently 
a total of 2,283 kg neomycin was used for pigs, mainly for weaners.
4.3.2 Antimicrobial consumption in cattle
In 2017, the overall consumption of antimicrobials in cattle 
decreased by approximately 600 kg compared to the previous 
two years, mainly due to a decrease in usage for cows and bulls 
(excl. intramammaries). The production of veal and beef decreased 
by approximately 5% from 2016 to 2017, while milk production 
continued to increase (Table 3.1). As shown in Figure 4.3, the usage 
pattern appears to have shifted away from the use of tetracyclines, 
sulfonamide/trimethoprim, extended spectrum penicillins and 
cephalosporins and towards an increased use of beta-lactamase 
sensitive penicillins, macrolides, amphenicols and aminoglycosides. 
The use of fluoroquinolones in cattle has been close to zero for 
the last decade. Fluoroquinolones may only be prescribed to food 
producing animals, as a last line drug, based on microbiological and 
resistance testing in an accredited laboratory. Use of fluoroquino-
lones for food producing animals is also notifiable to the DVFA.
The use of cephalosporins (all generations) used for systemic treat-
ment (orally and parenterally) was reduced to 9 kg in 2017. This 
represents a 69% decrease since 2014 (29 kg), when the cattle 
Table 4.2 Use of antimicrobial agents for intramammary application in cattle in DADD’s (1000s), Denmark  
DANMAP 2017
Table  4.3 Number of treatments with antimicrobial agents for intramammary application in cattle, Denmark  
DANMAP 2017
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Doses per antimicrobial class DADDs (1000's) 
Penicillins(a) 201 211 211 236 282 314 318 324 311 317 275 262 216
Aminoglycoside-benzylpenicillin 
combinations(b)
130 104 101 101 110 93 48 47 58 90 143 154 206
Cephalosporins, 
1st generation
103 98 89 85 89 89 99 105 111 113 96 89 86
Cephalosporins, 
3rd and 4th generation
110 124 127 112 76 51 34 30 24 21 10 6 3
Others(c) 21 20 16 15 14 12 9 8 0 0 11 10 11
Total 566 558 544 549 570 559 508 514 504 541 535 521 522
Total DADD per cow per year 1.0 1.0 1.0 1.0 1.0 1.0 0.9 0.9 0.9 1.0 1.0 0.9 0.9
Note: For intramammary treatment, 1 DADD is defined as the dose to treat two teats for 24 hours
a) Includes benzylpenicillin, cloxacillin, and cloxacillin-ampicillin combinations (QJ51CE, QJ51CF, QJ51RC)
b) Mainly dihydrostreptomycin-benzylpenicillin combinations; includes also combinations of penicillin/aminoglycoside with bacitracin or nafcillin 
(QJ51RC)
c) Lincosamides, neomycin-lincomycin combinations and trimethoprim-sulfonamide combinations
Note: Includes data for intramammaries registered for use in cattle.  For intramammary therapeutic treatment, 1 DADD is defined as the dose to treat two 
teats for 24 hours. For drying off treatment, 1 DADD is defined as the dose to treat 4 teats. 
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Total doses per indication (a) DADDs (1000's)
Drying off treatment  (4 teats) 73 75 71 76 82 99 97 117 125 140 154 160 168
Therapeutic treatment (2 teats) 420 408 388 377 378 350 307 279 253 259 227 202 186
Figure 4.7 Total use of colistin in production animals,  
Denmark 
DANMAP 2017
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industry decided to phase out its use, and an 85% reduction since 
2008 (60 kg), when cephalosporin consumption was at its peak. 
The use of 3rd and 4th generation cephalosporins is low in cattle 
and mostly used for systemic treatment.
The majority of antimicrobials administered parenterally to 
cattle are used for dairy cows and prescribed mainly for mas-
titis. The overall level of intramammary treatment remained 
unchanged from 2016 to 2017. The antimicrobial use for in-
tramammary application measured in DADDs is shown in Table 
4.2. Since 2013, the use of penicillins and cephalosporins (all 
generations) has been reduced while the use of aminoglyco-
side-benzylpenicillin combinations has increased.
The board of Danish dairy and beef producers has recently 
renewed its strategy for good udder health. The goals are a 20% 
reduction in use of antimicrobials for treatment of mastitis and 
other cattle diseases as well as lowering geometric mean bulk 
tank cell counts to 150.000 by the year 2020. In addition, the 
dairy industry will promote use of dry cow therapy and mastitis 
treatment with simple penicillins. Since 2009, the number of 
antibiotic treatments at drying-off has increased and the relative 
proportion of drying-off treatment versus therapeutic treatment 
has shifted markedly from 22% versus 78% in 2010 to 48% ver-
sus 52% in 2017(Table 4.3). During the same period the use of 
3rd and 4th generation cepahlosporins has decreased markedly.
4.3.3 Antimicrobial consumption in poultry
In Denmark, poultry production comprises mainly broiler 
production, followed by egg layers and turkey production. 
In addition, there is a small production of ducks, geese, and 
game birds.
Danish broiler farms have a very high level of biosecurity 
and the antimicrobial consumption in broiler production is 
generally low compared with other species. Accordingly, a 
few disease outbreaks in some farms can markedly affect 
and cause considerable fluctuations in the national statistics 
on antimicrobial usage. This was the case in late 2014 and 
throughout 2015. In 2016, use of antimicrobials for poultry 
(excl. turkeys) decreased sharply again and in 2017 the us-
age was further reduced to 848 kg. For broilers, amoxicillin 
has been the most commonly used antimicrobial agent for 
more than a decade, but in both 2016 and 2017 tetracy-
cline was the most commonly used antimicrobial (Table 4.1). 
Cephalosporines have not been used in the poultry industry 
for more than a decade.
VetStat does not allow differentiation of the use of antimi-
crobials between different sectors of the poultry production. 
However, the consumption for turkeys was identified by com-
bining information from the Central Husbandry Register with 
information provided by poultry veterinarians and the industry 
(personal communication: S. Astrup, PoultryVet, and M. Nielsen 
Blom, Danish Agriculture and Food Council) and the information 
in VetStat.
The annual usage in turkeys can also be notably affected by 
disease outbreaks in few flocks. In 2017, the antimicrobial use 
was approximately at the same level as in 2016 (Table. 4.1), 
almost half (45%) of which was tetracyclines (Table. 4.1).
4.3.4 Antimicrobial consumption in aquaculture, fur 
animals and companion animals
The antimicrobial consumption in aquaculture continued to de-
crease from 2016 to 2017 by a further 23% to 1,697 kg (Table 
4.1). This is the lowest level of antimicrobial use for aqua-
culture ever recorded in VetStat. The antimicrobial consump-
tion is mainly three compounds; sulphonamide/trimethoprim 
comprised 40%, quinolones 38% and amphenicols 21%, when 
measured in kg active compound.
Antimicrobial consumption in aquaculture is mostly influenced by 
the summer temperatures, because diseases are more likely to 
occur in warmer waters. In recent years, the aquaculture industry 
has developed new and better vaccines and improved vaccina-
tion strategies to reduce the risk of diseases that may require 
antibiotic treatment. A combination of favourable weather condi-
tions (lower temperatures during summer – particularly in 2017) 
and a positive effect of the revised vaccination strategies may 
explain the reduced consumption seen over the last few years 
[personal communication: N. H. Henriksen, Danish Aquaculture].
The use of antimicrobial in mink has a distinct seasonal varia-
tion, with high use from the spring when the mink kits are 
born and again when they are weaned, furthermore there is 
usually an increase in antimicrobial use again in the autumn. 
The production of mink has increased significantly over the 
last decade, peaking at 17.8 million in 2015. In 2017, 17.1 mil-
lion mink were produced in Denmark (Source: Kopenhagen Fur).
With the exception of 2013 and 2014, the use of antimicrobial 
agents in mink production has increased every year for more 
than a decade, from less than two tonnes in 2004 to more 
than six tonnes in 2017 yielding a treatment intensity of ap-
proximately 43 DADD per 1000 animals per day, i.e. on a given 
day in 2017, approximately 4% of Danish the mink were being 
treated with an antimicrobial. However, in 2017 there was no 
apparent increase in diagnostic submissions to provide an ex-
planation for the increased use (National Veterinary Institute, 
DTU). This suggests that diagnostics are increasingly done by 
the veterinarians in private practice, and since these results 
are not collected systematically, there is a lack of informa-
tion on which diseases are being treated in the Danish mink 
production [Dansk Veterinær Tidsskrift (in Danish), 5, 2018, 
pager 45] . It is particularly the use of tetracyclines, penicil-
lins with extended spectrum and combinations penicillins that 
have increased over the past five years (Figure 4.3). Use of 
fluoroquinolones and cephalosporins in fur animal production 
has been close to zero for more than a decade. 
A voluntary action plan to reduce the use of antimicrobials 
in mink is under development. The plan, which will include 
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restrictions on the use of antimicrobials and require increased 
diagnostic submissions from mink, will be implemented in 
2018. 
The use of prescribed medical zinc (zinc oxide) in mink 
production has fluctuated remarkably over the past three 
years. It seems that in 2016 an unusually high level of use 
occurred (1,045 kg)where as in 2014, 2015 and 2017, only 
approximately 500 kg was prescribed. In the mink production, 
medical zinc is applied topically on pre-weaning mink kits in 
the nest boxes.
The information available on antimicrobial consumption in 
companion animals is not as complete as for production ani-
mals, and a substantial amount of the antimicrobials used for 
companion animals are entered into VetStat without defining 
animal species. In Tables 4.4 and 4.5, all antimicrobial agents 
registered for use in dogs, cats and horses have been includ-
Table 4.5 Estimated use of antimicrobial agents for dogs and cats measured in kg active compound, Denmark 
DANMAP 2017
Table 4.4 Estimated use of antimicrobial agents for horses measured in kg active compound, Denmark 
DANMAP 2017
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2013 1 0 0 0 0 1 0 <1 13 0 0 893 5 914
2014 1 0 0 0 0 0 0 <1 15 0 0 1024 6 1047
2015 3 0 0 0 0 0 0 <1 10 0 0 1049 4 1067
2016 1 0 0 0 <1 0 0 <1 8 0 <1 1117 5 1131
2017(b) 1 0 0 0 <1 0 0 <1 9 0 <1 1172 3 1184
Note: Data for 2017 and 2016 were extracted from VetStat 6th August 2018. The estimates include all antimicrobial agents registered, by the 
either the pharmacy or veterinarians for use in horses. Furthermore, antimicrobial agents, where no animal species is given, were allocated to 
horses based on relevant type of preparation (eg. oral paste) or registration. Antimicrobials administered parenterally - with no information on 
animal species - are not included  
a) Penicillins with extended spectrum and combination penicillins, incl. b-lactamase inhibitors
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2012 22 <1 272 13 67 7 49 0 42 651 <1 306 51 1483
2013 19 <1 231 12 63 5 42 0 31 642 <1 292 45 1383
2014 21 <1 213 12 69 6 34 1 31 653 <1 300 35 1376
2015 18 <1 157 13 68 4 32 0 25 655 1 235 39 1249
2016 17 <1 137 14 69 3 30 0 20 718 <1 276 40 1326
2017(b) 18 1 111 13 67 2 29 0 19 718 <1 280 38 1296
Note: Data from 2017 was extracted from VetStat on 6th August 2018. Data include all antimicrobial agents registered, by the either the 
pharmacy or veterinarians for use in pets. Furthermore, antimicrobial agents, where no animal species is given, were allocated to pets based 
on relevant type of preparation (eg. tablets, eye- or eardrops) or registration. Antimicrobials administered parenterally - with no information on 
animal species - are not included
a) Penicillins with extended spectrum and combination penicilins, incl. b-lactamase inhibitors 
b) In 2016, approximately 222 kg of the sulfonamides and trimethoprim registered for pets are products (oral paste) typically used for horses
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ed. Furthermore, it is assumed that a substantial part of the 
antimicrobial agents where no animal species is given, have 
been used for companion animals. We have estimated this 
proportion using similar principles as described in DANMAP 
2016, Textbox 4.4 and is briefly described in table 4.5. 
Measured in kg active compound, the overall antimicrobial 
consumption appears to have increased for slightly for 
horses, while it has been reduced for pets. 
A large proportion of antimicrobials used for companion 
animals are prescribed for treatment of chronic or recurrent 
disease, mainly dermatitis. Due to the close contact between 
owners and their pets, the repeated use of critically impor-
tant antimicrobials may pose a risk to the owners.
In 2017, the use of fluoroquinolones for use in pets was 13 
kg, which comprised the majority of fluoroquinolones used in 
animals in 2017. Similarly, the pets accounted for a signifi-
cant proportion (111 kg or 62%) of the use of cephalosporins 
used in animals.
However, over the past years, since the treatment guidelines 
by Danish Veterinary Association (November 2012) were first 
published, the use of cephalosporins has been reduced by 
59%, which is in line with the treatment guidelines, recom-
mending that use of critically important antimicrobials should 
be reduced as much as possible. Thus, antimicrobial use in 
pets appears to be shifting away from the use of cephalo-
sporins, sulfonamides and trimethoprim and towards broad 
spectrum penicillins, in particular amoxicillin with betalacta-
mase inhibitor.
Birgitte Borck Høg 
For further information: Birgitte Borck Høg, bibo@food.dtu.dk
 
Textbox 4.1
Political agreement on the veterinary strategy, 2018 – 2021
 
In December 2017, all members of the Danish parliament reached a joint political agreement on theveterinary strategy in the 
years 2018-2021. The agreement is called “Veterinærforlig III” and replaces “Veterinærforlig II” covering the previous four 
years.
The agreement includes a large number of goals and initiatives covering antimicrobial resistance, livestock-MRSA, the Danish 
animal disease contingency plans, animal welfare, as well as new research in the field. 302.6 million DKK (40.7 million €) has 
been set aside over the next four years to fund the different initiatives.
The core of the agreement is that healthy production animals is 1) the foundation of a low antimicrobial use and a low oc-
currence and development of resistance, 2) a significant contribution to increased animal welfare and 3) a prerequisite for 
an efficient and sustainable production with good economy and increased export. Hence, the main goal of the agreement is 
producing healthy production animals.
The largest project in the political agreement is “Healthy Animals”. This project covers continued efforts in monitoring and 
regulating antimicrobial use, an upgrade to the VetStat database, improved biosecurity, continued surveillance and monitoring 
for antimicrobial resistance, and the creation of an expert council on veterinary medicines.
As one of its remits, the council will support the Danish Veterinary and Food Administration in decisions regarding the regula-
tion of antimicrobial use. The council will consist of 9 members from both veterinary and human health sector, since the use 
of antimicrobials in production animals and the emergence of antimicrobial resistance needs to be addressed in a One Health 
perspective. 
Pia Jul 
For further information: Pia Jul, Piaju@fvst.dk
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Textbox 4.2
Effects of the differentiated Yellow Card initiative from 2016 
The Yellow Card initiative was introduced in 2010 to reduce the use of antimicrobials in pig production in Denmark. By targe-
ting the farms with highest consumption of antimicrobials, the Yellow Card initiative works as an incentive for pig producers to 
contribute towards the goal of reducing the overall use of antimicrobials (see DANMAP 2010).
In 2016, the Danish Veterinary and Food Administration (DVFA) further developed the Yellow Card by including a multiplica-
tion factors to adjust the amount used of some of the antimicrobial agents. The multiplication factors were determined by the 
DVFA and are used as risk mitigation tools for each class of antimicrobials. 
Fluoroquinolones and cephalosporins are classified as critically important in treatment of humans and have been allocated 
the highest multiplication factor of ten. Fluoroquinolones are also under further restrictions by Danish law and the Danish pig 
industry has since 2010 voluntarily phased out the use of 3rd and 4th generation cephalosporins. 
At first tetracyclines were allocated the multiplication factor of 1.2. This reduced the use of tetracyclines in the following months. In 
January 2017, the factor for tetracyclines was increased to 1.5 to promote a further reduction and the use continued to decline. 
In 2016, the European Medicines Agency (EMA) recommended that colistin should only be used as a second line treatment in 
animals. Although Denmark was well below the threshold suggested by EMA, the Danish government increased the multiplication 
factor for colistin from one to ten as a precautionary measure. The use of colistin for pigs has consequently dropped to almost zero.
The differentiated Yellow Card has proven to be an efficient tool to promote prudent overall antimicrobial use in pig herds and 
to discourage use of certain critically important antimicrobials.
Pia Jul 
For further information: Pia Jul, Piaju@fvst.dk
Figure 1 Use of selected antimicrobial agents in pigs per month (from april 2016), Denmark 
DANMAP 2017
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5. Antimicrobial consumption in humans
    Highlights: In 2017, the total consumption of antimicrobials in humans was 17.55 defined 
daily doses per 1000 inhabitants per day (DID), lower than the consumption in 2016 (18.45 
DID) and a decade ago in 2008 (18.09 DID). Overall, the consumption of antimicrobials 
increased from its first registrations in the DANMAP report 1996 (13.60 DID) until 2011 
(19.80 DID) and has since levelled off. 
  Penicillins: In 2017, penicillins remained the most frequently consumed antimicrobial 
agents in both primary health care (67%) and hospital care (53%), but within the past de-
cade marked changes within the group of penicillins were observed. Thus, the consumption 
of beta-lactamase penicillins in primary health care decreased with 27% from 5.31 DID in 
2008 to 3.88 DID in 2017. In 2017, they accounted for 25 % of the total and 38% of all the 
penicillins consumed. Simultaneously, the consumption of the three other groups of penicil-
lins increased markedly; in 2017, beta-lactamase resistant penicillins accounted for 1.56 DID 
(9.8%), penicillins with extended spectrum for 3.67 DID (24%) and combination penicillins 
for 1.18 DID (7.7%) of the total in primary health care, respectively. At hospitals, the com-
bination penicillins and penicillins with extended spectrum were the biggest antimicrobial 
drug groups consumed in 2017 (16% and 19%, respectively). 
  Antimicrobials of critical interest: In Denmark, fluoroquinolones, cephalosporins and car-
bapenems are defined as antimicrobials of critical interest, cephalosporins and carbapenems 
being used solely at hospitals. In 2017, the consumption of the three drug classes consti-
tuted altogether 23% of the consumption at hospitals, a slight increase from 22% observed 
the year before, but a decrease from 31% in 2008. The increase in 2017 was observed for 
all five regions of Denmark and was mainly driven by a slighter increase in the use of car-
bapenems from 4.06 DBD to 4.26 DBD (6.0%) and a more marked increase of cephalosporins 
from 10.58 DBD to 12.49 DBD (18 %). These increases are probably linked to a longlasting 
shortage of piperacillin with tazobactam, where the consumption fell from 9.32 DBD to 7.75 
DBD (- 17%). 
  Fluoroquinolones continued the decreasing trend observed since 2010, but with more pro-
nounced decreases for the past two years. In 2016, fluoroquinolones accounted for a con-
sumption of 8.37 DBD, corresponding to 8.2% of the total consumption at hospitals, in 2017 
this had decreased to 8.06 DBD, corresponding to 7.3% of the consumption at hospitals. In 
primary care, fluoroquinolones constituted with 0.44 DID 2.9% of the total consumption. 
  In 2017, the total antimicrobial consumption at hospitals was measured at 110.28 DBD and 
323.53 defined daily doses per 100 admissions (DAD), respectively, a rise from 104.21 DBD 
and 310.68 DAD the previous year. From 2008 to 2017, the total consumption at hospitals 
increased with 43% and 2.8%, when measured in DBD and DAD, respectively.
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5.1 Introduction
In Denmark, all consumption of human medicine including 
antimicrobials is recorded through the Register of Medicinal 
Product Statistics at the Danish Health Data Authority. The pri-
mary sector has submitted antimicrobial sales data since 1994, 
whereas the hospital sector has submitted data since 1997. 
Recording of the consumption in the primary sector covers 
all antimicrobials on prescription from general practitioners, 
medical specialists and dentists as well as prescriptions written 
to patients at hospitals upon discharge. No over-the-counter 
sale takes place, all sale is through pharmacies and based on 
prescription only. This enables an almost complete surveillance 
of all systemic antimicrobials used in Denmark. For the hospital 
sector, only data from public somatic hospitals is included – 
data from psychiatric hospitals, private hospitals, hospices and 
rehabilitation centers were omitted since they contribute with 
only a low consumption of antimicrobials (2.1% in 2017), and in 
many ways differ from the patient population at public somatic 
hospitals. For more detailed information on data reporting and 
registration, please see chapter 9, materials and methods.
In this chapter, the term ‘antimicrobial agents’ covers all sys-
temic antibacterial agents for human use listed in the Anatom-
ical Therapeutic Chemical (ATC) Classification under the code 
J01. The only other antimicrobials included are metronidazole 
(ATC code P01AB01) and vancomycin (ATC code A07AA09), 
since these constitute important systemic antibacterial 
treatments as well. Their consumption has been included in 
DANMAP since 2014. Tuberculostatica, antiviral and antifungal 
drugs are not included, but textbox 5.2 deals with the con-
sumption of antifungal compounds and resistance patterns of 
human invasive isolates of Candida and Aspergillus.
In DANMAP 2017, all numbers in the figures and tables were 
updated 10 years retrospectively, to correct for possible 
changes that may have happened in the data registers after 
data extraction for the report. Thus, minor changes may exist 
between the present and former reports. 
Further information and further numbers on the use of antimi-
crobials in Denmark can be found at www.medstat.dk and  
http://esundhed.dk/sundhedsregistre/LSR/ANT/Sider/ANT.aspx.
The Danish healthcare system has undergone big changes 
since the DANMAP collaboration began in 1995. Most notably 
are the establishment of a more centralized hospital system, 
building on gathering highly specialized functions and skills 
in few tertiary care hospitals, paralleled by a reduction in the 
number of secondary care hospitals. Thus during the last two 
decades the number of hospitals in Denmark offering 24 hour 
acute care has diminished from 80 public somatic hospitals 
in 1995 to 43 in 2004. For 2020, it is expected that all acut 
care function can be merged to 21 public hospitals. A new 
political plan for the Danish Health system from 2018 and 
onwards is focusing on enforcement of the primary sector by 
moving a substantial part of the ambulatory care and reha-
bilitation from the hospitals back to the municipalities. This 
demands a restructuring and the strengthening of collabora-
tion between all sectors.
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Figure 5.1 Total consumption of systemic antimicrobial agents in humans in primary health care vs. hospital care, (DID), Denmark 
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5.2 Total consumption (Primary Health Care and 
Hospital Care Sectors)
In 2017, the total consumption of antimicrobials in Denmark 
was 17.55 defined daily doses per 1000 inhabitants per day 
(DID), which is 4.8% less than the consumption in 2016 (18.45 
DID) and 3.0% less than the consumption a decade ago in 
2008 (18.09 DID), (Figure 5.1). The total consumption in 2017 
corresponds to 50,925 kg active compound consumed (Table 
A5.2.1 in web annex).
Overall, the consumption of antimicrobials showed no sig-
nificant trends during the first five years of registration from 
1996 (13.40 DID) until 2000 (13.63 DID), but increased 
steadily and markedly until 2011 (19.80 DID) and has since 
decreased slightly but continuously. The recent decreases are 
solely due to decreases in consumption in the primary health 
sector, which accounts for approximately 90% of the total 
consumption and thus has a significant impact on the overall 
consumption patterns (Figure 5.1). 
According to the annual reports from the European Center for 
Disease Control (ECDC) the European average in antimicrobial con-
sumption in 2016 was approximately 22 DID; for the other Nordic 
countries (Iceland, Finland, Norway and Sweden) the average in 
2016 was 16.19 DID, which is comparably close to the Danish 
average. Denmark has, together with Sweden the highest propor-
tion of beta-lactamase sensitive penicillins consumed compared to 
the total antimicrobial consumption (> 25%). Regarding the con-
sumption of combination penicillins, the Nordic countries are less 
similar, reflecting that in spite of comparable health care systems 
and a tradition of a generally restrictive use of antimicrobials, the 
Nordic countries probably still differ in recommendations on the 
use of specified antimicrobial drug classes. [https://ecdc.europa.
eu/en/antimicrobial-consumption/database/quality-indicators]. 
5.3 Primary Health Care
5.3.1 Total consumption in Primary Health Care in DID
In 2017, the total consumption of antimicrobials in primary 
care was 15.42 DID, a decline of 6.0% from 2016 (16.41 DID). 
This is the first significant annual decline since 2012 (Table 
5.1). Since 1998, the consumption has increased 17% from 
13.09 DID , (Figure 5.1).
Beta-lactamase sensitive penicillins continued to be the big-
gest group consumed with 3.88 DID (accounting for 25% of 
the total consumption in primary care). They were followed 
closely by penicillins with extended spectrum with a consump-
tion of 3.67 DID (corresponding to 24% of the total consump-
tion). Macrolides remained the third biggest group consumed 
with 1.62 DID (accounting for 11% of the total consumption).
In total, the group of penicillins accounted for 10.30 DID, 67% 
of the total antimicrobials consumed. A decade ago in 2008, 
they accounted for 9.98 DID, 62% of the total antimicrobials 
consumed that year.
A distribution of the different antimicrobial classes between prima-
ry care and hospital care is shown in Figure A5.2.1 in web annex.
ATC group(a) Therapeutic group
Year
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
J01AA                        Tetracyclines               1.55 1.62 1.70 1.74 1.76 1.96 1.66 1.61 1.61 1.42
J01CA               Penicillins with extended spectrum 3.28 3.31 3.48 3.57 3.40 3.48 3.53 3.61 3.62 3.67
J01CE                        Beta-lactamase sensitive penicillins     5.31 5.13 5.26 5.29 4.67 4.65 4.39 4.33 4.15 3.88
J01CF                        Beta-lactamase resistant penicillins     1.13 1.14 1.17 1.22 1.20 1.30 1.36 1.38 1.47 1.56
J01CR                        
Combinations of penicillins, including beta-
lactamase inhibitors   
0.27 0.45 0.68 0.89 1.04 1.22 1.30 1.42 1.42 1.18
J01D                        Cephalosporins and other β-lactam antibiotics        0.04 0.04 0.04 0.03 0.03 0.03 0.03 0.03 0.03 0.03
J01EA                        Trimethoprim and derivatives   0.49 0.48 0.51 0.5 0.52 0.53 0.55 0.56 0.56 0.56
J01EB                        Short-acting sulfonamides       0.28 0.27 0.26 0.24 0.22 0.22 0.21 0.18 0.16 0.15
J01EE                        
Combinations of sulfonamides and trimethoprim, 
including derivatives
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
J01FA                        Macrolides                  2.29 2.21 2.44 2.6 2.19 1.94 1.79 1.77 1.82 1.62
J01FF                        Lincosamides                0.03 0.03 0.04 0.04 0.04 0.05 0.05 0.05 0.06 0.06
J01GB Aminoglycosides 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01
J01MA                        Fluoroquinolones            0.52 0.52 0.57 0.57 0.55 0.52 0.5 0.49 0.48 0.44
J01XC                        Steroid antibacterials (combination fusidic acid)     0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
J01XE Nitrofuran derivatives (nitrofurantoin) 0.47 0.49 0.51 0.5 0.49 0.49 0.48 0.45 0.43 0.26
J01XX                       Other antibacterials (methenamine >99%)                0.27 0.26 0.27 0.26 0.25 0.24 0.24 0.25 0.27 0.28
J01XD and P01AB* Nitroimidazole derivatives (metronidazole) 0.24 0.26 0.27 0.28 0.28 0.28 0.28 0.28 0.28 0.25
J01+P01AB Antibacterial agents for systemic use (total) 16.21 16.26 17.25 17.80 16.71 16.95 16.41 16.46 16.41 15.42
Table 5.1 Consumption of antimicrobial agents for systemic use in primary health care (DDD/1000 inhabitant-days), Denmark 
 DANMAP 2017
a) From the 2018 edition of the Anatomical Therapeutic Chemical (ATC) classification system 
*) all metronidazole preparations, formerly only listed as J01XD, 10 years retrospective data included in the DANMAP report since 2014
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5.3.2 Trends in consumption of the leading 
antimicrobials in DID  
Penicillins. In Denmark, penicillins are the only beta-lactams 
used in primary care; other beta-lactams such as cephalosporins, 
monobactams and carbapenems are solely used in hospital 
care and primarily at somatic hospitals with surgical or acute 
care functions. Although the total consumption of penicillins 
has changed only slightly over the years, considerable changes 
have been observed within the group of penicillins during the 
past decade. Since 2008, the consumption of beta-lactamase 
sensitive penicillins has decreased almost continuously with 27%, 
paralleled by a 29% decrease of macrolides (from 5.31 DID to 3.88 
DID and from 2.29 DID to 1.62 DID, respectively), (Figure 5.2a, 
5.2b and Table 5.1). For both drug classes, this is probably the 
result of a more restrictive use of antimicrobials in primary care in 
general, since the decrease in DID is followed by an overall decline 
in the number of treated patients and the number of redeemed 
antimicrobial prescriptions (Table 5.2 and 5.3). In Denmark, these 
two antimicrobial classes are the main drugs used for treatment 
of upper airway infections. Recommendations regarding overuse 
of antibiotics in general will thus have the biggest impact on beta-
lactamase sensitive penicillins and macrolides. 
For the same period from 2008 to 2017, continuous increases 
in the consumption of the three other penicillin groups’ were ob-
served: Penicillins with extended spectrum increased with 12%, 
the beta-lactamase resistant penicillins with 38% and the combi-
nation penicillins including beta-lactamase inhibitors with > 300% 
(Figure 5.2a and 5.2b). Thus, while the beta-lactamase sensitive 
penicillins constituted 53% of the group of penicillins consumed 
in 2008, in 2017 they constituted only 38%, (not shown).
The proportion of the main atnimicrobials used in primary 
healthcare is shown in Figure 5.3. The most remarkable 
change for the year 2017 was the marked decline in the con-
sumption of combination penicillins including beta-lactamase 
inhibitors (represented solely by amoxicillin with clavulanic 
acid), which after years of steady increase (from 0.27 DID in 
2008 to 1.42 DID in 2015 and 2016) suddenly decreased 
to 1.18 DID in 2017, (Figure 5.2a and Table 5.1). As for the 
beta-lactamase sensitive penicillins and macrolides these 
changes are probably related to initiatives on a more prudent 
use, as they also were followed by a reduced number of pa-
tients treated and reduced number of prescriptions redeemed 
(Table 5.2 and 5.3). The combination penicillins are a popular 
choice in the treatment of upper respiratory tract infections 
- but their main use is in the treatment of patients suffering 
from COLD and severe bronchitis or pneumonia. For these a 
clear decrease in the number of prescriptions was noted.
The increases described for the penicillins with extended spec-
trum from 3.28 DID in 2008 to 3.67 DID in 2017 are primarily 
due to increases in the consumption of pivmecillinam, account-
ing for about two thirds of this drug class (Table 5.1 and Figure 
5.4). While pivmecillinam increased with 1.2% from 2016 to 
2017 and with 70% since 2008, pivampicillin decreased with 
9.1% from 2016 to 2017 and with 63% from 2008 to 2017. 
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Figure 5.2b Changes in the consumption (DID) by leading groups of antimicrobial agents (J01) in the primary  
sector, 2008-2017, Denmark
 DANMAP 2017
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Amoxicillin increased with 3.7% from 2016 to 2017, but has 
decreased from 2008 to 2017 with 27%. In 2017, pivmecil-
linam accounted for 2.49 DID, amoxicillin for 0.95 DID and 
pivampicillin for 0.18 DID. 
The increased consumption of beta-lactamase resistant penicil-
lins from 1.13 DID in 2008 to 1.56 DID in 2017 is paralleled by 
an increased consumption at hospitals as well and follows the 
increased occurrence of staphylococcal infections observed in 
recent years (see section 8.7).
Tetracyclines are the fifth biggest group of antimicrobials 
consumed in Denmark. In 2017, they accounted for 1.42 DID, 
corresponding to 9.2% of the total consumption in primary 
health care. During the last decade, the consumption has de-
creased by 8.2% from 1.55 DID in 2008. In 2013, the consump-
tion peaked unexpectedly at 1.96 DID but has since shown 
continuing decreases. Tetracyclines are used by all age groups 
above 12 years and by both genders, (Figures 5.6a and 5.7a).  
Fluoroquinolones represent the smallest drug class among the 
leading antimicrobials. In 2017, they accounted for 0.44 DID, cor-
responding to 2.9% of the total consumption in primary care. From 
2008 (0.52 DID) until 2010 and 2011 (peaking at 0.57 DID) the 
consumption of fluoroquinolones followed the general increasing 
trends in the total consumption and has since been decreasing, 
resulting in an overall decrease of 15% from 2008 to 2017, (Figure 
5.2a and Figure 5.3). In Denmark, fluoroquinolones are designated 
as “antimicrobials of special, critical interest” by the National Health 
Authority and they are mentioned in the national recommendations 
on use of antibiotics issued in 2012. According to these, fluoroqui-
nolones are to be solely used for treatment of very few specific 
infections, where they are considered the drug of choice (e.g. 
exacerbation in a patient with chronic obstructive lung disease and 
known penicillin allergy). They are also recommended in the case of 
infection with multidrug resistant bacteria, where microbiological re-
sults point towards a fluoroquinolone to be the best or only choice.
5.3.3 Measures at user level
In this and the following sections, the consumption of antibiot-
ics is described at user level in either the number of prescrip-
tions per 1000 inhabitants or the number of treated patients 
per 1000 inhabitants. The measures are thus based on 
information available through the sales to an individual and do 
not include the amount of antibiotics, mainly penicillins, sold to 
clinics, dentists and doctors on call. 
In 2017, the total number of prescriptions was 489.49 per 1000 
inhabitants, a 6.3% reduction from the 522.19 prescriptions per 
1000 inhabitants in 2016 and a 19% reduction compared to the 
606.26 prescriptions per 1000 inhabitants in 2008 (Table 5.2). 
In 2017, the average number of prescriptions redeemed per 
patient was 1.92, (not shown). In 2008, the number was 1.95. 
The number of treated patients in 2017 was 255.40 per 1000 
inhabitants, a decrease of 18% compared to the 311 treated 
patients per 1000 inhabitants in 2008, (Table 5.3). 
Trends in the number of prescriptions and treated patients for 
the different antimicrobial classes followed mainly the trends 
already described for the consumed DIDs. Most pronounced 
for the ten year period were the decreases in the number of 
prescriptions per 1000 inhabitants for beta-lactamase sensitive 
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penicillins (-31%), sulphonamides (-30%), macrolides (-35%), tet-
racyclines (-24%) and penicillins with extended spectrum (-5.1%). 
Similar decreases were noted for the decade when measured in 
the number of patients treated with beta-lactamase sensitive 
penicillins (-28%), sulphonamides (-35%) and macrolides (-31%). 
Also for penicillins with extended spectrum and for tetracyclines, 
decreases were observed, (-9.0% and -19%, respectively).
Fluoroquinolones decreased with 21% in both the number of 
prescriptions per 1000 inhabitants and the number of treated 
patients. A comparison of the different indicators of consump-
tion is presented in Figure 5.5. 
In 2017, the average DDD/prescription remained with 11.08 
at the same level as in 2016 (11.09), an increase of 18% com-
pared to the 9.42 DDD/prescription in 2008 (Figure 5.5).
5.3.4 Consumption of antimicrobials in children
The total consumption in children of all age groups continued 
the decreases observed for the past decade, regardless of the 
indicator used (Figures 5.6a and 5.6b). In 2017, altogether 7.35 
DID were consumed by children and young from 0 to 19 years, 
corresponding to 202.84 treated patients per 1000 inhabitants 
(children) and 325.73 prescriptions issued per 1000 inhabitants 
(not shown).
Table 5.2 Number of prescriptions per 1000 inhabitants for leading antimicrobial agents in primary health care, Denmark DANMAP 2017
ATC group(a) Therapeutic group
Year
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
J01AA                        Tetracyclines               20.92 21.62 22.49 22.7 22.55 22.89 20.01 17.90 17.18 15.87
J01CA               Penicillins with extended spectrum 120.31 119.28 127.23 125.17 115.89 114.28 113.85 113.54 113.16 114.24
J01CE                        Beta-lactamase sensitive penicillins     216.09 205.85 212.19 213.32 186.88 180.51 170.73 163.11 157.13 148.34
J01CF                        Beta-lactamase resistant penicillins     42.22 42.1 42.32 42.75 40.41 41.24 41.04 40.82 41.87 41.82
J01CR                        
Combinations of penicillins, including beta-
lactamase inhibitors  
7.05 11.15 16.53 21.11 24.71 28.01 29.02 30.73 31.13 27.06
J01E                       Sulphonamides and trimethoprim 48.89 47.17 47.35 45.05 43.85 43.53 41.52 38.39 36.41 34.25
J01FA                        Macrolides                 91.47 87.24 97.34 104.22 85.87 74.50 68.02 68.01 68.85 59.93
J01MA                        Fluoroquinolones           22.07 21.71 23.69 23.15 22.14 20.64 19.67 19.51 18.74 17.34
J01X                       Other antibacterials (methenamine >99%)  17.34 17.93 17.49 18.24 18.03 17.41 16.73 16.28 15.82 10.17
P01AB Nitroimidazole derivatives (metronidazole) 18.00 19.02 19.67 19.69 19.67 19.26 19.06 19.16 18.63 17.23
J01 (incl. P01) Antibacterial agents for systemic use (total) 606.26 595.28 628.78 638.08 582.69 565.16 542.59 530.63 522.19 489.49
a) From the 2018 edition of the Anatomical Therapeutic Chemical (ATC) classification system
Numbers used in this table is based on registred sales to individuals
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It is important to note that measuring the consumption in chil-
dren in Defined Daily Doses is problematic, since the system of 
Defined Dailys Doses was developed based on the “maintenance 
dose per day for its main indication in adults” (https://www.
whocc.no/ddd/definition_and_general_considera/). For children, 
different pharmacodynamics and –kinetics apply and especially 
dosing in the younger classes is based on doses per bodyweight 
in kg. Still, assuming that dosage regimens did not vary con-
siderably within the last decade, it is possible to compare the 
consumption in each age group with itself over time. Thus, the 
consumption of DIDs in the different age groups show a clear 
tendency to reductions for especially penicillins and macrolides, 
a trend that can also be observed in the number of prescriptions 
on these drugs issued to children, (Figure 5.6a and b).
From 2008 to 2017, the total DIDs consumed in 0 to 4 year olds 
decreased with 33%, in 5 to 9 year olds with 14%, in 10 to 14 year 
olds with 13% and in the young adults (15-19 year olds) with 15%. 
The corresponding number of prescriptions redeemed for all young 
age groups in total (0 to 19 year olds) decreased from 478.89 
to 325.73 prescriptions per 1000 inhabitants (-32%) and from 
276.43 to 202.84 treated patients per 1000 inhabitants (-27%) 
for the decade, respectively. Differences in reduction varied from a 
decrease of 39% in the number of prescriptions for the youngest 
(0 - 4 years old) to -24% for the oldest, (15 to 19 year olds). When 
measured in the number of treated patients, the decreases varied 
from - 30% in the youngest to -20% in the adolescents. 
In the youngest age group of 0 to 4 year olds, the boys 
received on average 12% more prescriptions than the girls – a 
trend that has been quite stable. Thus in 2008, they received 
883.81 versus 778.17 prescriptions per 1000 inhabitants 
(children) and in 2017, 535.89 versus 476.69 prescriptions 
per 1000 inhabitants, respectively (not shown). For the 5 to 
19 year olds, opposite trends with girls receiving 18% more 
prescriptions on average were observed. 
In general, children are more often treated with antibiotics com-
pared to other age groups, since they are more prone to infections. 
Many of these will be viral or quickly passing bacterial infections 
that do not demand antibiotic treatment. Also, antibiotic treatment 
in the young may have pronounced and prolonged effects not only 
on the existing but also on the development of the normal flora 
of their mucosa. Finally, working with young – and their parents 
– on their perception of infections and the need for treatment 
is assumed to have a beneficial effect on the consumption of 
antibiotics in the future. Thus, paving the ground for a rational use 
of antimicrobials in the young may be of great interest to both the 
individual and the community as a whole, which makes it a core 
focus in antibiotic campaigns in Denmark and a central element in 
the National Action Plan on the reduction of antibiotics from 2017. 
As for the general population, penicillins are the main antibiot-
ics used in the treatment of bacterial infections in children. 
Beta-lactamase sensitive penicillins account for approximately 
25-30% of the consumption. Penicillins with extended spec-
trum, primarily amoxicillin take the lead in the treatment of 
upper respiratory infections in small children (age 0 to 4 years). 
The decreases observed in the consumption of amoxicillin 
when measured in DID are mirrored in a reduced number of 
children treated with the drug (Figure 5.6a and 5.6b). 
Macrolides play an important role in the treatment of infections in 
children and the young. They are the drug of choice for respira-
tory tract infections with Mycoplasma pneumoniae, and in young 
school aged children the consumption of macrolides will often 
mirror Mycoplasma epidemics. No epidemic occurred in the winter 
of 2016 or 2017. Macrolides are also used in the adolescents for 
the treatment of sexually acquired infections, e.g. Chlamydia. This 
is probably the reason for the relatively high consumption of mac-
rolides in the 15 to 19 year olds (64.79 prescriptions per 1000 
inhabitants per year compared to 17.85 prescriptions for the 10 
to 14 year olds, 21.19 prescriptions for the 5-9 year olds and 
Table 5.3 Number of treated patients per 1000 inhabitants for leading antimicrobial  
agents in primary health care, Denmark   DANMAP 2017
ATC group(a) Therapeutic group
Year
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
J01AA                        Tetracyclines               12.73 13.02 13.44 13.66 13.53 13.85 12.2 11.32 11.04 10.33
J01CA               Penicillins with extended spectrum 81.27 81.07 85.04 84.19 77.29 76.09 75.32 74.87 74.05 73.95
J01CE                        Beta-lactamase sensitive penicillins     164.38 158.72 162.81 164.34 145.5 142.16 134.79 130.06 125.69 119.17
J01CF                        Beta-lactamase resistant penicillins     29.89 29.87 30.02 30.34 28.5 29.07 29.24 28.85 29.70 29.92
J01CR                        
Combinations of penicillins, including 
beta-lactamase inhibitors   
4.95 8.02 11.7 14.95 17.31 19.71 20.52 22.03 22.17 19.87
J01E                       Sulphonamides and trimethoprim 30.49 29.51 29.31 27.63 26.47 26.15 24.65 22.45 21.17 19.85
J01FA                        Macrolides                  66.84 64.44 72.67 78.75 64.72 56.15 51.38 51.75 53.21 45.95
J01MA                        Fluoroquinolones            17.05 16.87 18.45 18.10 17.24 16.04 15.30 15.04 14.37 13.35
J01X                       Other antibacterials (methenamine >99%) 7.43 7.67 7.53 7.74 7.54 7.48 7.16 7.35 7.47 5.00
P01AB01 Nitroimidazole derivatives (metronidazole) 16.28 16.28 16.73 16.9 16.86 16.51 16.31 16.47 16.03 14.82
J01 (incl. 
P01AB01)
Number of treated patients in total 311.37 306.41 318.69 324.91 296.32 289.47 278.62 273.49 269.72 255.40
a) From the 2018 edition of the Anatomical Therapeutic Chemical (ATC) classification system 
Numbers used in this table is based on registred sales to individuals
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38.93 prescriptions for the 0-4 year olds for 2017, not shown). 
After an overall increase in the number of prescriptions on 
macrolides issued to children and adolescents from 2008 (60.64 
prescriptions per 1000 inhabitants) to 2011 (73.47 prescriptions 
per 1000 inhabitants), the number of prescriptions has since 
decreased to 35.97 prescriptions per 1000 inhabitants in 2017. 
Decreases were noted for all, but were most obvious in the 15 
to 19 year olds (from 111.19 prescriptions per 1000 inhabitants 
in 2008, corresponding to a decrease of 42%). This decrease is 
encouraging and may be a result of educational campaigns from 
the Danish Health Authority on sexually transmitted infections.
Tetracyclines account for a considerable part of the consump-
tion of antimicrobials among adolescents due to the treatment 
of acne. Treatments last long (up to six months) and in addition 
may be repeated in a situation of relapse in patients, who may 
be suffering from the condition for years. Furthermore, within 
the same family/at the same family doctor, there may be the 
tendency to treat younger siblings if a treatment course in an 
elder brother or sister has been of success. Both genders are 
affected, but there exist clear differences in prescription habits 
between boys and girls. Thus, among girls the treatment periods 
are longer and extend into the young adults of 20 to 24 years, 
while boys primarily are treated in shorter periods at the age 
of 15 to 19 years. In 2008, 15 to 19 year old boys received 
69.99 prescriptions per 1000 inhabitants per year on average, 
whereas girls received 50.63, corresponding to 31.93 versus 
27.76 patients treated per 1000 inhabitants. In 2017, the num-
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Numbers used in this table is based on registred sales to individuals
ber of 15-19 year old boys receiving treatment had declined to 
25.52 treated patients (corresponding to 44.27 prescriptions) 
per 1000 inhabitants, while the number of 15 to 19 year old 
girls had increased to 30.86 treated patients (corresponding to 
51.10 prescriptions redeemed) per 1000 inhabitants. 
5.3.5 Consumption of antimicrobials according to gender
Differences between the genders regarding consumption of antimi-
crobials are well known. In general, women receive more treatment – 
a trend driven by a much higher consumption of antimicrobials used 
for the treatment of urinary tract infections. Thus, the consumption 
of sulphonamides, trimethoprim and nitrofurantoin is three times 
higher for women than for men. Moreover, the consumption of 
pivmecillinam in women doubles the consumption in men. Also for 
beta-lactamase sensitive penicillins and macrolides the differences 
in consumption, especially when measured in DID, are substantial. 
For tetracyclines, there are less significant differences in gender 
and for the consumption of fluoroquinolones, no differences have 
been observed through the years, (Figure 5.7a and 5.7b). 
From 2008 to 2017, the number of treated women per 1000 inhabit-
ants decreased from 360.20 to 301.75 (-16%) and the number of treat-
ed men per 1000 inhabitants from 261.64 to 208.60 (-20%). During 
the same period, the amount of DDD/prescription increased for women 
from 9.16 to 10.81 (18%), and for men from 9.83 to 11.50 (17%), (not 
shown). Altogether the consumption in women decreased from 18.43 
DID to 17.75 (-3.7%), and in men from 12.83 DID to 11.94 (- 6.9%). 
Drugs for the treatment of upper respiratory tract infections. 
For both women and men a decrease in the consumption of beta-
lactamase sensitive penicillins and macrolides was observed. For 
women the consumption decreased for the beta-lactamase sensi-
Table 5.4 Consumption of antimicrobial agents for systemic use in primary health care at regional level, Denmark DANMAP 2017
Region Indicator
Year
2012 2013 2014 2015 2016 2017
Capital Region DDD/1000 inhabitants/day 16.85 16.93 16.28 16.14 15.96 14.97
Prescriptions/1000 inhabitants 599.16 576.83 549.62 533.71 519.29 488.57
Region Zealand DDD/1000 inhabitants/day 16.72 16.89 16.51 16.90 17.19 16.23
Prescriptions/1000 inhabitants 618.59 601.42 579.82 575.42 574.97 539.01
Region of Southern Denmark DDD/1000 inhabitants/day 16.16 16.51 15.84 15.82 15.78 14.81
Prescriptions/1000 inhabitants 598.44 588.83 556.51 540.26 530.29 496.63
Central Denmark Region DDD/1000 inhabitants/day 15.31 15.48 15.13 15.18 15.12 14.11
Prescriptions/1000 inhabitants 531.91 512.72 499.96 494.41 487.31 457.81
North Denmark Region DDD/1000 inhabitants/day 15.23 15.42 15.13 15.16 15.34 14.19
Prescriptions/1000 inhabitants 557.63 541.29 525.41 510.30 509.18 472.23
Denmark (total) DDD/1000 inhabitants/day 16.17 16.36 15.87 15.89 15.87 14.86
Prescriptions/1000 inhabitants 582.69 565.16 542.59 530.63 522.20 489.49
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tive penicillins from 5.58 DID in 2008 to 4.03 DID in 2017 and for 
the macrolides from 2.63 DID in 2008 to 1.85 DID in 2017. For 
men the changes were from 4.53 DID to 3.38 DID and from 1.82 
DID to 1.28 DID, respectively, in the same decade, (Figure 5.7a).
Drugs for the treatment of urinary tract infection. From 2008 
to 2017 the consumption of pivmecillinam in women increased 
continuously, from 4.18 DID to 5.01 DID, while it remained more 
stable in men. Since urinary tract infection (UTI) is a common condi-
tion in many women and contributes significantly to the number of 
antimicrobial treatments, several Danish studies have investigated 
in better diagnostic tests.  Especially in elderly women, it can be 
difficult to distinguish unspecific symptoms from an actual urinary 
tract infection, not least due to transient asymptomatic bacteriuria. 
In 2016, the national antibiotic campaign focused on reducing 
the amount of antimicrobials consumed in the treatment of UTIs 
in women using two different approaches: one broadcasting an 
educating movie on the social media targeted young women, the 
other directed at health personnel at nursing homes dealing with 
confused or dement elderly women with unspecific signs of UTI. 
No significant decreases were observed for neither pivmecillinam 
nor the other three “urinary drugs” (nitrofurantoin, sulfamethizol or 
trimethoprim) for 2017, but a decreasing trend in the consumption 
of especially nitrofurantoin was noted, (Figure 5.7a).
Tetracyclines. As mentioned in section 5.3.4, the treatment of 
acne in adolescence is the main driver of consumption and con-
tributes considerably to the total consumption of tetracyclines 
with both DIDs and the number of redeemed prescriptions and 
patients treated as well. While the number of DIDs consumed 
did not change much in women (primarily used by girls from 
15 to 24 years) from 1.66 DID in 2008 to 1.67 DID in 2017, it 
decreased slightly in men (primarily used by boys from 15 to 
19 years) – from 1.41 DID in 2008 to 1.15 DID in 2017 (Figure 
5.7a). Increases in the occurrence of sexually transmitted infec-
tions and changes in the treatment recommendations for these 
may challenge the consumption of tetracyclines in the future.
5.3.6 Prescribing activity in primary health care
Although Denmark has a very homogenous population with 
relatively small geographic and socioeconomic variations, con-
siderable differences in the prescription habits among medical 
doctors are frequently observed. In 2017, the Central Denmark 
Region had the lowest prescribing activity, when compared to 
the other four, with 14.11 DID and 457.81 prescriptions per 
1000 inhabitants, (Table 5.4). The Region of Zealand had the 
highest prescribing activity with 16.23 DID and 539.01 prescrip-
tions per 1000 inhabitants. For all regions, significant decreases 
in the DIDs and number of prescriptions issued (on average 8.1% 
in DID and 16% in the number of prescriptions per 1000 inhabit-
ants) for the six years shown were observed, (Table 5.4). 
There may be several reasons to the differences in the number 
of prescriptions redeemed, e.g. the density of the population and 
number of general practitioners as well as the proportion of el-
derly or chronically ill in a given geographic area. Due to differing 
organization of general practitioners and clinical practices across 
the country comparison of prescribing habits based on the indi-
vidual clinical praxis is difficult. A clinical praxis can be based on 
a single physician working solo but can also be a collaboration of 
up to seven physicians sharing facilities and staff. In addition, due 
to the lack of general practitioners in some areas, several new 
models of “health houses” served by physicians and other health 
staff are being established these years. General practitioners can 
follow their own prescription habits through the website www.
ordiprax.dk, a closed IT system that collects all prescribed data 
and enables comparison with other practice on a regional level. 
Support of the general practitioners regarding their prescribing 
habits is in general provided through regional medicine consul-
tants, who also have access to Ordiprax on each clinic level, thus 
being able to monitor consumption and give individual advice. 
From 2018, the general practitioners in defined geographical 
areas are being joined in “quality clusters” for mutual support.  
In Figure 5.8, the number of prescriptions on municipality level is 
shown, spanning from 394 to 648 prescriptions per 1000 inhabit-
ants. In 2017, most municipalities lay within the range of 450 to 
570 prescriptions per 1000 inhabitants. From the 98 municipalities 
in Denmark, four were excluded from the figure due to very small 
populations (typically islands). At web annex more maps and tables 
describing the prescribing activities on municipality level are shown. 
As mentioned in the introduction, consumption in the primary 
sector includes prescriptions issued from hospital doctors upon dis-
charge of a patient. In the past decade, the number of prescriptions 
issued through hospital doctors increased notably, probably due 
to changes in hospital work flow with shortening of bed days and 
increasing activity in ambulatory care. In 2017, hospital doctors ac-
counted for 62.63 prescriptions per 1000 inhabitants (13% of the 
antimicrobials sold at pharmacies). In 2008, it was 38 prescriptions 
per 1000 inhabitants (corresponding to 6% of sales), (not shown). 
Figure 5.8 Number of primary health care prescriptions/1000 
inhabitants in Danish municipalities, 2017 DANMAP 2017
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Textbox 5.1
University of Copenhagen Research Centre for Control of Antibiotic 
Resistance (UC-CARE) – a multidisciplinary One Health approach.
Introduction: UC-Care is an initiative based on a One Health or One Medicine-concept grown from the increasing evidence 
indicating that antimicrobial resistance can be successfully combated only through intersectorial collaboration. UC-Care was 
established in 2013 as a four-year center of excellence at University of Copenhagen. 
Although we to some extent understand the molecular biology of antibiotic resistance and know some of the factors contrib-
uting to spread of resistant bacteria, still several questions remain unanswered. Meanwhile immediate solutions are limited by 
the lack of new antibiotics, the long and expensive development process necessary to bring new drug leads from discovery to 
market, and not least conflicting rationales commonly encountered in current antibiotic use.
Drug discovery and development alone is thus not sufficient to mitigate antibiotic resistance problems neither on the short nor on 
the long term. A holistic and multidisciplinary approach is urgently warranted to qualify antibacterial interventions and to preserve 
the clinical efficacy of antibiotics through infection control and rational antibiotic use in both human and veterinary medicine. 
By acknowledging the very complex nature of the problem, University of Copenhagen supported a multidisciplinary initia-
tive by 4.3 million € and thereby enabled a synergistic combination of a very broad array of topics, merging research within 
veterinary and medical sciences with life sciences, social sciences and humanities. As such, UC-Care was a unique and holistic 
initiative contributing with a truly novel approach alleviating some of the major negative effects from antibiotic resistance.
The beauty of breadth and depth: UC-Care initially counted researchers from a total of 14 Departments at the Health and Medical 
Sciences, Faculty of Sciences, Faculty of Social Sciences and Faculty of Humanities, respectively. The center focused on six major, 
vastly different, areas all considered critical for future advancement in the fight against antibiotic resistance: 1) Research on new 
drug principles to revert antibiotic resistance or to inhibit horizontal gene transfer. Investigations aiming at enhancing in vivo effi-
cacy of synthetic antimicrobial peptides and antisense peptide nucleic acids, both headed by Professor Fredrik Björkling. 2) Develop-
ment of new interventions to lower antibiotic use in animals including novel bacterial vaccine platforms headed by Professor Anders 
Miki Bojesen. 3) Optimized treatment regimens and formulations against biofilm-related infections and intracellular pathogens 
headed by Professor Niels Høiby. 4) Definition of evidence-based diagnostic protocols allowing rational antibiotic use headed by 
Professor Lars Bjerrum. 5) Sustainability assessment of intervention strategies in livestock production headed by Professor Jørgen 
Dejgård Jensen. 6) To understand how societal factors influence antibiotic use headed by Assoc. Professor Carsten Strøby Jensen.
Several additional senior scientists along with 21 PhD-students and 12 Postdocs were associated with the research centre. Most junior 
scientists had supervisors at different Departments or even Faculties to stimulate a more holistic approach to the research questions. 
Major outputs and future perspectives: UC-Care aimed at providing solutions – some on a short term, while others would 
not be achieved within the lifetime of the centre. Still, already some discoveries hold great promise and may turn into high 
impact interventions to the benefit of society in general. More than 120 peer-reviewed papers have been published within the 
centre as well as more than 250 mDKK have been generated in external funding by the projects principle investigators.
Revival of known antimicrobials: Amongst the most significant discoveries, we have developed and validated a high-
throughput screening assay designed to detect bacterial envelope-permeabilizing helper drugs. This new tool has been 
exploited to enhance antimicrobial drug penetration by significantly increasing cell envelope permeability, ultimately making 
bacteria susceptible to antibiotics to which they were intrinsically resistant.
Prevention by smart vaccines: Two novel vaccine platform technologies have been developed and demonstrated to induce 
serotype-independent immunity, a rather unique invention in the bacterial field where several vaccines currently are needed for en-
suring adequate protection. If one or few vaccines can provide a high level of protection without the need for antibiotics it will truly 
revolutionize vaccinology. Vaccine production has to happen at a very low cost, the sales price being decisive for their later applica-
tion and use, since pig and poultry productions are characterized by very low profit margins and antibiotics generally are cheap. 
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Improved diagnostics allow lowered use: Antibiotic treatment in relation to common diseases like urinary tract infections 
is a challenge, since large quantities of antibiotics are prescribed for humans, pets and some food producing animals, e.g. pigs. 
Analyzes of the results of a substantial number of cases covering each area confirm that prescription of antibiotics based only 
on symptoms (which by far is the most common practice) cause up to 40% overuse of antibiotics. This can be largely counter-
acted by increased use of available point-of-care diagnostics. 
Development of a new research field: Being truly interdisciplinary, UC-Care also focused on how antibiotic resistance affects 
societal areas besides the traditional fields, as human health and veterinary sciences. The research area looked at application 
of social scientific knowledge in ensuring the most effective or rational way of introducing important actions in the control of 
resistant bacteria, without simultaneously introducing stigma processes on defined populations. An example of investigation 
could be persons employed in the food producing industry, working at the interface between interests from the consumer and 
ethical questions. Raising pigs demands the use of antibiotics, no matter how rational the application is, thus contributing to 
the pressure from the use of antimicrobials. In Denmark, the production of pigs is also associated with an increased risk of being 
carrier of livestock associated MRSA (LA-MRSA), thereby posing a risk to the public due to possible transmission of LA-MRSA. A 
project thus focused on interrogating key professions, like veterinarians, pig farmers and farm workers on their perception on 
the situation, and investigate in their willingness but also resistance to supporting different measures of LA-MRSA control.  
This is an important, but not very developed research agenda that has appeared through the project activities. 
Common One-Health course for veterinary and medical students: As a direct outcome of the UC-Care activities, a common 
course for veterinary and medical students including a broad range of topics associated with antimicrobial resistance has now 
become a compulsory part of the curricula at University of Copenhagen. This means that more than 400 students will engage in 
the one health antibiotic resistance agenda on an annual basis. The course has been completed twice already and appears to be 
well received by the students and represent a good opportunity for teachers to meet.  
Inspiring multidisciplinarity and barriers to be broken: Although the intentions were good and the overall goal was quite 
clear, a considerable amount of energy still had to be diverted towards creating a fruitful research environment across fields 
with little or no tradition for collaboration. If not clear from the beginning, all participants in the UC-Care consortium soon 
realized that combatting antimicrobial resistance requires a highly heterogeneous approach at several levels to comprehend 
the complexity of the field. Performing research on a platform with a very high level of diversity, while aiming at placing most 
activities in perspective of each other, appeared to be an ambitious, yet very rewarding task. Clearly, most research fields are 
relatively narrow in their natural conformation so although most researchers had lots of experience from collaboration with 
people from different disciplines, it was rather challenging to combine basic research originating in life science with basic 
research rooted in humanities. Traditions in scientific approach and research communication differ substantially and from a 
practical point, this might give rise to difficulties at publishing common papers/books while maintaining a clear incentive for all 
involved. UC-Care remains as a non-mural center, yet no longer receives funding for the coordinating activities. This means that 
particularly fields like social science and humanities have difficulties at keeping up their engagement and ultimately will result 
in losses of some of the multidisciplinary input, we found so important. The challenges experienced at research level reflect 
very well what can be witnessed in the surrounding society. This underlines a high level of communication being crucial to 
ensure a good base for a mutual understanding required for any advancement.
UC-Care coordinator and Professor Anders Miki Bojesen, miki@sund.ku.dk 
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5.4 Hospital Care
5.4.1 Introduction
Antimicrobial consumption at hospitals is reported to DAN-
MAP once a year through the Register of Medicinal Product 
Statistics at the Danish Health Data Authority. Reporting is 
based on deliverances from the hospital pharmacies to the 
different clinical departments and includes all generic products 
that are supplied through general trade agreements between 
the hospital and different medical suppliers. In case of short-
ages in deliverance of specific products, the hospitals have to 
apply for special deliverances through the Danish Medicines 
Agency. These special deliverances are reported separately 
to DANMAP. For surveillance purposes, it has to be assumed 
that the amount of delivered antimicrobials is identical to 
the consumption at the different departments. But in reality, 
antimicrobials may be exchanged between different specialties 
and departments belonging to the same trust, which makes 
precise calculations of the consumption on specialty level dif-
ficult. In DANMAP, reporting of data on hospital consumption is 
therefore kept at a national or regional level. Data on hospital 
level can be supplied upon request.
Information on consumption at individual patient level is still 
lacking for the hospital sector. This information is expected 
to be available through the future national “Hospital Medicine 
Register”, which is currently being developed. 
DANMAP 2017 covers the total sales on systemic antimi-
crobials (all ATC code J01 as well as ATC code P01AB01 and 
A07AA09) reported from all Danish hospitals. Consumption at 
private hospitals and psychiatric departments is excluded, in 
2017 accounting for approximately 2.1% of the total hospital 
consumption. 
The consumption of antimicrobial agents in hospital care is 
presented as DDD per 100 occupied bed-days (DBD) and as 
DDD per 100 admissions (DAD) to account for hospital activity. 
Moreover, data are presented as DID to enable comparison 
with primary health care. 
As mentioned, during the past decade the hospitalization 
patterns in Denmark changed notably – the shortening of bed 
days at hospitals and the increasing ambulatory care function, 
including increased surgical activity, cause increased pressure 
on the health system at municipality level. There is thus an 
increased demand for “acute care beds” for patients dismissed 
from hospital, but not yet ready for continuing treatment at 
home. For these sector-crossing patients it is important to 
ensure continuation of antibiotic treatment, including the 
possibility to change from intravenous to per oral treatment. 
In 2017, fifty-three different antibiotics were used at Danish 
hospitals.  When divided into groups according to routes of ad-
ministration, 20 could be used parenterally and orally, 18 could 
be used only parenterally and 10 only orally. The remaining 
five antibiotics could be administered either rectal or through 
inhalation. For an overview of formulations available, please 
see Figure A5.4.3 at webannex.
The increasing number of invasive infections and infections at 
other sites also induces pressure into the system, increasing the 
demand for proper antibiotics (see section 8.0 introduction). Since 
selection pressure for the emergence of antimicrobial resistance 
increases with increasing hospital activity, the selection pressure 
has increased considerably from 2008 to 2017, see Figure A5.4.2. 
Table 5.5 presents data on regional hospital activity for 2017.
In 2017, the number of admissions at Danish hospitals was 
1,379,113, while the number of bed-days was 4,046,115 (data 
from the Danish National Patient Register, June 2018). The an-
nual proportion of occupied hospital beds was in 2017 between 
80 and 86%, but especially the Central Denmark Region and 
the Capital Region experienced longer periods with overcrowd-
ing of patients. Since 2008, the number of bed-days decreased 
with altogether 17%, while the number of admissions increased 
with 15%. When measured in bed-days and admissions per 
1000 inhabitants, the changes were -24% and + 10%, respec-
tively. During the decade, activity in ambulatory care incerased 
with 26%. On average, the number of bed-days decreased 
with 2.1% yearly, while the number of admissions on average 
increased with 1.6% per year, (Figure A5.4.2 in web annex). 
5.4.2 Somatic hospitals – DDD per 100 occupied  
bed days (DBD)
In 2017, the consumption of antimicrobial agents in somatic 
hospitals was 110.28 DBD, 5.3% higher than the 104.41 DBD 
in 2016 and 43% higher than the consumption measured a 
decade ago in 2008 (76.89 DBD). This is the highest consump-
tion measured this decade, (Table 5.6).
The four penicillin groups accounted for altogether 58.32 DBD, 
corresponding to 53% (Table 5.6, Figure 5.9). In 2017, penicil-
lins with extended spectrum constituted 20.39 DBD of the 
consumption in somatic hospital, a 14% increase from 2016 
(17.91 DBD), making it the biggest group consumed (19%). 
Combination penicillins constituted 17.17 DBD, decreas-
ing 7.8% from 2016, making them the second largest group 
Region No. bed-days  
somatic 
hospitals(a)
No. admis-
sions somatic 
hospitals(a)
The Capital Region of Denmark 1,477,131 485,597
The Sealand Region 598,676 234,083
Region of Southern Denmark 778,641 257,042
Central Denmark Region 814,234 289,816
North Denmark Region 377,433 112,575
Denmark(b) 4,046,115 1,379,113
Table 5.5 Activity in somatic hospitals, Denmark  DANMAP 2017
Source: The Danish Health Data Authority (www.sds.dk)
a) Excluding private hospitals, psychiatric hospitals, specialised clinics, 
rehabilitation centres and hospices
b) Compared to 2016 no. bed-days has decreased by 0.8% and no. 
admissions increased på 0.6%
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consumed in 2017 (16%). Beta-lactamase sensitive penicillins 
accounted for 11.32 DBD (10%) and beta-lactamase resistant 
penicillins for 9.44 DBD (9%).
Trends for the consumption of penicillins for the last decade 
were comparable to the trends observed for the primary sec-
tor. The combination penicillins increased steeply by 13.16 
DBD (328%), the penicillins with extended spectrum and beta-
lactamase resistant penicillins less markedly, but still continu-
ously with 6.07 DBD (42%) and 2.30 DBD (32%), respectively, 
(Figure 5.10 and 5.11).  
The consumption of beta-lactamase sensitive penicillins had 
shown continuous increases from 8.02 DBD in 1997 to its 
peak of 12.17 DBD in 2005. For the past decade it remained 
relatively stable oscillating between 9.14 and 10.36 DBD. 
The increase from 2016 to 2017 was the first marked change 
since 2005, increasing with 1.02 DBD, (Table 5.6). 
Notable trends for other antimicrobials for the past decade 
were increases observed for tetracyclines, for combinations of 
sulfonamides and trimethoprim and for macrolides. Although 
tetracyclines only account for a minor part of the antimicrobi-
als consumed at hospitals, the drug class has been continuous-
ly increasing during the past decade; in 2008 they accounted 
for 0.87 DBD, while in 2016 and 2017 the consumption had 
increased to 2.17 DBD. In 2017, the proportion of tigecyclin 
constituted close to zero of the tetracyclines consumed. Con-
sumption of combinations of sulfonamides and trimethoprim, 
(not shown). increased from 2.47 DBD in 2008 to 5.42 DBD in 
2017, a total increase of 119% for the decade. Finally, a rise in 
macrolides was observed from 3.15 DBD in 2008 to 6.02 DBD 
in 2017 (91%), (Table 5.6 and Figure 5.11). 
In 2017, the consumption of the groups of antimicrobials used 
as first line treatment for the leading infections at hospitals 
increased again, a trend following the described increasing 
ATC 
group(a)
Therapeutic group
Year
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
J01AA            Tetracyclines               0.87 1.12 1.10 1.17 1.64 1.55 1.74 1.88 2.17 2.17
J01CA            Penicillins with extended spectrum 14.32 14.89 14.01 13.97 15.24 15.37 16.48 17.19 17.91 20.39
J01CE            Beta-lactamase sensitive penicillins 10.32 9.63 9.14 10.01 10.34 10.34 10.36 10.14 10.30 11.32
J01CF            Beta-lactamase resistant penicillins 7.14 7.24 7.52 8.40 8.66 9.25 9.61 9.91 9.34 9.44
J01CR            
Combinations of penicillins. incl. 
beta-lactamase inhibitors   
4.01 5.30 6.63 8.67 11.89 13.92 16.11 17.99 18.61 17.17
J01DB                  First-generation cephalosporins 0.16 0.12 0.12 0.12 0.12 0.11 0.06 0.04 0.04 0.04
J01DC Second-generation cephalosporins 11.00 11.89 12.01 15.21 14.14 12.57 11.73 10.48 9.52 11.12
J01DD Third-generation cephalosporins 1.17 1.18 1.02 1.10 1.06 1.10 1.03 1.07 1.06 1.37
J01DF Monobactams 0.00 0.00 0.03 0.14 0.14 0.14 0.06 0.03 0.01 0.01
J01DH Carbapenems 2.05 2.19 2.44 3.55 3.80 4.10 2.82 4.15 4.02 4.26
J01EA            Trimethoprim and derivatives   0.53 0.51 0.39 0.35 0.39 0.41 0.52 0.46 0.43 0.48
J01EB            Short-acting sulfonamides       0.47 0.43 0.34 0.26 0.21 0.19 0.18 0.15 0.13 0.13
J01EE            
Combinations of sulfonamides and 
trimethoprim. incl. derivatives 
2.47 2.26 1.86 2.92 3.28 4.30 4.70 5.09 5.22 5.42
J01FA            Macrolides                  3.15 3.30 3.40 3.49 3.58 3.46 3.89 4.61 4.99 6.02
J01FF            Lincosamides                0.42 0.47 0.44 0.49 0.61 0.65 0.65 0.58 0.63 0.65
J01GB Aminoglycosides 1.71 1.52 1.63 1.90 2.13 2.18 1.62 1.70 2.01 2.32
J01MA            Fluoroquinolones            9.65 10.11 9.78 9.98 9.93 9.98 9.93 9.40 8.37 8.06
J01XA Glycopeptides 0.68 0.93 0.98 1.22 1.26 1.32 1.16 1.08 1.09 1.32
J01XB            Polymyxins                 0.05 0.07 0.09 0.08 0.09 0.17 0.27 0.26 0.30 0.29
J01XC            Steroid antibacterials (fusidic acid)     0.26 0.29 0.32 0.25 0.23 0.22 0.23 0.17 0.11 0.07
J01XD                 Imidazole derivatives 3.33 3.63 3.68 3.87 4.09 4.16 4.51 4.30 4.60 4.74
J01XE
Nitrofuran derivatives (nitrofuran-
toin)
0.34 0.38 0.33 0.35 0.38 0.39 0.37 0.33 0.29 0.30
J01XX05 Methenamine 0.13 0.10 0.09 0.12 0.10 0.09 0.07 0.10 0.09 0.08
J01XX08 Linezolid 0.21 0.20 0.20 0.29 0.31 0.36 0.34 0.44 0.37 0.37
J01XX09 Daptomycin 0.02 0.02 0.02 0.01 0.02 0.02 0.03 0.04 0.05 0.08
P01AB01
Nitroimidazole derivatives (metro-
nidazole)
2.35 2.56 2.53 2.50 2.42 2.33 2.05 2.08 2.26 2.12
A07AA09
Intestinal antiinfectives (vanco-
mycin)
0.10 0.18 0.26 0.41 0.48 0.50 0.52 0.48 0.49 0.53
J01, 
P01AB01, 
A07AA09
Antibacterial agents for systemic 
use, including metronidazole and 
vancomycin
76.89 80.52 80.39 90.84 96.53 99.20 101.05 104.12 104.41 110.28
Table 5.6 Consumption of antimicrobial agents for systemic use in somatic hospitals (DDD/100 occupied bed-days), Denmark DANMAP 2017
a) From the 2018 edition of the Anatomical Therapeutic Chemical (ATC) classification system
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trends for the number of invasive isolates, (Figure 5.10 and 
Figure 8.0.2). In 2017, the leading antimicrobials constituted 
82.08 DBD of the total consumption of 110.28 DBD (74%). In 
2016 it was 76.83 DBD of a total of 104.41 DBD (74%). 
5.4.3 Other measures of consumption at somatic hospitals 
– DDD per 100 admissions (DAD)
The consumption of antimicrobials at hospitals can also be 
measured in relation to hospital activity calculated in number of 
patients “passing through”, i.e. DDD per 100 admissions (DAD). 
In 2017, the total consumption was 323.53 DAD, a 4.0% increase 
from the 310.68 DAD in 2016 and 2.7% increase from 314.64 DAD 
in 2008. The highest peak observed through the past decade was 
that of 2017, (Table 5.7). The trends in DAD reflect for most antimi-
crobials the trends observed in DBD. Yet differences in the number 
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Figure 5.10 Total somatic hospital consumption (DBD) by leading groups of antimicrobial agents (J01),  
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Figure 5.9 Distribution of the total consumption of antimicrobial agents in somatic hospitals, Denmark DANMAP 2017
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of patients treated with the specific drug class and the use of the 
individual antimicrobials in the treatment of acutely or chronically 
ill patients may exist compared to hospital activity. The observed 
rates of increases were more marked, when measured in DBD than 
in DAD for all the antimicrobial classes, (Tables 5.6 and 5.7). 
At regional level, the hospital activity mirrors the density of 
the population, (Table 5.5). Trends in consumption showed 
similar, parallel increases for the past decade and are shown in 
DBD and DAD, respectively, (Figure 5.12).  
A comparison of the usage of antimicrobials of the different 
antimicrobial classes in animals and humans, respectively 
measured in kg. active substance is presented in Table A5.2.1 
in web annex. For comparison of consumption at hospitals with 
the consumption in the primary sector measured in DID go to 
Table 5.1 and Table A5.4.1 and  Figure A5.2.1 in web annex.
5.4.4 Changes in consumption of antimicrobials of critical 
interest
In 2017, the three groups of antimicrobials of critical interest in 
Denmark (cephalosporins, fluoroquinolones and carbapenems) 
constituted together 23% of the total consumption at hospi-
tals. In 2016, it was 22% and ten years ago, in 2008, it was 
31%, (not shown). Cephalosporins accounted with altogether 
12.54 DBD for 11% of the total consumption, a slight increase 
from the 10% in 2016. Second generation cephalosporins 
are the most used at hospitals and accounted for 11.12 DBD. 
Fluoroquinolones accounted for 8.06 DBD, a 3.7% reduction 
from 8.37 DBD in 2016 (Table 5.6). The consumption of fluo-
roquino- lones peaked in the years of 2009 to 2013 and has 
since shown slight declines. Carbapenems accounted in 2017 
for 4.26 DBD, a 6% increase from the 4.02 DBD in 2016, (Table 
5.6). A large decrease in the consumption of carbapenems was 
observed from 2013 to 2014 (4.10 to 2.82 DBD). 
Trends in the consumption of cephalosporins, fluoroquinolones 
and carbapenems are shown in Figure 5.10 and 5.11 and on 
regional level in Figure 5.13. From 2012 to 2016, The Region of 
Southern Denmark and The Capital Region of Denmark showed 
clear and continuing declines in the consumption, while the three 
other regions more or less maintained their levels. For all five re-
gions, increases in the consumption of the three critical important 
antimicrobials were observed from 2016 to 2017, (Figure 5.13). 
The consumption of the three critical antimicrobial groups will 
be monitored closely in the future due to several local, regional 
and national initiatives, probably the most important one being 
reductions aimed at by the “National Quality and Learning 
Teams”, an initiative spanning all Danish regions. These work 
on applying principles of antibiotic stewardship in many of 
the acute care hospitals, at emergency departments, and in 
medical departments with a relatively high number of acute 
patients. The regional initiatives are supported by the imple-
mentation of the third measurable goal in the National Action 
Plan on antibiotics from 2017, aiming at a 10% reduction in 
the consumption of cephalosporins, fluoroquinolones and 
carbapenems from 2016 to 2020. 
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Figure 5.11 Changes in the consumption (DBD) by leading groups of antimicrobial agents (J01) in the hospital sector,  
2008-2017, Denmark  DANMAP 2017
*Comb. of penicillins, incl. beta-lactamase inhibitors (J01CR) increased with more than 8.0 DBD (13.16 DBD)
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ATC 
group(a)
Therapeutic group
Year
2008(b) 2009 2010 2011 2012 2013 2014 2015 2016 2017
J01AA            Tetracyclines               3.55 4.21 3.88 3.95 5.35 4.98 5.39 5.70 6.47 6.36
J01CA            Penicillins with extended spectrum 58.60 55.90 49.40 47.31 49.7 49.41 51.15 52.28 53.28 59.82
J01CE            Beta-lactamase sensitive penicillins 42.22 36.17 32.24 33.91 33.74 33.24 32.17 30.83 30.65 33.22
J01CF            Beta-lactamase resistant penicillins 29.23 27.16 26.53 28.44 28.24 29.74 29.85 30.12 27.78 27.69
J01CR            
Comb. of penicillins. incl. beta-
lactamase inhibitors   
16.41 19.91 23.38 29.37 38.77 44.74 50.01 54.69 55.38 50.37
J01DB                  First-generation cephalosporins 0.64 0.47 0.44 0.40 0.40 0.37 0.20 0.14 0.13 0.13
J01DC Second-generation cephalosporins 45.00 44.65 42.37 51.50 46.11 40.40 36.43 31.85 28.32 32.64
J01DD Third-generation cephalosporins 4.77 4.44 3.61 3.72 3.45 3.55 3.19 3.25 3.16 4.03
J01DF Monobactams 0.01 0.00 0.12 0.49 0.47 0.46 0.20 0.08 0.03 0.02
J01DH Carbapenems 8.41 8.22 8.60 12.01 12.38 13.19 8.77 12.62 11.95 12.49
J01EA            Trimethoprim and derivatives   2.18 1.91 1.38 1.17 1.28 1.33 1.63 1.41 1.29 1.40
J01EB            Short-acting sulfonamides       1.94 1.61 1.21 0.88 0.70 0.62 0.55 0.47 0.38 0.38
J01EE            
Comb. of sulfonamides and trim-
ethoprim. incl. derivatives 
10.11 8.47 6.58 9.89 10.68 13.81 14.59 15.48 15.54 15.90
J01FA            Macrolides                  12.88 12.39 11.98 11.81 11.68 11.12 12.09 14.02 14.83 17.66
J01FF            Lincosamides                1.72 1.77 1.55 1.66 1.99 2.09 2.03 1.77 1.88 1.91
J01GB Aminoglycosides 6.98 5.70 5.73 6.43 6.96 6.99 5.03 5.16 5.98 6.81
J01MA            Fluoroquinolones            39.48 37.95 34.51 33.80 32.38 32.06 30.82 28.56 24.91 23.64
J01XA Glycopeptides 2.78 3.48 3.47 4.14 4.12 4.23 3.59 3.29 3.25 3.86
J01XB            Polymyxins                 0.21 0.25 0.32 0.28 0.30 0.54 0.85 0.78 0.88 0.86
J01XC            Steroid antibacterials (fusidic acid)     1.06 1.10 1.12 0.85 0.75 0.72 0.72 0.50 0.34 0.20
J01XD                 Imidazole derivatives 13.63 13.64 12.99 13.10 13.34 13.37 13.99 13.06 13.69 13.92
J01XE
Nitrofuran derivatives (nitrofuran-
toin)
1.38 1.42 1.18 1.20 1.22 1.26 1.14 0.99 0.85 0.87
J01XX05 Methenamine 0.53 0.36 0.30 0.39 0.34 0.30 0.23 0.30 0.28 0.25
J01XX08 Linezolid 0.84 0.76 0.72 0.99 1.01 1.14 1.06 1.33 1.09 1.09
J01XX09 Daptomycin 0.06 0.06 0.07 0.05 0.06 0.07 0.10 0.12 0.15 0.24
P01AB01
Nitroimidazole derivatives (metro-
nidazole)
9.61 9.62 8.92 8.45 7.88 7.49 6.36 6.31 6.73 6.23
A07AA09
Intestinal antiinfectives (vanco-
mycin)
0.42 0.66 0.91 1.39 1.55 1.60 1.62 1.44 1.46 1.55
J01, 
P01AB01, 
A07AA09
Antibacterial agents for systemic 
use, including metronidazole and 
vancomycin (total)
314.64 302.29 283.53 307.57 314.88 318.83 313.74 316.56 310.68 323.53
Table 5.7 Consumption of antimicrobial agents for systemic use in somatic hospitals (DDD/100 admitted patients), Denmark
 DANMAP 2017
a) From the 2018 edition of the Anatomical Therapeutic Chemical (ATC) classification system
b) The number of admissions was affectedly low in 2008 due to a major hospital strike
Additionally, extra attention will be paid to the consumption 
of cephalosporins next year. Due to shortages of piperacil-
lin with tazobactam in 2017, it may have been necessary to 
reintroduce cephalosporins in the treatment of acutely ill, 
septic patients at several hospitals. Thus, an increase of the 
overall consumption of cephalosporins was expected to occur 
and was observed, moving from 10.63 DBD in 2016 to 12.54 
DBD in 2017. Simultaneously a decrease in the consumption 
of piperacillin with tazobactam was observed (Figure 5.14). 
5.4.5 National initiatives on continued reductions of the 
antimicrobial consumption
The National Action Plan on the reduction of antibiotics in hu-
mans launched in July 2017 uses two measurable goals directed 
at the consumption trends in the primary care. The first goal 
aims at a continued general reduction in the number of pre-
scriptions issued in Denmark (from 462 prescriptions per 1000 
inhabitants among general practitioners, medical specialists and 
dentists in 2016 to 350 prescriptions per 1000 inhabitants in 
2020). The second goal focuses on the more prudent choice of 
antimicrobials emphasizing the importance of continued use 
of beta-lactamase sensitive penicillins as the drug of choice in 
many common infections, especially in respiratory infections. 
The mentioned third goal aiming at a reduced consumption of 
the three critical antimicrobials focuses on the prudent use of 
antibiotics at hospitals. The goal is challenged through short-
ages like the mentioned failure in deliverance of piperacillin/
tazobactam. It is woth considering how delivery of important 
small(er) spectrum antibiotics can be ensured also in the future.
The National Action Plan was issued by the Danish Health Ministry 
and supported by the National antibiotic council representing all 
relevant health institutions, organizations and specialties working 
with the prevention, control and treatment of infections in Denmark. 
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Together with the National Action Plan, a One Health Strategy was 
published, building on the National Action Plan on controlling the 
development of antimicrobial resistance from 2010. Both are avail-
able at the Danish Ministry of Health’s homepage at www.SUM.dk
Reducing the amount of antimicrobials consumed can only be 
achieved through parallel actions on the continued improve-
ment of diagnostics and through infection control measures. 
`Central Unit for Infectious Disease Prevention & Hygiene´ at 
Statens Serums Institut supports many of the National anti-
biotic initiatives through recommendation guidelines aimed 
at hospitals and health care settings. These are available at 
https://www.ssi.dk/Smitteberedskab/Infektionshygiejne/ 
Retningslinjer/NIR.aspx (only available in Danish).
Karoline Skjold Selle Pedersen and Ute Wolff Sönksen 
For further information: Ute Wolff Sönksen, uws@ssi.dk
0
20
40
60
80
100
120
140
2012 2013 2014 2015 2016 2017
D
D
D
/1
0
0
 b
ed
 d
ay
s
Capital Region of Denmark
Region Zealand
Region of Southern Denmark
Central Denmark Region
North Denmark Region
Denmark
0
50
100
150
200
250
300
350
400
2012 2013 2014 2015 2016 2017
D
D
D
/1
0
0
 a
dm
is
si
on
s
Capital Region of Denmark
Region Zealand
Region of Southern Denmark
Central Denmark Region
North Denmark Region
Denmark
Figure 5.12 Consumption of antimicrobials used at hospitals, regional levels, 2012-2017, Denmark  DANMAP 2017
DANMAP 201756
ANTIMICROBIAL CONSUMPTION IN HUMANS5.
10
15
20
25
30
35
40
2012 2013 2014 2015 2016 2017
D
D
D
/1
0
0
 b
ed
-d
ay
s
Capital Region of Denmark
Region Zealand
Region of Southern Denmark
Central Denmark Region
North Denmark Region
Denmark
0
2
4
6
8
10
12
14
16
18
20
08 09 10 11 12 13 14 15 16 17
D
D
D
/1
0
0
 b
ed
-d
ay
s
Combinations of penicillins, incl. beta-lactamase inhibitors
(J01CR)
Piperacillin and beta-lactamase inhibitor (J01CR05)
Amoxicillin and beta-lactamase inhibitor (J01CR02)
0
10
20
30
40
50
60
08 09 10 11 12 13 14 15 16 17
D
D
D
/1
0
0
 a
dm
is
si
on
s
Combinations of penicillins, incl. beta-lactamase inhibitors
(J01CR)
Piperacillin and beta-lactamase inhibitor (J01CR05)
Amoxicillin and beta-lactamase inhibitor (J01CR02)
Figure 5.13 Antimicrobials of special critical interest, 2012-2017, Denmark  DANMAP 2017
Figure 5.14 Consumption of combination penicillins (J01CR), 2012-2017, Denmark (DAD and DBD)  DANMAP 2017
57DANMAP 2017
5.ANTIMICROBIAL CONSUMPTION IN HUMANS
Textbox 5.2
Consumption of antifungal compounds and resistance patterns of 
human invasive isolates of Candida 
Invasive candidiasis including candidaemia is the most severe manifestation of Candida infection. The Candidaemia diagnosis is 
made by detecting the yeast in the blood stream directly by culturing the blood. Candidaemia is a serious condition with an overall 
mortality as high as 30-40% despite advances in antifungal therapy [1]. There are several risk factors and risk groups associated 
with candidaemia such as: critically ill patients with long stay at intensive care departments, patients who undergo abdominal sur-
gery, patients with haematologic malignancies or cancer, transplant recipients, patients treated with broad-spectrum antibiotics, low 
birth weight neonates and preterm infants and patients receiving  parenteral nutrition or with a central vascular catheter in place [2].
There were few data on the epidemiology of fungaemia in Denmark until 2003 and therefore a surveillance programme cover-
ing 53% of the Danish population was initiated in 2003 [3]. The surveillance program was extended in 2004 to cover 64% of 
the Danish population [4] and subsequently the entire population  [5, 6, 7].
The surveillance programme has the purpose of reporting the epidemiological trends of Candida species isolated from blood 
including susceptibility patterns and to report on antifungal consumption, in the primary health care sector and hospitals. 
Demographic data such as age, gender and geography are included.
A steady increasing incidence has been reported until it peaked in 2011 at 10.1/100,000 inhabitants [6, 7]. This number is 
higher than in any other Nordic countries and higher than most other countries worldwide. Subsequently, the average inci-
dence has stabilized at 8.4/100,000 inhabitants in 2012 to 2015. The highest incidence was observed in the elderly (patients 
over 50 years) with a significant increase among males between 80-89 years in 2012-2015 and the incidence was generally 
higher for males than for females [7].
Across the 12 years of surveillance (2004-2015), the number of Candida albicans, the predominant species, decreased, while 
C. glabrata, the second most frequent species, increased significantly (Fig 1). In addition, C. glabrata was increasingly found in 
elderly and in women compared to men in all 10-year intervals above age 40 years [7]. 
A decreased susceptibility to fluconazole was observed with significantly fewer isolates susceptible to fluconazole from 2012 
to 2015 (60.6%) compared with 2008-2011 (65.2%) and 2004-2007 (68.5%). Simultaneaously the proportion of  C. glabrata 
increased. C. glabrata has a reduced intrinsic susceptibility to azoles and the increasing proportion of C. glabrata was observed 
concomitantly with an increasing and high use of azoles both in the primary and in the hospital sector, suggesting that a selection 
pressure has played a role in the changing species distribution. Systemic azoles are extensively used in Danish primary health care 
sector. For example, fluconazole is used as treatment of vaginitis, despite the fact that topical azoles can be used, and itraconazole 
is used for skin and nail infections, though terbinafine is the recommended first line therapy, when systemic treatment is required.
There are some Candida species, which are intrinsically less susceptible to echinocandins, i.e. Candida parapsilosis, Candida 
fermentati and Candida guilliermondii. A feared emerging pathogen, Candida auris is uniformly resistant to fluconazole, and a 
variable proportion concomitantly resistant to echinocandins and/or amphotericin B, thus being multi-drug resistant. C. auris has 
caused hospital outbreaks in UK and Spain, but it has not been found in Denmark yet. Of note, acquired echinocandin resistance 
emerged among Candida isolates from 0% in 2004-2007 to 0.6% in 2008-2011 and to 1.7% in 2012-2015. Although still un-
common, this increase in acquired echinocandin resistance is concerning, particularly as an acquired resistance is most commonly 
found in C. glabrata rendering this species multidrug resistant. On the contrary resistance to Amphotericin B remained low [7]. 
The antifungal consumption in Denmark per 1,000 inhabitants (790 DDDs in 2015) is higher than in the other Nordic countries 
(512, 321 and 762 DDDs, for Norway, Sweden and Finland, respectively) (Fig 2). Denmark witnessed an increase in antifungal 
use from 2004 to 2013-2014 with a stabilization in 2014-2015 for amphotericin B, echinocandins, voriconazole, terbinafine, 
fluconazole, itraconazole and ketoconazole, while the last four antifungals were predominantly used in the primary health 
care system from 2004 to 2015 (99.8%, 69.9%, 94.7% and 87.9%, respectively) [6,7]. Denmark had a higher consumption of 
azoles specifically (237 DDDs) compared to 87, 109, and 164 DDDs in Norway, Sweden and Finland, respectively) [7]. 
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In conclusion, the epidemiology of candidaemia differentiates from that of most other countries by a high incidence particu-
larly in the older age groups and in men, and by an increasing proportion of the fluconazole resistant species C. glabrata, now 
exceeding 30%. Exposure to azoles for ≥ 7 days alters the colonizing flora, from where invasive infections arise [1]. Therefore, 
unnecessary systemic azole use should be limited in order to revert the continued increase of invasive C. glabrata infections [7].
We would like to thank our colleagues at the reference laboratory for Candida and Aspergillus for their great work and efforts. 
Raluca Datcu, Karen Marie Thyssen Astvad, Rasmus Krøger Hare, Maiken Cavling Arendrup 
For further information: Maiken Cavling Arendrup, maca@ssi.dk
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Consumption of antifungal compounds and resistance patterns 
of human invasive isolates of Aspergillus
Epidemiology: Aspergillus is a spore producing mould, ubiquitously dispersed in the air, allowing an airborne route of infec-
tion (1). It causes a number of serious acute and chronic infections (1). Overall, invasive aspergillosis (IA), covering pulmonary 
aspergillosis, infections of other organs and the central nervous system, has an estimated burden of 3-500,000 cases world-
wide (1). High risk of IA has primarily been restricted to immunocompromised (neutropenic) patients and allogeneic stem cell 
transplant (HSCT) recipients, but influenza among critically ill - but otherwise immunocompetent - patients has increasingly 
been highlighted as a significant risk factor (2). The attributable mortality rates of IA is 30-50% and the applicability of sensi-
tive and specific diagnostics methods as well as targeted treatment of infections play a key role in the management (3). 
In Denmark, detailed knowledge on the overall epidemiology and burden of IA is still lacking. A previous three-month labora-
tory based study (January-April 2010) covering approximately one third of the Danish population but the majority of critically 
ill patients, investigated 11,368 airway samples for Aspergillus in order to understand the burden of chronic and invasive 
aspergillosis (4). Overall, 151 patients had positive Aspergillus cultures (>90% A. fumigatus). Among these, 9% had proven or 
probable invasive aspergillosis (following internationally defined criteria (5)), 3% had chronic allergic bronchopulmonary asper-
gillosis (ABPA) and the remaining 88% were considered colonised. overall this led to a conservative estimate of 50-60 cases/
year or 0.9-1.1/100,000 inhabitants, assuming that no cases of IA occurred in the rest of Denmark (4). Another study based on 
previous epidemiological studies and rough estimates gave a population based approximation of 294 IA cases/year, resulting 
in an incidence of 5.3/100,000 inhabitants among 5.6 million Danes. This estimate is five times higher than the first study, 
primarily driven by the assumption that 1.3% of admitted chronic obstructive pulmonary disease (COPD) cases develop IA. 
While this may be an overestimation, several IA cases are probably never diagnosed, illustrated by a recent autopsy study (6). 
Thus the actual incidence may be between 1-5/100,000 inhabitants. This uncertainty illustrates the need for surveillance of 
invasive fungal infections in Denmark to clarify the actual prevalence and possible consequences associated with the disease.
Antifungal (azole) resistance: The antifungal drug class used for prophylaxis and first-line treatment of IA is triazoles with 
only two less efficacious and i.v.-only alternatives (3,7). Indeed, the emerging azole resistance constitutes one of the most 
serious threats for IA patients and is responsible for increased mortality rates to 80-100% (3,8). Two routes of resistance 
development are described in the primary pathogen A. fumigatus; 
1) in vivo selection of resistance during long-term azole treatment
2) ex vivo in the environment, as a consequence of extensive azole fungicide used in the agriculture (9,10). 
Azole resistance mechanisms are primarily structural changes or upregulation of the azole target lanosterol 14 α-demethylase 
encoded by cyp51A (3). Generally, azole resistance evolved in vivo is linked to non-synonymous mutations in cyp51A lead-
ing to single amino acid changes in hot-spots of the encoded protein, e.g. G54, G138, M220 and G448 (3). On the other hand, 
azole-resistant isolates obtained from environmental samples (air and soil) has almost exclusively been attributed to a tandem 
repeat (TR), 34, 46 or 53 base pairs in length in the promoter of cyp51A and with or without specific mutations in cyp51A, 
i.e. TR34/L98H, TR46/Y121F/T289A or TR53 (3). The latter situation is aggravated by several conditions. First, environmental 
resistance-mechanisms confer cross-resistance to medical triazoles; second, both azole exposed and azole naïve patients 
worldwide are continuously being diagnosed with azole resistant A. fumigatus infections; third, azole resistance is continu-
ously being detected in environmental A. fumigatus isolates; and fourth, in some countries, environmental azole resistance 
accounts for the majority of azole-resistant infections (3,9). In the Netherlands, which has a vast tulip production and associ-
ated azole fungicide use, 90% of the reported clinical azole resistance cases of IA is due to the TR34/L98H or TR46/Y121F/
T289A genotypes (11). As a consequence, European Center for Disease Control (ECDC) made a risk assessment on the impact 
of environmental usage of triazoles on the development and spread of resistance to medical triazoles in Aspergillus species 
(10). Conversely, large centres for chronic pulmonary aspergillosis in the UK, may explain a majority of in vivo selected azole 
resistance (12). 
Textbox 5.2 continued...  
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Due to the lack of a surveillance programme for mould infections in Denmark, a recent attempt to clarify azole resistance rates 
was made as a laboratory based study, which has a considerable drawback, as no clinical background information was included 
(13). The study covered 1162 clinical respiratory A. fumigatus isolates collected from 2010-2014 and presented around 4% 
and 6% azole resistance among patients and isolates, respectively. Importantly, around 50% azole resistance was due to the 
environmental mechanisms, TR34/L98H or TR46/Y121F/T289A (13). The data now includes isolates from recent years 2015-
2017 (unpublished data). Dividing the entire period 2010-2017 in two four-year periods, the incidence of azole resistance 
was 2.8% (17/613) in 2010-2013 and 4.3% (24/568) in 2014-2017, while the proportion of azole-resistant isolates were 
3.5% (26/754) and 6.3% (48/757), respectively (Figure 3).
Using the updated numbers, environmental azole-resistance is responsible for 43% and 45% azole-resistant isolates and 
patients respectively. 
The high proportion of environmental azole-resistance among Danish clinical isolates has not been correlated to Danish envi-
ronmental studies (8). Despite several sampling periods involving both soil and air samples and a total of 215 A. fumigatus iso-
lates recovered, only four isolates from 2009 displayed azole resistance with the TR34/L98H resistance mechanism (8,13,14). 
This paradox, discussed by Astvad et al., could be seasonal variation and suboptimal sampling periods (8). Recently, a collabora-
tion between SSI and a group from the Department of Agroecology, Aarhus University, Denmark was initiated. Collectively, sev-
eral hundred air samples have been collected with a Burkard airsampler from 2012-2016, allowing DNA extracted from spores 
obtained each day during the summer period through several years. A recently developed real-time PCR assay enabled direct 
detection of the primary environmental resistance mechanism (TR34/L98H) detected in Denmark (unpublished data). However, 
due to low sensitivity in this assay, requiring the specific amplification of cyp51A, among 826 samples, only 141 (17%) had 
a positive detection of A. fumigatus cyp51A. Samples were from 11 crop fields scattered mainly on Lolland-Falster but also 
near the Agroecology Department at Flakkebjerg, Slagelse. Of 141 samples, two samples (1.4%) both obtained in 2016 were 
positive for TR34/L98H, constituting 5.6% (1/18) or 5.9% (1/17), when only considering the two involved crop fields. Despite, 
a high uncertainty with this finding, it underlines the fact that environmental azole resistance is present, probably in small 
numbers, but limitations of such method, involving a low number of spores, could potentially underestimate the actual burden. 
Figure 4 illustrates the worldwide spread of environmental azole resistance and the agricultural fungicide use (by continent). 
Although the specification of specific azoles used is lacking, a large overall consumption in Western Europe correlates well 
with a high occurrence of environmental azole-resistant A. fumigatus isolates (15).
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In conclusion, azole resistance is emerging and driven by long-term azole therapy in patients as well as in the environment due 
to the extensive use of azole fungicides in the agriculture. The latter is a critical concern as environmentally derived resis-
tance is detected on a global scale and because azole resistance is continuously detected in both clinical and environmental A. 
fumigatus isolates. This constitutes a significant threat, especially to patients suffering from the critical IA disease responsible 
for elevated mortality rates up to 100%. Further knowledge of the Danish epidemiology of aspergillosis as well as a more 
exact clarification of azole resistance rates are demanded. Improved and collaborative research within clinical and agricultural 
science may help understand the origin of environmental resistance and may help manage this external threat.
We would like to thank our colleagues at the reference laboratory for Candida and Aspergillus for their great work and efforts. 
Rasmus Krøger Hare, Karen Marie Thyssen Astvad and Maiken Cavling Arendrup 
For further information: Maiken Cavling Arendrup, maca@ssi.dk
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Figure 4 Illustration of the global market share of azole fungicides as well as coloured countries where  
environmental azole resistance (TR34/L98H, TR46/Y121F/T289A, TR53) has been found in clinical and/or  
environmental A. fumigatus isolates. A large share is being used in Western Europe, which is considered an  
epi-center for especially the TR34/L98H resistance mechanism (3,15).  DANMAP 2017
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6
Textbox 5.3
Antimicrobial resistance and consumption of antimicrobials in the 
Faroe Islands
Background: The Faroe Islands (FI) consist of 18 islands inhabited by approx. 49,000 inhabitants, 19,000 of whom live in the 
capital Tórshavn. The main hospital (Landssjúkrahúsið, LS, with 120 beds), is located in Tórshavn, and there are two smaller 
hospitals in Klaksvik (22 beds) and Súðuroy (22 beds). The Faroese healthcare system is comparable to the Danish healthcare 
system with general practitioners responsible for primary care and hospitals providing secondary care. LS has a local as well as 
a centralised function. In the case of specific diseases, demanding highly specialised care, patients are referred to hospitals in 
Denmark or other foreign hospitals. 
Data and data sources: Data on antimicrobial consumption for FI and for the hospitals were supplied by the Chief Pharmaceu-
tical Office. Data on MRSA and other resistant bacteria were obtained from LS, as were bed-days.
Resistant microorganisms: MRSA and ESBL-producing Enterobacteriales (Escherichia coli and Klebsiella pneumoniae) are 
continuously surveyed and screening is performed according to guidelines. Since April 2015, vancomycin-resistant entero-
cocci (VRE) have been an increasing problem – especially at LS. Throughout 2015, systematic periodic screening of VRE was 
performed in the wards. From 2016 and onwards, screening was mainly performed after transfer of patients from hospitals 
abroad (including Denmark). Thus, the VRE data are based on results from screening and clinical samples.  Since the beginning 
of surveillance, a total of 56 patients were colonised or infected with MRSA (surveillance period 2004-2017), 70 with ESBL-
producing Enterobacteriales (2006-2017), and 162 with VRE (2015-2017).
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Antimicrobial consumption at Landssjúkrahúsið: The total antimicrobial consumption was 56.13 DDD/100 bed-days (DBD), 
representing a decrease compared to 2016. Special attention to three broad-spectrum antimicrobials, cephalosporins, carbapen-
ems and fluoroquinolones is still required: In 2017, the consumption of cefuroxime was 10.79 DBD, a decrease of 12% from 
12.27 DBD in 2016, still constituting 19% of the total antibiotic consumption at LS. Moreover, the consumption of carbapenems 
increased from 2.27 DBD in 2016 to 2.45 DBD in 2017 (8% increase) and that of ciprofloxacin increased from 3.18 DBD to 
3.85 DBD (21% increase) (Fig. 1). Consumption of mecillinams (pivmecillinam and mecillinam) continued to increase from 0.43 
DBD in 2012 to 4.52 in 2017, with a significant increase of 27% from 2016 to 2017. The use of penicillinase-stable penicillins 
increased as well, from 3.63 DBD in 2016 to 5.62 in 2017, (not shown). 
Antimicrobial consumption in primary healthcare: In 2017, the total antimicrobial consumption in primary healthcare was 
13.85 DDD/1,000 inhabitants/day (DID) – similar to that of 2016. The distribution of antimicrobial consumption is shown in Fig. 
2. Remarkable are the proportions of ampicillins, penicillinase-stable penicillins and mecillinams (with increases of 13%, 8% and 
13% respectively, compared to 2016), whereas the consumption of ciprofloxacin remained at almost the same level as in 2016 
(3% increase). As this probably reflects a somewhat changed practice in treatment of urinary tract infections (UTI) (Fig. 3), it 
also stresses the continued need to screen patients for carnitine transporter gene defect (CTD), a gene defect common in the 
Faeroe island population. This is especially relevant for the elderly, which are more at risk of acquiring a UTI and therefore may 
undergo antibiotic treatment, where pivmecillinam can be safely used only in patients without the gene defect. 
Antimicrobial consumption in primary vs. secondary healthcare: The consumption at the three hospitals was based on 
purchase data and constituted 11% of the total antimicrobial human consumption, while the consumption in primary healthcare 
was based on prescription data and constituted 89%.
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Conclusion: In 2017, the antimicrobial consumption decreased at LS and remained at the same level in primary healthcare.The 
consumption of cefuroxime finally seems to be reduced, a positive trend which to some extent probably is due to a shift to pen-
icillinase-stable penicillins in the treatment of infections caused by staphylococci. Unfortunately, the consumption of carbapen-
ems as well as ciprofloxacin seems to continue their increase at LS. It is, however, encouraging to observe a continued increase in 
the use of mecillinams, both at LS and in primary healthcare, a tendency that might be enhanced by screening of elderly for CTD. 
Further implementation of antibiotic stewardship and a continued focus on adherence to general infection control precautions are 
the necessary steps in the effort to reduce development and spread of antimicrobial resistance in LS and in primary healthcare.
Elsebeth Tvenstrup Jensen, Súsanna Kristiansen, Ann Winther Jensen, Anne Kjerulf, 
Lena Lambaa, Hjørdis Reinert, Shahin Gaïni, and Niels Joensen. 
For further information: Elsebeth Tvenstrup Jensen, etj@ssi.dk
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6. Resistance in zoonotic bacteria
6.1 Introduction
Zoonoses are infectious diseases that can be transmitted be-
tween animals and humans, either through direct contact with 
animals or indirectly by contaminated food or environment. 
Zoonotic bacteria, such as Salmonella and Campylobacter, 
can develop resistance towards antimicrobial agents, which 
subsequently may lead to limited treatment possibilities, pro-
longed illness and treatment failure of human infections. The 
development and spread of antimicrobial resistance is multi-
factorial and can happen in many ways, including antimicrobial 
treatment of animals and humans, transfer of genes between 
bacteria or dissemination of successful clones carrying resis-
tance genes.
A more detailed description of the trends and sources of 
zoonoses in Denmark and of national surveillance and control 
programmes can be found in the Annual Report on Zoonoses in 
Denmark 2017 [www.food.dtu.dk].
Salmonella Typhimurium, Salmonella Enteritidis, Campylo-
bacter jejuni and Campylobacter coli have been included in the 
DANMAP programme since 1995, where isolates were recov-
ered for susceptibility testing in samples from broilers, cattle 
and pigs as well as from human cases. Sampling of fresh meat 
was initiated from 1997. Since 2014, sampling and testing of 
Salmonella and Campylobacter have been done in accordance 
with the EU harmonised monitoring of antimicrobial resistance 
[Decision 2013/652/EU].    
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    Highlights: Salmonella Typhimurium remained the most prevalent Salmonella serotype iso-
lated from Danish pigs and pork. Monophasic S. Typhimurium variants represented about two 
thirds of these, which is similar to the pattern in human Salmonella serotypes. The domi-
nance of monophasic Salmonella isolates influences the resistance patterns in all popula-
tions with high levels and increasing resistance to tetracycline, ampicillin and sulfonamides.  
 
Resistance levels to critically important antibiotics are low and fluoroquinolone (ciprofloxa-
cin) resistance has not been identified in S. Typhimurium from Danish pigs and pork since 
2010 and 2007, respectively. Among human cases, resistance to quinolones remained 
higher among isolates from the travel-related cases than among cases acquired in Denmark. 
Resistance to 3rd generation cephalosporins and carbapenems was very low in S. Typhimuri-
um from human cases with no travel history and not found in the Salmonella isolates from 
Danish pigs and pork. 
 
Resistance to quinolones (nalidixic acid and ciprofloxacin) was the most common resistance 
in Campylobacter jejuni from all populations: broilers, cattle and humans. The resistance lev-
els are increasing in all three populations. Around one third of all isolates from animal origin 
and domestically acquired human cases were resistant to ciprofloxacin, whereas almost all 
the travel associated human isolates were resistant. 
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6.2 Salmonella
Salmonella is the second most frequent zoonotic bacterial 
pathogen in humans in Denmark and can have a severe impact 
on both animal production and human health [Annual Report 
on Zoonoses in Denmark 2017].
In Denmark, S. Enteritidis and S. Typhimurium are the sero-
types that most frequently are associated with human illness. 
Human cases caused by S. Enteritidis are frequently associ-
ated with consumption of contaminated eggs, whereas S. 
Typhimurium cases often are associated with contaminated 
pork, beef and poultry meat.
Salmonella isolates for DANMAP 2017 were derived from 
national surveillance and control programmes. Pig isolates 
originate from slaughterhouses, where representative samples 
from healthy pigs (caecum) and pork (carcass swabs) are 
collected each year. Salmonellosis is a notifiable disease in 
humans and isolates from nearly all reported S. Typhimurium 
cases are susceptibility tested. Only one isolate per farm, meat 
sample or human case was included in this report. For further 
details see Chapter 9, Materials and Methods.
The occurrence of Salmonella in domestic broilers, layers and 
cattle as well as some other types of Danish and imported 
meat are monitored in Denmark each year. However, these 
are not included in DANMAP 2017, as only few isolates were 
found and thus, fall below the inclusion threshold for DANMAP 
of 15 isolates per population. The data are however reported 
to EFSA, and are included in the European Union summary 
report on antimicrobial resistance in zoonotic and indicator 
bacteria from humans, animals and food in 2017.
The DANMAP report highlights the resistance in S. Typhimuri-
um, because they are the most important serotype in public 
health. However, resistance in other Salmonella serotypes 
from pigs and pork is also monitored for 2011 and onwards, 
which is the year Denmark started to susceptibility test all 
serotypes according to EU legislation.
In DANMAP, S. Typhimurium includes the monophasic variants 
with antigenic formulas S. 4, [5],12:i:- as recommended by the 
European Food Safety Authority [EFSA journal 2010. 8(10): 
1826]. 
The antimicrobials recommended by EFSA were used for 
susceptibility testing. MIC distributions and occurrence of 
resistance among isolates from pigs, pork and humans are 
presented in the web annex (Tables A6.1 - A6.5).
6.2.1 Salmonella in pigs and domestically  
produced pork – all serotypes
From 295 representative pig caeca and 11,166 pig carcass 
swabs (pork) sampled on Danish slaughterhouses 119 Sal-
monella isolates were obtained. A total of 113 of these were 
tested for antimicrobial resistance. As in the previous years, S. 
Typhimurium (including the monophasic variants) and S. Derby 
were the most common serotypes, representing 95% of all the 
isolates (Figure 6.1). Last year S. Typhimurium overtook S. Der-
by as the most prevalent serotype from domestically produced 
pigs and pork. This trend continued in 2017, with only 38% S. 
Derby and 57% S. Typhimurium. Interestingly, the proportions 
of S. Derby and S. Typhimurium isolates in pigs arriving at the 
slaughterhouse are similar (48% vs. 48%), but in the meat S. 
Typhimurium is more frequent than S. Derby (62 % vs. 32%). 
0
20
40
60
80
100
120
2011 2012 2013 2014 2015 2016 2017 2011 2012 2013 2014 2015 2016 2017
(340) (374) (402) (173) (139) (129) (44) (148) (120) (148) (60) (78) (94) (69)
P
er
ce
nt
Derby 4,[5] , 12:i:- Typhimurium Infantis Livingstone London Other serovar Not typeable
Pigs Pork
Danish
Figure 6.1 Relative distribution (%) of Salmonella serotypes from pigs and Danish pork, Denmark DANMAP 2017
Note: Number of isolates included each year is presented in the parenthesis 
DANMAP 201770
RESISTANCE IN ZOONOTIC BACTERIA6.
Monophasic S. Typhimurium were the most common isolates in 
pork (42%), which will affect the resistance patterns in meat in 
2017, because monophasic S. Typhimurium strains tend to be 
more resistant than S. Derby.
6.2.2 S. Typhimurium in pigs  
and domestically produced pork
S. Typhimurium remains the most important zoonotic serotype 
originating from pigs. A total of 64 S. Typhimurium (21 diphasic 
and 43 monophasic variants) were isolated from Danish pigs 
and pork in 2017. The level of fully susceptible S. Typhimurium 
isolates in pigs (19%) and from domestically produced pork 
(14%) remained similar to 2016 (15% and 12%) (Table 6.1). 
As in the previous years, resistance towards ampicillin, tet-
racycline and sulfonamide were common in S. Typhimurium 
isolates. Sulfonamide resistance was more frequent in isolates 
from pork than from pigs, probably reflecting the larger propor-
tion of monophasic variants in pork. 
Resistance to ampicillin declined significantly in pigs from 
68% in 2016 to 48% in 2017. A slight decline in sulfonamide 
resistance and a small increase in tetracycline resistance were 
observed, but because of the small number of isolates (21), 
we are only 65% certain that these observations are differ-
ent from last years. The decrease in ampicillin resistance was 
mainly driven by the fact that no resistance was found in the 
seven diphasic S. Typhimurium isolates. The proportion of sul-
fonamide and ampicillin resistant monophasic S. Typhimurium 
remained high at 71%. 
In domestically produced pork, the resistance trends were 
more stable most likely due to a larger sample size. A decline 
was observed in tetracycline resistance, but this was not a sig-
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a) Includes isolates verified as monophasic variants of S. Typhimurium with antigenic formulas S. 4,[5],12:i:-
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nificant change. Gentamycin resistance increased to 12% from 
2% in 2016 (Figure 6.2). This year, 56% of the S. Typhimurium 
isolates carried the ASuT resistance profile and 68% were 
multi-resistant. Two monophasic Salmonella isolates were sen-
sitive to all antibiotics and seven only resistant to tetracycline. 
One monophasic isolate from pork was resistant to azithromy-
cin and sulfonamide.
None of the S. Typhimurium isolates from pigs or domestic 
pork were resistant to quinolones (ciprofloxacin and nalidixic 
acid), cephalosporins (cefotaxime and ceftazidime) or car-
bapenems (meropenem), providing 95% confidence that these 
resistances are not present in more than 13% of S. Typhimuri-
um isolates from pigs and 7% S. Typhimurium from pork (See 
Chapter 9, Materials and Methods).
Tetracyclines, macrolides (mainly Tylosin and Tilmicosin), 
pleuromutilins and beta-lactamase sensitive penicillins are the 
main antimicrobial agents used in pigs in Denmark (Figure 4.4). 
The distinct changes in usage of tetracycline over the last 4-5 
years in pigs were not reflected in the 2017 levels of resis-
tance in S. Typhimurium from pigs and domestically produced 
pork. The levels of resistance to tetracycline continued to 
increase, despite an almost 50% reduction in DAPD of tetracy-
cline in Danish pigs since 2013. This is due to the continued 
increase of the proportion of monophasic Typhimurium vari-
ants, which dominates the resistance patterns and often are 
multi-resistant (Figure 6.2).
6.2.3 Resistance in other relevant Salmonella serotypes 
in pigs and pork
S. Derby was isolated from 21 slaughter pigs and from 22 
Danish pork samples. S. Derby is common among pigs, but only 
few human cases (n=12) were reported in Denmark in 2017 
[Annual Report on Zoonoses in Denmark 2017]. In 2015, 72% 
of S. Derby were sensitive to all antimicrobials tested, in 2016 
the proportion was 63%, and in 2017 60% of S. Derby isolates 
were fully sensitive to all antimicrobials tested. Resistance 
to tetracycline, ampicillin, sulphonamides and trimethoprim 
were most common, either alone or in combination. Only 15% 
of isolates were multi-resistant, one isolate was resistant to 
azithromycin and two to chloramphenicol, but no resistance to 
any other antimicrobials was found.
6.2.4 Resistance in Salmonella in imported pork
A total of 153 samples were collected from imported pork, 
yielding 16 Salmonella isolates (11% positive). Half of these 
were monophasic Salmonella, five were diphasic S. Typhimuri-
um, two S. Derby and the last one was a S. London isolate. One 
monophasic, both S. Derby isolates and the S. London isolate 
were sensitive to all antibiotics in the panel. Of all the isolates, 
44% were multi-resistant. One S. Typhimurium isolate was 
resistant to nalidixic acid and ciprofloxacin and multi-resistant, 
but apart from that isolate all the other exhibited patterns 
similar to the Danish meat.
6.2.5 Salmonella in humans. 
In 2017, Salmonella continued to be the second most frequent 
cause of bacterial intestinal infections in Denmark. A total 
of 1,067 human laboratory-confirmed cases of salmonellosis 
were reported (18.5 cases per 100,000 inhabitants). The most 
common serotypes were S. Typhimurium (including the mono-
phasic variants) and S. Enteritidis with 5.0 and 3.9 cases per 
100,000 inhabitants, respectively [Annual report on Zoonoses 
in Denmark 2017].
6.2.6 S. Typhimurium in humans
The serotypes of Salmonella were mainly established from 
whole genome DNA sequences. Salmonella Typhimurium, 
including the monophasic variants were most commonly 
identified among the human cases (290 cases) and MIC data 
from 288 of these isolates were included in this report. The 
monophasic variants represented approximately two thirds of 
the S. Typhimurium cases (174 monophasic and 114 dipha-
sic). Information on patient travel history was available for 
72% of the 288 case, 19% of the cases were categorised as 
travel associated, 52% were likely acquired in Denmark, and 
the remaining cases had unknown travel status (Table 6.1). A 
total of 80 human cases were considered ‘outbreak-related’ 
Antimicrobial 
agent
Pigs Pork Human cases
Danish
%
Danish
%
Domestically 
acquired 
%
Travel 
abroad 
reported
%
Total
%
Tetracycline 71 63 68 65 67
Tigecycline 0 0 <1 11 3
Chloramphenicol 5 19 17 11 13
Ampicillin 48 77 73 62 68
Cefotaxime 0 0 2 4 2
Ceftazidime 0 0 1 4 1
Meropenem 0 0 0 0 0
Trimethoprim 10 12 1 15 6
Sulfonamide 52 81 74 71 70
Azithromycin 0 2 0 5 1
Gentamicin 5 12 5 5 5
Ciprofloxacin 0 0 3 11 5
Nalidixic acid 0 0 <1 4 2
Colistin 0 0 <1 2 <1
Fully  
Sensitive (%)
19 14 22 24 22
Number of 
isolates
21 43 151 55 288
Table 6.1 Resistance (%) among Salmonella  
Typhimurium(a) isolates from pigs, Danish pork  
and human cases(b), Denmark DANMAP 2017
a) Include isolates verified as monophasic variants of S. Typhimurium 
with antigenic formulas S. 4,[5],12:i:- 
b) An isolate was categorised as ‘domestic’ if the patient did not travel 
outside Denmark one week prior to the onset of the disease
c) All strains classified as tigecyline resistant had a MIC value that was 
one dilution step higher than the ECOFF
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Figure 6.3 Resistance (%) in Salmonella Typhimurium(a) in human cases(b), Denmark DANMAP 2017
a) Include isolates verified as monophasic variants of S. Typhimurium with antigenic formulas S. 4,[5],12:i:-
b) An isolate was categorised as ‘domestic’ if the patient did not travel outside Denmark one week prior to the onset of the disease
and originated from 11 outbreaks of which 7 were caused by 
monophasic S. Typhimurium. The largest outbreak included 16 
patients. None of the outbreaks were associated with travel.
As in the previous years, high levels (67-70%) of resistance to 
ampicillin, sulfonamide, and tetracycline were observed (Table 
6.1). Isolates that exclusively exhibited resistance towards the 
three antimicrobials were especially common among monopha-
sic Salmonella, and 62% of all monophasic variants (n = 108) 
harboured this resistance profile.
The levels of resistance in strains from domestically acquired 
cases are at the same levels as in the previous years with two 
minor deviations (Figure  6.3). From 2016 to 2017, an increase 
from 10% to 16% was observed for chloramphenicol resistance 
and a significant decrease from 9% to 1% was observed for 
trimethoprim. The increase in chloramphenicol resistance can 
be explained by two outbreaks that were caused by chloram-
phenicol resistant strains. There is no obvious explanation for 
the decrease in trimethoprim resistance, but trimethoprim resis-
tance was not observed among the 80 outbreak strains tested.
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The levels of resistance in isolates from human cases associ-
ated with travel are also in line with the observed levels in the 
previous years. The level of fluoroquinolone resistance (cip-
rofloxacin) decreased from 18% to 11% from 2016 to 2017, 
but the level is still significantly higher in travel-associated 
isolates compared to isolates from domestic cases (Figure 6.3). 
Resistance to colistin was observed in isolates from both 
domestically acquired (<1%) and travel associated human 
cases (2%). The level of cephalosporin resistance was 2% for 
cefotaxime and 1% in ceftazidime. Carbapenem resistance 
(meropenem) was not observed in any of the tested strains.
6.3 Campylobacter
Thermotolerant Campylobacter spp. are the most commonly 
reported causes of gastrointestinal bacterial infections in 
humans in Denmark as well as in the European Union [EU Sum-
mary Report 2014, ECDC/EFSA 2015]. In Denmark, 85-95% of 
the human campylobacteriosis cases are caused by C. jejuni.
Campylobacter are widespread in nature and the most impor-
tant reservoirs are the alimentary tract of wild and domesticat-
ed birds and mammals. Among sporadic human cases, broilers 
have been identified as the primary source of infection, though 
other sources such as untreated water and other infected 
animals are also important.
In 2017, most of the Campylobacter isolates for DANMAP 
were obtained by sampling of randomly selected broilers and 
cattle at slaughter (caecum). In humans, Campylobacteriosis 
is a notifiable disease, but only a selection of isolates from 
reported human C. jejuni cases are susceptibility tested. Only 
one isolate per farm or human case was included. For details 
see Chapter 9, Materials and Methods. The susceptibility meth-
ods follow EFSAs recommendations and MIC distributions for 
C. jejuni from broilers, cattle and humans are presented in the 
web annex (Tables A6.6 - A6.7).
6.3.1 C. jejuni in broilers 
A total of 43 C. jejuni isolates were derived from 163 broiler 
flocks sampled throughout the year. The level of fully sensi-
tive isolates from broilers was 74%, which was similar to 
previous years.
Resistance to ciprofloxacin (26%) and nalidixic acid (26%) 
were most frequently observed and always in the same 
isolates (Table 6.2). Since 2007, a slow increase in proportion 
of ciprofloxacin resistant isolates has been observed from ap-
proximately 10% in 2006 to 26% in 2017, despite little or no 
use of quinolones in the poultry industry since 2009. The Dan-
ish increasing trend of resistance to quinolones is similar to 
the increasing trend of ciprofloxacin resistance in the EU, but 
the levels in Denmark still remain much lower than in the EU, 
where overall 62-66% of isolates were resistant to quinolones 
[EFSA 2018. EFSA Journal 16(2): 5182]. All ciprofloxacin resis-
tant isolates were also resistant to nalidixic acid suggesting a 
chromosomal resistance mechanism. 
Tetracycline resistance increased slightly from 12% to 16% in 
broilers after a steady increase peaking in 2013 followed by a 
drop back to 2008 level. All tetracycline resistant isolates were 
also resistant to ciprofloxacin and nalidixic acid. Thus, there is 
no clear relationship between resistance and the use of tetra-
cycline in broilers, which increased sharply from 2012 to 2015 
and decreased in 2016.
No resistance to erythromycin, gentamycin or streptomycin was 
observed in 2017, suggesting that resistance to these antimi-
crobials are only present in 7% or less of the Campylobacter 
isolates from broilers (See Chapter 9, Materials and Methods).
Table 6.2 Resistance (%) in Campylobacter jejuni isolates from animals, meat of  
Danish and imported origin and human cases(a), Denmark DANMAP 2017
a) An isolate is categorised as domestically acquired if the patient did not travel outside Denmark one week prior to the onset of disease
Antimicrobial agent
Cattle Broilers Humans
Danish
%
Danish
%
Domestically 
acquired
%
Travel abroad
%
Total
%
Tetracycline 7 16 22 68 32
Erythromycin <1 0 1 6 2
Streptomycin <1 0 0 - -
Gentamicin 0 0 1 3 1
Ciprofloxacin 30 26 37 92 49
Nalidixic acid 30 26 37 92 49
Fully sensitive (%) 67 74 59 8 48
Number of isolates 236 43 252 79 397
DANMAP 201774
RESISTANCE IN ZOONOTIC BACTERIA6.
Figure 6.5 Resistance (%) among Campylobacter jejuni from cattle, Denmark DANMAP 2017
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Figure 6.4 Resistance (%) among Campylobacter jejuni from broilers, Denmark DANMAP 2017
Note: Number of isolates included each year is presented in the parenthesis
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6.3.2 C. jejuni in cattle
A total of 236 C. jejuni isolates were isolated from 297 cattle 
caeca taken at slaughter from all over Denmark. All isolates 
were susceptibility tested. Most of the isolates (67%) were 
fully sensitive and the remaining isolates were resistant to cip-
rofloxacin, tetracycline, streptomycin and erythromycin (30%, 
7% 1% and 1% of all isolates, respectively) and to various 
combinations of these (Table 6.2).
Resistance to ciprofloxacin continued to increase, although the 
consumption of fluoroquinolones by cattle in Denmark is almost 
none (Figure 6.5). The epidemiology of these resistant strains 
is unknown, but the co-resistance with nalidixic acid suggested 
chromosomal resistance rather than plasmid borne. Resistance 
to streptomycin increased in 2016, but the levels are back to 
1% in 2017, suggesting the peak may have been a result of the 
small sample size last year. A reduction in resistance to tetracy-
cline was also observed after two years of high prevalence. The 
use of tetracycline in cattle has decreased over the last 5 years, 
but it is uncertain whether the decline in antimicrobial resis-
tance is directly associated to less use. 
6.3.3 Campylobacter in humans
Campylobacter, and in particular C. jejuni, continued to be 
the most frequent cause of bacterial intestinal infections in 
Denmark in 2017 with a total of 4,257 reported human labora-
tory confirmed cases of campylobacteriosis (73,9 per 100,000 
inhabitants) [Annual Report on Zoonoses in Denmark 2017].
A representative selection of Campylobacter isolates sub-
mitted to Statens Serum Institut (SSI) by regional clinical 
microbiological laboratories were identified to species level 
and susceptibility testing was performed on 397 isolates of 
C. jejuni. A total of 252 of these isolates were from patients 
with no history of travel abroad, 79 isolates were from travel-
associated cases and 66 isolates were from patients with no 
information on travel.
Among the domestically acquired infections, 148/252 (59%) 
of isolates were fully sensitive to all the antimicrobials tested. 
The proportion was significantly lower for isolates from travel-
associated cases (6/73, 8%) (Table 6.2).
In isolates from domestically acquired cases, the most frequent 
resistance profile was the combination of ciprofloxacin and 
tetracycline, which was found in 44% of the resistant isolates. 
Resistance to erythromycin and gentamicin were observed 
in 1% of the isolates (Table 6.2). The levels of resistance in iso-
lates from domestically acquired cases were similar to previous 
years (Figure 6.6).
In line with previous years, the level of resistance in isolates 
from travel-associated cases was higher than the levels in 
isolates from domestically acquired cases. The difference 
was statistically significant for ciprofloxacin, tetracycline, 
and erythromycin. From 2016 to 2017, a significant increase 
in ciprofloxacin resistance was observed and it reached an 
all-time high with 92% in isolates from patients with a travel 
history in 2017.
Johanne Ellis-Iversen, Helle Korsgaard, Mia Torpdahl and Jeppe Boel 
For further information: Johanne Ellis-Iversen, joell@food.dtu.dk
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Figure 6.6 Resistance (%) among Campylobacter jejuni from humans(a), Denmark DANMAP 2017
Note: Number of isolates included each year is presented in the parenthesis. The '-' indicate data for application of 2016 cut-offs not available or 
less than 25 isolates were available
a) An isolate was categorised as ‘domestic’ if the patient did not travel outside Denmark one week prior to the onset of the disease
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Textbox 6.1
Resistance in bacteria from diagnostic submissions from pigs
 
Data on susceptibility of three important veterinary pathogens Escherichia coli O149, Streptococcus suis, and Actinobacillus 
pleuropneumoniae were obtained from the routine diagnostic laboratory investigation of isolates from dead and diseased pigs 
submitted to SEGES Pig Research Centre’s Laboratory for Pig Diseases in Kjellerup. The number of isolates belonging to other 
bacterial species was too small to be included in this overview.
The antimicrobial susceptibility testing was carried out using the broth microdilution method with SensiTitre. Since approved 
clinical breakpoints are not available for most of the drug-bacterium combinations, the results are presented both as MIC distri-
butions, which allows for the reader’s own interpretation, and as % resistant isolated according to the clinical breakpoints that 
are currently in use at both DTU National Veterinary Institute and Laboratory for Pig Diseases.
E. coli O149
Enterotoxigenic E. coli (ETEC) in combination with Brachyspira pilosicoli and Lawsonia intracellularis are the most prevalent 
causes of bacterial diarrhoea in Danish pigs. Most cases of diarrhoea that require treatment occur during the weaning period 
and tetracyclines, neomycin or aminopenicillins are the compunds of choice. The most virulent ETEC strains belong to serovars 
O138, O139, O141, and O149, are haemolytic and positive for enterotoxin and for F4 or F18 fimbrial adhesins, which are used 
for attachment to the intestinal mucosa. In general, the F18 positive strains belong to the serovars O138, O139 and O141, while 
serovar O149 carry the F4 fimbriae. The MIC distributions and resistance data for the 72 serovar O149 isolates from 2017 are 
shown in Table 1. High resistance levels were recorded for ampicillin, streptomycin, sulphonamides, tetracyclines, trimethoprim, 
and spectinomycin. Numerically, tetracycline, ampicillin, and sulphonamides resistance decreased compared to 2016, whereas 
resistance to trimethoprim, streptomycin, and spectinomycin increased. It is uncertain whether the decrease in tetracycline 
resistance is due to natural variation or whether it is a trend following the decrease in tetracycline usage. An increase was also 
noted for florfenicol, now mounting 18% compared to 10% in 2016 and 2015, but 3% in 2012 and zero in 2011. The reasons for 
this apparent steady increase need further investigation. Isolates that were resistant to florfenicol were also resistant to chlor-
amphenicol, but resistance levels to chloramphenicol did not increase. Fourteen isolates (19%) were resistant to nalidixic acid 
compared to 10% in 2016. These isolates also had increased MIC values to ciprofloxacin, but all remained under the breakpoint. 
This finding is surprising, since no quinolones are used in Danish pig production. Notably, resistance to colistin remains at 
zero. The relatively high resistance levels to many compounds increase the benefits of susceptibility testing before treatment. 
The resistance profile of the serovar O139 isolates deviated somewhat from that of O149, and in general O139 shows less 
resistance. Among 76 O139 isolates from 2016 and 2017 combined, only 3 (4%) were resistant to florfenicol, while no isolates 
were resistant to nalidixic acid or neomycin, and resistance to other compounds were lower or at the same level as for O149 
isolates (data not shown). In Denmark, the serovar O139 is almost exclusively responsible for edema disease and carries F18 
fimbriae and verotoxin 2e, but no enterotoxins. Prophylaxis of edema disease is often performed effectively by vaccination, 
while this is still not the case for diarrhoea caused by the other serovars of E. coli. 
Actinobacillus pleuropneumoniae
Actinobacillus pleuropneumonia causes pleuropneumonia in pigs. Severity differs with serotype, but common clinical signs are 
fever, coughing, depression, loss of appetite, and bloody discharge from the nose. Outbreaks need rapid onset of treatment 
to minimize losses, but fortunately, A. pleuropneumoniae remains to have a predictable resistance pattern and low resistance 
to most compounds, including florfenicol and macrolides like tilmicosin, tildipirosin and tulathromycin, which are often used for 
treatment. MIC distributions and percent resistance are shown in Table 2. All 135 isolates were resistant to erythromycin, but 
almost fully susceptible to all other compounds, including to other macrolides. There are several O-serotypes, the far most 
prevalent ones among the clinical isolates being O2 and O6, but resistance patterns did not differ between the two serotypes.
Streptococcus suis
Streptococcus suis may cause several different infectious conditions in pigs, such as meningitis, otitis media, arthritis, pneumonia, 
and septicaemia, and causes losses to the farmers due to increased mortality and veterinary costs. MIC distributions and percent 
resistant isolates are shown in Table 3. Resistance in the 152 isolates was highest to macrolides (erythromycin), streptomycin, and 
tetracyclines, although resistance to tetracyclines had decreased from 51% in 2016 to 40% in 2017. All isolates were susceptible to 
both penicillin and florfenicol. Several serotypes of S. suis exist and in Danish pig production the serotypes 1, 2, 7, and 9 are the most 
often isolated. There seems to be differences in resistance patterns between serotypes, however, this needs further investigation.
 
Karl Pedersen, Charlotte Mark Salomonsen, Sven Erik Jorsal 
For further information: Karl Pedersen, kape@food.dtu.dk 
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Note: Interpreted by clinical break-points for Streptococcus isolates from pigs as applied by DTU National Veterinary Institute and The Danish 
Pig Research Centers Laboratory for Pig Diseases. Breakpoints are indicated as vertical dotted lines. Confidence intervals are calculated as 
95% binomial proportions presenting Wilson intervals. White fields represent the range of dilutions tested. MIC values equal to or lower than 
the lowest concentration tested are presented as the lowest concentration. MIC values greater than the highest concentration in the range are 
presented as one dilution step above the range
Table 1 Distribution of MICs and resistance (%) in clinical Escherichia coli O149 from pigs (n=72), Denmark DANMAP 2017
Note: Interpreted by clinical break-points for Actinobacillus isolates from pigs as applied by DTU National Veterinary Institute and The Danish 
Pig Research Centers Laboratory for Pig Diseases. Breakpoints are indicated as vertical dotted lines. Confidence intervals are calculated as 
95% binomial proportions presenting Wilson intervals. White fields represent the range of dilutions tested. MIC values equal to or lower than 
the lowest concentration tested are presented as the lowest concentration. MIC values greater than the highest concentration in the range are 
presented as one dilution step above the range
Table 3 Distribution of MICs and resistance (%) in clinical Streptococcus suis from pigs (n=152), Denmark DANMAP 2017
Note: Interpreted by clinical break-points for E. coli isolate from pigs as applied by DTU National Veterinary Institute and The Danish Pig 
Research Centers Laboratory for Pig Diseases. Confidence intervals are calculated as 95% binomial proportions presenting Wilson intervals. 
Vertical solid lines indicate EUCAST epidemiological cut-off values. Breakpoints are indicated as vertical dotted lines if different from the 
corresponding epidemiological cut-off values. White fields represent the range of dilutions tested. MIC values equal to or lower than the 
lowest concentration tested are presented as the lowest concentration. MIC values greater than the highest concentration in the range are 
presented as one dilution step above the range
Antimicrobial  
agent
Clinical 
breakpoint  
μg/ml
%  
Resistant
95%  
Confidence 
interval 
Distribution (isolates) of MICs
0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256
Tetracycline >4 2.2 [0-5]   12.6 54.1 29.6 0.7 0.7 2.2
Florfenicol >4 0.0 [0-1.4] 3.0 88.9 7.4 0.7
Ampicillin >2 0.7 [0-2.7] 99.3 0.7
Penicillin >2 0.7 [0-2.7] 0.7 0.7 3.0 23.0 42.2 26.7 3.0 0.7
Ceftiofur >4 0.0 [0-1.4] 96.3 3.0 0.7
Sulfa-trimethoprim >2 0.0 [0-1.4] 45.9 48.1 5.9
Erythromycin >0.5 100.0 [100-100] 2.2 28.9 65.9 3.0
Tulathromycin >8 1.5 [0-3.9] 2.2 50.4 45.9 0.7 0.7
Tilmicosin >16 0.0 [0-1.4] 2.2 37.8 59.3 0.7
Tiamulin >16 0.0 [0-1.4] 0.7 0.7 24.4 60.7 13.3
Spectinomycin >64 0.0 [0-1.4] 2.2 34.1 63.7
Antimicrobial  
agent
Clinical 
breakpoint  
μg/ml
%  
Resistant
95%  
Confidence 
interval 
Distribution (isolates) of MICs
0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 512 >512
Tetracycline >4 40.1 [32.4-47.8] 8.6 16.4 15.8 19.1 0.7 0.7 11.2 27.6
Chloramphenicol >8 0.0 [0-1.2] 15.1 75.7 9.2
Florfenicol >16 0.0 [0-1.2] 25.0 73.7 1.3
Penicillin >2 0.0 [0-1.2] 89.5 2.6 3.9 1.3 2.6
Sulfa-trimethoprim >2 8.6 [4-13.1] 80.3 1.3 3.9 5.9 3.3 1.3 2.0 2.0
Trimethoprim >8 9.9 [5.1-14.7] 75.5 0.7 0.7 8.6 4.6 1.3 8.6
Erythromycin >0.5 48.7 [40.8-56.5] 50.7 0.7 0.7 0.7 0.7 1.3 45.4
Streptomycin >16 47.4 [39.5-55.2] 9.2 26.3 17.1 16.4 3.3 27.6
Tiamulin >16 23.7 [17-30.4] 5.9 7.9 21.1 28.3 5.9 4.6 2.6 13.8 9.9
Spectinomycin >64 25.7 [18.8-32.5] 45.4 28.9 2.0 23.7
Antimicrobial  
agent
Clinical 
breakpoint  
μg/ml
%  
Resistant
95%  
Confidence  
interval 
Distribution (isolates) of MICs
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 >1024
Tetracycline >8 62.5 [51.6-73.4] 36.1 1.4 2.8 59.7
Chloramphenicol >16 23.6 [14-33.3] 50.0 23.6 2.8 4.2 1.4 18.1
Florfenicol >16 18.1 [9.2-26.9] 4.2 51.4 26.4 18.1
Ampicillin >16 45.8 [34.6-57] 6.9 43.1 4.2 1.4 44.4
Cefotaxime >0.25 2.8 [0-7.2] 97.2 2.8
Sulfonamide >256 61.1 [50.1-72.1] 38.9 1.4 59.7
Trimethoprim >8 55.6 [44.4-66.7] 44.4 55.6
Apramycin >16 9.7 [2.7-16.7] 87.5 2.8 9.7
Gentamicin >4 9.7 [2.7-16.7] 80.6 9.7 4.2 4.2 1.4
Neomycin >8 13.9 [5.9-21.9] 86.1 1.4 12.5
Streptomycin >16 77.8 [68.3-87.2] 20.8 1.4 16.7 8.3 16.7 36.1
Ciprofloxacin >2 0.0 [0-2.5] 69.4 9.7 1.4 15.3 4.2
Nalidixic acid >16 19.4 [10.4-28.5] 77.8 2.8 19.4
Colistin >8 0.0 [0-2.5] 98.6 1.4
Spectinomycin >64 56.9 [45.8-68.1] 37.5 1.4 4.2 20.8 36.1
Table 2 Distribution of MICs and resistance (%) in clinical Actinobacillus pleuropneumoniae from pigs (n=135), Denmark DANMAP 2017
continued ... Textbox 6.1
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Textbox 6.2
MRSA contamination of human volunteers after  
short time visit in MRSA positive pig farms
 
Spread of MRSA from pig farms to the community and ultimately to the hospitals is a major concern. In 2017, people with 
contact to pigs comprised 84% (n = 1,019) of all new LA-MRSA cases, while the remaining 16% (n = 193) of the new LA-MRSA 
cases did not report any contact to pigs and thus may have been colonized or infected due to secondary transmissions. Spread 
of LA-MRSA from pig farms most likely occurs by humans carrying MRSA out of the farms. Knowledge of the extent to which 
this happens is therefore pivotal for designing initiatives to prevent spread of LA-MRSA.
In 2016, a study of four trials was conducted to investigate the frequency and duration of MRSA carriage in humans after a 
short-term exposure at a methicillin-resistant Staphylococcus aureus (MRSA) positive pig farm.  
The group of altogether 34 volunteers stayed for 1 hour at the pig farm. In two of the trials, the influence of farm work with 
pig contact was studied. In these trials, the volunteers were allocated into an active group (collecting nasal and skin swabs 
from the pigs) and a passive group (standing in the row between the pens). In order to diminish individual factors for MRSA 
carriage, a crossover study design was chosen, meaning that the volunteers changed group after a three-week washout pe-
riod. In the two other trials, all volunteers were passive. The quantities of MRSA in nasal swabs, throat swabs, and air samples 
were measured at different time points and analyzed in relation to relevant covariates. After the visits in the pig farm, 94% 
of the volunteers had acquired MRSA with no significant differences between volunteers in the active or passive group. Two 
hours after the volunteers left the stable, the nasal MRSA count had declined to unquantifiable levels in 95% of the samples. 
After 48 hours, 94% of the volunteers were MRSA-negative. One volunteer was MRSA positive at day 7 but negative at day 
14. An example of the MRSA decrease in nasal specimens of the volunteers after leaving the farm is shown in Figure 1.
All volunteers carried personal air samplers to measure their individual exposure to MRSA. These experiments showed a positive 
correlation between the nasal MRSA level immediately after leaving the stable and personal exposure to airborne MRSA. Being in the 
active group resulted in the highest level of personal exposure and nasal MRSA counts. Nasal MRSA carriage was therefore positively 
correlated to personal exposure to airborne MRSA and farm work involving pig contact but no association was observed between 
MRSA carriage and face touching behavior, nasal methicillin-susceptible Staphylococcus aureus (MSSA) carriage, age, or gender (1). 
Figure 1 Nasal MRSA count (CFU/ml swab fluid) of human volunteers 0, 1 and 2 hours  
after leaving the stable. One example from the four trials is shown. DANMAP 2017
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The increase in human MRSA carriage among the volunteers with pig contact therefore seems to depend on the increased 
concentration of airborne MRSA during work and not directly on physical contact with pigs. MRSA was not detected in any of 
the throat samples.
In conclusion, the short-term exposure to airborne MRSA poses a substantial risk for farm visitors to become nasal carriers, but 
the carriage is typically cleared within hours to a few days. The risk for short-time visitors to cause secondary transmissions of 
MRSA is most likely negligible due to the observed decrease to unquantifiable levels in 95% of the nasal samples after only 2 
hours. Interventions to reduce the level of airborne MRSA or the use of facemasks might consequently reduce nasal contami-
nation. 
In a different experiment in 2017, the effect of wearing P2 facemasks (normal dust masks) to prevent MRSA contamination 
during a short-term visit was investigated.  A total of 118 human volunteers from five agricultural colleges were randomly al-
located into a mask-wearing group and into a control group. After a one-hour stay on a MRSA positive pig farm, on average 9% 
of the participants wearing masks were MRSA-positive compared to 62% of the participants not wearing masks. An odds ratio 
of 18.9 (CI: 6.4-56.2) for being MRSA-positive was found for those not wearing masks compared to those wearing masks. 
Introducing masks to short-time visitors in MRSA positive pig farms may therefore protect against MRSA contamination during 
the farm stay. Due to the fast clearance of MRSA from the nose, the implications for secondary transmission by short-time 
visitors however seems negligible. Working with P2 facemasks is only allowed for 3 hours daily and thus cannot be used as 
protection for farmworkers staying at the farms for longer periods. Use of facemasks as protection against MRSA coloniza-
tion could however be of interest for people that are repeatedly exposed to MRSA at pig farms for shorter periods, example 
veterinarians. 
Both studies were part of the One Health LA-MRSA program (OHLAM) sponsored by the Ministry of Environment and Food. 
The first study was conducted by Statens Serum Institut in collaboration with the National Research Centre for the Working 
Environment (Angen et al. 2017). The second study was conducted by Statens Serum Institut in collaboration with SEGES.  
Øystein Angen, Jesper Larsen, and Anders Rhod Larsen 
For further information: Øystein Angen, ysan@ssi.dk
References:
Transmission of Methicillin-Resistant Staphylococcus aureus to Human Volunteers Visiting a Swine Farm. Angen Ø, Feld L, 
Larsen J, Rostgaard K, Skov R, Madsen AM, Larsen AR. Appl Environ Microbiol. 2017 Nov 16;83(23). 
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7.1 Introduction
Enterococci (E. faecium and E. faecalis) and Escherichia coli 
are included in the DANMAP programme to monitor antimi-
crobial resistance in Gram-positive and Gram-negative bac-
teria, respectively. These bacterial species were selected as 
indicators of occurrence of antimicrobial resistance in different 
reservoirs through the food chain for several reasons. They are 
ubiquitous and present as commensals in the gut microbiota of 
both animal and human reservoirs, they can acquire antimicro-
bial resistance and resistance genes may be maintained as a 
response to antimicrobial selective pressure, and finally they 
have the potential both to cause infections in humans and to 
transfer antimicrobial resistance to pathogenic bacteria of the 
same or other species. 
Extended-spectrum beta-lactamase-producing (ESBL/AmpC) 
bacteria exhibiting resistance to third-generation cephalospo-
rins are one of the fastest spreading antimicrobial resistance 
problems in both humans and production animals worldwide. 
Recently, several studies have found similar ESBL/AmpC genes, 
plasmids and/or clones of E. coli isolates in animals and meat 
thereof and in human infections, which suggests a zoonotic 
link. Carbapenemase-producing Enterobactericeae (CPE) are an 
even greater threat to human health, since carbapenems are 
the last-line antimicrobial agents for treatment of infections 
caused by multidrug-resistant Gram-negative bacteria.
Since 2014, sampling and testing of Enterococcus spp., indica-
tor E. coli and ESBL/AmpC-producing E. coli have been per-
formed according to the EU harmonised monitoring of antimi-
crobial resistance [Decision 2013/652/EU]. In DANMAP 2017, 
indicator bacteria and ESBL/AmpC producing E. coli originate 
from caeca of pigs and cattle at slaughter. ESBL/AmpC produc-
ing E. coli from and in pork and beef at retail were also included 
in the EU mandatory sampling.
7. Resistance in indicator bacteria
    Highlights: In 2017, resistance to erythromycin and tetracycline was observed in 55% and 
78% of the Enterococcus faecalis isolates from Danish pigs, respectively. A few gentamicin-
resistant isolates (non-HLGR) were observed, where as resistance to other antimicrobial 
agents critical to human medicine was not detected.
  The proportion of fully susceptible indicator E. coli increased slightly in poultry and pigs, 
and decreased slightly in cattle in 2017 compared to 2016. Resistance patterns and levels 
in indicator E. coli from poultry, pigs and cattle were overall similar to previous years and no 
resistance to colistin, meropenem and tigecycline was detected.
  ESBL/AmpC-producing E. coli were recovered from 25% and 7% of the samples from Danish 
pigs and cattle, from 1% and 4% of the samples from domestically produced pork and beef, 
and from 14% and 3% of the samples from imported pork and beef. The ESBL/AmpC occur-
rence in E. coli from the sources monitored in 2017 was comparable to the levels observed 
in 2015. ESBL/AmpC genotypes were determined for isolates from meat only. CTX-M-1 was 
the most common ESBL in E. coli from domestically produced pork and imported pork and 
beef. CTX-M-14, CTX-M-15, and CTX-M-1 were equally prevalent in domestically produced 
beef isolates. No plasmid-mediated AmpCs such as CMY was detected. 
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7.2 Enterococci
DANMAP 2017 Enterococcus faecalis isolates originate from 
randomly collected caecal samples from healthy fattening pigs 
at slaughter. The antimicrobials recommended by EFSA were 
used for MIC testing.
MIC distributions and occurrence of resistance among E. faecalis 
from pigs are presented in the web annex (Table A7.1). E. faecalis 
is considered intrinsically (i.e. naturally) resistant to streptogramin 
A and B (quinupristin/dalfopristin), and interpretation of the MIC 
testing for this antimicrobial agent was not evaluated in DANMAP. 
7.2.1 E. faecalis in pigs 
A total of 55 E. faecalis isolates were derived from 295 pig 
caeca from samples taken from all over Denmark. In 2017, 
the majority of E. faecalis from Danish pigs were resistant to 
tetracycline (78%) and half of the isolates were resistant to 
erythromycin (55%, Table 7.1). Tetracyclines and macrolides 
(e.g. erythromycin) are the most commonly used antibiotics in 
the Danish pig production (Figure 4.4). All isolates resistant 
to erythromycin were also resistant to tetracycline (n=30). 
Chloramphenicol resistance was also common (24%), and all 
chloramphenicol resistant isolates was also co-resistant to 
both erythromycin and tetracycline (n=13). Twelve isolates 
(22%) were susceptible to all antimicrobials tested.
From 2004 to 2012, increasing resistance to erythromycin 
(from approximately 30% to 56%) and chloramphenicol (from 
less than 5% to around 20%) was reported in E. faecalis from 
pigs (Figure 7.1). However, over the last five years, the ob-
served levels of resistance have varied more or less within the 
same ranges, where the reduced number of available isolates 
probably is a contributing factor. 
Tetracycline resistance varied between 80% and 90% dur-
ing 2004-2012, not reflecting the visible increase in use of 
tetracycline in the Danish pig production during the same 
period (Figure 4.4). Since 2013, the consumption of tetracy-
cline in pigs is reduced around 50% (Figure 4.4; all age groups, 
adjusted) and the observed levels of tetracycline resistance 
in 2015 (73%) and 2017 (78%) was significantly lower than 
in 2013 (91%). More samples are needed to verify whether 
the reduction in use will lead to a reduction in tetracycline 
resistance. 
Antimicrobial agent Pigs
Danish
%
Tetracycline 78
Tigecycline 0
Chloramphenicol 24
Ampicillin 0
Erythromycin 55
Gentamicin 7
Ciprofloxacin 0
Vancomycin 0
Teicoplanin 0
Linezolid 0
Daptomycin 0
Fully sensitive (%) 22
Number of isolates 55
Table 7.1 Resistance (%) among Enterococcus  
faecalis from pigs, Denmark DANMAP 2017
Figure 7.1 Resistance (%) among Enterococcus faecalis from pigs, Denmark DANMAP 2017
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Note: An isolate is considered fully sensitive if susceptible to all 
antimicrobial agents included in the test panels
Resistance to gentamicin was observed in four isolates, all in 
combination with resistance to erythromycin, tetracycline and 
chloramphenicol. None of the isolates displayed high-level 
resistance to gentamicin, defined as resistance to MIC values 
>128 mg/L. From 2004-2015, high-level resistance to genta-
micin was observed in 6% to 20% of the E. faecalis isolates 
from Danish pigs (Figure 7.1).
Resistance to ampicillin, ciprofloxacin, daptomycin, linezolid, ti-
gecycline and vancomycin was absent, providing 95% certainty 
that resistance to these compounds are presented in less than 
5% of E. faecalis from pigs in 2017. Resistance to ampicillin, 
vancomycin, tigecycline and linezolid have not been observed 
since these compounds were included in the test panel in 
2005. A few isolates resistant to ciprofloxacin and daptomycin 
have been observed since 2005.
7.2.2 Perspectives
Enterococci are commensal bacteria in the intestine in both 
animals and humans; however both pathogenic strains of E. 
faecalis and E. faecium can cause human disease (chapter 8.5). 
Since 2012, an increase in vancomycin resistant E. faecium has 
been observed in Danish hospitals, whereas only few vanco-
mycin resistant E. faecalis have been observed [Textbox 8.3]. 
Multi-locus sequence typing (MLST) have shown that E. fae-
calis from hospital outbreaks often belongs to specific MLST 
clonal complexes, however some of these sequencetypes have 
also been observed in food and animals. In Denmark (2001-
2002), the same E. faecalis ST16 with high-level resistance to 
gentamicin (HLGR) were found in patients with endocarditis 
(2 of 20 HLGR isolates), from pigs (18 of 19 HLGR isolates) 
and from pork (1 of 1 HLGR isolate) [Larsen et al. 2010. Emerg 
Infect Dis. 16(4):682]. Since then, the presence of this HLGR 
ST16 type in patients and Danish pigs have not been investi-
gated further, however none of the 55 isolates were high-
level resistant to gentamicin, providing 95% certainty that 
resistance to these compounds are presented in less than 5% 
of E. faecalis from pigs in 2017. In comparison, 3.3% of the 
E. faecalis collected from pigs in 2001 displayed high-level 
resistance to gentamicin.
7.3 Indicator Escherichia coli
All isolates originated from caecal samples randomly col-
lected from healthy pigs, broilers and cattle at slaughter. 
The antimicrobials recommended by EFSA were used for MIC 
determination. Only one isolate per farm was included. MIC 
distributions and occurrence of resistance among indicator E. 
coli are presented in the web annex (Table A7.2). These results 
were obtained using the non-selective isolation procedure. 
Results obtained by using selective procedures for detection 
of cefotaxime-resistant E. coli are reported in section 7.4.
7.3.2 Indicator E. coli from broilers
A total of 115 indicator E. coli isolates from broilers were 
tested for antimicrobial susceptibility out of 135 samples 
processed (Table 7.2). More than half (63%) of indicator E. 
coli were susceptible to all antimicrobials tested. Moderate 
(12-17%) occurrence of resistance to ampicillin, nalidixic acid, 
ciprofloxacin, sulfonamide, tetracycline and trimethoprim was 
observed. Low (3-6%) occurrence of chloramphenicol and gen-
tamicin resistance and no occurrence of resistance to the other 
compounds tested were observed (Table 7.2). Occurrence of 
resistance to nalidixic acid and ciprofloxacin, was significantly 
higher in E. coli from broilers compared to E. coli from pigs and 
cattle.
A total of 17 resistance profiles were detected among the 42 
resistant isolates. These profiles ranged from resistance to 
one antimicrobial (or two antimicrobials from the same class) 
in the majority of resistant isolates (nalidixic acid/ciprofloxa-
cin, 24%; tetracycline, 10%; ampicillin, sulphamethoxazole 
or trimethoprim 5%) to resistance to compounds from four 
antimicrobial classes in 9% of resistant isolates. Resistance to 
nalidixic acid/ciprofloxacin was noticeably observed in 33% of 
resistant isolates mainly alone (71%) but also in combination 
with resistance to gentamicin (29%), which is also a critically 
important antimicrobial for human medicine. Co-resistance to 
ampicillin, sulfonamide and trimethoprim (ASuTm resistance 
profile) was the most common profile of resistance to antimi-
crobials from different classes and was found in 33% of the 
resistant isolates mostly in combination tetracycline and/or 
chloramphenicol resistance.
Antimicrobial agent
Broilers Cattle Pigs
Danish
%
Danish
%
Danish
%
Tetracycline 14 8 37
Tigecycline 0 0 0
Chloramphenicol 6 6 6
Ampicillin 17 6 36
Cefotaxime 0 <1 0
Ceftazidime 0 <1 0
Meropenem 0 0 0
Trimethoprim 17 2 30
Sulfonamide 17 7 35
Azithromycin 0 0 1
Gentamicin 3 <1 2
Ciprofloxacin 12 0 <1
Nalidixic acid 12 0 <1
Colistin 0 0 0
Fully sensitive (%) 63 90 49
Number of isolates 115 181 172
Table 7.2 Resistance (%) among Escherichia coli  
from animals, Denmark DANMAP 2017
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Figure 7.2 Resistance (%) among E. coli from animals, Denmark DANMAP 2017
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Compared to 2016, occurrence of resistance to any compound 
except gentamicin declined (Figure 7.2). The decline in ampicil-
lin resistance was statistically significant. The percentage of 
fully susceptible isolates was the second highest after 2014, 
which is the year when the current antimicrobial panels were 
introduced (Figure 7.3).
7.3.2 Indicator E. coli from pigs
A total of 172 indicator E. coli isolates from 193 pig caeca 
were tested for antimicrobial susceptibility (Table 7.2). Ap-
proximately half (49%) of the isolates from pigs were suscep-
tible to all antimicrobials tested. High (30-37%) occurrence of 
resistance to ampicillin, sulfonamide, tetracycline and trime-
thoprim and low (2-6%) occurrence of resistance to gentamicin 
and chloramphenicol were observed. Occurrence of resistance 
to the remaining antimicrobials tested was very low (≤ 1%) or 
not detected (Table 7.2). Occurrence of resistance to ampicillin, 
sulfonamide, tetracycline and trimethoprim was significantly 
higher in E. coli from pigs compared to E. coli from broilers, 
which is noteworthy even though none of these compounds 
is classified among the critically important antimicrobials for 
human medicine.
A total of 23 resistance profiles were detected among the 87 
resistant isolates. These profiles ranged from resistance to 
one antimicrobial in a moderate proportion of resistant isolates 
(tetracycline, 16% and trimethoprim, 2%) to resistance to 
compounds of four and even five antimicrobial classes in 8% 
and 1% of resistant isolates, respectively. Co-resistance to 
ampicillin, sulfonamide and trimethoprim (ASuTm resistance 
profile) was the most common profile of resistance to antimi-
crobials from different classes found in 53% of the resistant 
isolates. The majority of isolates with this profile exhibited 
additional resistance to tetracycline alone or in combination 
with resistance to other compounds including critically impor-
tant antimicrobials such as azithromycin and nalidixic acid/
ciprofloxacin (1% of resistant isolates), azithromycin (1%) and 
gentamicin (1%). Gentamicin resistance was also observed in 
combination with ampicillin and tetracycline resistance (1%) 
and tetracycline resistance (1%). 
Compared to 2016, occurrence of resistance underwent minor 
fluctuations that were not statistically significant for any 
antimicrobial (Figure 7.2). The percentage of fully susceptible 
isolates was the highest since 2014, when the current antimi-
crobial panels were introduced (Figure 7.3).
7.3.3 Indicator E. coli from cattle
A total of 181 indicator E. coli isolates from 190 cattle caeca 
were tested for antimicrobial susceptibility (Table 7.2). The 
vast majority of isolates (90%) was susceptible to all tested 
antimicrobials. Low (2-8%) occurrence of ampicillin, chloram-
phenicol, sulphonamide, trimethoprim and tetracycline resis-
tance was observed. Occurrence of resistance to the remaining 
antimicrobials was very low (<1%) or not detected (Table 7.2). 
This included also resistance to cefotaxime and ceftazidime 
(3rd generation cephalosporins) which was found only in one 
isolate that could not be classified as ESBL or AmpC phenotype 
and was defined as “other phenotype” based on current inter-
pretive criteria (See chapter 9, Materials and methods).
Twelve resistance profiles were detected in the 18 resistant 
isolates, varying from resistance to one antimicrobial class in 
a moderate proportion of resistant isolates (tetracycline, 11% 
and chloramphenicol or ampicillin/ertapenem, 5%) to resis-
tance to compounds of four antimicrobial classes in 22% of the 
resistant isolates. The latter consisted of resistance to ampicil-
lin, chloramphenicol, sulfamethoxazole (and trimethoprim in 
one isolate) and tetracycline.
Compared to 2016, there was an increase in occurrence of 
all resistances observed, though not statistically significant 
(Figure 7.2). The percentage of fully susceptible isolates was 
the second highest after 2016 in the 4-year period since the 
introduction of the current antimicrobial panels (Figure 7.3).
7.3.4 Perspectives
In 2017, the most common resistance patterns described in 
indicator E. coli from broilers, pigs and cattle included resistance 
to ampicillin, sulfamethoxazole, trimethoprim and/or tetracy-
cline, which is similar to what has been described in previous 
DANMAP reports and, more broadly, at EU level [EUSAMR report 
2016, EFSA/ECDC 2017]. These resistances occurred in different 
Figure 7.3 Proportion of fully susceptible Escherichia coli 
isolates from broilers, cattle and pigs, Denmark DANMAP 2017
Note: An isolate is considered fully susceptible if susceptible to all 
antimicrobial agents included in the test panels. Confidence intervals 
are calculated as 95% binomial proportions presenting Wilson intervals
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prevalence in the various animal populations likely reflecting the 
current and past usage of antimicrobials in animals. The determi-
nants of resistance to these antimicrobials are often genetically 
linked and use of one compound can select for resistance to dif-
ferent antimicrobials. 
The antimicrobial resistance phenotypes detected in animal-
origin indicator E. coli of most relevance to human health were 
ciprofloxacin resistance in E. coli from broilers and azithromycin 
resistance in E. coli from pigs. The ciprofloxacin resistance 
phenotype occurred in a moderate but noticeable proportion of 
broiler isolates (12%). Although the molecular bases of cipro-
floxacin resistance were not investigated, the phenotype was 
indicative of chromosomal mutations and, as a consequence, 
the main risk to human health is linked to the potential of these 
strains to cause disease. The azithromycin resistance phe-
notype was detected in a very low proportion of pig isolates 
(1%) and thus the potential human risk, which might derive by 
infections with these strains and/or transfer of azithromycin 
resistance to pathogenic strains appears to be very low.
Resistance to other antimicrobials relevant for human medi-
cine such as colistin, cefotaxime, ceftazidime, meropenem and 
tigecycline was not detected, which indicates that the true 
prevalence of these resistance phenotypes was below 2% in 
E. coli from pigs and cattle and below 3% in E. coli from broilers 
(see Chapter 9, Materials and Methods). However, cefotaxime- 
and ceftazidime-resistant E. coli were detected when using a 
highly sensitive method (selective enrichment) as detailed in 
the following paragraph.
7.4 Extended-spectrum beta-lactamase (ESBL)-, 
AmpC- and carbapenemase-producing E. coli
DANMAP 2017 includes ESBL/AmpC- and carbapenemase-
producing E. coli from caeca of pigs and cattle at slaughter 
and from Danish and imported pork and beef at retail. Samples 
were collected randomly and cultured directly in a selec-
tive enrichment for detection of cefotaxime-resistant E. coli 
Antimicrobial agent
Pigs Pork Cattle Beef
Danish
%
Danish
%
Imported Danish
%
Danish
%
Imported
%
Tetracycline 53 0 75 23 43 33
Tigecycline 0 0 0 0 0 0
Chloramphenicol 11 0 25 5 29 0
Ampicillin 100 100 100 100 100 100
Cefoxitin 73 0 25 46 0 0
Cefotaxime 100 100 100 100 100 100
Ceftazidime 99 100 100 68 57 100
Cefepime 36 100 75 55 100 100
Meropenem 0 0 0 0 0 0
Ertapenem 0 0 0 0 0 0
Imipenem 0 0 0 0 0 0
Trimethoprim 37 100 25 9 29 67
Sulfonamide 52 100 50 23 43 67
Azithromycin 4 33 0 0 0 0
Gentamicin 1 0 25 9 29 0
Ciprofloxacin 3 0 25 0 29 0
Nalidixic acid 1 0 25 0 0 0
Colistin 0 0 0 0 0 0
CPE phenotypes 0 0 0 0 0 0
ESBL phenotypes 27 100 75 50 100 100
AmpC phenotypes 73 0 25 45 0 0
Other phenotypes 0 0 0 5 0 0
Number of isolates 73 3 4 22 7 3
Number of samples 295 248 29 297 170 120
Table 7.3 Antimicrobial resistance (%) and classification of the beta-lactam resistance phenotype (%) of  
ESBL/AmpC-producing Escherichia coli from pigs and cattle and meat thereof, Denmark DANMAP 2017
Note: Isolates recovered by the selective enrichment methods described in the EURL-AR laboratory protocol (January 2017)
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and carbapenemase-producing E. coli (CPE, including strains 
producing OXA-48-like enzymes). Obtained E. coli isolates were 
then used for testing of MIC of the antimicrobials recommend-
ed by EFSA. Whole genome sequencing (WGS) and in silico 
bioinformatics tools were used to determine ESBL/AmpC/CPE-
encoding genes of isolates from meat. MIC distributions and 
occurrence of resistance among ESBL/AmpC–producing E. coli 
isolates are presented in the web annex (Table A7.3-A7.4).
7.4.1 ESBL/AmpC and carbapenemase-producing E. coli 
from pigs and domestically produced pork
A total of 295 samples from pigs and 248 samples from 
domestically produced pork resulted in 73 (25%) and 3 (1%) 
isolates, respectively (Table 7.3). The number of investigated 
samples and occurrence of ESBL/AmpC-producing E. coli iso-
lates from Danish pigs and pork were similar to those tested 
and identified in 2015 (Figure 7.4). Most samples were also 
examined for CPE. No CPE isolates were recovered, suggesting 
that we can be 95% certain that CPE isolates are only present 
in 1% or less of slaughter pigs and domestically produced pork.
Among the 73 ESBL/AmpC -producing E. coli isolates from pigs, 
73% belonged to an AmpC phenotype and 27% to an ESBL 
phenotype displaying 100%, 97%, 73%, and 36% resistance 
to cefotaxime, ceftazidime (3rd generation cephalosporins), 
cefoxitin (2nd generation cephalosporin), and cefepime (4th 
generation cephalosporin), respectively (Table 7.3). In com-
parison to 2015, no significant changes were observed in the 
occurrence of samples with either AmpC or ESBL phenotypes 
(18% vs. 21% and 7% vs. 7%, Figure 7.4). The ESBL/AmpC 
genotypes of isolates from pigs were not determined.
The three ESBL/AmpC-producing E. coli isolated from domesti-
cally produced pork displayed an ESBL phenotype and  all har-
boured the CTX-M-1-encoding gene. By multi-locus sequence 
typing (MLST), two of the isolates were ST117 and one was 
ST88. The CTX-M-1-encoding gene and the STs observed 
(ST117 and ST88) were also found among ESBL/AmpC-produc-
ing E. coli from domestically produced pork in 2015 (Table 7.4).
The 76 ESBL/AmpC-producing E. coli isolates from pigs and do-
mestically produced pork exhibited varying levels of resistance 
to other antimicrobials. No resistance to tigecycline and colistin 
was detected. (Table 7.3) Resistance to quinolones was low, 
only 3% (n = 2) and 1% (n = 1) of the ESBL/AmpC-producing E. 
coli from pigs were resistant to ciprofloxacin and nalidixic acid, 
respectively, suggesting that the isolates harboured a plasmid-
mediated quinolone resistance gene. Different combinations 
of multidrug-resistance were observed in five pig isolates 
primarily including ampicillin, chloramphenicol, tetracycline, 
sulphonamides, and trimethoprim. One pig isolate resistant to 
all these drugs was, in addition, resistant to both ciprofloxacin 
and nalidixic acid. 
Resistance to gentamicin and azithromycin was observed 
in a few ESBL/AmpC–producing E. coli from pigs (n = 3) and 
domestically produced pork (n = 1). The ESBL/AmpC–producing 
isolates resistant to azithromycin were also resistant to ampi-
cillin, ciprofloxacin, tetracycline and sulphonamides. Azithromy-
cin belongs to the critically important antimicrobials for human 
medicine and resistance to it is increasing in isolates originat-
ing from Europe and globally. 
Resistance to sulphonamides and trimethoprim was observed 
in the ESBL/AmpC -producing E. coli isolates from pigs and 
domestically produced pork, and 29 (38%) of the isolates were 
resistant to both sulphonamides and trimethoprim as well as 
to ampicillin and tetracycline. Co-resistance to sulphonamides 
and trimethoprim is likely attributable to the presence of class 
1 integrons, which occasionally also harbour genes encoding 
resistance to ampicillin, tetracycline and chloramphenicol.
Table 7.4 Number of ESBL/AmpC and CPE enzymes detected in E. coli isolates from  
beef and pork of Danish and imported origin, Denmark DANMAP 2017
Enzymes
Pork Beef
Danish Imported Danish Imported
2015 2017 2015 2017 2015 2017 2015 2017
CTX-M-1 2 3 0 2 0 2 3 2
CTX-M-14 0 0 0 1 2 3 0 0
CTX-M-15 1 0 1 0 0 2 2 0
CTX-M-32 0 0 0 0 0 0 1 0
TEM-52C 0 0 0 0 0 0 0 1
Chromosomal AmpC 2 0 0 1 0 0 0 0
Number of ESC positive samples 4 3 1 4 2 7 6 3
Number of tested samples 239 248 50 29 149 170 166 120
Note: Among the isolates from meat of Danish origin from 2017, ESBL enzymes was detected in eight sequence types: CTX-M-1 in ST88, ST362, 
ST117 and ST1434; CTX-M-14 in ST34 and ST162; CTX-M-15 in ST58 and ST224. Isolates recovered by the selective enrichment method 
described in the EURL-AR laboratory protocol (January 2017)
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Figure 7.4 Occurrence (%) of samples with ESBL/AmpC-producing E. coli from cattle, beef, pigs and pork, Denmark  DANMAP 2017
7.4.2 ESBL/AmpC and carbapenemase-producing E. coli 
from cattle and domestically produced beef
A total of 297 samples from cattle and 170 samples from 
domestically produced beef resulted in 22 (7%) and 7 (4%) 
isolates, respectively (Table 7.3). The number of investigated 
samples and occurrence of ESBL/AmpC-producing E. coli isolates 
from cattle and domestically produced beef were similar to 
those tested and identified in 2015 (Figure 7.4). Most samples 
were also examined for CPE and no CPE isolates were recovered, 
suggesting, with 95% confidence, that CPE isolates may be 
present in less than 1% of the samples from cattle and in less 
than 2% of the samples from domestically produced beef.
Among the 22 ESBL/AmpC-producing E. coli isolates from 
cattle, 5% displayed an ESBL phenotype and 45% an AmpC 
phenotype, with 100%, 68%, 46%, and 55% resistance to 
cefotaxime, ceftazidime, cefoxitin, and cefepime, respectively 
(Table 7.3). One isolate was classified as ‘other phenotype’. 
This strain was susceptible to carbapenems and cefoxitin, 
resistant to all tested 3rd and 4th generation cephalosporins 
but with no synergy when the two 3rd generation cephalo-
sporins were combined with clavulanic acid (see definitions in 
chapter 9, Materials and Methods). The ESBL/AmpC genotypes 
of isolates from cattle were not determined. 
All seven ESBL/AmpC-producing E. coli isolates from 
domestically produced beef exhibited an ESBL phenotype 
(Table 7.3). By whole genome sequencing, three ESBL types 
were detected, and each isolate was positive for one ESBL 
type only. The seven isolates harboured CTX-M-14- (n = 3), 
CTX-M-1- (n = 2), and CTX-M-15- (n = 2) encoding genes. 
The three strains harbouring the CTX-M-14-encoding gene 
belonged to two STs by MLST: ST34 (n = 2) and ST162. 
The two CTX-M-1- and two CTX-M-15-producing strains 
belonged to different STs: ST362 and ST1434, and ST58 
and ST224, respectively (Table 7.4). Only ST58 and ST362 
were reported in 2015, both in association with the CTX-M-
1-encoding gene.
The ESBL/AmpC-producing E. coli isolates from cattle and 
domestically produced beef exhibited, in general, a moder-
ate level of resistance to chloramphenicol, sulphonamides, 
tetracycline and trimethoprim and no resistance to tigecycline, 
azithromycin and colistin (Table 7.3). Two ESBL/AmpC -produc-
ing E. coli isolates from domestically produced beef and one 
isolate from cattle exhibited a multidrug-resistance profile 
besides being ESBL/AmpC–producers. This profile included re-
sistance to ampicillin, gentamicin, sulphonamides, tetracycline, 
and trimethoprim. No resistance to nalidixic acid was observed 
in domestically produced beef whereas two isolates (29%) 
exhibited resistance to ciprofloxacin, thus suggesting plasmid-
mediated quinolone resistance. No resistance to fluoroquino-
lones was observed among the ESBL/AmpC -producing E. coli 
isolates from cattle. 
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7.4.2 ESBL/AmpC and carbapenemase-producing E. coli 
from imported pork and beef
Samples from imported pork (29) and beef (120) yielded four 
(14%) and three (3%) ESBL/AmpC-producing isolates, respec-
tively (Table 7.3). Most samples were also examined for CPE 
and no CPE isolates were recovered. 
No statistically significant changes were observed in the 
occurrence of ESBL/AmpC-producing E. coli in these sources 
from 2015 to 2017. ESBL phenotypes were more prevalent 
compared to AmpC phenotypes. The AmpC phenotypes were 
observed in 3.4% of samples from imported pork from 2017 
whereas they were not observed in the samples collected in 
2015 (Figure 7.4). 
The ESBL/AmpC-producing E. coli isolates from imported pork 
in general exhibited a moderate level of antimicrobial resis-
tance and included one multi-resistant isolate that showed 
resistance to antimicrobials from five different classes besides 
being an ESBL producer.  ESBL/AmpC -producing E. coli isolates 
from imported beef exhibited susceptibility to most of the 
antimicrobials tested. In both sources, no resistance to tige-
cycline, azithromycin and colistin was observed. In addition, 
in the isolates from imported beef, no resistance to chloram-
phenicol, fluoroquinolones and gentamicin were observed. In 
contrast, isolates from imported pork conferred exhibited resis-
tance to these compounds and to sulphonamides, tetracycline 
and trimethoprim (Table 7.3).
Genotyping by whole genome sequencing of the four ESBL/
AmpC-producing E. coli isolates from imported pork revealed 
i) CTX-M-1-encoding gene in E. coli ST117 (n=1) and ST2668 
(n=1);  ii) CTX-M-14 encoding gene in E. coli ST455 (n=1), and 
iii) upregulation of chromosomal ampC (by C42T mutation) in E. 
coli ST88 (n=1). Genotyping of the three ESBL/AmpC-produc-
ing E. coli isolates from imported beef revealed CTX-M-1-en-
coding gene in E. coli ST69 and ST362, and TEM-52-encoding 
gene in E. coli ST446 (Table 7.4). None of the STs found in 
2017 were observed in 2015. 
7.4.5 Perspectives 
As in 2015, no carbapenemase-producing E. coli were detected 
in the approximately one-thousand samples from the domestic 
pig and cattle production examined during 2017. Carbapen-
ems are critically important for treatment of severe infections 
caused by multidrug-resistant Gram-negative bacteria in hu-
man patients, thus it is important to continue monitoring for 
introduction of CPE in the Danish animal populations to take 
prompt action in case CPE emerges. 
In 2017, ESBL/AmpC-producing E. coli occurred in samples 
from Danish pigs, cattle and domestically produced meat at 
levels comparable to those observed in 2015. In 2017, the 
most frequent beta-lactam resistance phenotype among 
ESBL/AmpC-producing E. coli from meat was the ESBL 
phenotype occurring in 1% and 4% of the samples from 
domestically produced pork and beef, respectively. Concern-
ing imported meat, the EU harmonised sampling required 
the packages of meat to be selected independently of the 
country of origin and, as only few isolates from imported 
meat were available in 2017, it is not possible to draw con-
clusions on trends or associations of ESBL/AmpC types with 
specific countries. In 2015, the EU harmonised monitoring 
reported an overall EU-prevalence of ESBL-producing E. coli 
of 7% and 5% from pork and beef, respectively [EUSAMR 
report 2016, EFSA/ECDC 2017].   
In textbox 7.1, ESBL/pAmpC-producing E. coli isolated from hu-
mans (bloodstream infection cases from 2017) and meat (iso-
lates from 2016 and 2017) were compared at whole genome 
sequence level. Close phylogenetic relatedness of CMY-2-pro-
ducing E. coli ST131 and CMY-2-producing E. coli ST429 from 
poultry and human origin indicated a possible zoonotic spread. 
Plasmid transfer of genes encoding ESBL/pAmpC enzymes was 
not investigated, and this, together with the occurrence and 
evolution of these E. coli ST/pAmpC combinations need to be 
monitored closely in the future to understand to what extent 
pAmpC E. coli infections in humans might be attributable to 
meat sources. 
Rene S. Hendriksen, Valeria Bortolaia, and Helle Korsgaard 
For further information: Helle Korsgaard, hkor@food.dtu.dk 
91DANMAP 2017
7.RESISTANCE IN INDICATOR BACTERIA
Textbox 7.1 
ESBL/pAmpC-producing Escherichia coli – comparison of isolates 
of animal origin with isolates obtained from human bloodstream 
infections
 
Background: ESBL/pAmpC-producing bacteria are widespread in both humans and production animals worldwide. Previous national and 
international studies have found similar ESBL/pAmpC producing E. coli in animals, meat and human infections, suggesting a zoonotic link. 
In this study, possible clonal zoonotic spread of ESBL/pAmpC producing E. coli was investigated by comparing whole-genome sequencing 
data from E. coli isolates of human and meat origin. Plasmid transfer of genes encoding ESBL/pAmpC enzymes was not investigated. 
Materials and methods: ESBL/pAmpC-producing E. coli isolates from production animals and meat (section 7.4) obtained in 2016 and 
2017 were compared with ESBL/pAmpC-producing E. coli isolates from human bloodstream infections (Textbox 8.1) obtained during 2017. 
Any possible clonal relationships between isolates sharing the same combination of ESBL/pAmpC genes and Multilocus Sequence Types 
(STs), were investigated by whole-genome based single-nucleotide polymorphism (SNP) analysis. The combination was further char-
acterized if <100 SNPs were observed between isolates of animal and human origin. 
Results: During 2016-2017, 85 samples from broiler meat, 24 samples from broilers, 10 samples from beef, and six samples 
from pork were tested positive for genes encoding ESBL/pAmpC enzymes. In 2017, 337 ESBL/pAmpC positive isolates were 
collected from human bloodstream infections. 
When comparing ESBL/pAmpC and ST from the different origins, the same combinations of ESBL/pAmpC and STs were de-
tected in E. coli of human and animal origin on seven occasions; CTX-M-1 in combination with ST69, ST88, ST117 and ST362, 
CMY-2 in combination with ST131 and ST429, and CTX-M-15 in combination with ST224. SNP-based comparisons were per-
formed for each of the seven combinations. Only for ST131 with CMY-2 and ST429 with CMY less than 100 SNPs between the 
isolates were observed.
The ST131 CMY-2-producing E. coli encompassed three samples from imported broiler meat from 2016 and one isolate from a 
patient with bloodstream infection from 2017. Between the E. coli isolate of human origin and two of the three E. coli isolates 
from broiler meat, 39 and 40 SNPs were detected. For the last isolate from broiler meat 1.014 SNPs were detected (Web an-
nex Figure A7.5). 
The ST429 CMY-2-producing E. coli encompassed 11 isolates obtained from broiler meat from 2016 (three import and eight 
Danish), three isolates obtained from Danish broilers from 2016 and one isolate obtained from a patient from 2017. Between 
the E. coli isolate of human origin and the isolates of animal origin, 6-118 SNPs were detected (Web annex Figure A7.6).
For the combinations ST69 with CTX-M-1, ST88 with CTX-M-1, ST117 with CTX-M-1, ST224 with CTX-M-15, and ST362 with 
CTX-M-1, more than 100 SNPs were observed between the isolates of animal and human origin. These five combinations were 
not investigated further.
Discussion and conclusion: ST131 E. coli is the most frequently detected ST among ESBL/pAmpC-producing E. coli isolates 
from human bloodstream infections in Denmark (Textbox 8.1), whereas the pAmpC enzyme CMY-2 is less frequent detected 
among E. coli isolates from humans. The opposite is seen for E. coli of animal origin, where the pAmpC enzyme CMY-2 is often 
detected, especially among broilers, but very few of the E. coli isolates of animal origin belong to ST131. The combination of 
ST131 and CMY-2 is not commonly observed in Denmark; neither from E. coli of animal origin nor from human origin. In 2016, 
the first ST131 CMY-2-producing E. coli isolate causing bloodstream infection in a Danish patient was detected, and in 2017 
another isolate was observed. During 2016-2017, three ST131 CMY-2-producing E. coli were detected from imported broiler 
meat by the DANMAP surveillance [DANMAP 2016, section 7.4]. Investigation of the clonal relationship of ST131 CMY-2-pro-
ducing E. coli from human and animal origin indicates possible clonality between the isolates from these reservoirs, suggesting 
a potential zoonotic link between isolates obtained from imported broiler meat and the isolate obtained from a patient with 
bloodstream infections.
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In 2014-2017, ST429 CMY-2 producing E. coli was isolated 18 times from broilers (animals and meat). In 2016, the first ST429 
CMY-2 producing E. coli isolate causing a bloodstream infection was observed. Investigation of the clonal relationship of ST429 
CMY-2 producing E. coli from human and animal origin suggested a close zoonotic link, with only six SNP differences between 
the human isolate (O) and the closest broiler (animal) isolate (G). Additionally, among nine of the isolates of animal origin (in-
cluding isolate G) 33 or less SNPs were detected, indicating high clonality between the isolates. 
The observation of close phylogenetic relations in ST131 CMY-2-producing E. coli and ST429 CMY-2-producing E. coli from ani-
mal origin and human bloodstream infections indicating a possible zoonotic spread should be noted. Occurrence and evolution 
of these ST/pAmpC combinations need to be monitored closely in the future. 
Louise Roer, Anette M. Hammerum, Frank Hansen, Helle Korsgaard, 
Valeria Bortolaia, Pimlapas Leekitcharoenphon, Henrik Hasman and Rene S. Hendriksen
For further information on the human isolates: Anette M. Hammerum, ama@ssi.dk 
For further information on the meat isolates: René S. Hendriksen, rshe@food.dtu.dk
continued ... Textbox 7.1
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Textbox 7.2
Whole genome sequence (WGS)-based prediction of antimicrobial 
resistance in clinical Escherichia coli from one day in Denmark 
 
Background: Next-generation sequencing techniques allow us to generate data that can be analysed in great detail regarding 
antimicrobial resistance genes, virulence factors and other determinants. In a hospital setting, WGS data from clinical isolates 
could potentially provide accurate species identification, predict the antimicrobial resistance (AMR) profiles, and inform about 
their source, transmission and relation to other isolates infecting multiple patients. We hypothesise that WGS can aid or even 
replace traditional diagnostic methods and eventually be routinely used in clinical microbiology laboratories to guide clinical 
decision making including the adequate pharmacotherapy to be prescribed to the patients. The objective of this study was to 
determine the AMR genotype-phenotype correlation in contemporary E. coli from clinical sources in Denmark.
Materials and methods: We describe the antimicrobial resistance phenotypes and genotypes of 170 E. coli isolates recovered 
from the 11 Danish Departments of Clinical Microbiology (DCM) on one single day in January 2018. These isolates represent 
all E. coli found in a subset of 500 isolates randomly selected among the 2,024 bacterial cultures processed by the DCMs on 
that day. As such, they represent a non-biased snapshot of the E. coli available from that day in the clinical settings in Den-
mark. Of the 170 isolates, 148 (87.1%) were from urine, eight (4.7%) were from blood, and the remaining 14 (8.2%) were from 
other sources including urethral and tracheal swabs, pus, faeces and abscess. Antimicrobial susceptibility testing (AST) was 
performed by broth microdilution using GN3F panel (Sensititre™ Gram Negative MIC Plate) and a custom colistin panel (Sensi-
titre™ Custom Plate). MIC interpretation was performed according to the EUCAST clinical breakpoints. WGS was performed by 
Illumina NextSeq and WGS data were analysed with CGE Bacterial Analysis Pipeline (https://cge.cbs.dtu.dk/services/cge/) and 
other public CGE services (https://cge.cbs.dtu.dk/services/).
Results: A total of 2,890 isolate-antimicrobial combinations were examined, including ampicillin, cefazolin, cefuroxime, cefoxi-
tin, cefpodoxime, ceftazidime, ceftriaxone, ertapenem, meropenem, ciprofloxacin, trimethoprim/sulfamethoxazole, gentamicin, 
tobramycin, amikacin, tetracycline, tigecycline and colistin. According to the EUCAST clinical breakpoints1 no isolates presented 
phenotypic resistance to meropenem, ertapenem, tigecycline and colistin and no genetic determinants of resistance to these 
antimicrobial agents were observed. A total of 91 isolates (53.5%) were fully susceptible to the antimicrobial agents consid-
ered and susceptibility was supported by the absence of genetic determinants conferring resistance to the antimicrobials 
tested. All remaining isolates (n=79, 46.5%) displayed antimicrobial resistance, with 15 (8.8%) being resistant to one antimi-
crobial agent, one (0.6%) being resistant to two antimicrobials of the same class (beta-lactam antimicrobials), 25 (14.7%) being 
resistant to two antimicrobial agents of different classes and 38 (22.4%) being resistant to three or more antimicrobial agents. 
Of the latter, 28 (16.5%) were resistant to antimicrobial agents of three or more different classes, eight (4.7%) were resistant 
to antimicrobial agents from two different classes and two (1.2%) were resistant to antimicrobials from the same class (in 
particular beta-lactam antimicrobials). 
Overall, genotype-phenotype concordance was observed for all but 14 isolate-antimicrobial combinations (Table 1). There was 
limited diversity of the antimicrobial resistance genes detected especially regarding the genes mediating resistance to criti-
cally important antimicrobial agents such as 3rd generation cephalosporins and fluoroquinolones. The availability of WGS data 
allowed a quick screening of the E. coli diversity based on multilocus sequence typing (MLST). The most prevalent MLST se-
quence types (STs) were ST-73 (n=22; 12.9%), ST-69 (n=19; 11.2%), ST-131 (n=13; 7.6%) and ST-95 (n=10; 5.9%), with other 
STs represented by six or less isolates each. All bacteria belonging to ST-131 (n=13) had the serotype O25:H4. Seven (53.8%) 
of the 13 ST131 isolates were resistant to 3rd generation cephalosporins, attributed either to blaCTX-M-15 (n=5) or blaCTX-M-27 
(n=2). These isolates correspond to 70% of all 3rd generation cephalosporin-resistant isolates observed in this study (n=10). 
1 EUCAST Clinical Breakpoints were used for all antimicrobials considered except: 
- Cefazolin: No EUCAST clinical breakpoint nor ECOFF available. CLSI clinical breakpoint was used (R ≥ 32 mg/L). 
- Cefoxitin: No EUCAST clinical breakpoint available. ECOFF was used (8 mg/L). 
- Cefpodoxime EUCAST clinical breakpoint (1 mg/L) not present in panel range. ECOFF was used (2 mg/L). 
-  Ertapenem: EUCAST clinical breakpoint (1 mg/L) and ECOFF (0,064 mg/L) not present in panel range. CLSI clinical breakpoint was used (R ≥ 2 
mg/L).
- Tetracycline: No EUCAST clinical breakpoint available. ECOFF was used (8 mg/L).
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Discussion and conclusion: WGS data were able to accurately predict 99.52% of resistant and susceptible phenotypic profiles 
for the 17 antimicrobials considered in a random and genetically diverse collection of 170 E. coli from clinical sources that 
presented various antimicrobial susceptibility profiles. Thus, WGS-based AMR prediction appears to be a promising antimicro-
bial susceptibility testing method for E. coli. Further work to assess the applicability of WGS-based AMR prediction to other 
clinically relevant bacteria as well as the impact of the obtained results on clinical decisions is ongoing. 
Ana Rita Rebelo, Valeria Bortolaia, Pimlapas Leekitcharoenphon, Bent Røder, Claus Østergaard, Dennis Schrøder Hansen, Esad Dzajic, 
Hans Linde Nielsen, María Kristín Björnsdóttir, Michael Kemp, Niels Frimodt-Møller, Niels Nørskov-Lauritsen, Svend Ellermann-Eriksen, 
Turid Snekloth Søndergaard, Henrik Westh,  Frank M. Aarestrup.
For further information: Ana Rita Rebelo, anrire@food.dtu.dk 
 
continued ... Textbox 7.2
Table 1 Total number of isolates resistant to selected antimicrobials based on EUCAST clinical breakpoints and respective 
antimicrobial resistance determinants detected by WGS DANMAP 2017
Antimicrobial agents
Number of 
resistant 
isolates
Genes or mutations responsible for resistance in resistant 
isolatesa
Number of resistant 
isolates with no 
responsible genes
Number of 
susceptible isolates 
with genes
AMP 66
blaTEM-1B (n=45); blaCTX-M-15 (n=6); blaTEM-1C (n=4); blaCTX-M-27 (n=2);
blaOXA-1 (n=3); blaTEM-1A (n=2); blaCTX-M-14 (n=1); blaTEM-1D (n=1); 
blaSHV-1 (n=1); blaDHA-1 (n=1)
0 1b
CZO 14
blaCTX-M-15 (n=6); blaTEM-1B (n=3); blaCTX-M-27 (n=2); blaDHA-1 (n=1); 
blaCTX-M-14 (n=1); blaTEM-1C (n=1)
0 1b
CUR and/or CXI 14
blaCTX-M-15 (n=6); blaCTX-M-27 (n=2); blaOXA-1 (n=2); blaDHA-1 (n=1); 
blaCTX-M-14 (n=1)
2c 2bd
CPO and/or CTZ and/
or CTR
10
blaCTX-M-15 (n=6); blaCTX-M-27 (n=2); blaDHA-1 (n=1);  
blaCTX-M-14 (n=1)
0 1b
MER and/or ERT 0 None 0 0
CIP 23
parC S80I, gyrA S83L, gyrA D87N/D87H e (n=17);  
parC S80I, gyrA S83L, gyrA D87N e and aac(6’)-Ib-cr (n=5); 
qnrS1 (n=1)
0 2f
TRS 37 dfrA17 (n=18); dfrA14 (n=5); dfrA1 (n=3); dfrA5 (n=4); 
dfrA7 (n=2); dfrA12 (n=2); dfrA8 (n=1)
2g 2
GEN and/or TOB and/
or AMI
12 aac(6’)-Ib-cr (n=5); aac(3)-IId (n=3); aac(3)-IIa (n=1); 
aac(3)-IVa (n=1); aac(6’)-Ib-cr and aac(3)-IIa (n=1)
1 0
TET and/or TIG 45 tet(A) (n=23); tet(B) (n=22) 0 0
COL 0 None 0 0
AMP: ampicillin, CZO: cefazolin, CUR: cefuroxime, CXI: cefoxitin, CPO: cefpodoxime, CTZ: ceftazidime, CTR: ceftriaxone, MER: meropenem, ERT: 
ertapenem, CIP: ciprofloxacin, TRS: trimethoprim/sulfamethoxazole, GEN: gentamicin, TOB: tobramycin, AMI: amikacin, TET: tetracycline, TIG: 
tigecycline, COL: colistin
a) In cases where several genes mediating the same phenotype were present, only one was included in the table. Discrepancies in phenotypic-
genotypic results can be found in the two right hand columns.
b) The isolate is the same for all four cases and presents the genes blaCTX-M-15 and blaOXA-1
c) One isolate presents the blaTEM-1C gene. One isolate does not present beta-lactam resistance determinants and is phenotypically susceptible 
to other cephalosporins.
d) One of the isolates is the one referred to in b. The other isolate presents a blaOXA-1 gene.
e) Isolates presented at least the three described point mutations simultaneously, with (n=21) or without (n=1) additional parC and/or parE 
point mutations.
f) One isolate presents the aac(6’)-Ib-cr gene without co-occurrence of gyrA, parC or parE point mutations. The remaining isolate presents the 
qnrB4 gene.
g) One isolate presents only sul1 without trimethoprim resistance determinants. The remaining isolate harbors sul1 and sul2 genes without 
trimethoprim resistance genes.
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8. Resistance in human clinical bacteria
    Highlights: DANMAP 2017 presents resistance data on invasive and other clinically im-
portant human infections reported from the Danish Departments of Clinical Microbiology 
(DCM) for the past decade. Overall, an increasing trend in the total number of blood isolates 
has been observed since 2009 and after a period with either decreasing or stable resis-
tance rates in clinical Escherichia coli and Klebsiella pneumoniae, an upward going trend in 
resistance was observed for several antimicrobial classes in 2017. For multidrug-resistant 
species; methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant entero-
cocci (VRE) and carbapenemase-producing organisms (CPO), the incidences/total number of 
isolates kept on increasing. (Textboxes 8.1, 8.2, 8.3 and section 8.7). 
 
For Escherichia coli (section 8.1), resistance to ciprofloxacin and cefuroxime in isolates from 
invasive infections showed increases from 2016-2017 (from 11% to 13% and from 8.6% to 
9.7%, respectively). For ciprofloxacin this is probably due to changes in clinical breakpoints 
for 2017. Cefuroxime was the only antimicrobial with continously increasing resistance rates 
measured over the past decade, (from 6.0 to 9.7% in invasive isolates and from 4.0 to 7.1% 
in isolates from hospital urines, respectively).  
 
Decreases were observed for sulfonamide and ampicillin resistance. For sulfonamide resis-
tance, an overall decrease from 38% til 29% has been observed since 2008. Likewise, the 
resistance rate for ampicillin from samples from primary health care (PHC) decreased, al-
though less markedly from 41% to 38% since 2008.  
 
Data on Klebsiella pneumoniae (section 8.2) were obtained from blood and urine samples 
as well. Although resistance rates in the invasive isolates in general have shown decreases 
since 2008, some tendencies of increase were observed in 2017. As for E. coli, significant 
increases were observed for resistance to ciprofloxacin, but also for piperacillin/tazobactam 
(from 5.4% to 9% and from 5.8% to 7.4%, respectively). Additionally, marked increases in 
mecillinam resistance and in sulfonamide resistance from 2016 to 2017 were observed for 
both hospital samples (from 8.9% to 16% for mecillinam and from 17% to 26% for sulfon-
amide) and PHC samples (from 9% to 17% for mecillinam and from 19% to 26% for sul- 
fonamide). 
 
The increasing resistance towards ciprofloxacin was also observed for Neisseria gonor-
rhoeae (section 8.8) – increasing from 18% in 2016 to 28% in 2017, though a significant, 
continuing decrease has been maintained since a peak of 75% in 2009. 
 
Moreover, data on methicillin-resistant Staphylococcus aureus (MRSA, section 8.7) re-
vealed a significant increase in the number of community-acquired infections since 2009. 
This increase in infections follows the increase in total number of newly diagnosed cases 
proportionally. Also the number of bacteraemias with Staphylococcus aureus increased after 
a stable period the past two years, reaching 2,104 isolates in 2017. 
 
For the first time, DANMAP 2017 includes resistance data on Haemophilus influenzae 
(textbox 8.4). H. influenzae has been monitored since 2014, where a total of 128 cases of 
systemic inflections were reported. In 2017, 115 cases were reported. A slightly increasing 
resistance to ampicillin should be noted. 
 
DANMAP 2017 also presents data on Mycoplasma genitalium (textbox 8.6), for which 
rapidly increasing resistances towards all antimicrobials available is worrisome. 
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8.0 Introduction
DANMAP receives national resistance data on invasive isolates 
from the 10 Departments of Clinical Microbiology (DCM) for all 
species causing bloodstream infections in humans in Den-
mark: Escherichia coli, Klebsiella pneumoniae, Enterococcus 
faecalis, Enterococcus faecium, Pseudomonas aeruginosa, 
Acinetobacter species and Staphylococcus aureus. In addition, 
DANMAP also receives resistance data for E. coli and K. pneu-
moniae from urine samples from either hospitalised patients 
or patients seen at the general practitioner. Surveillance has 
been performed since 1995. In the very beginning, based on 
the reporting from two DCM, but quickly joined and supported 
by most clinical microbiological laboratories. From 2009 to 
2014, DANMAP received data from all but one DCM resulting 
in a coverage of approx. 95% of the population. Since 2015, all 
DCM have participated in the program, thus representing the 
complete Danish population. Data are reported once yearly, 
submitting resistance on the first annual isolate per patient. 
For further information on the resistance testing and reporting 
see chapter nine, materials and methods. 
DANMAP also receives resistance data from the reference labo-
ratories at SSI, where strains from several species are submitted 
for descriptive and/or surveillance purposes. Thus, all invasive 
strains of Staphylococcus aureus have been submitted on a vol-
untary basis since 1957. Also voluntary is the submission of in-
vasive beta-haemolytic streptococci, while invasive Streptococ-
cus pneumoniae and Haemophilus influenzae are mandatory to 
submit. The detection of methicillin-resistant S. aureus (MRSA) 
and Neisseria gonorrhoeae from all clinical sites is notifiable and 
the submission of the isolated strains mandatory. 
In addition, the DCM submit isolates from hospital samples of ES-
BL-producing E. coli from blood and vancomycin-resistant entero-
cocci (VRE) and carbapenemase-producing organisms (CPO) from 
all clinical sites, irrespective of infection or colonisation, based on 
a mutual agreement to survey the development and spread of 
these often multi-resistant bacteria at Danish hospitals. 
From 2009 to 2017, the total number of reported invasive 
isolates increased by 33% (from 8,277 to 10,975 isolates). 
The largest increase observed was for E. faecium (89%). The 
only species decreasing was S. pneumoniae (-27%). Table 
8.0.1 presents the percentage distribution of invasive species 
in 2009 and 2017, respectively. The biggest changes were 
observed in E. coli, increasing its proportion by 3.9%, and S. 
pneumoniae decreasing by 5.4%.
In 2017, the number of isolates maintained the increasing trend 
with E. coli constituting close to 50% of the total (Figure 8.0.1).
Figure 8.0.2 follows the absolute proportional changes for 
each species year by year. 
The increase in the total number of isolates probably mirrors 
demographic changes with a growing population of elderly and of 
chronically ill or immunocompromised. These changes are paral-
leled by increasing activity at hospitals during the past decade, 
where the number of admissions increased with 10% and the 
number of treated patients in ambulatory care with 26%. In 2017, 
hospital activity amounted to 221 admissions and 647 bed days 
per 1000 inhabitants, combined with 1350 ambulatory treatments 
per 1000 inhabitants.  The increasing number of invasive infec-
tions is of concern to a health care system that is under pressure. It 
demands fast and effective antibiotic treatment, while increasing 
the risk for the development of resistant infections and the spread 
of these in hospital environments with fragile patient popula-
tions. It also underlines the need for a health system with firmly 
established infection prevention and control and an understand-
ing of the importance of proper diagnostics and a rational use of 
antibiotics, reserving the most broad-spectrum antibiotic classes to 
the few patients with the still rare, multi-resistant infections.  
Table 8.0.1 Distribution of species in invasive isolates (based on 
total number of isolates) and the percentage change from 2009 
to 2017, Denmark DANMAP 2017
Species 2009 2017 % change
E. coli 42.67% 46.60%     3.92%
S. aureus 16.89% 18.19%     1.30%
S. pneumoniae 12.03% 6.62%    -5.41%
K. pneumoniae 9.93% 10.78%     0.85%
E. faecium 5.07% 7.23%     2.15%
E. faecalis 8.22% 6.18%    -2.04%
P. aeruginosa 5.18% 4.41%    -0.77%
47%
18%
7%
11%
6%
7%
4%
E. coli; 47% S. aureus; 18% S. pneumoniae; 7%
K. pneumoniae; 11% E. faecalis; 6% E. faecium; 7%
P. aeruginosa; 4%
Figure 8.0.1 Distribution of species from invasive  
isolates, 2017, Denmark  DANMAP 2017
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Test for trend in resistance
For the first time, this chapter contains results of trend analysis applied to reported resistance rates for E. coli and K. pneumoniae. 
Significance levels were calculated for the main seven antimicrobials. 
The Cochran-Armitage test for trend in proportions was performed on susceptibility data through five and ten years respectively. 
This test was chosen because of its ability to uncover trends in binomial proportions explained by an ordinal variable.
One sided tests was performed and the respective significance levels have been reported by the p-value and marked by an arrow 
indicating probability of increase or decrease. The one-sided p-value for trend is computed as:
The null-hypothesis shared by both computations assumes no trend. One-sided tests were chosen because of a preliminary ex-
pected direction in trend.
Most of the significant probabilities are commented and considered together with the graphs to highlight the situation of antimi-
crobial resistance. 
Note that the significance levels are reported here to support the interpretations of the graphs and thus should be interpreted 
with caution.
P1= { Prob(Z>T)      if T>0 }Prob(Z<T)      if T≤0
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Figure 8.0.2 Number of submitted invasive isolates (from 2009 to 2017) for each of the species under surveillance. DANMAP 2017
This chapter describes the resistance rates along with sam-
pling details and surveillance data for the above-mentioned 
bacteria along with a couple of other. In addition, this report 
presents data on Haemophilus influenzae for the first time. 
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8.1 Escherichia coli
Escherichia coli (E. coli) is the most frequent cause of com-
munity- and hospital acquired urinary tract infections and of 
bacteraemia in Denmark. It is part of the normal intestinal 
flora in both animals and humans, where it comes into close 
proximity to many other bacterial species. Transferred resis-
tance mechanisms from other bacterial species to E. coli are 
frequently seen. Some E. coli contain virulence factors that 
dispose for gastrointestinal illnesses of varying severity, such 
as the often mild Traveller’s diarrhoea or the severe gastroin-
testinal illness associated with the development of haemolytic 
uremic syndrome.
8.1.1 Blood isolates from hospitalised patients
For 2017, DANMAP received data on the antibiotic suscepti-
bility in 5,114 E. coli isolates from blood cultures from all 10 
Departments of Clinical Microbiology (DCM) in Denmark. All 
10 DCM routinely (>75% of isolates) tested for resistance to 
ampicillin, ciprofloxacin, piperacillin/tazobactam, gentamicin, 
cefuroxime, 3rd generation cephalosporin and carbapenems. 
Tested 3rd generation cephalosporins were either cefpodox-
ime, ceftazidime or cefotaxime, while the tested carbapenem 
was meropenem for all DCM in 2017. In addition, nine DCM 
routinely tested for mecillinam resistance and four routinely 
tested for resistance to amoxicillin/clavulanic acid. Resistance 
testing was mainly performed by disc diffusion. The presented 
data consist of the reported interpretation results, performed 
by the DCM, based on the S-I-R system.
Resistance results for 2017 for all tested antibiotics, presented 
as a national mean for each antibiotic class, are summarized in 
Table 8.1.1. In Figure 8.1.1, rates of resistance are shown for 
the past decade – here data are presented as a national mean, 
when at least six DCM performed routine testing. Time trends 
and significance levels of these, based on the resistance rates 
five and ten years back, respectively, are presented in Figure 
8.1.1 c). Test results for mecillinam resistance in invasive E. coli 
has been excluded from Figure 8.1.1, since the S-I-R interpreta-
tion rules for the individual DCM differ and/or vary over time, 
making comparison of the results difficult and time trends 
unreliable.
A continuous increase in the number of reported E. coli isolates 
from blood cultures was observed throughout the years, 
from 3,426 isolates in 2010 to 5,114 isolates in 2017 (a 
49% increase), Figure 8.1.1 a). As discussed previously (see 
introduction to this chapter and DANMAP 2016) this may be 
due to several factors such as demographic changes, improved 
culturing methods, and changes in hospital workflow. When 
comparing these steep increases in positive blood cultures to 
Figure 8.1.1 Resistance (%) in Escherichia coli invasive isolates from humans, 2008-2017, Denmark   DANMAP 2017
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Substance
Time trends (Cochran-Armitage test)
10 years  
(2008 - 2017)
5 years 
(2013 - 2017)
Ampicillin    p = 0.1    p = 0.31
Piperacillin/tazobactam    p = 0.16*    p = 0.42
Gentamicin    p = 7.702e-06    p = 0.02
Ciprofloxacin    p = 0.01    p = 0.47
Cefuroxime    p = 1.881-07    p = 0.27
3rd generation cephalosporins    p = 0.32    p = 0.03
Carbapenem    p = 0.12    p = 0.15
Note: Figure 8.1.1 a) Resistance results and the total number of 
positive blood isolates are presented. b) Resistance rates excluding 
ampicilin. c) Time trends and significance levels for the past five and 
10 years, respectively (Cochran-Armitage test). The number (n) in 
parentheses represents either the total number of positive isolates or 
the individual numbers of isolates tested for that specific antibiotic 
in 2017. *For piperacillin/tazobactam a nine years test is performed, 
since data are not complete before 2009.
a) b)
c)
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the actual numbers of blood cultures taken, as registered in 
the Danish Microbiology Database, MiBa, a marked increase in 
the sampling number was also observed; from approximately 
365,000 in 2010 to approximately 548,000 in 2017, a 50% 
increase (Data extracted from MiBa on all collected blood cul-
turing samples with a unique sample ID, for the time period of 
January 1st 2010 to December 31st 2017). It seems reasonable 
to investigate for possible causal factors, including systematic 
typing of some of the strains to better understand potential 
clonal nosocomial outbreaks that may have passed unnoticed.
In 2017, the proportion of ciprofloxacin resistant strains 
increased markedly (12.8%) compared to 2016 (11.1%). But 
these recent changes in resistance rates may reflect a change 
in the interpretation of S-I-R more than a true epidemiologic 
change, since new EUCAST breakpoints for ciprofloxacin were 
implemented in most of the Danish DCM as for January 2017. 
During the last decade resistance to ciprofloxacin showed 
significant decreases in time trend analysis. 
For cefuroxime and gentamicin in invasive E. coli, significant 
increasing trends in resistance were observed for the last 
decade, but reverting to a decreasing trend in resistance to 
gentamicin for the past five years. Also for 3rd generation 
cephalosporins in invasive E. coli, the resistance rate decreased 
during the last five years. (For more details see Figure 8.1.1 a), 
b) and c)). 
The number of carbapenem resistant E. coli isolates remained 
continuously very low with three carbapenem resistant and 
two intermediary resistant E. coli isolates in 2017 – the same 
level as previous years. Although still at a low level, the risk 
of increasing levels of carbapenem resistance in the future is 
worrisome. The level of multi-resistant (combined resistance to 
3rd generation cephalosporins, ciprofloxacin and gentamicin) 
invasive E. coli remained at around 2%, Table 8.1.2. No pan-
resistant E. coli have been described in Denmark yet. 
8.1.2 Urine isolates from hospitalised patients
For 2017, DANMAP received data on the antibiotic susceptibil-
ity in 46,884 E. coli isolates, cultured in urine samples from 
hospitalised patients from all 10 DCM in Denmark. 
All 10 DCM routinely (>75% of isolates) tested for resistance to 
mecillinam and gentamicin; in addition nine DCM routinely tested 
for resistance to ampicillin, ciprofloxacin and 3rd generation cepha-
Table 8.1.1 Resistance (%) in Escherichia coli isolates from humans, Denmark, 2017 DANMAP 2017
Substance
Blood isolates, hospitals
%
Urine isolates, hospitals
%
Urine isolates, primary health care
%
Ampicillin 46 42 38
Mecillinam 14 7.5 5.5
Piperacillin/tazobactam 4.5 3.7 3.1
Amoxicillin/clavulanic acid 17 14 8.3
Sulfonamide 31 29
Trimethoprim 23 23
Nitrofuratoin 1.2 1.1
Gentamicin 6.0 4.9 4.1
Ciprofloxacin 13 10 8.4
Cefuroxime 9.7 7.1 5.0
3rd generation cephalosporins 6.7 6.2 4.5
Carbapenem <1 <1 <1
Max. number of isolates tested for 
resistance to the presented antibiotics
5113 46580 73478
All rates of resistance are presented for each antibiotic in each of the three groups as a mean of the resistance rates reported by the DCM. 
Included are all DCM that report testing for >75% of the isolates in each antibiotic/sample group.  
2014  
% (N)
2015 
% (N)
2016 
% (N)
2017 
% (N)
Resistance 1.8 (72) 2.3 (93) 1.8 (87) 1.8 (88)
Percentage (no.) of isolates tested for combined resistance 
(multiresistance)
90 (4039) 88 (4071) 98 (4763) 95 (4883)
Total number of blood isolates 4495 4614 4841 5114
Table 8.1.2 Combined resistance to 3rd generation cephalosporins, ciprofloxacin, and gentamicin (multiresistance) 
in blood E. coli isolates from humans, Denmak   DANMAP 2017
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losporins; eight DCM routinely tested for resistance to cefuroxime, 
piperacillin/tazobactam, and trimethoprim; seven DCM routinely 
tested for carbapenem resistance; six DCM routinely tested for 
sulfonamide resistance and five DCM routinely tested for resis-
tance to nitrofurantoin and amoxicillin/clavulanic acid. 
Resistance results for 2017 for all tested antibiotics are sum-
marized together with the results from the invasive isolates as a 
national mean for each antibiotic in Table 8.1.1. In Figure 8.1.2, 
rates of resistance are presented as a national mean when at 
least six DCM performed routine testing. Time trends and sig-
nificance levels, based on the resistance rates for the past five 
and 10 years respectively, are presented in Figure 8.1.2 c).
Time trend analysis revealed that mecillinam gentamicin, cefu-
roxime and 3rd generation cephalosporins all had significantly 
increasing resistance rates looking back 10 years. Looking back 
five years, the increases were no longer significant for mecil-
linam and gentamicin. For ciprofloxacin the resistance rates was 
significantly decreasing looking at time trends both 10 and five 
years back. (For more details see Figure 8.1.2 a), b) and c)).
The level of carbapenem resistance remained continuously low 
with total reports of 11 resistant and 8 intermediary resistant 
E. coli urine isolates from hospitalised patients in 2017.
8.1.3 Urine isolates from primary health care
For 2017, DANMAP received data on the antibiotic susceptibil-
ity in 73,497 E. coli isolates, cultured in urine samples from pri-
mary health care, from nine DCM in Denmark. These nine DCM 
cover all samples from primary health care in Denmark, since 
one Danish DCM only handles hospital samples. In general, 
many GPs perform culturing of urine samples at their practice 
and thus only a selected number will be referred to a DCM. In 
the Capital Region of Denmark there is one private laboratory 
in addition, performing culturing of urine samples from primary 
care.
All nine DCM routinely (>75% of isolates) tested for resistance 
to ampicillin, mecillinam and 3rd generation cephalosporins; 
eight DCM routinely tested for resistance to sulphonamide, 
trimethoprim and ciprofloxacin; six DCM routinely tested 
for nitrofurantoin resistance; four DCM routinely tested for 
resistance to gentamicin and cefuroxime; three DCM routinely 
tested for carbapenem resistance and two DCM routinely 
tested for resistance to amoxicillin/clavulanic acid and piper-
acillin/tazobactam. 
As for the results from invasive isolates and isolates from hos-
pital urines, resistance results for 2017 for all tested antibiot-
ics are shown as national means in Table 8.1.1. In Figure 8.1.3, 
rates of resistance are presented as a national mean when at 
least six DCM performed routine testing. Time trends and sig-
nificance levels, based on the resistance rates for the past five 
and 10 years respectively, are presented in Figure 8.1.3 c). 
Figure 8.1.2 Resistance (%) in Escherichia coli urine isolates  
from humans in hospitals, Denmark  DANMAP 2017
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Substance
Time trends (Cochran-Armitage test)
10 years  
(2008 - 2017)
5 years 
(2013 - 2017)
Ampicillin    p = 0.08    p = 0.09
Mecillinam    p < 2.2e-16    p = 0.4
Piperacillin/tazobactam    p = 0.08
Sulfonamide    p = 0.08    p = 0.09
Gentamicin    p = 4.223e-12    p = 0.18
Ciprofloxacin    p < 2.2e-16    p = 1.074e-13
Cefuroxime    p < 2.2e-16    p = 1.301e-08
3rd generation cephalosporins    p = 6.469e-14    p = 0.01
b)
c)
Note: Figure 8.1.2 a) Resistance results and total number of positive 
urine isolates are presented. b) Resistance rates excluding ampicilin, 
sulfonamide and trimethoprim. c) Time trends and significance 
levels for the past five and 10 years respectively. The number (n) in 
parentheses represents either the total number of positive isolates or 
the individual numbers of isolates tested for that specific antibiotic in 
2017.
a)
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A very steep increase (150%) in reported E. coli isolates 
cultured from urine samples from primary health care has been 
observed since 2010. Data extractions from MiBa for the same 
period show a steep increase in the total number of submitted 
urines for culturing as well. In 2010 in between 164,000 and 
206,000 urine samples were submitted to the DCM from the 
primary sector, compared to in between 430,000 and 439,000 
urine samples in 2017, representing an increase in between 
114% and 162%. The imprecision in the numbers extracted 
from MiBa is caused by, in some cases, difficulties in categori-
sation of hospital vs primary care urines. 
Time trend analysis revealed that resistance to 3rd generation 
cephalosporins has increased significantly both in the past 
decade and in the past five years. Mecillinam resistance rates 
have increased in the past five years. Ciprofloxacin, sulfon-
amide and ampicillin resistance rates have decreased both in 
the past decade and in the past five years. (For more details 
see Figure 8.1.3 a), b) and c)).
In 2017, three carbapenem resistant and five intermediary re-
sistant E. coli isolates from primary health care were reported.
Conclusion
A substantial increase in the total number of E. coli found in 
blood cultures and in urine samples submitted from the pri-
mary sector to the DCM were observed since 2010 (beginning 
of the observation period). In the same time period, a cor-
responding increase in the total numbers of registered blood 
cultures and urine samples from the primary sector occured. 
The numbers of E. coli found in urine samples from hospitals 
showed less increases as did the total numbers of registered 
urine samples from hospitals. It is reasonable to conclude that 
at least part of the increase in the number of E. coli isolates is 
due to an increased number of performed cultures. It remains 
to be answered whether these increases also could be due to 
changes in E. coli virulence. 
Time trend analyses for all three categories of E. coli isolates 
revealed an increase in cephalosporin (cefuroxime and 3rd 
generation cephalosporins) resistance rates both for the past 
decade, and for resistance rates in urines also for the past five 
years. One exception was the resistance to 3rd generation 
cephalosporins in invasive E. coli, which showed decreasing 
resistance rates in invasive E. coli in the past five years. 
The time trends for ciprofloxacin showed decreasing resis-
tance in the past ten years for all categories, which is positive. 
The time trends for gentamicin resistance rates were decreas-
ing for the past five years. In urine isolates, the time trends for 
sulfonamide resistance rates were decreasing and for mecil-
linam rather stable. 
Sissel Skovgaard and Stefan S. Olsen 
For further information: sisk@ssi.dk
Figure 8.1.3 Resistance (%) in Escherichia coli urine isolates from 
humans in primary health care, Denmark  DANMAP 2017
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Substance
Time trends (Cochran-Armitage test)
10 years  
(2008 - 2017)
5 years 
(2013 - 2017)
Ampicillin    p < 2.2e-16    p = 3.064e-11
Mecillinam    p = 0.5    p = 8.329e-05
Sulfonamide    p < 2.2e-16    p < 2.2e-16
Ciprofloxacin    p < 2.2e-16    p = 0.0001
3rd generation cephalosporins    p < 2.2e-16    p = 0.0006
a)
b)
c)
Note: Figure 8.1.3 a) Resistance results and total number of positive 
urine isolates are prensented. b) Resistance rates excluding ampicilin, 
sulfonamide and trimethoprim. c) Time trends and significance 
levels for the past five and 10 years respectively. The number (n) in 
parentheses represents either the total number of positive isolates or 
the individual numbers of isolates tested for that specific antibiotic in 
2017.
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Figure 8.2.1 Resistance (%) in Klebsiella pneumoniae blood 
isolates from humans, Denmark   DANMAP 2017
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Substance
Time trends (Cochran-Armitage test)
10 years  
(2008 - 2017)
5 years 
(2013 - 2017)
Piperacillin/tazobactam    p = 0.47
Gentamicin    p < 2.2e-16    p = 0.03
Ciprofloxacin    p < 2.2e-16    p = 0.28
Cefuroxime    p = 8.386e-07    p = 0.13
3rd generation cephalosporins    p = 3.111e-05    p = 0.05
Carbapenem    p = 0.12    p = 0.29
Note: Figure 8.2.1 a) Resistance results and the total number of 
positive blood isolates are presented. b) Time trends and significance 
levels for the past five and 10 years, respectively (Cochran-Armitage 
test). The number (n) in parentheses represents either the total 
number of positive isolates or the individual numbers of isolates 
tested for that specific antibiotic in 2017.
8.2 Klebsiella pneumoniae
Klebsiella pneumoniae (K. pneumoniae) is capable of colonis-
ing the gastrointestinal and respiratory tract in humans, espe-
cially in hospitalised patients. It may cause infections such as 
urinary tract infections, severe pneumonia and blood stream 
infections – the latter especially in patients with indwelling 
devices - and may give rise to nosocomial outbreaks. K. pneu-
moniae rather easily acquires and is able to transfer plasmid 
borne resistance traits.   
8.2.1 Blood isolates from hospital patients
For 2017, DANMAP received data on the antibiotic susceptibil-
ity in 1,183 K. pneumoniae isolates from blood cultures from 
all 10 DCM in Denmark. All 10 DCM routinely (>75% of isolates) 
tested for resistance to ciprofloxacin, piperacillin/tazobactam, 
gentamicin, cefuroxime, 3rd generation cephalosporin and car-
bapenem. Tested 3rd generation cephalosporins were either 
ceftazidime, ceftriaxone, cefotaxime or cefpodoxime and the 
tested carbapenem was meropenem. In addition, nine DCM rou-
tinely tested for mecillinam resistance and four DCM routinely 
tested for resistance to amoxicillin/clavulanic acid. Resistance 
testing was mainly performed by disc diffusion. The presented 
data consist of the reported interpretation results, performed 
by the DCM, based on the S-I-R system.
Resistance results for 2017 for all tested antibiotics, present-
ed as a national mean for each antibiotic class, are summarized 
in Table 8.2.1. In Figure 8.2.1 rates of resistance are shown for 
the past decade – here data are presented as a national mean, 
when at least six DCM have performed routine testing. Time 
trends and significance levels, based on the resistance rates 
for the past five and ten years respectively, are presented in 
Figure 8.2.1 b). Test results for mecillinam resistance in inva-
sive K. pneumoniae are excluded from Figure 8.2.1, since the 
S-I-R interpretation rules for the individual DCM differ and/or 
Substance Blood isolates, hospitals Urine isolates, hospitals Urine isolates, primary health care
% % %
Mecillinam 19 16 17
Piperacillin/tazobactam 7.4 6.7 7.6
Amoxicillin/clavulanic acid 19 16 14
Sulfonamide 26 25
Trimethoprim 26 27
Nitrofuratoin 13 15
Gentamicin 3.2 3.6 2.1
Ciprofloxacin 9.0 7.6 5.4
Cefuroxime 11 9.4 5.0
3rd generation cephalosporins 7 7.1 4.9
Carbapenem <1 <1 <1
Max. number of isolates tested for 
resistance to the presented antibiotics
1183 8092 8939
All proportions of resistance are presented for each antibiotic in each of the three groups as a mean of the resistance rates reported by the 
DCM. Included are all DCM that repports testing for >75% of the isolates in each antibiotic/sample group.  
Table 8.2.1 Resistance (%) in Klebsiella pneumoniae isolates from humans, Denmark, 2017  DANMAP 2017
a)
b)
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vary over time, making comparison of the results difficult and 
time trends unreliable.
As for E. coli isolates from blood cultures, a continuous increase 
in the number of reported K. pneumoniae isolates from blood 
cultures was observed throughout the years, from 799 isolates in 
2010 to 1,183 isolates in 2017 (a 48% increase), Figure 8.2.1 a). 
This matches a 50% increase in actual numbers of blood cultures 
taken in the same time period, as registered in the Danish Microbi-
ology Database, MiBa, as described in section 8.1.1.
Curves and time trend analysis revealed that resistance rates 
have decreased markedly over the past 10 years for gentamicin, 
ciprofloxacin, cefuroxime and 3rd generation cephalosporins, but 
with lesser or insignificant decreases in the past five years. (For 
more details see Figure 8.2.1 a) and b)). The increased cipro-
floxacin resistance rate in 2017 compared to 2016 may reflect a 
change in interpretation of S-I-R more than a true epidemiologic 
change as described in section 8.1.1, E. coli blood isolates.
The number of carbapenem resistant isolates remained continuous-
ly very low with three carbapenem resistant and none intermediary 
resistant invasive K. pneumoniae isolates in 2017. Although still at 
a low level, the risk of increasing levels of carbapenem resistance in 
the future is worrisome. The level of multi-resistant (combined resis-
tance to 3rd generation cephalosporins, ciprofloxacin and gentami-
cin) invasive K. pneumoniae remained at around 2%, Table 8.2.2. No 
pan-resistant K. pneumoniae have been described in Denmark yet.
2014  
% (N)
2015 
% (N)
2016 
% (N)
2017 
% (N)
Resistance 3.0 (26) 1.1 (9) 1.6 (18) 2.4 (27)
Percentage (no.) of isolates tested for combined 
resistance (multiresistance)
91 (859) 89 (840) 98 (1131) 95 (1122)
Total number of blood isolates 943 943 1156 1183
Table 8.2.2 Combined resistance to 3rd generation cephalosporins, ciprofloxacin, and gentamicin (multiresistance) in K. pneumoniae 
blood isolates from humans, Denmark 
 DANMAP 2017
Figure 8.2.2 Resistance (%) in Klebsiella pneumoniae urine isolates from humans in hospitals, Denmark    DANMAP 2017
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
0
5
10
15
20
25
30
35
40
09 10 11 12 13 14 15 16 17
N
um
be
r o
f 
po
si
ti
ve
 u
rin
e 
is
ol
at
es
Number of positive urine isolates (n = 8106)
Mecillinam (n = 8092)
Piperacillin/tazobactam (n = 6033)
Ciprofloxacin (n = 7711)
Cefuroxime (n = 6266)
Gentamicin (n = 7980)
3rd gen. cephalosporin (n = 7751)
Carbapenem (n = 4988)
Sulfonamide (n = 5252)
%
 re
si
st
an
t 
is
ol
at
es
0
2
4
6
8
10
12
14
16
18
09 10 11 12 13 14 15 16 17
%
 re
si
st
an
t 
is
ol
at
es
Substance
Time trends (Cochran-Armitage test)
10 years  
(2008 - 2017)
5 years 
(2013 - 2017)
Mecillinam    p = 0.01    p < 2.2e-16
Piperacillin/tazobactam    p = 0.2
Gentamicin    p < 2.2e-16    p = 0.03
Ciprofloxacin    p < 2.2e-16    p = 0.008
Cefuroxime    p = 4.316e-12    p = 0.5
3rd generation cephalosporins    p < 2.2e-16    p = 0.4
Note: Figure 8.2.2 a) Resistance results and total number of 
positive urine isolates are presented, b) Resistance rates excluding 
sulfonamide and the number of positive urine isolates. c) Time trends 
and significance levels for the past five and nine years respectively. 
The number (n) in parentheses represents either the total number of 
positive isolates or the individual numbers of isolates tested for that 
specific antibiotic in 2017.
a) b)
c)
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8.2.2 Urine isolates from hospitalised patients
For 2017, DANMAP received data on the antibiotic susceptibil-
ity in 8,106 K. pneumoniae isolates cultured in urine samples 
from hospitalised patients from all 10 DCM in Denmark. All 
10 DCM routinely (>75% of isolates) tested for resistance 
to mecillinam and gentamicin; nine DCM routinely tested for 
resistance to ciprofloxacin and 3rd generation cephalosporins; 
eight DCM routinely tested for resistance to cefuroxime and 
trimethoprim; seven DCM routinely tested for resistance to 
sulfonamide, piperacillin/tazobactam and carbapenem and 
five DCM routinely tested for resistance to nitrofurantoin and 
amoxicillin/clavulanic acid.
Resistance results for 2017 for all tested antibiotics are sum-
marized together with the results from the invasive isolates 
as a national mean for each antibiotic in Table 8.2.1. In Figure 
8.2.2, rates of resistance are presented as a national mean 
when at least six DCM performed routine testing. Time trends 
and significance levels, based on the resistance rates for the 
past five and nine years, respectively, are presented in Figure 
8.2.2 c).
As for the number of invasive isolates, an increase (41%) in 
reported K. pneumoniae isolates cultured from hospital urine 
samples has been observed since 2010. Data extractions 
from MiBa for the same period show a smaller increase of only 
1.6% to 15% in the total number of submitted hospital urine 
cultures - the imprecision is due to uncertainty regarding the 
correct categorisation of some urines as hospital or primary 
care samples. 
In 2017, a very steep increase in the resistance to mecillinam 
was observed in urine isolates from hospitals. The same steep 
increase was observed for sulfonamide resistance. Otherwise 
the trends are similar to the trends observed for invasive K. 
pneumonia with decreased resistance to gentamicin, cipro-
floxacin, cefuroxime and 3rd generation cephalosporins for 
the past 10 years and with a less pronounced or insignificant 
decrease for the past five years. (For more details see Figure 
8.2.2 a), b) and c)).
In 2017, 13 carbapenem resistant and six intermediary 
resistant K. pneumonia isolates from hospital urines were 
reported.
8.2.3 Urine isolates from primary health care
For 2017, DANMAP received data on the antibiotic suscep-
tibility in 8,948 K. pneumoniae isolates cultured in urine 
samples from primary health care from nine DCM in Den-
mark. These nine DCM cover all samples submitted from the 
general practitioner to clinical laboratories in Denmark. In 
general, many GPs perform culturing of urine samples at their 
practice and thus only a selected number will be referred to 
a DCM. In the Capital Region of Denmark there is one private 
laboratory in addition, performing culturing of urine samples 
from primary care.
Note: Figure 8.2.3 a) Resistance rates and total numbers of 
positive urine isolates are presented. b) Resistance rates excluding 
sulfonamide, trimethoprim. c) Time trends and significance levels for 
the past five and nine years, respectively (Cochran-Armitage test). 
The number (n) in parentheses represents either the total number of 
positive isolates or the individual numbers of isolates tested for that 
specific antibiotic in 2017.
Figure 8.2.3 Resistance (%) in Klebsiella pneumoniae urine isolates 
from humans in primary health care, Denmark  DANMAP 2017
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Substance
Time trends (Cochran-Armitage test)
9 years  
(2008 - 2017)
5 years 
(2013 - 2017)
Mecillinam    p = 0.06    p < 2.2e-16
Sulfonamide    p < 2.2e-16    p = 6.048e-14
Ciprofloxacin    p < 2.2e-16    p = 0.0003
3rd generation cephalosporins    p = 1.016e-05    p = 0.13
b)
c)
a)
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Resistance testing for mecillinam and 3rd generation cepha-
losporins was performed routinely at all nine DCM (>75% of 
isolates); eight DCM routinely tested for resistance to sul-
fonamide, trimethoprim and ciprofloxacin; five DCM routinely 
tested for nitrofurantoin resistance; four DCM routinely tested 
for resistance to gentamicin and cefuroxime; three DCM rou-
tinely tested for carbapenem resistance and two DCM rou-
tinely tested for resistance to amoxicillin/clavulanic acid and 
piperacillin/tazobactam.
As for the results from invasive isolates and isolates from hos-
pital urines resistance results for 2017 for all tested antibiot-
ics are shown as national means in Table 8.2.1. In Figure 8.2.3, 
rates of resistance are presented as a national mean when at 
least six DCM performed routine testing. Time trends and sig-
nificance levels, based on the resistance rates for the past five 
and nine years respectively, are presented in Figure 8.2.3 c).
Also the total number of K. pneumoniae isolates in urine 
samples from primary health care saw a very steep increase 
(180%) since 2010. As mentioned in section 8.1.3, E. coli in 
urine samples from primary health care, the increase in the 
total number of urine samples submitted to the DCM from the 
primary sector, was in-between 114% and 162%.
As for K. pneumoniae in urine samples from hospitals, a very 
steep increase in resistance to mecillinam and sulfonamides, was 
noted in 2017. (For more details see Figure 8.2.3 a), b) and c)).
Three carbapenem resistant and none intermediary resistant 
isolates were reported in 2017.
Conclusion
As for E. coli, the continuing increase in total numbers of 
isolates of K. pneumoniae is worrisome and explanations for 
this needs to be further investigated. In 2017, a very steep 
increase in resistance in K. pneumoniae to mecillinam and 
sulfonamides was observed, after a period with decreasing re-
sistance rates. Decreased resistance to gentamicin, ciprofloxa-
cin, cefuroxime and 3rd generation cephalosporins for the past 
10 years and with a less or insignificant decrease in the past 
five years was observed. Despite the worrying tendencies, the 
proportions of resistance to the critically important antibiotics 
seemed tethered, which is encouraging. 
Sissel Skovgaard and Stefan S. Olsen 
For further information: sisk@ssi.dk
8.3 Pseudomonas aeruginosa
Pseudomonas aeruginosa is an opportunistic pathogen caus-
ing relatively rare but serious disease in humans. P. aeru-
ginosa typically infects the pulmonary tract, urinary tract, 
burns, wounds, and also causes bloodstream infections. It is a 
relatively frequent coloniser of medical devices (e.g. indwell-
ing catheters). P. aeruginosa infection is a serious problem in 
immunocompromised patients with e.g. cancer and in patients 
with cystic fibrosis. The case fatality rate in these patients 
is high. P. aeruginosa is intrinsically resistant to the majority 
of antimicrobial agents. The antimicrobial classes which can 
be used for treatment include some fluoroquinolones, some 
aminoglycosides, some beta-lactams (piperacillin-tazobactam, 
ceftazidime and carbapenems) and colistin.
8.3.1 Blood isolates from hospital patients
For 2017, DANMAP received data on the antibiotic susceptibil-
ity in 484 P. aeruginosa isolates from blood cultures from all 10 
Departments of Clinical Microbiology (DCM) in Denmark. For all 10 
DCM, resistance testing to ciprofloxacin, gentamicin, ceftazidime, 
meropenem and piperacillin/tazobactam was performed on a 
routine basis (>75% of isolates) using primarily disc diffusion or 
Etest. The presented data consist of the reported interpretation 
results, performed by the DCM, and are based on the S-I-R system.
Data are presented in Figure 8.3.1.
Resistance levels to all tested antimicrobial agents were not 
significantly different from the levels in 2016. 
Conclusion
10 years with surveillance of invasive P. aeruginosa indicate 
that the situation in Denmark is quite stable. EARS-Net 2016 
reported an increasing trend in resistance in the EU/EEA popula-
tion–weighted mean against ceftazidime in 2013-2016 (13.0% 
in 2016) and decreasing resistances in the EU/EEA population–
weighted mean against fluoroquinolones (15.0% in 2016), ami-
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Figure 8.3.1 Resistance (%) in Pseudomonas aeruginosa blood 
isolates from humans, Denmark           DANMAP 2017
Note: The number (n) in parentheses represents either the total 
number of positive isolates or the individual numbers of isolates 
tested for that specific antibiotic in 2017.
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noglycosides (10.0% in 2016) and carbapenems (15.0% in 2016), 
while resistance towards piperacillin/tazobactam (16.3% in 2016) 
did not change significantly. Denmark remained at or below 5% 
resistance proportions in invasive P. aeruginosa isolates in 2017.
Sissel Skovgaard and Stefan S. Olsen 
For further information: sisk@ssi.dk
8.4 Acinetobacter species
The genus Acinetobacter includes several species and is found 
widespread in nature, in soil, water and/or animals and humans. 
In humans, Acinetobacter can colonise the skin and wounds 
but may also be the cause of hospital-acquired infections like 
central line-associated bloodstream infections, nosocomial 
pneumonia, urinary tract infections and wound infections. Many 
of the different subspecies are phenotypically alike, and thus 
identification at species level can be difficult. Species belong-
ing to the A. baumannii group are considered the most clinically 
important. Acinetobacter species possess an inherent resistance 
to a broad range of antibiotics because of a low membrane 
permeability and constitutive expression of efflux systems. The 
antimicrobial classes which can be used for treatment include 
some fluoroquinolones, aminoglycosides, carbapenems and 
colistin. For especially A. baumannii, multiresistant clones are 
widespread in the hospital environment in many south- and east 
European countries, where they cause problems with outbreaks 
in fragile patient subpopulations at e.g. intensive care units. Of 
worldwide concern are severely war-wounded soldiers colonised 
or infected with multiresistant A. baumannii.
8.4.1 Blood isolates from hospital patients 
For 2017, DANMAP received data on the antibiotic susceptibil-
ity in 70 Acinetobacter species isolated from blood cultures 
from all 10 Departments of Clinical Microbiology (DCM) in 
Denmark. All 10 DCM routinely (>75% of isolates) tested 
for resistance to ciprofloxacin and gentamicin and nine DCM 
routinely tested for meropenem resistance. Resistance testing 
was mainly performed by disc diffusion. The presented data 
consist of the reported interpretation results, performed by 
the DCM and are based on the S-I-R system.
Data are presented in Table 8.4.1 and in Figure 8.4.1.
Compared to 2016, no change in total isolate numbers of invasive 
Acinetobacter species or in resistance proportions was observed.
Conclusion
In 2012, significantly more Acinetobacter isolates from blood 
were resistant towards ciprofloxacin, gentamicin and merope-
nem (resistance observed in 10-12% of the isolates) than the 
following years. In 2016 and 2017, resistance was only found 
in 0-3%. In EARS-Net, marked differences in resistance profiles 
across Europe have been reported with more than 50% of the 
isolates being resistant to at least one of the three surveyed 
antimicrobials (fluoroquinolones, aminoglycosides and carbapen-
ems). Particularly the Baltic and southern and south-eastern 
countries of Europe reported on problems with high resistance,  
where the proportion of multiresistant Acinetobacter spp. for 
some countries even outnumbers the proportion of carbapene-
mase-producing enterobactereales (CPE). All northern countries 
reported below 2% combined resistance in 2016.
Sissel Skovgaard and Stefan S. Olsen 
For further information: sisk@ssi.dk
Tabel 8.4.1 Invasive Acinetobacter spp, Denmark. Number of resistant isolates per year per antibiotic and number of tested isolates 
per year per antibiotic DANMAP 2017
Substance
2012 2013 2014 2015 2016 2017
res. n res. n res. n res. n res. n res. n
Ciprofloxacin 10 83 5 72 2 69 4 71 2 72 1 70
Gentamicin 8 77 1 65 1 70 3 71 0 70 0 70
Meropenem 6 58 1 52 1 62 3 68 0 69 0 67
Total number of blood isolates 84 72 72 71 72 70
Note: res. = number of resistant isolates. n = number of tested isolates.
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Figure 8.4.1 Resistance (%) in Acinetobacter species blood 
isolates from humans, Denmark DANMAP 2017
Note: The number (n) in parentheses represents either the total 
number of positive isolates or the individual numbers of isolates 
tested for that specific antibiotic in 2017.
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Textbox 8.1 
Characterization of ESBL/pAmpC- and carbapenemase-producing 
Escherichia coli from bloodstream infections, 2017 Denmark 
Background: The resistance to third-generation cephalosporins in Escherichia coli most often occurs through production 
of extended-spectrum beta-lactamases (ESBLs), carbapenemases, plasmid-mediated AmpC (pAmpC) or through mutations 
within the promoter/attenuator region of chromosomal AmpC (cAmpC). Before 2007, the occurrence of third-generation 
cephalosporin-resistant E. coli (3GC-R Ec) isolated from bloodstream infections in Danish patients was low. 
The aim of the present study was to characterize the resistance genes encoding 3GC-R or meropenem resistance and 
Multilocus Sequence Types (MLSTs) of ESBL, pAmpC and carbapenemase-producing E. coli from bloodstream infections 
reported in 2017 in Denmark.
Material and Methods: During January 2017 through December 2017, all Danish departments of clinical microbiology collected 
their 3GC-R (reported as ceftazidime, ceftriaxone, cefpodoxime or cefotaxime resistance) and carbapenemase-producing E. coli 
from bloodstream infections. The isolates were sent to Statens Serum Institut for further characterization. Only one isolate per 
patient/per year was included in the study. 
The isolates were whole genome sequenced, assembled by SPAdes v. 3.11.0, and in silico analysed for acquired ESBL-, pAmpC-, 
and carbapenemase genes and MLST using The Bacterial Analysis Pipeline – Batch upload version 1.0 from Center of Genomic 
Epidemiology (https://cge.cbs.dtu.dk/services/cge/). For isolates with no ESBL-, pAmpC-, or carbapenemase-encoding genes 
detected, the sequences were investigated for promotor mutations presumed to up-regulate cAmpC.
Results: In 2017, whole genome sequencing data were obtained from 354 E. coli isolates. Genes encoding ESBL-, pAmpC-  
and/or carbapenemase production were detected in 337 isolates, compared to 312 isolates in 2016. In 2017, 17 isolates 
were cAmpC hyper producers only; these isolates were not further investigated. 
The regional distribution of the 337 isolates with ESBL-, pAmpC- and carbapenemase encoding genes was compared to data 
from previous years (Table 1 and Figure 1). 
Demographic data was available for all 337 E. coli isolates in 2017; 209 (62%) of the patients were men and 128 (38%) were 
women, compared to 166 (53%) and 146 (47%), respectively, in 2016. Thus, a significant increase of men from 2016 to 2017 
(p = 0.023) was observed. The average age at diagnosis was 70 years, ranging from below one to 98 years. Forty-eight patients 
(14%; 31 men and 17 women) of the 337 patients died within 30 days of diagnosis (average age at death was 74 years;  
ranging from 51 to 94 years). 
From 2014 to 2017, the reported cases of 3GC- and carbapenem-resistant E. coli in bloodstream infections have changed from 245 
to 337 per year. In The Capital Region, the number of reported cases was stable (110 cases in 2014 and 112 cases in 2017). Com-
paring the countrywide distribution, the number of cases decreased significantly from 45% to 33% (p = 0.004) through the years. 
In the regions of Southern Denmark and Central Denmark, the number of reported cases almost doubled from 2014 to 2017; from 
43 to 76 cases in Southern Denmark and from 43 to 80 cases in Central Denmark. The distribution for the two regions changed 
from 18% in both regions to 23% and 24%, respectively, resulting in a total significant increase (p = 0.007) from 2014-2017 
caused by the two regions. For the remaining two regions, Region Zealand and North Denmark Region, the number of cases varied 
during the four years, but the region-wide distribution returned in 2017 to the levels observed in 2014. 
Among the 337 isolates, 21 different ESBL, pAmpC and carbapenemase-enzymes were detected (Table 2), including one novel 
CMY-variant (CMY-162).  As in previous years, CTX-M-15 was the most prevalent enzyme (49%) followed by CTX-M-27 (15%), 
and CTX-M-14 (15%) (Table 2). Two isolates carried the carbapenemase enzyme OXA-181 together with CMY-2. In several 
E. coli isolates, more than one gene encoding ESBL/pAmpC and/or carbapenemases were detected (Table 2). Plasmid-mediated 
colistin resistance genes (mcr-1 – mcr-5), were not observed in 2017. 
In 2017, the 337 E. coli isolates belonged to 64 different MLSTs. In 2017, ST131 was still the most common sequence type 
(ST) with 52% belonging to this type. Other commonly observed sequence types were ST38 (6%), ST69 (6%), ST405 (3%), 
ST648 (2%), ST1193 (2%), ST410 (2%), and ST12 (2%), whereas the remaining isolates belonged to STs, which were only 
detected in 1-5 isolates (<1-2% per type) (Table 3). 
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Among the 175 E. coli isolates belonging to ST131, CTX-M-15 (55%) was most common, followed by CTX-M-27 (24%), CTX-
M-14 (10%) and CTX-M-101 (5%). The carbapenemase producing OXA-181/CMY-2 isolates belonged to ST410. 
 
Conclusion: Almost one half of the isolates carried CTX-M-15 (49%), a trend also observed in previous Danish studies of 
ESBL-producing E. coli from bloodstream infections [DANMAP 2016, Roer et al. JAC. 2016, Hansen et al. Microb. Drug Res. 
2014], whereas only two isolates were carbapenemase producers (OXA-48 group). A minor part (3%) of the isolates carried 
CMY-variants, of which one novel pAmpC-encoding gene was observed (CMY-162). 
The MLST distribution did not change according to previous years; the worldwide disseminated ST131 clone was still  
strongly represented in 2017 (52%). In addition, a large amount of other international STs related to spread of 3GC- and 
carbapenemase-resistance (e.g., ST38, ST69, ST405, ST648, ST1193, ST410 and ST12) was observed. 
Louise Roer, Frank Hansen, Anette M. Hammerum and Henrik Hasman 
For further information: Anette M. Hammerum, ama@ssi.dk 
Table 1 Distribution of ESBL and carbapenemase-producing E. coli from bloodstream infections DANMAP 2017
 2014 2015 2016 2017
Region Numbers % Numbers % Numbers % Numbers %
The Capital Region of Denmark 110 45 116 42 111 36 112 33
The Zealand Region 27 11 14 5 36 12 38 11
Region of Southern Denmark 43 18 45 16 67 21 76 23
Central Denmark Region 43 18 59 21 66 21 80 24
North Denmark Region 22 9 41 15 32 10 31 9
Total Numbers 245 275 312 337
Table 2 Most common ESBL enzymes and carbapenemases detected in E. coli from bloodstream infections, Denmark DANMAP 2017
 2014 2015 2016 2017
Enzyme Number % Number % Number % Number %
CTX-M-151 121 49 139 51 157 50 164 49
CTX-M-271 25 10 33 12 44 14 52 15
CTX-M-141 38 16 33 12 40 13 49 15
CTX-M-1 10 4 7 3 8 3 17 5
CTX-M-551 8 3 14 5 6 2 13 4
CTX-M-101 12 5 15 5 14 4 9 3
CTX-M-3 4 2 4 1 7 2 8 2
CMY-21 10 4 6 2 10 3 7 2
CTX-M-14b 5 2 5 2 9 3 3 < 1
Other CMY variants1 4 2 10 4 3 < 1 3 1
Other ESBL enzymes 14 6 16 6 27 9 18 5
OXA-48-group1 3 1 3 1 1 < 1 1 < 1
1In some isolates more than one enzyme was detected in 2017
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Textbox 8.1 continued...  
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Figure 1 Region-wide distribution of ESBL and carbapenemase-producing E. coli from bloodstream infections.  DANMAP 2017
For each region, the annual percentage was calculated based on the total number of reported cases in Denmark in the corresponding year, 
and reported as the relative distribution. 
Table 3 Distribution of MLSTs in E. coli from bloodstream infections, Denmark 2017  DANMAP 2017
 2014 2015 2016 2017
MLST Number % Number % Number % Number %
ST31 121 49 139 51 157 50 164 49
ST38 25 10 33 12 44 14 52 15
ST405 38 16 33 12 40 13 49 15
ST410 10 4 7 3 8 3 17 5
ST69 8 3 14 5 6 2 13 4
ST648 12 5 15 5 14 4 9 3
ST12 4 2 4 1 7 2 8 2
ST88 10 4 6 2 10 3 7 2
ST1193 5 2 5 2 9 3 3 < 1
Other STs1 4 2 10 4 3 < 1 3 1
1 less than 5 isolates per ST in 2017
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Textbox 8.2 
Carbapenemase producing bacteria in Denmark, 2017 
 
Background: Carbapenems comprise one of the only classes of antimicrobial agents that can be used for treatment of infections with 
multi-resistant Gram-negatives like Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa and Acinetobacter baumannii. 
Treatment options for infections with carbapenem-resistant bacteria are often none or suboptimal. Resistance can be caused by the 
presence of various carbapenemases of which the most frequently occurring are K. pneumoniae carbapenemase (KPC), Oxacillinase 
(OXA), Verona integron-encoded metallo-β-lactamase (VIM), New Delhi metallo-β-lactamase (NDM) and Imipenemase (IMP).
In recent years, Danish Departments of Clinical Microbiology (DCM) have on a voluntary basis submitted carbapenem resistant 
isolates for verification and genotyping at Statens Serum Institut. The present textbox describes carbapenemase-producing 
Enterobacterales (CPE), Pseudomonas spp. and Acinetobacter spp.  
 
Carbapenemase-producing organisms: During 2017, 123 carbapenemase-producing organisms (CPO) were detected from 
115 patients compared with 115 CPO from 99 patients in 2016 leading to a 6% overall increase of submitted CPO isolates 
compared to 2016. More than one isolate from the same patient were included, if the isolates belonged to different bacterial 
species and/or if the isolates harboured different carbapenemases. 
Enterobacterales: In 2017, 104 CPE isolates were detected from 96 patients compared to 82 CPE from 72 patients in 2016 
(Figure 1) leading to a 26% increase of submitted CPE isolates compared to 2016. In 2017, 27 of the patients had been 
travelling abroad prior to detection of the CPE; 13 of the patients had no history of recent travel and for the remaining 57 
patients, travel information was unavailable (Figure 2). 
Seven of the 104 CPE isolates produced both NDM and OXA-48 group enzymes, 71 produced OXA-48-like enzymes and 22 
were NDM-producing (Figure 1). Furthermore, three KPC-producing isolates and one VIM-producing isolate were detected. 
The NDM-1 producing Citrobacter freundii outbreak, which started in 2012 in the North Denmark Region, continued in 2017 
(Table 1). Until the end of 2017, 19 patients had been involved in this outbreak in the period 2012-2017. None of these pa-
tients had a prior history of travel noted in their hospital records. The origin of the NDM-1 producing C. freundii was unknown. 
NDM-1 plasmid transfer to other CPE was also detected for samples from the patients involved in the outbreak [Hammerum et 
al. 2016, J. Antimicrob. Agents, 71:3117-3124]. 
Another large outbreak was detected in Zealand with spread of ST410 NDM-5/OXA-181 E. coli. The first patient with ST410 NDM-
5/OXA-181 E. coli was hospitalised in the Capital Region in 2015 after hospitalisation in Egypt [Overballe-Petersen et al. 2018, Gen-
ome Announc.6(5): e01542-17]. The other patients with ST410 NDM-5/OXA-181 E. coli were hospitalised in the Region Zealand in 
2016 and 2017. By the end of 2017, ten patients had been involved in this outbreak [Roer et al. 2018, mSphere. 2018 Jul 18;3(4). 
pii: e00337-18].
Spread of ST101 OXA-48 producing K. pneumoniae were detected between two patients. Furthermore, it seemed very likely 
that the increase in OXA-48 producing CPE was due to plasmid transfer, but this was not investigated further. 
Finally, three patients had OXA-436 producing CPEs in 2017. Genomic analysis revealed that spread of OXA-436 producing E. cloacae 
had occurred between two patients. OXA-436 is a novel carbapenemase belonging to the OXA-48 enzyme group and has according to 
our knowledge only been detected in Danish patients [Samuelsen et al. 2017, Antimicrob. Agents and Chemother 62(1): e01260-17].
Acinetobacter spp: In 2017, 15 carbapenemase producing Acinetobacter spp isolates were detected compared to 26 isolates 
in 2016. In 2017, 13 OXA-23 producing A. baumannii isolates were detected from 13 patients. Nine of these patients had 
been travelling prior to detection. A possible spread of OXA-23 producing A. baumannii was detected between two patients, 
of which the first had been travelling to Turkey. Furthermore, a possible spread of OXA-72 producing Acinetobacter bereziniae 
was detected between two patients without known travel history.
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RESISTANCE IN HUMAN CLINICAL BACTERIA8.
Textbox 8.2 continued... 
 
Pseudomonas spp: In 2017, two VIM-2 producing P. aeruginosa and two IMP-producing P. putida were detected. One of the 
patients with IMP-producing P. putida had been travelling, whereas no information was given for the other three patients. 
 
Conclusion: The occurrence of carbapenemase-producing bacteria in Denmark is increasing, a trend worrisome to patients 
and clinicians. Especially the spread of CPE is of concern, since Enterobacterales can be carried in the intestine for a long time 
without any symptoms of infections, which makes outbreak control difficult.    
Henrik Hasman, Frank Hansen, Louise Roer and Anette M. Hammerum 
For further information: Anette M. Hammerum, ama@ssi.dk
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Figure 1 Numbers of carbapenemase-producing Enterobacterales (CPE), 2008-2017, Denmark DANMAP 2017
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8.5 Enterococci
Enterococci constitute a part of the normal intestinal microbi-
ota in humans and animals and colonise the host in beneficial 
co-existence. More than 54 species belonging to the genus 
Enterococcus have been described, but the majority of the 
human infections are caused by E. faecalis and E. faecium. 
Enterococci are inherently resistant to many groups of anti-
biotics and thereby get a selective advantage in e.g. hospi-
talised patients under antibiotic treatment. Most common 
clinical infections caused by Enterococcus species include 
urinary tract infections, bacteraemia and bacterial endocardi-
tis (an inflammation process of the inner tissues of the heart, 
usually the valves). Found in hospital environment, bacteria 
can lead to colonisation or infection of a hospitalised patient. 
The source of hospital infection is often associated with the 
use of medical supplies, such as catheters, as well as other 
instruments and medical devices. Use of antibioitics in these 
patients increases the risk for an enterococcal infection. 
Therapy of enterococcal infections is complicated and has 
limited options due to its high level of natural antimicro-
bial resistance. In severe cases, enterococcal infections are 
treated with vancomycin. Combinational therapy based on 
a synergistic effect of beta-lactam antibiotics (penicillin/
ampicillin) with an aminoglycoside (most often gentamicin) 
or glycopeptide (vancomycin) is required in cases of endocar-
ditis. More recent antibiotics, such as linezolid (oxazolidinone) 
and daptomycin (lipopeptide) are the only options for treat-
ment of the multiresistant, vancomycin-resistant Enterococ-
cus (VRE), which adapts to persist in the health care facili-
ties. A new antibacterial from the oxazolidinone-class with 
restrictive indications for usage was introduced to the Danish 
market in 2015. 
8.5.1 Blood isolates from hospital patients
For 2017, DANMAP received data on the antibiotic susceptibil-
ity in 678 E. faecalis and 793 E. faecium isolates from blood 
cultures from all 10 Departments of Clinical Microbiology (DCM) 
in Denmark. All 10 DCM routinely (>75% of isolates) tested for 
resistance to ampicillin and vancomycin in both species; six DCM 
routinely tested for linezolid resistance in E. faecium and three 
DCM routinely tested for linezolid resistance in E. faecalis. One 
DCM routinely tested for high-level resistance to gentamicin in 
both species. Resistance testing was mainly performed by disc dif-
fusion. The presented data consist of the reported interpretation 
results, performed by the DCM and are based on the S-I-R system. 
 
Resistance rates to all tested antibiotics for 2017 are present-
ed as a national mean of the combined DCM reportings in Table 
8.5.1. In Figure 8.5.1, total numbers of invasive isolates of  E. 
faecalis and E. faecium and the rates of resistance to vanco-
mycin in both for the past decade are shown. 
Total number of invasive isolates 
From 2016 to 2017, the total number of bacteraemia cases 
increased from 606 to 678 for E. faecalis and from 692 to 793 
for E. faecium.
Ampicillin-resistance
No change was observed in 2017 compared to 2016.
Vancomycin-resistance
The proportion of invasive E. faecium with transferable 
vancomycin-resistance (7.1%) remained unchanged compared 
to 2016. Still, the proportion of invasive vancomycin-resistant 
E. faecium is high in Denmark , especially when compared to 
the other Nordic countries, France and Spain, all of which stay 
below 2.5% [EARS-Net 2016]. None vancomycin-resistant E. 
faecalis from bloodstream infections were reported in 2017. 
Table 8.5.1 Resistance (%) in invasive E. faecalis and E. faecium isolates from humans, 2017 DANMAP 2017
Substance E. faecalis E. faecium Number of tested isolates (number of DCM)
% % E. faecalis E. faecium
Ampicillin 0.3 94 670 (10) 779 (10)
Vancomycin 0.0 7.1 674 (10) 791 (10)
Linezolid 2.3 1.6 264 (3) 491 (6)
High-level gentamicin 7.1 43 56 (1) 46 (1)
All proportions of resistance are presented for each antibiotic as a mean of the resistance rates reported by the DCM. Included are all DCM that 
repports routine testing (> 75% of the isolates). The number in parentheses tells the number of included DCM. 
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High-level gentamicin resistance 
The proportion of high-level gentamicin resistance (MIC > 128 
mg/L) was reported from only one DCM (>75% of isolates tested) 
as in the previous 10 years, Table 8.5.1. Based on these rather 
sparse data, a decreasing trend in High-level gentamicin resistance 
in invasive E. faecalis has been observed over the decade, from 
35% in the first years to 20% in 2016 and 7.1% in 2017. In E. fae-
cium the level has been oscillating between 55% and 75% in the 
same time period, but in 2017 the resistance decreased to 43%. 
Linezolid-resistance 
In 2017, linezolid resistance was routinely examined in 
264/678 invasive E. faecalis and 491/793 invasive E. faecium 
(according to reporting from three and six DCM, respectively). 
Resistance to linezolid was found in six cases of invasive E. 
faecalis and in eight cases of invasive E. faecium, correspond-
ing to 2.3% and 1.6% of the tested isolates, respectively, 
(Table 8.5.1). This is worrisome, since in 2016 only one line-
zolid resistant case in each species was reported. But due to 
selective antibiotic testing concerning linezolid at most DCM, 
it is not possible to directly compare data from the two years. 
In DANMAP 2016, we reported on a specific survey from one 
DCM regarding linezolid resistance in non-invasive E. faecalis 
and E. faecium. In these, resistance to linezolid was found in 
1.3% and 4.2%, respectively. 
Conclusion 
An ongoing increase of invasive enterococci, mainly caused by an 
increase in invasive E. faecium, has been observed during the last 
16 years (Figure 8.1.1 DANMAP 2015). The increase is combined 
with firstly, an increase in ampicillin resistant E. faecium (65% 
in 2002 and more than 90% since 2010) and since 2013, an 
increase in vancomycin resistant E. faecium. In 2017, no further 
increase in vancomycin resistant rates in invasive E. faecium 
was observed but the total number of VRE isolates still kept 
increasing as discussed in textbox 8.3 on whole-genome based 
surveillance of VRE. Due to the limited options of treatment of 
VRE-infections, the use of oxazolidinones and lipopeptides must 
be reserved to the treatment of these patients.
Sissel Skovgaard and Stefan S. Olsen 
For further information: sisk@ssi.dk
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Figure 8.5.1 Number of isolates of Enterococcus faecalis and Enterococcus faecium and rates of resistance to vancomycin (%) in 
bloodstream isolates from humans, 2008-2017, Denmark 
DANMAP 2017
Note: The number (n) in parentheses represents either the total number of positive isolates or the individual numbers of isolates tested for that 
specific antibiotic in 2017. In 2008 and 2009 the presented data covers 75% of the Danish population. From 2010 to 2014 data covers 95% of 
the Danish population and from 2015 the total Danish population is covered.
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Textbox 8.3
Emergence of clinical vanA E. faecium in Denmark, 2017  
Background: Enterococcus faecalis and Enterococcus faecium are commensal bacteria in the human intestine and belong to the 
most common bacteria causing disease in humans (see section 8.0 and 8.5). During the last decade an increase in the occurrence of 
vancomycin-resistant enterococci (VRE) has been observed in Denmark and internationally, often found in outbreaks related to hospi-
tal care and the treatment of severely ill patients, causing concern and demanding intensification of efforts on infection control. 
Surveillance of VRE: Since 2005, Danish Departments of Clinical Microbiology (DCM) have voluntarily submitted VRE for species iden-
tification, genotyping and surveillance to the Antimicrobial Resistance Reference Laboratory at Statens Serum Institut (SSI). Since 2013, 
an increase in clinical VRE isolates has been observed (Figure 1 and Figure 2), mainly driven by increases observed in the Capital Region.
To determine any underreporting in the submissions, the number of VRE submitted to SSI in 2016 and 2017 were compared to 
the number of clinical VRE reported by the DCMs to MiBa (the Danish Microbiology Database (https://miba.ssi.dk/Service/English.
aspx)). From this comparison, it was discovered that the number of submitted VRE isolates were not complete, since 80 and 81 
patients were missing from surveillance in 2016 and 2017, respectively (Figure 1). In 2017, 429 VRE isolates were submitted to 
SSI. Among these, two patients had both a vancomycin resistant E. faecium and a vancomycin resistant E. faecalis. By adding the 
80 and 81 VRE isolates extracted from MiBa, this added up to 510 VRE isolates from altogether 508 patients in 2017 compared 
to 515 VRE isolates from 515 patients in 2016 (Figure 1).  
In 2017, 66 of the VRE isolates were obtained from 66 patients with bloodstream infections, compared to 51 patients in 2016 and 
27 patients in 2015. Twenty-nine of the 66 patients (44%), died within 30 days of diagnosis. Many of the VRE patients were chroni-
cally ill patients and the high mortality probably owes to this. 
As for the former years, a geographic distribution was observed with the Capital Region contributing with the highest number. 
Of the 510 clinical VRE isolates detected in 2017, 348 (68%) were from hospitals located in the Capital Region (Figure 2). 
Sequence analysis of the submitted strains: From 2015 through 2017, all clinical VRE isolates sent to SSI have been 
submitted for whole-genome sequencing (WGS). In total, 429 VRE were submitted to WGS in 2017. From the WGS data, MLSTs 
and van-genes were extracted in silico. Most of the clinical VRE (415) were vanA E. faecium (Figure 1).
Core genome MLST (cgMLST) analysis was performed on the 425 vancomycin-resistant E. faecium isolates (Table 1). The majority 
of the E. faecium isolates belonged to three sequence types, ST80, ST117 and ST203. The STs were all part of the CC17 complex, 
which are commonly detected in hospitals outside Denmark. cgMLST subdivided the 425 vanA E. faecium isolates into 58 complex 
types (CTs). The most prevalent cgMLSTs are shown in Table 1. As for the last two years, ST203-CT859 was the most prevalent 
sequence type, constituting 61% of the 425 WGS vancomycin-resistant E. faecium isolates (Table 1). Comparison to the cgMLST.org 
database, previous studies, and personal communications with neighboring countries revealed that the novel complex type ST203-
CT859 emerged in December 2014 and spread to the South of Sweden and the Faroe Islands during 2015 [Hammerum et al. 2017 
J. Antimicrobial. Chemother.]. One patient with ST203-CT859 vanA E. faecium was transferred from Denmark to Greenland in 2017, 
but the VRE strain did not spread to other patients in Greenland (Anne Kjerulf, personal communication).
Compared to 2015, the number of vanA E. faecium isolates belonging to ST80-CT14 has decreased in 2016 and 2017 (Table 
1). This type was also detected in the Capital Region in 2013 (www.cgMLST.org), however the cgMLST database did not con-
tain any non-Danish ST80-CT14 isolates.
Conclusion: The high number of VRE cases in 2017 in Denmark is worrying. VRE can be carried in the intestine for a long period 
without showing any symptoms. Moreover, they can persist in the hospital environment, which makes infection control difficult. 
Infection control should include proper cleaning, good hand hygiene, VRE screening and subsequent isolation of patients.
Anette M. Hammerum, Louise Roer, Sissel Skovgaard, Stefan S. Olsen and Henrik Hasman 
For further information: Anette M. Hammerum, ama@ssi.dk 
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Textbox 8.3 continued...  
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Figure 1 Numbers of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis isolates 
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Table 1 Description of the most common types of vancomycin resistant Enterococcus faecium  send to SSI according to multilocus 
sequence type (MLST) and coregenome MLST (cgMLST), 2015-2017, Denmark     
 DANMAP 2017
2015 2016 2017
ST80-CT14 22% 9% 4%
ST80-CT24 6% 4% 3%
ST80-CT860 2% 3% N.D.
ST80-CT866 4% 2% 2%
ST80-CT871 1% 1% 3%
ST80-CT993 N.D. 3% 2%
ST80-CT1064 N.D. <1% 2%
ST80-CT1160 N.D. N.D. 2%
ST117-CT873 1% 3% N.D.
ST203-CT859 51% 63% 61%
ST1421-CT1134 N.D. <1% 3%
Numbers of E. faecium 369 427 425
Vancomycin-variable enterococci (VVE)  
Background: In recent years, E. faecium harboring the vanA gene complex, but being phenotypically vancomycin susceptible, 
has been reported from several countries including Denmark. These enterococci are referred to as vancomycin-variable entero-
cocci (VVE). In Canada and Norway, VVE have caused nosocomial outbreaks and development of revertant mutants becoming 
vancomycin resistant in vitro and in vivo has been described. This makes the detection of VVE highly clinically relevant in order 
to avoid treatment failure with vancomycin. VVE can only be detected by molecular methods, and cannot be cultured on a 
selective vancomycin-containing media.
Surveillance of VVE: In 2015 and 2016, in the Capital Region of Denmark, sporadic VVE with different genetic background 
have been detected in relation to concurrent VRE-outbreaks [BJ Holzknecht, personal communication]. Due to this, in 2017 E. 
faecium isolates obtained from blood cultures were tested by vanA PCR for VVE in two of the three DCM in the Capital Region. 
VVE were detected in 4% and 7% of the tested E. faecium isolates, respectively. This increase was mainly due to the spread of 
one single clone, which displays variable vancomycin susceptibility due to a deletion in the vanX gene and belongs to ST1421-
CT1134. [TA Hansen, J. Antimicrob. Agents, published online, 2018].
In the remaining Danish Regions, VVE have not been reported. With the exception of one DCM in the Region of Southern Den-
mark, systematic molecular testing has not been undertaken.
Conclusion: The detection of VVE is clinically relevant, although it requires molecular testing. The increase in VVE in Denmark 
is of concern, especially since VVE are likely to be underdiagnosed. Close surveillance of VVE is important in the future. 
Barbara Holzknecht, Henrik Hasman, Mette Pinholt, Anette M. Hammerum, and Kristian Schønning 
For further information: Barbara Juliane Holzknecht, barbara.juliane.holzknecht@regionh.dk 
and Kristian Schoenning, Kristian.Schoenning@regionh.dk
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8.6 Streptococci
Streptococci include Streptococcus pneumoniae (pneumococci), beta-
haemolytic streptococci (BHS) and non-haemolytic streptococci (NHS). 
All streptococci are Gram-positive bacteria that may in varying degree 
and frequency be the cause of both common and severe infections. 
In the following section, the surveillance of pneumococci and beta-
haemolytic streptococci causing invasive disease is presented.
8.6.1 Pneumococci 
The surveillance of pneumococci causing invasive disease in 
Denmark happens through mandatory submission of clinical 
isolates to Statens Serum Institut (SSI). At SSI, the isolates are 
serotyped and tested for antimicrobial susceptibility.
771 cases of invasive pneumococcal disease (Streptococcus 
pneumoniae ) were registered in Danish patients in 2017, and 
isolates were received from 741 of these cases. The isolates 
originated from either blood (694 isolates from bacteraemias, of 
which 14 patients also had a positive isolate from cerebrospinal 
fluid) or from cerebrospinal fluid alone (40 isolates). Seven isolates 
were moreover received from other, normally sterile sites (ascites, 
pleura, joint), but results from these are by tradition not included 
in this report. The 734 isolates from blood or cerebrospinal fluid 
belonged to 41 different serotypes, and 693 isolates were fully 
susceptible to both penicillin and erythromycin (94.4%).
For penicillin, 28 isolates (3.8%) were intermediary susceptible 
and none were resistant. For erythromycin, 26 isolates (3.5%) 
were resistant. For both antibiotics, the values of non-susceptibil-
ity in 2017 were lower than registered in the DANMAP report for 
2016 (6.2% for penicillin and 4.8% for erythromycin). Moreover, 
they were lower than reported for the last six years, Figure 8.6.1.
When comparing to results from neighbouring countries, the 
levels of penicillin non-susceptibility reported in 2016 to 
EARS-Net were: Sweden (7.1%), Norway (4.4%) and Germany 
(4.0%), and the levels of erythromycin non-susceptibility were: 
Sweden (5.8%), Norway (9.5%) and Germany (7.8%). The re-
sults of non-susceptibility for invasive pneumococci from Den-
mark in 2017 were thus lower than the reported values from 
2016 from both Denmark and the neighbouring countries. 
For pneumococci, antibiotic susceptibility is closely connected to 
serotypes of which there are a minimum of 92 different known 
today. Vaccines and natural fluctuation influence the incidence 
of infections caused by different serotypes. Thus, the differences 
in serotype-distributions should be kept in mind, when comparing 
the percentages of non-sensitive isolates from different years. 
The serotypes with more than 25% non-susceptibility to erythromy- 
cin were: 6B, 14, 15A, 19F and 25A, while serotypes with more than 
25% non-susceptibility to penicillin were: 6B, 14, 15A, 23B and 25A. 
All isolates belonging to 22 different serotypes were fully suscep-
tible to both antibiotics (n = 230), (Figure 8.6.2 and Table 8.6.1).
The five most dominant serotypes in 2017 were: 8, 12F, 22F, 
3 and 9N (n = 432), and the non-susceptibility data for these 
were 0.23% for penicillin and 0.69% for erythromycin. The 
childhood vaccine contains 13 serotypes (n = 91). For these, 
resistance was 5.5% penicillin and 6.6% to erythromycin.
In summary, the levels of non-susceptibility to penicillin and 
erythromycin in invasive pneumococci show a high degree of 
variation through the years. However, the levels in 2017 were 
found to be slightly lower than for the last six years.
8.6.2 Beta-haemolytic streptococci
Beta-haemolytic streptococci (BHS) are divided into serologi-
cal groups according to antigenic properties of their polysac-
charide capsule. In human infections, groups A, B, C and G are 
the most frequent species. Approximately 10% of humans are 
asymptomatic throat carriers of any BHS group. 
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Streptococcus pyogenes (group A streptococci; GAS) causes phar-
yngitis, tonsillitis, otitis media, wound infections, and superficial 
skin infections, but also more severe infections such as bacter-
aemia, necrotising myofasciitis, and rarely meningitis. The rate of 
asymptomatic throat carriage of GAS is approximately 2%.
Streptococcus agalactiae (group B streptococci; GBS) may 
be present in the vaginal flora of 20-25% of women in the 
childbearing age and may cause meningitis and septicaemia 
in the newborn due to transmission during labor. In addition, 
GBS infections have increasingly been observed in elderly and 
immuno-compromised patients in recent years. 
Streptococcus dysgalactiae subsp. equisimilis (group C strepto-
cocci; GCS, and group G streptococci; GGS) predominantly cause 
soft-tissue infections and sometimes bacteraemia. 
This section presents data on antimicrobial resistance in non-
duplicate invasive isolates (i.e. from blood or cerebrospinal 
fluid) of BHS submitted in 2017 to the Neisseria and Strep-
tococci Reference laboratory (NSR) at Statens Serum Institut. 
Isolates are received from all DCMs in Denmark. Submission is 
voluntary and not all DCMs submit BHS of all groups. 
Infections with BHS are usually treated with penicillins or macro-
lides, hence all submitted isolates of BHS group A, B, C and G are 
tested for susceptibility to penicillin, erythromycin and clindamycin 
as well as inducible clindamycin resistance. Susceptibility testing 
is performed with disk diffusion methods. If resistance is detected, 
MIC is determined with Etest. All results are interpreted according 
to MIC breakpoints issued by EUCAST (http://www.eucast.org/).
Figure 8.6.3 shows the resistance findings for the years 2013 
through 2017. The numbers of submitted isolates of GAS, GBS, 
GCS and GGS changed in 2017 compared to 2016: GAS; 204 
isolates (+17%), GBS; 150 isolates (-18%), GCS; 121 isolates 
(+13%), and GGS; 223 (-5%). Although the trend is less clear, 
also for the BHS there seems to be an increasing trend in the 
number of invasive isolates throughout the surveillance years 
that follows the trends for most bacteraemias described in 
the introduction of this chapter. All isolates were fully suscep-
tible to penicillin. The erythromycin resistance rate was virtu-
ally unchanged for GBS and GGS, but increased from 5.2% to 
7.4% for GAS and decreased from 8.4% to 3.3% for GCS. The 
clindamycin resistance rate increased for all groups except GCS.  
The percentage of strains with inducible clindamycin resistance 
was virtually unchanged for GAS and GGS, but showed a marked 
decrease for GBS and GCS. The percentage of fully susceptible 
isolates was unchanged for GBS and GGS, but continued to 
decrease for GAS (from 95% to 92%) and increased for GCS 
(from 91% to 97%).
Conclusions 
The number of submitted isolates in 2017 compared to 2016 
increased for GAS and GCS and decreased for GBS and GGS. As for 
most other bacteraemias the total number of BHS has been increas-
ing over the years. The erythromycin resistance rate increased for 
GAS but remained unchanged or declining for GBS, GCS and GGS.  
Steen Hoffmann, Tine Dalby & Hans-Christian Slotved 
For further information: Steen Hoffmann, hof@ssi.dk
Serotype Number of isolates PEN-S, ERY-S PEN-S, ERY-R PEN-I, ERY-S PEN-I, ERY-R
8 192 191 1
12F 69 68 1
22F 58 58
3 57 57
9N 56 55 1
20 26 26
16F 21 20 1
35B 20 18 2
11A 19 17 1 1
24F 19 15 4
23A 18 18
15A 16 10 1 5
15B 14 13 1
6C 13 12 1
19F 13 9 2 2
33F 13 12 1
35F 13 13
23B 11 3 7 1
17F 10 8 2
Table 8.6.1 Number of isolates and distribution of resistance in the most common sero-types of pneumococci  
from blood and spinal fluid, Denmark DANMAP 2017
DANMAP 2017120
RESISTANCE IN HUMAN CLINICAL BACTERIA8.
0
20
40
60
80
100
120
140
160
180
200
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
8 12F 22F 3 9N 20 16F 35B 11A 24F 23A 15A 15B 6C 19F 33F 35F 23B 17F
N
um
be
r o
f 
is
ol
at
es
Su
sc
ep
ti
bi
lit
y
Serotype
PEN-S, ERY-S PEN-S. ERY-R PEN-I, ERY-S PEN-I, ERY-R Number of isolates
Figure 8.6.2 Penicillin and erythromycin susceptibility among Streptococcus pneumoniae serotypes  DANMAP 2017
0
50
100
150
200
250
0
5
10
15
20
25
2013 2014 2015 2016 2017
N
um
be
r o
f 
is
ol
at
es
R
es
is
ta
nc
e 
(%
)
GBS Total number of isolates
Erythromycin resistant
Clindamycin resistant
Additionally, inducible
clindamycin resistance
Susceptible to
penicillin, erythromycin
and clindamycin
0
50
100
150
200
250
0
5
10
15
20
25
2013 2014 2015 2016 2017
N
um
be
r o
f 
is
ol
at
es
R
es
is
ta
nc
e 
(%
)
GCS
0
50
100
150
200
250
0
5
10
15
20
25
2013 2014 2015 2016 2017
N
um
be
r o
f 
is
ol
at
es
R
es
is
ta
nc
e 
(%
)
GGS
0
50
100
150
200
250
0
5
10
15
20
25
2013 2014 2015 2016 2017
N
um
be
r o
f 
is
ol
at
es
R
es
is
ta
nc
e 
(%
)
GAS
Figure 8.6.3 Beta-haemolytic streptococci, 2013-2017, Denmark: Results of susceptibility testing DANMAP 2017
121DANMAP 2017
8.RESISTANCE IN HUMAN CLINICAL BACTERIA
Textbox 8.4
Surveillance of invasive isolates of Haemophilus influenzae   
This is the first report of invasive Haemophilus influenzae cases for DANMAP. 
Haemophilus influenzae is part of the normal upper respiratory tract flora, where colonisation varies with age. H. influenzae 
can also be the cause of infections, with otitis media and bacterial sinusitis being the most common clinical manifestations. 
Invasive infections with H. influenzae happen rarely and occur predominantly in the very young and the elderly but may also 
afflict individuals with underlying conditions, such as chronic obstructive pulmonary disease or cancer. H. influenzae can be 
divided into six capsular serotypes (a, b, c, d, e and f), as well as non-capsular (non-typeable, NTHi). Introduction of the poly-
saccharide type B vaccine in 1993 significantly reduced the number of cases with systemic infection caused by H. influenzae 
type b (Hib) isolates. The dominating serotype is now NTHi for which no vaccine exists.
Invasive Haemophilus influenzae: 
Surveillance of invasive Hib is mandatory by submission of the isolate to Statens Serum Institut (SSI). By tradition, non-
invasive Hib and non-typable NTHi isolates are often voluntarily submitted as well. The received isolates are serotyped by the 
reference laboratory at SSI. Adherence to surveillance is not complete, but the remaining cases can be identified through data 
extraction from the Danish Microbiological Database (MiBa). Thus for all invasive infections, data results of antibiotic suscepti-
bility testing is available, while data on serotype is only available for isolates submitted to SSI. 
The present report includes all episodes of invasive H. influenzae identified in MiBa through January 2014 to December 2017. 
A total of 469 cases of invasive infections with H. influenzae were identified through MiBa, covering data from all 10 Depart-
ments of Clinical Microbiology (DCM) in Denmark. In 72.1% (338/469) of the identified episodes isolates were submitted 
to SSI, while information on the remaining 131 cases was only available through MiBa. Only the data for two antimicrobial 
agents, ampicillin and cefuroxime, was selected for the present analysis as these are the most frequently tested (410 tested 
for ampicillin and 367 for cefuroxime, 353 tested for both). 
The overall prevalence of invasive H. influenzae cases was stable throughout the four-year period. The highest number of 
cases was observed in 2014 (n = 128) and the lowest number in 2016 (n = 106). The number of cases in 2017 was 115. 
The distribution of collection sites was as follows: Blood (n = 428; 91.6%), cerebrospinal fluid (n = 21; 4.5%), pleura effusion 
(n = 15; 3.2%) and synovial fluid (n = 4; 0.9%). Additionally, one single isolate of H. influenzae was extracted from brain tissue. 
The highest proportion of invasive H. influenzae cases was observed in the groups of infants and children between zero and 
two years of age and in adults above 55 years of age, (Figure 1).  
For all invasive H. influenzae isolates, a mean susceptibility of 82% was found for ampicillin and a mean susceptibility of 84% 
was found for cefuroxime in the four-year period. Rates of non-susceptibility for ampicillin and cefuroxime for either one (Ta-
ble 1 and 2) as well as in combination (Figure 2 and Table 3) were relatively stable during all four years.  
Out of all the H. influenzae isolates submitted to the National Reference Laboratory at SSI during the four-year period, the 
prevalence of H. influenzae type b isolates was 7.1% (24/338). During the period, a statistically significant increase (p-value: 
0.0174) of Hib-positive isolates was observed in 2017 (11/115; 9.5%) compared to 2016 (1/106; 0.9%), 2015 (8/120; 6.6%) 
and 2014 (4/128; 3.1%). Four of the 24 Hib-positive cases were associated with meningitis disease, two of these appeared in 
the group of neonates (2/4; 2016 and 2017). The majority of overall Hib-positive isolates was recognised in young children in 
the age between 0 and 4 years (5/24; 20.8%) and adults above 65 years of age (11/24; 45.8 %). 
The prevalence of non-susceptibility to ampicillin and cefuroxime in Hib-positive isolates remained low during all four years. 
For ampicillin, 18% were found non-susceptible (4/22; two isolates with unknown susceptibility) and all of the nine tested iso-
lates from 2017 were susceptible to ampicillin. For cefuroxime, only one single isolate (5%) was found non-susceptible (1/20; 
four isolates with unknown susceptibility), and all of the eleven tested isolates from 2017 were susceptible to cefuroxime. 
One Hib isolate found in 2016 was non-susceptible to both antimicrobials. 
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Textbox 8.4 continued...
No resistant isolates of type a (n = 3) or type e (n = 7) were detected. Non-susceptibility for type f (n = 43) was 2% for am-
picillin (1/41, excluding two isolates with unknown susceptibility) and 3% for cefuroxime (1/38, five isolates with unknown 
susceptibility). Non-susceptibility for NTHi (n = 261) was 20% (50/244; 17 isolates with unknown susceptibility) on average for 
ampicillin and 14% (32/221; 40 isolates with unknown susceptibility) for cefuroxime.
Conclusion: 
In conclusion, antimicrobial non-susceptibility in Danish isolates of invasive H. influenzae is low but highly dependent on serotype, with 
the non-typeable isolates showing the highest degree of non-susceptibility. Since the non-typeable isolates account for the highest 
prevalence in invasive H. influenza infections, it should be considered to include these strains in the program on mandatory submissions. 
Acknowledgements: We wish to thank the 10 Departments of Clinical Microbiology in Denmark for the voluntary submission of 
invasive H. influenzae of all types to the reference laboratory.
Veronika Vorobieva Solholm Jensen and Tine Dalby 
Correspondence and requests for additional information should be addressed to Ute Wolff Sönksen, uws@ssi.dk
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Figure 1  Proportion of different serotypes in invasive H. influenzae cases according to age (n = 469), 2014-2017, Denmark
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Tabel 1 Susceptibility (abs. and %) to ampicillin in invasive H. influenzae cases (n = 469), 2014-2017, Denmark DANMAP 2017
Year Total number of isolates ND¹ Ampicillin-S Ampicillin-R % S² % R³
2014 128 22 87 19 82 18
2015 120 16 87 17 84 16
2016 106 10 81 15 84 16
2017 115 11 81 23 78 22
Overall 469 59 337 74 82 18
ND¹ - Results for susceptibility testing for Ampicillin are unknown 
% S² - Percent of susceptible isolates 
% R³ - Percent of resistant isolates
Tabel 2 Susceptibility (abs. and %) to cefuroxime in invasive H. influenzae cases (n = 469), 2014-2017, Denmark  DANMAP 2017
Year Total number of isolates ND¹ Cefuroxime-S Cefuroxime-I Cefuroxime-R % S² % non-S³
2014 128 39 75 1 13 84 16
2015 120 32 77 0 11 88 13
2016 106 17 72 1 16 81 19
2017 115 14 86 2 13 85 15
Overall 469 102 310 4 53 84 16
ND¹ - Results for susceptibility testing for Ampicillin are unknown 
% S² - Percent of susceptible isolates 
% non-S³ - Percent of non-susceptible isolates 
Table 3 Combined results of susceptibility testing to ampicillin and cefuroxime in invasive H. influezae cases  
(n = 353), 2014-2017, Denmark DANMAP 2017
Year Total number of isolates tested AMP-S CXM-S AMP-S CXM-I AMP-R CXM-S
2014 86 67 1 6 6 0 6
2015 85 67 0 10 3 0 5
2016 86 68 1 4 3 0 10
2017 96 73 1 9 2 1 10
Overall 353 275 3 29 14 1 31
Percent 100% 78% 1% 8% 4% 0% 9%
AMP = ampicillin and CXM = cefuroxime
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8.7 Staphylococcus aureus
Staphylococcus aureus is part of the normal flora of the skin 
and mucosa in approximately 50% of humans. Some people 
only carry S. aureus intermittently, whereas others carry S. 
aureus for longer time. S. aureus causes infections ranging 
from superficial skin infections i.e. impetigo and boils to more 
invasive infections such as post-operative wound infections, 
infections related to intravenous catheters and prosthetic 
devices, septic arthritis, osteomyelitis, endocarditis and bacte-
raemia. Some of these may have a fulminant progress and are 
associated with high mortality.
In Denmark, a voluntary surveillance program of all S. aureus 
bacteraemia (SAB) cases was established in 1957. The adher-
ence to surveillance is high. A comparison to the number of 
bacteraemia cases registered in the Danish Microbiology Data-
base (MiBa) since 2010 proofed the number of cases reported 
to SSI to be almost complete (94-97%). 
Laboratory and clinical notification of Methicillin-resistant S. 
aureus (MRSA) has existed since November 2006. 
At SSI, all isolates are initially tested using a multiplex PCR 
detecting: the spa, mecA, hsd, scn and pvl gene (lukF-PV). 
spa is used as S. aureus specific marker and for subsequent 
typing by Sanger sequencing, mecA to determine MRSA 
status, and scn and hsd as markers for human adaptation 
and relation to CC398, respectively. PVL is rarely found in 
methicillin-susceptible S. aureus (MSSA) causing bacterae-
mia but has been closely associated with certain community 
acquired (CA) MRSA strains. PVL has also been closely linked 
to skin abscesses and the very rare condition of severe necro-
tising pneumonia. Isolates positive for mecA and the CC398 
specific hsd fragment but negative for scn (human adaptive 
factor) and pvl genes are considered typical Livestock MRSA 
(LA-MRSA) and are not spa typed. All others including human 
adapted CC398 isolates are spa typed. All bacteraemia cases 
and mecA negative presumptive MRSA are tested for pres-
ence of the mecC gene.
A representative selection of bacteraemia isolates are tested 
for antimicrobial susceptibility against 17 antimicrobials. In 
2017 testing was performed in approximately every fourth 
strain (n = 551). For MRSA cases, demographic and epidemio-
logical information is registered. Based on the epidemiological 
information each case is classified with respect to possible 
place of acquisition: hospital (HA), community (CA), healthcare-
associated with a community onset (HACO), import (IMP) and 
livestock-associated (LA) MRSA. For CA and HACO, classifica-
tion is separated into known and not known exposure.
Note: nt = not tested
n web annex table A8.1 the distribution of MICs and resistance for all tested antimicrobial agents are shown.
Antimicrobial 
agent
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
% % % % % % % % % %
Methicillin 1.3 1.6 1.4 1.4 1.2 1.7 2.9 1.5 2.1 2.2
Penicillin 77 77 75 77 74 76 77 71 71 72
Erythromycin 5 7 5 7 6 7 8 7 7 6
Clindamycin 4 6 4 6 6 6 8 7 6 5
Tetracycline 3 2 3 2 2 3 5 4 3 3
Fusidic acid 9 9 13 13 14 15 15 16 12 14
Rifampicin <1 <1 <1 <1 <1 0 <1 <1 <1 <1
Norfloxacin 2 2 3 4 4 5 6 6 4 4
Kanamycin 1 1 1 <1 1 2 2 3 1 1
Linezolid 0 0 0 0 0 0 0 0 0 0
Mupirocin <1 <1 <1 <1 <1 <1 <1 <1 0 <1
Trimethoprim-
sulfamethoxazole
nt nt nt <1 1 1 1 <1 <1 <1
Table 8.7.1 Resistance (%) in isolates from Staphylococcus aureus bacteraemia cases, Denmark DANMAP 2017
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Surveillance of bacteraemia 
In 2017, a total of 2,104 S. aureus bacteraemia cases corre-
sponding to 36.6 cases per 100,000 inhabitants were reported 
from the Departments of Clinical Microbiology (DCM) in Den-
mark. This is the first increase in three years, after a plateau 
of approximately 1,900 annual cases from 2014 to 2016. A 
decade ago, in 2008, 1,344 cases were reported, corresponding 
to 24.5 cases per 100,000 inhabitants. Forty-six (2.2%) of the 
bacteraemia cases in 2017 were caused by MRSA. The percent-
age of methicillin-resistant bacteremias has increased slightly 
but steadily within the last decade, measured at 1.3% in 2008. 
Still, Denmark remains at a notably lower level than the majority 
of the other countries participating in EARS-Net, where the EU/
EEA population-weighted mean MRSA percentage was 13.7% 
in 2016 [EARS-Net 2016]. Four of the 46 MRSA cases were 
caused by LA-MRSA CC398 (7 LA-MRSA CC398 in 2016). The 30 
days mortality was 23% (486 patients), while the mortality for 
the MRSA bacteraemia cases was 20% (n = 9). 
Antimicrobial resistance in S. aureus bacteraemia isolates from 
2008–2017 is presented in Table 8.7.1. For most antimicrobial 
agents, the susceptibility remained, in 2017, at the same level 
as the previous years, the highest frequency of resistance to 
other antimicrobials than penicillin being observed for fusidic 
acid (14%), erythromycin (6%), clindamycin (5%) and norfloxa-
cin (4%). Together with resistance to methicillin, the resistance 
to fusidic acid is the only one with slight but continuous 
increases for the past decade. 
Typing revealed 623 different spa types distributed in 28 dif-
ferent CC groups (the ten most prevalent spa types represent-
ing 33% of the total amount are presented in Table 8.7.2). The 
PVL toxin was present in 26 (1.2%) cases of which seven were 
MRSA. The 26 PVL presenting isolates were distributed among 
20 different spa types and 11 different CC groups.
Surveillance of methicillin-resistant S. aureus 
In 2017, a total of 3,579 MRSA cases were detected (62.3 per 
100,000 inhabitants). This was close to the number observed 
in Denmark in 2016 (3,550; Figure 8.7.1). A case was defined 
when a person for the first time tested positive for a specific 
MRSA strain without regard to infection or colonisation. MRSA 
isolates were confirmed by detection of either the mecA or 
more uncommonly, the mecC gene.
Although the number of cases leveled in 2017 compared to 
2016, an increasing trend has been observed since 2009. 
CC398 cases constituted 35% (n = 1,251) of new MRSA cases, 
of which 1,212 belonged to the LA-MRSA CC398 and the 39 
other to a human adapted variant harboring the PVL encod-
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Table 8.7.2 The ten most prevalent spa types demonstrated in SAB and in non LA-CC398 MRSA cases, Denmark 2017 DANMAP 2017
SAB MRSA
spa type CC group(a) No. of cases spa type CC group(a) No. of cases No. causing 
 infections (%)
t127 CC1 128 t304 CC8 249 90 (36)
t091 CC7 85 t223 CC22 199 66 (33)
t002 CC5 81 t002 CC5 162 91 (56)
t084 CC15 75 t127 CC1 141 63 (45)
t230 CC45 70 t019 CC30 103 75 (73)
t012 CC30 65 t008 CC8 99 59 (60)
t021 CC30 52 t005 CC22 93 41 (44)
t701 CC8 51 t044 CC80 49 30 (61)
t008 CC8 44 t437 CC59 38 29 (76)
t015 CC45 43 t690 CC88 34 7 (21)
a) CC = Clonal complex
ing genes. The number of LA-MRSA CC398 was slightly lower 
compared to 2016. Screening for the carriage of LA-MRSA 
upon contact with the healthcare system (being admitted to 
hospital, undergoing planned surgery or when being pregnant) 
was included in the Danish MRSA prevention program in 2012. 
Many farmers were voluntarily screened in 2014 and 2015, 
following screening of the animals at their farms or when 
household screening was performed due to a positive sample 
from a family member. The leveling in number of cases with 
LA-MRSA may be influenced by the fact that only new cases 
are registered in the surveillance and many people in contact 
with livestock have already been tested positive. 
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MRSA isolates carrying mecC were detected in 35 cases (1.0%) 
in 2017 (9 in 2009, 21 in 2010, 37 in 2011, 24 in 2012, 41 in 
2013,  53 in 2014, 61 in 2015 and 45 in 2016). Twenty-two 
of the cases (63%) had infections at the time of diagnosis. 
One patient had contact to cattle, another to sheep, both 
known reservoirs for mecC MRSA, while the remaining patients 
reported no known contact to any livestock.
The total number of cases and the number of cases presenting 
with infection according to epidemiological classification are 
shown in Table 8.7.3. Most of the cases (84%) were acquired 
in Denmark. At the time of diagnosis, 41% (n = 1,471) of cases 
had infection, which was higher compared to 2015 and 2016 
but similar to previous years. 
The epidemiological classification of MRSA infections 
2007–2017 is shown in Figure 8.7.2. The number of hospital 
acquired infections (n = 63) has increased compared to previ-
ous years but is still at a low level. The increase may partly be 
explained by several outbreaks in neonatal wards. In 2017, 
the number of CA infections continued the increasing trend 
and were by far the largest group (n = 654), while infections 
caused by LA-MRSA CC398 increased to 272 (Figure 8.7.2). 
The number of health care workers with MRSA (infections or 
colonisations) increased from 40 cases in 2016 to 54 cases in 
2017.
Molecular typing of the MRSA strains. 
In total, spa typing revealed 340 different strain types, not 
including isolates belonging to LA-CC398, of which 260 types 
were associated with clinical infections. The 10 dominating 
non LA-CC398 spa types isolated in 2017 are listed in Table 
8.7.2. They constituted 50% of the total number of non LA-
CC398 MRSA isolates. Ten spa types constituted 48% of the 
1,175 clinical infections with non LA-CC398 MRSA. The pvl 
gene was detected in 30% of the infections and in 11% of the 
asymptomatic carriers and most often in relation to isolates 
with spa types t019 (n = 99), t008 (n = 69), t005 (n = 53), 
t044 (n = 47) and t002 (n = 44).
Resistance among MRSA isolates 
Resistance data for non-LA-CC398 isolates is presented in 
Table 8.7.4. Every other non-LA-CC398 isolate received in 
2017 was tested (n = 1,193). Resistance prevalences were 
similar to previous years.
Andreas Petersen and Anders Rhod Larsen 
For further information: Andreas Petersen, aap@ssi.dk
Note: Numbers shown in bold are totals
Table 8.7.3 Epidemiological classification of new 
MRSA cases, Denmark, 2017    
  DANMAP 2017
Epidemiologic 
classification
Exposure No. of 
cases (% of 
total)
No. (%) of 
cases with 
infections 
Imported (IMP) 581 (16) 316 (54)
Hospital-
acquired (HA)
100 (3) 44 (44)
Health-care 
associated,  
community 
onset (HACO)
218 (6)
with known exposure 39 18 (46)
without known 
exposure
179 141 (79)
Health care 
worker
54 (2) 21 (39)
Community-
acquired (CA)
1402 (39)
with known exposure 744 144 (19)
without known 
exposure
658 510 (78)
LA-MRSA CC398 1212 (34)
with known exposure 1019 174 (17)
without known 
exposure
193 98 (51)
Unknown/
missing
12 5
Table 8.7.4 Resistance (%) in non LA-CC398 MRSA isolates, Denmark 2017 DANMAP 2017
%
non-CC398 
Erythromycin 34
Clindamycin 27
Tetracycline 24
Fusidic acid 16
Rifampicin 1
Norfloxacin 20
Kanamycin 26
Linezolid 0
Mupirocin <1
Trimethoprim-sulfamethoxazole 3
Number of tested isolates 1193
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Textbox 8.5
Incidence of multiresistant bacteria in Greenland   
Background: Greenland has a population of 55,860 inhabitants (January 2017) and Nuuk is the capital with around 16,000 
inhabitants. Greenland has its own Ministry of Health and the country is divided into five health regions. There are five smaller 
hospitals, one national hospital and 11 health care centres in the five health regions. The national and largest hospital, Dron-
ning Ingrids Hospital (182 beds), is situated in Nuuk. Around 15-16,000 persons are admitted to hospital once or several times 
a year. Patients with specific or serious diseases that cannot be treated at Dronning Ingrids Hospital are transferred to Denmark 
or Iceland for further treatment e.g. haemodialysis, cancer treatment, brain surgery etc.  
Resistant bacteria: From 2000 to 2017, 46 patients have been diagnosed with methicillin-resistant Staphylococcus aureus 
(MRSA), 87 patients with extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, three patients with vanco-
mycin-resistant enterococci (VRE), and 147 patients with Clostridium difficile infection, among whom 49 had the 027 type.
MRSA: Up to 2015 there were only altogether 14 patients with MRSA, but since a nearly 4-fold increase in incidence of MRSA 
has been observed (see Figure 1). During 2017, the number of patients with MRSA increased due to an outbreak in Tasiilaq. This 
outbreak, consisting of 12 persons, is to date the biggest MRSA-outbreak ever described in Greenland and at the first report of 
MRSA from the East coast. 
The first person in the outbreak was a new-born. This child was born by caesarean section at the hospital in Tasiilaq. Few days 
after discharge, the child was readmitted due to conjunctivitis in both eyes. Unexpectedly, this infection was due to MRSA and 
therefore screening procedures for MRSA were established in the child’s family (a large household consisting of 17 persons) as 
well as at the hospital including all hospital staff (38 persons). Furthermore, a mother and new-born child, who had shared room 
with the MRSA-positive child during the hospital stay (including their household of 13 persons), were screened.
In the family of the index case, one more child and four adults were tested MRSA-positive (a half-brother to the new-born, 
the mother, the father, the grandmother, and the uncle).The remaining six MRSA-positive persons were all hospital staff. It is 
unclear where the spread originated but all 12 persons carried the same MRSA-strain (t304 CC6) which is a common strain in 
Denmark but never seen in Greenland before. 
After treatment for MRSA-carrier state according to the MRSA guideline - in some cases treatment was performed twice - all 
were MRSA-negative except the new-born child, who was positive in samples from the perineum. In families with children below 
the age of two years, it can be very difficult to treat the MRSA-carrier state and because most children spontaneously “loose” 
MRSA before the age of two years, treatment of these families is usually not done. However, because the child was living in a 
big household, a treatment attempt was made.
No further spread of MRSA was seen in the family/household or at the hospital. 
This outbreak illustrates the fact that transmission of MRSA in hospital is mainly seen at wards with new-born/premature chil-
dren due to close contact between the children and healthcare workers, and to close contact in families.
VRE: In spite of ongoing VRE outbreaks in Denmark, so far only three patients have been diagnosed with VRE in Greenland. Two 
patients were colonised with VRE in the rectum and one patient had pleurisy – in all three cases VRE occurred after hospitalisa-
tion in Denmark. No transmission was seen within the wards.
CPO: In recent years, an increase in incidence of carbapenemase-producing organisms (CPO) in Denmark has been observed but 
until now, no CPO has been reported in Greenland. 
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Other resistant bacteria: Most of the other resistant bacteria observed were imported from Denmark or abroad, but in some 
cases, especially in patients with ESBL-producing Enterobacteriaceae, treatment with broad-spectrum antimicrobial agents in 
Greenland has probably selected for these bacteria. From 2012 to 2013, there were outbreaks with C. difficile type 027 at the 
hospitals, and transmission within the country occurred. But due to a great effort on infection prevention and control from the 
hospital staff, these outbreaks were quickly controlled. Of the 11 new C. difficile cases in 2017, two belonged to the 027 type. 
 
Consumption of antimicrobial agents:  All antimicrobial agents in Greenland are purchased and distributed from the National 
Pharmacy. Due to a new IT-system at the National Pharmacy, it is not possible to show data for antimicrobial consumption/pur-
chase at the present time.  
Conclusion: Through many years, the incidence of MRSA in Greenland has been very low but since 2015 an almost 4-fold 
increase has been recorded due to several outbreaks. The increase in incidence might be explained by factors such as import 
of the strains from Denmark and abroad from persons hospitalised or traveling, and possible transmission within Greenland. In 
some of the outbreaks the epidemiology was unknown.
The continuing of surveillance, compliance to screening procedures (especially of patients admitted to hospitals abroad), a 
persistent focus on the use of broad-spectrum antimicrobial agents, and compliance to guidelines for infection prevention and 
control are necessary in order to combat MRSA and other multiresistant bacteria in Greenland also in the future.  
Anne Kjerulf, Jette Holt, Lydia Maria Helms, Anne Birgitte Jensen, Peter Poulsen 
For further information: Anne Kjerulf, alf@ssi.dk
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Figure 1 Increasing numbers of MRSA in Greenland
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8.8 Neisseria gonorrhoeae 
Neisseria gonorrhoeae is the causative agent of the sexually 
transmitted infection gonorrhoea, which is usually located in 
the urethra in males and cervix in females. N. gonorrhoeae 
(gonococci) may sometimes be detected in specimens from the 
pharynx or rectum in either gender. In females, the finding of 
gonococci in rectal specimens is usually due to contamination 
with vaginal secretion, while in men who have sex with men 
(MSM) it is due to unprotected anal sex. In both males and 
females, the condition is generally asymptomatic. Pharyngeal 
gonorrhoea is virtually always asymptomatic. 
Complications of gonorrhoea include e.g. salpingitis, epididy-
mitis, orchitis, and prostatitis. Furthermore, conjunctivitis may 
occur in newborns after transmission from an infected mother 
during labour and rarely in adults following direct inoculation.
Surveillance  
Since 1962, the Departments of Clinical Microbiology in 
Denmark have submitted isolates of gonococci to the Neis-
seria and Streptococcus Reference (NSR) laboratory at Statens 
Serum Institut for national surveillance of antimicrobial resis-
tance. Most of the received isolates are from urethra or cervix, 
while clinicians only rarely obtain specimens from rectum and 
pharynx. Occasionally, the NSR laboratory receives strains iso-
lated from other anatomical sites, such as conjunctivae, joint 
fluid, blood, Bartholin’s abscess, etc.
At the NSR laboratory, ceftriaxone, ciprofloxacin and azithro-
mycin MICs are determined using the Etest® on chocolate agar 
incubated at 35 °C in 5% CO2. The breakpoints used are those 
defined by EUCAST. Both resistant and intermediary suscep-
tible isolates are categorised as resistant in this report. The 
Nitrocephin assay is used to test for penicillinase production.
As part of NSR’s participation in ECDC’s surveillance of sexu-
ally transmitted infections since 2009, 110-120 gonococcus 
isolates are consecutively collected every year and investi-
gated for susceptibility to an expanded panel of antimicrobial 
agents. This panel includes cefixime and in selected years also 
spectinomycin and sometimes gentamicin. 
Submitted isolates and resistance results
In 2017, isolates from 1,473 unique cases of gonorrhoea were 
retrieved. The annual number has increased markedly from 
2011 through 2016 (Figure 8.8.1), partly because the now 
widespread use of combined nucleic acid amplifications tests 
for Chlamydia trachomatis and N. gonorrhoeae has identified 
unexpected cases of gonorrhoea (followed by culture), and 
partly due to an increasing incidence of gonorrhoea, especially 
among young heterosexual persons, among whom an increas-
ing proportion are women.
The ciprofloxacin resistance rate was 28% in 2017 (18% in 
2016, 29% in 2015 and 46% in 2014), thus still markedly 
lower than the peak of 75% in 2009 (Figure 8.8.1). The per-
centage of strains producing penicillinase was 9%. It fluctu-
ated between 22% in 2005 and 7% in 2016. Azithromycin 
resistance was detected in 10% of the cases. 
Ceftriaxone resistant gonococci (MIC > 0.125 mg/L) as well 
as ceftriaxone treatment failure in patients with gonorrhoea 
has occurred in several countries in recent years.  During 2003 
through 2009, the proportion of isolates with ceftriaxone MIC 
≥  0.008 mg/L gradually increased from 40% to nearly 75% 
(Figure 8.8.2), but during recent years this shift has nearly 
reversed (44% in 2014 and 17% in 2015). In 2017, there was 
a single case among the submitted isolates with ceftriaxone 
MIC of 0.25 mg/L and azithromycin MIC of 0.25 mg/L. 
The National Board of Health issued guidelines in 2015 for the 
diagnosis and treatment of sexually transmitted infections. 
A combination of high dose ceftriaxone (500 mg i.m.) and 
azithromycin (2 g) is recommended for the treatment of gonor-
rhoea. Ciprofloxacin 500 mg p.o. may be used for treatment if 
the strain is fully susceptible. 
In a subset of 118 isolates, resistance against cefixime (MIC 
> 0.125 mg/L) was 0.8% in 2017 (0% in 2016 and 2015). Ce-
fixime is an orally administered cephalosporin that has never 
been used in Denmark. Resistance against spectinomycin was 
0% in 2017 like in 2016 and 2015. MIC values for gentami-
cin were 1 to 4 mg/L, but no breakpoints are defined for this 
agent against gonococci. However, the distribution of gentami-
cin MICs were a little lower than during preceding years.
Conclusions  
The incidence of gonorrhoea remained at the high level it had 
reached in 2016 following substantial increases. The ciproflox-
acin resistance rate increased in 2017 for the first time after 
almost a decade of decreasing. Although resistance problems 
are still not present in Denmark, the emerging ceftriaxone 
treatment failures in other countries underlines the impor-
tance of maintaining the centralised national surveillance of 
antimicrobial resistance in gonococci. 
Steen Hoffmann 
For further information: Steen Hoffmann, hof@ssi.dk
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Textbox 8.6
Mycoplasma genitalium   
Background: Mycoplasma genitalium is a relatively newly discovered sexually transmitted bacterium with the first report 
of isolation appearing in 1981. It is extremely fastidious and slow to grow in culture, and its role as a pathogen could not be 
determined until the development of PCR-based methods in the 1990s. M. genitalium causes non-gonococcal urethritis (NGU) 
in men and women and cervicitis and pelvic inflammatory disease (PID) in women. It has been associated with infertility by 
serology, but causality is not proven. The association between M. genitalium and adverse pregnancy outcome is not completely 
established either; a meta-analysis showed a significant association, but in Denmark, the prevalence in pregnant women is low, 
and thus, it is not considered to be a major problem in pregnancy.
Epidemiology: In population-based studies of individuals not seeking health care, M. genitalium is found with the highest 
prevalence in the age group 15-35 years of age, but unlike chlamydia, older age groups are also relatively commonly represent-
ed. The overall prevalence in the population is slightly lower than that of C. trachomatis (1-3% M. genitalium positive in most 
studies) but much higher than that of Neisseria gonorrhoeae.
In symptomatic patients, M. genitalium is detected in 15-25% of NGU and 20-30% of those with C. trachomatis negative NGU. 
Due to the difficulty in treatment of the infection, 35-50% of men with persistent NGU are M. genitalium positive. It is estimat-
ed that 5-15% of PID is caused by M. genitalium.
Diagnosis:  The only relevant diagnostic method is nucleic acid amplification tests (NAATs) on first-void urine from men and 
vaginal swab material from women. All positive results should be followed by testing for macrolide resistance mediating muta-
tions and treatment should await the result of this test if possible.
Treatment: M. genitalium is susceptible to tetracyclines in vitro, but treatment with doxycycline eradicates only around 30% of 
the infections. 
Azithromycin has traditionally been the first line antimicrobial with an eradication rate of approximately 85% in studies per-
formed before 2009, but in recent years, this rate has declined dramatically due to a rapid development of high-level macrolide 
resistance, though. The resistance rate varies significantly between countries (see Figure 1 for a compilation of resistance 
studies in Europe) from <20% in Sweden to >50% in Denmark and Norway. The reason for this difference in resistance rates 
between the Nordic countries is most likely the widespread use of azithromycin 1 g single-dose for treatment of chlamydia in 
Denmark and Norway compared to doxycycline for first-line treatment of chlamydia and urethritis/cervicitis of unknown aetiol-
ogy in Sweden. A dramatic example of selection of macrolide resistance is provided from Greenland where nearly 100% of the 
infections are caused by strains with macrolide resistance. This is most likely due to the very high prevalence of C. trachomatis 
infection and the resulting frequent use of 1 g single-dose therapy with azithromycin.
It is estimated that each round of azithromycin treatment of a susceptible infection leads to selection of resistance in 10% of 
the treated patients. This is the background for the recommendation of a test of cure after more than three weeks after initia-
tion of treatment.
Second-line treatment for patients failing azithromycin treatment or with documented macrolide resistance at the time of diagno-
sis is moxifloxacin (400 mg once daily for 7 days). However, resistance to fluoroquinolones is also increasing worldwide. At present, 
approx. 5% of Danish M. genitalium patients carry strains with mutations associated with fluoroquinolone resistance and most 
of these infections are also macrolide resistant, leading to a situation where no registered treatment alternatives are available in 
Denmark. Some success in treating these multidrug-resistant (MDR) strains has been achieved with pristinamycin, a streptogramin 
class antimicrobial only registered in France. However, pristinamycin eradicates only 75% of the infections and is available only on 
a special permit (the clinic for sexually transmitted diseases at Bispebjerg Hospital has pristinamycin available).
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Discussion: M. genitalium is rapidly developing resistance to all available antimicrobials and treatment should always be di-
rected with regard to macrolide resistance testing. The use of azithromycin 1 g single-dose for chlamydia and urethritis/cervici-
tis of unknown aetiology should be minimised and first-line treatment should be changed to doxycycline 100 mg twice daily for 
7 days. This is in accordance with the newest European guidelines, since it also has a better effect on rectal chlamydia, which is 
more common than previously recognised and a suspected cause of re-infection. 
Screening for M. genitalium in asymptomatic patients is not recommended, since there is no evidence of benefit for the patient 
or on a population level.
Systematic surveillance of antimicrobial resistance is being established in Denmark and is needed to guide treatment recom-
mendations. New antimicrobials and combinations of the already available ones are subject to a number of in vitro studies in 
Denmark and Internationally.
Jørgen Skov Jensen 
For further information: Jørgen Skov Jensen, jsj@ssi.dk
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Figure 1 Prevalence of macrolide resistance mediating mutations in M. genitalium in Europe. 
Data compiled from published data sources DANMAP 2017
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9. MATERIALS AND METHODS
9. Materials and methods
9.1 General information
For the DANMAP 2017 report, population sizes and geographi-
cal data were obtained from Statistics Denmark [www.dst.
dk] and data on general practitioners from the Danish Medical 
Association [www.laeger.dk].
The epidemiological unit for pigs and cattle was defined at the 
individual farm level, meaning that only one isolate per bacte-
rial species per farm was included in the report. The individual 
flock of broilers was defined as the epidemiological unit, and 
for food the epidemiological unit was defined as the individual 
meat sample.
For humans, the epidemiological unit was defined as the indi-
vidual patient and the first isolate per species per patient per 
year was included.
An overview of all antimicrobial agents registered for humans 
and animals in Denmark is presented in Table 3.2.
9.2 Data on antimicrobial consumption in animals
9.2.1 Data 
In Denmark, all antimicrobial agents used for treatment are 
available on prescription only. Until 2007, antimicrobial agents 
were exclusively sold by pharmacies or as medicated feed from 
the feed mills. However, since April 2007, the monopoly was 
suspended and private companies (four in 2017) were given 
license to sell prescribed veterinary medicinal products for 
animals, when following strict guidelines, identical to those 
applied to pharmacies. Furthermore, in 2007 price setting 
of antibiotic was liberalised, which allowed for discounts to 
veterinarians, when buying larger quantities.
A pharmacy or company either sells the medicine to veterinar-
ians for use in their practice or for re-sale to farmers, or sells 
the medicine directly to the animal holder on presentation of a 
prescription. By law, veterinarians are allowed only very small 
profits on their sale of medicine (5%), to limit the economic 
incentive to overprescribe.
In 2017, 99% of antimicrobial agents were purchased through 
pharmacies and the drug trading companies, while 1% were 
purchased from the feed mills. These numbers did not include 
prescribed zinc oxide from the feeding mills for the pigs. 
For cattle, 82% of antimicrobial agents used in 2017 were 
purchased from pharmacies, whereas 10 years ago more than 
80% of the antimicrobial agents used in cattle was purchased 
through the veterinarian. In aquaculture, approximately 60% is 
purchased through the feed mills.
Data on all sales of veterinary prescription medicine from the 
pharmacies, private companies, feed mills and veterinarians are 
sent electronically to a central database called VetStat, which 
is hosted by the Danish Veterinary and Food Administration. 
Prior to 2001, all data on antimicrobial sales were derived from 
pharmaceutical companies. Veterinarians are required by law 
to report all use of antibiotics and prescriptions for production 
animals to VetStat monthly. For most veterinarians, the regis-
tration of data is linked to the writing of invoices. The elec-
tronic registration of the sales at the pharmacies is linked to 
the billing process and stock accounts at the pharmacy, which 
ensures a very high data quality regarding amounts and type 
of drugs. Data are transferred daily from pharmacies to The 
Register of Medicinal Product Statistics at SSI and to VetStat. 
However, VetStat does not have any validation on data entry 
and slight typing errors from vets may occur.
In addition, data on coccidiostatics as feed additives (non-pre-
scription) and antimicrobial growth promoters (not in use since 
2000) have also been collected by VetStat, providing an almost 
complete register of all antimicrobial agents used for animals in 
Denmark for the past twenty years. In very rare instances, medi-
cines are prescribed on special license and will not be included in 
VetStat (i.e. medicines not approved for marketing in Denmark).
The VetStat database contains detailed information about 
source and consumption for each prescription item: date of 
sale, identity of prescribing veterinarian, source ID (identity 
of the pharmacy, feed mill, or veterinarian practice report-
ing), package identity code and amount, animal species, age 
group, disease category and code for farm-identity (CHR 
Danish Central Husbandry Register). The package code is a 
unique identifier, relating to all information on the medicinal 
product, such as active ingredient, content as number of unit 
doses (e.g. number of tablets), package size, and code of the 
antimicrobial agent in the Veterinary Anatomical Therapeutic 
Chemical (ATCvet) classification system.
Knowledge of the target animal species enables the presen-
tation of consumption data in “defined animal daily doses” 
(DADD) a national veterinary equivalent to the international 
defined daily doses (DDDs) system applied in the human field 
[www. whocc.no]. The data presented  in DANMAP 2017 
were extracted from VetStat on 6th August 2018.
9.2.2 Methods
In DANMAP, we report use of antimicrobials dispersed in differ-
ent animal populations. As a first step, the amount of antimicro-
bial agents used in animals is measured in kg active compound, 
to enable an overall crude comparison of consumption in differ-
ent animal species and in the veterinary and human sectors. 
Thereafter, a more detailed comparison of the quantity of 
antimicrobials used is performed, taking into account their 
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potency, formulation, route of administration and the age of 
the animals (where relevant), by generating Defined animal 
daily doses (DADDs).
Numerator - DADD
Defined animal daily dose (DADD) is the average maintenance 
dose per day for a drug used for its main indication in the appro-
priate animal species. The DADD is not defined at product level 
but for each antimicrobial agent, administration route and animal 
species and when appropriate, also age group. DADD has been 
specifically defined for use in DANMAP and does not always 
completely match the “prescribed daily dose” or the recommend-
ed dosage in the Summaries of Product Characteristics (SPC).
A DADD group is defined for each antimicrobial agent by 
administration route, pharmaceutical form and animal species; 
and when appropriate also by age group;
1.  Minor inconsistencies are corrected (e.g. due to rounding 
of numbers);
2.  Approved dosage for the most widely used antimicrobial 
products are given priority above dosage for products 
that are rarely used;
3.  Approved dosage for older products within the group are 
maintained as the common DADD even if a new product 
is approved with a higher dosage;
4.  If the dosage for a group shows large variation in ap-
proved dosages of the products, the dosages provided by 
”The Veterinary Formulary” [British Veterinary Associa-
tion 2005, 6th edition] are applied;
5.  Dosages may vary within active compound and admin-
istration route, if different dosages have been approved 
for different age group/indication or formulation.
When principle 3 and 4 are conflicting, principle 5 is applied.
Denominator - biomass
Trends in antimicrobial consumption in pigs are presented in 
DADD per 1,000 animals per day (DAPD). The number of animals 
in a population (in epidemiological terms: the population at risk) 
is represented by their live biomass. The biomass of a species 
is calculated, taking into account average live bodyweight and 
the average lifespan in each age group. The estimation of live 
biomass and thus the number of standard animals at risk per 
day depends on the available data sources for each species.
Pig production: The estimation was based on the number of 
pigs produced, including exports at different ages [Statistics 
Denmark; Danish Agriculture and Food Council], productivity 
data for each year [Danish Agriculture and Food Council, 2016] 
and census data for breeding animals [Statistics Denmark, 
2016]. The average weight and life span for the growing ani-
mals (piglets, weaners and finishers) were estimated from the 
annual productivity numbers. The estimation methods were 
developed in cooperation with Danish Agriculture and Food 
Council. There are no statistics on average weight of breed-
ing animals available, so an estimated average weight had to 
be assumed. However, the size of the breeding animals has 
probably increased over the last decade, but this could not be 
accounted for. 
Cattle production: The live biomass of the cattle population is 
estimated from census data [Statistics Denmark] and the aver-
age live weight of the different age groups. The Danish cattle 
population is mainly dairy, particularly Holstein Friesian, but 
also other breeds such as Jersey and a small population of beef 
cattle. Most of the cattle slaughtered are dairy cows and bull 
calves of dairy origin. The average live weight was estimated 
for 10 different age and gender categories.
Broiler (Gallus gallus): The live biomass was estimated based 
on number of broilers produced [Statistics Denmark; Danish Ag-
riculture and Food Council], an average live weight at slaughter 
of 1.97 kg after an estimated average life span of 30 days. 
The mean live biomass per broiler is assumed to be half of the 
weight at slaughter.
Turkey production: The live biomass is estimated based on 
the number of turkeys produced [Statistics Denmark; Danish 
Agriculture and Food Council] and an average live weight at 
slaughter of 21 kg for male turkeys and 11 kg for hens after 
an estimated average life span of 20 weeks and 15.5 weeks, 
respectively [Danish Agro; S. Astrup, personal communication]. 
The estimated mean live biomass per turkey is assumed to be 
half of the weight at slaughter.
Fur animals: The live biomass of mink is estimated from pro-
duction data [Kopenhagen Fur] and carried out as described by 
Jensen et al., 2016 [Prev. Vet. Med., 26: 170].
Pet animals: Only dogs and cats are taken into account, as the 
other population sizes are negligible in Denmark, and relatively 
rare in veterinary practice. The population is based on census data 
[Statistics Denmark, 2000] estimating 650,000 cats and 550,000 
dogs. The number of dogs in Denmark has been relatively stable 
during the last ten years [Danish Dog register, 2012]. The aver-
age live weight for cats and dogs were estimated to 4 kg and 20 
kg, respectively (based on pedigree registration data).
Aquaculture: The estimation is based on data from the Danish 
AgriFish Agency (Ministry of Environment and Food) on pro-
duced amounts in each subtype of production, and information 
on the typical lifespan and entrance and exit body weights, 
and were calculated in cooperation with Danish Aquaculture 
[N.H. Henriksen, Danish Aquaculture].
Treatment proportion - DAPD - DADD per 1,000  
animals per day
The treatment proportion is calculated as the number of 
DADDs administered to an animal species during a year (in 
thousands) divided by the number of standard animals at risk 
per day. The number of standard animals at risk per day takes 
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into account species differences in average body-mass and 
lifespan. When relevant, the numbers of DADDs and standard 
animals at risk are estimated for specific age groups, or simply 
as number of doses (DADDs) used to treat one kg of animal 
divided with the total estimated biomass (in tonnes). 
DAPD is a statistical measure, which provides a rough estimate of 
the proportion of animals treated daily with an average main-
tenance dose of a particular antimicrobial agent. For example, 
10 DAPDs indicate that an estimated 1% of the population, on 
average, receives a certain treatment on a given day. The DAPD 
is also referred to as the treatment proportion or treatment inten-
sity. In principle, the metric DAPD is parallel to the metric used in 
pharmaco-epidemiology for the human sector, Defined daily dose 
per 1000 inhabitants per day (DID), see Section 9.9.2. In 2017, 
DAPD calculations were carried out for pigs only.
Due to a relative high number of pigs exported around 30 kg; 
an adjusted measure of consumption per pig was calculated. 
The adjustment is based on the assumption that pigs exported 
at 30 kg, on average, received the same amount of antimicrobi-
al agents before export, as other pigs from farrowing to 30 kg. 
Antimicrobial use per pig produced (adjusted) is calculated as: 
[DADDs + DADDw + (1+Q)*DADDf] / (biomass-days-total + 
Nw*5,800(kg*days)), where
DADDs= the amount of antimicrobial agents used in sows
DADDw = the amount of antimicrobial agents used in weaners
DADDf = the amount of antimicrobial agents used in finishers
Q is the proportion of weaning pigs exported around 30 kg
Nw= the number of pigs exported at 30 kg bodyweight
Nw*5,800= the the number of biomass days the exported pigs 
would have contributed to the live biomass if not exported
9.3 Collection of bacterial isolates - animals and meat
9.3.1 Animals
Since 2014, most isolates available for DANMAP have been col-
lected in accordance with the EU harmonised monitoring of anti-
microbial resistance in zoonotic and commensal bacteria [Decision 
2013/652/EU]. The legislation requires, in addition to sampling 
for the national Salmonella control programmes in poultry farms, 
sampling of broilers and fattening turkeys at slaughter in even 
years (2014-2020) and sampling of fattening pigs and cattle < 
1 year at slaughter in odd years (2015-2019). In 2017, samples 
from pigs were examined for ESBL/AmpC and carbapenemase 
producing E. coli, indicator E. coli, Salmonella and Enterococcus 
faecalis. Samples from cattle were examined for ESBL/AmpC and 
carbapenemase producing E. coli, indicator E. coli and Campylo-
bacter jejuni. Additionally, sampling of Campylobacter jejuni and 
indicator E. coli from broilers was carried out (Table 9.1).
Meat inspection staff or abattoir personnel at the slaughter houses 
collected caecal samples from healthy pigs, cattle (< 1 year) and 
broilers. For pigs and cattle, the samples were collected through-
out 2017, and the sampling was stratified per slaughterhouse 
by allocating the number of samples from domestically produced 
animals collected per slaughterhouse proportionally to the annual 
throughput of the slaughterhouse. For broilers, the sampling took 
place in the two major Danish slaughterhouses during August 
and September; in order to collect isolates during the expected 
high-prevalence period of Campylobacter. Four intact caeca from 
each broiler flock were pooled into one sample. For pigs and cattle, 
samples contained 30-100 g caecal material from a single animal. 
All samples were processed at the Danish Veterinary and Food 
Administration’s (DVFA) laboratory in Ringsted, including anti-
microbial susceptibility testing and Salmonella serotyping.
Salmonella from layers, broilers, turkeys and cattle are not 
included in DANMAP 2017 due to low numbers of isolates 
available from the national surveillance [Annual Report on 
Zoonoses in Denmark, 2017].
9.3.2 Meat
The EU harmonised monitoring requires, in addition to 
sampling for the national Salmonella control programmes 
at slaughter, sampling at retail of broiler meat in even years 
(2014-2020) and sampling of pork and beef in odd years 
(2015-2019) [Decision 2013/652/EU].
In 2017, ESBL/AmpC producing E. coli were isolated from 
packages of fresh, chilled pork and beef collected in Dan-
ish wholesale and retail outlets throughout the year by 
the regional DVFA officers (Table 9.1). Products with added 
saltwater or other types of marinade were excluded and the 
packages were selected without pre-selecting based on the 
country of origin. The number of establishments and samples 
selected by each regional DVFA control unit was proportional 
to the number of establishments in the region in relation to 
the total number of establishments in the country. One unit 
of product (minimum of 200 g) was collected and all samples 
were processed at the DVFA laboratory. 
The Salmonella isolates from pork originate from the national 
control programme at the slaughterhouses (Table 9.1), where 
the carcasses are swabbed in four designated areas (the jaw, 
breast, back and ham) after min. 12 hours of chilling (cover-
ing 10x10cm). The numbers of swabs collected depend on 
the slaughterhouse capacity. All samples were processed at 
Industry laboratories. Isolates from all Salmonella positive 
samples were send to the DVFA laboratory, where one isolate 
per sample was serotyped and susceptibility tested. 
Salmonella from broiler meat and beef are not included in DAN-
MAP 2017 due to low numbers of isolates available from the na-
tional surveillance programmes [Annual Report on Zoonoses in 
Denmark, 2017]. Campylobacter from broiler meat for DANMAP 
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originate from the national control program: Intensified Control 
of Salmonella and Campylobacter in fresh meat. However, in 
2017 very few Campylobacter isolates from domestically pro-
duced broiler meat found and therefore not included in DANMAP.
9.4 Microbiological methods – isolates from  
animals and meat
9.4.1 Salmonella
Salmonella was isolated in accordance with the methods 
issued by the NMKL [NMKL No. 187, 2007] or Annex D, ISO 
6579 [ISO6579:2002/Amd 1:2007]. Serotyping of isolates 
was performed by Whole Genome Sequencing using the Illu-
mina MiSeq platform, paired-end sequencing 2x250 cycles. For 
bioinformatics, a CGE service (Centre for Genomic Epidemiol-
ogy, DTU) for Salmonella serotyping was applied based on the 
genetic background for antigenic formulas given by the White-
Kauffmann-Le Minor Scheme. Only one isolate per serotype 
was selected from each herd, flock or slaughter batch.
9.4.2 Campylobacter
Campylobacter from broilers and cattle was isolated and identi-
fied according to the methods issued by the NMKL [NMKL 
No. 119, 2007] followed by species-determination by BAX® 
rtPCR assay.  Pre-enrichment in Bolton broth was used for 
cattle samples, whereas direct spread of caecal sample on to 
selective agar was used for broiler samples. Only one C. jejuni 
isolate per broiler flock, cattle herd or per batch of fresh meat 
was selected.
9.4.3 Indicator E. coli
Indicator E. coli from broilers, pigs and cattle was isolated by 
direct spread of caecal sample material onto violet red bile 
agar incubated for 24h at 44°C. Presumptive E. coli was identi-
fied on TBX agar incubated at 44°C o/n. Only one indicator E. 
coli isolate per flock or herd was selected.
For specific isolation of ESBL/AmpC and carbapenemase-
producing E. coli from caecal samples, the present EURL-AR 
laboratory protocol describing the selctive enrichment proce-
dures was applied in accordance with the EU harmonized moni-
toring. Only one ESBL/AmpC producing E. coli isolate per pig 
herd, cattle herd and meat sample was selected (no isolates of 
carbapenemase-producing E. coli was detected).
9.4.5 Enterococcus
Enterococcus from pigs were isolate from an adequate 
amount of caecal material suspended in 2 ml BPW. The sus-
pension was streaked onto Slanetz Bartley agar and incubat-
ed 48h at 41.5°C. Two colonies resembling typical E. faecalis 
were sub-cultivated on blood agar. Species identification was 
done by rtPCR. Only one isolate of E. faecalis was selected 
per herd. 
All samples were processed at the Danish Veterinary and Food 
Administration’s (DVFA) laboratory in Ringsted including Sal-
monella serotyping, except for isolation of Salmonella from pig 
carcasses, which  was carried out at Industry laboratories.
Table 9.1 Legislative and voluntary sampling plans under national control programmes and EU  harmonised monitoring that contribute 
isolates to DANMAP 2017 
 DANMAP 2017
Bacteria Origin of isolates Legislative 
sampling 
frequency 
(2013/652/EU)
Number of samples  
in 2017
Salmonella spp. On-farm samples from laying hens, broilers and fattening turkeys 
(breeder and production flocks)
Annually 4993 flocks
Caecal samples from fattening pigs Odd years 295 pigs
Carcasses of broilers Annually 259 flocks 
Carcasses of fattening pigs and cattle <1 year Annually 4466 cattle carcasses, 
11155 pig carcasses
Campylobacter jejuni Caecal samples from broilers Even years 163 flocks
Caecal samples from cattle <1 yr 297 cattle
Indicator E. coli Caecal samples from broilers Even years 135 flocks
Caecal samples from fattening pigs and cattle <1 yr Odd years 190 cattle, 
193 pigs
Specific monitoring 
of ESBL/AmpC – 
producing E. coli
Caecal samples from fattening pigs and cattle <1 yr Odd years 297 cattle, 
295 pigs
Fresh pork and beef at retail Odd years 290 beef samples, 
277 pork samples
WGS data for collected ESBL/AmpC isolates 17 isolates
Enterococcus spp. Caecal samples from fattening pigs 295 pigs
Note: All animal samples originate from different flocks/herds. All food samples originate from different slaughter batches, batches of Danish or 
imported meat ready for retail or packages of fresh meat at retail
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9.5 Susceptibility testing – isolates from animals and meat
Antimicrobial susceptibility testing of Salmonella, Campylobacter, 
E. coli and Enterococcus was performed as Minimum Inhibitory 
Concentration (MIC) determination using broth microdilution by 
Sensititre (Trek Diagnostic Systems Ltd.). Inoculation and incu-
bation procedures were in accordance with the CLSI guidelines 
[Clinical and Laboratory Standards Institute, USA] and the European 
standard ISO 20776-1:2006. The isolates were tested for antimi-
crobial susceptibility in accordance with the Decision 2013/652/
EU about the EU harmonized monitoring of antimicrobial resistance.
The relevant quality control strains were used at the laborato-
ries: Escherichia coli ATCC 25922, Enterococcus faecalis ATCC 
29212 and Campylobacter jejuni ATCC 33560.' 
Isolates from animals and meat were tested for antimicrobial 
susceptibility at the DVFA laboratory in Ringsted that is ac-
credited by DANAK (the national body for accreditation). 
9.6 Whole genome sequencing –isolates from animals 
and meat
In addition to Salmonella serotyping performed by sequenc-
ing (Section 9.4.1), whole genome sequencing (WGS) and in 
silico bioinformatic tools were also used to detect the genetic 
background of the ESBL/AmpC and carbapenemase-producing 
E. coli. At the DVFA laboratory in Ringsted, strains were se-
quenced using the Illumina Miseq platform followed by bioin-
formatics analysis at DTU National Food Institute from Centre 
for Genomic Epidemiology (www.genomicepidemiology.org; 
https://cge.cbs.dtu.dk//services/all.php) including: 
1.  De novo assembly using SPAdes [Bankevich et al. 2012. J 
Comput Biol. 19(5): 455]; 
2.  MLST using MLST Finder 2.0 [Larsen et al. 2012. J Clin 
Micobiol. 50(4): 1355];
3.  Detection of antimicrobial resistance genes using Res-
Finder 3.0 which includes chromosomal mutations leading 
to resistance to beta-lactams, quinolones and colistin as 
well as acquired resistance genes  [Zankari et al. 2012. J 
Antimicrob Chemother. 67(11): 2640; Zankari et al. 2017. J 
Antimicrob Chemother. 72(10): 2764];
4.  Detection of virulence genes using VirulenceFinder 1.5 
[Joensen et al. 2014. J Clin Micobiol. 52(5): 1501], and;
5.  Detection of plasmid replicons using PlasmidFinder 1.3 
[Carattoli et al. 2014. Antimicrob Agents Chemother. 
58(7): 3895]. 
9.7 Data handling – isolates from animals and meat
For the samples processed at the DFVA laboratory, sampling de-
tails and laboratory results were stored in the DVFA Laboratory 
system. Following validation by DVFA, data were electronically 
transferred to DTU National Food Institute. At the DTU National 
Food Institute, data were harmonised and one isolate per epide-
miological unit was selected for reporting. All data are stored in 
an Oracle database at isolate level (9i Enterprise Edition®). The 
database contains all antimicrobial data reported in DANMAP or 
to EFSA since 2007 (partial dataset from 2001-2006). 
Variables include: bacterial species (subtype where applicable), 
date of sampling, animal species or food type, herd identifier and 
country of origin whenever possible. MIC values were retained as 
continuous variables in the database, from which binary variables 
were created using the relevant cut-off from 2017 for all years. 
Since 2007, data have been interpreted using EUCAST epidemio-
logical cut-off values with a few exceptions described in Table 9.2.  
All MIC-distributions are presented in the web annex at www. 
danmap.org. Each of the tables provides information on the 
number of isolates, the applied interpretation of MIC-values and 
the estimated level of resistance and confidence intervals calcu-
lated as 95% binomial proportions presenting Wilson intervals. 
Classification of CPE, ESBL and AmpC phenotypes was done 
according to the scheme provided by EFSA [EFSA 2018. EFSA 
Journal 16(2):5182]: 
1. CPE phenotype if meropenem MIC >0.12; 
2.  ESBL phenotype if cefotaxime/ceftazidime MIC >1 and 
meropenem MIC <=0.12 and cefoxitin MIC <=8 and 
synergy (clavulanic acid and cefotaxime/ceftazidime);
3.  ESBL-AmpC phenotype if cefotaxime/ceftazidime MIC >1 
and meropenem MIC <=0.12 and cefoxitin MIC >8 and 
synergy (clavulanic acid and cefotaxime/ceftazidime);
4.  AmpC phenotype if cefotaxime/ceftazidime MIC >1 and 
meropenem MIC<=0.12 and cefoxitin MIC>8 and no-
synergy (clavulanic acid and cefotaxime/ceftazidime);
5. Other phenotype if not in 1-4.
Synergy is defined by MIC value of clavulanic acid combined 
with cefotaxime or ceftazidime at least 8-times higher than 
the MIC of cefotaxime or ceftazidime alone, respectively. 
All handling, validation and analysis of results were carried out 
using Microsoft Excel, Oracle and SAS®Software, SAS Enter-
prise Guide 6.1.
Significance tests of differences between proportions of 
resistant isolates were calculated using SAS®Software, SAS 
Enterprise Guide 6.1 using univariable Chi-square, or Fish-
er’s Exact Tests as appropriate. All changes and differences 
yielding p<0.05 were commented on in the text, whereas 
the remaining data was visualised in figures or tables only.
Some types of resistances were looked for, but not found by 
the DANMAP monitoring system, yielding a prevalence of zero. 
It is not possible for surveys to prove freedom from diseases or 
resistances in populations, but with a defined confidence, sur-
veys can identify the maximum possible prevalence given that 
the survey failed to find any positives [Textbox 6.2, DANMAP 
2016]. This maximum prevalence was calculated for the report 
using 95% confidence and assuming a perfect test by a prob-
ability formula to substantiate freedom from disease [Cameron 
and Baldock 1998, Prev. Vet. Med]. 
Link to calculation example: http://epitools.ausvet.com.au/
content.php?page=HerdSens5&Sens=1&SampleSize=100&
Population=&TargetSeH=0.95. 
141DANMAP 2017
9.MATERIALS AND METHODS, ANIMALS
Table 9.2 Interpretation criteria for MIC-testing by EUCAST epidemiological cut-off values and  
the corresponding EUCAST clinical breakpoints DANMAP 2017
Note: EUCAST epidemiological cut-off values (ECOFFs) and EUCAST clinical breakpoints listed unless noted
a) The EUCAST ECOFF (>2) for colistin was applied for S. Typhimurium and other serotypes, except for S. Enteritidis and S. Dublin where ECOFF >8 
was applied according to investigations presented in DANMAP 2011
b) No current EUCAST ECOFF is available, apply complementary interpretative thresholds as suggested by EFSA [EFSA Supporting publication 
2017:EN-1176]
c) Inducible clindamycin resistance is included
Salmonella E. coli E. faecalis C. jejuni S. aureus
Antimicrobial agent ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Ampicillin >8 >8 >8 >8 >4 >8
Azithromycin >16 (a) >0 >16 (a) >0
Cefepime >0.125 (a) >4 >0.125 >4
Cefotaxime >0.5 >2 >0.25 >2
Cefotaxime/
clavulansyre
>0.5 (a) >0 >0.25 (a) >0
Cefoxitin >8 >0 >8 >0 >4
Ceftaroline >1
Ceftazidime >2 >4 >0.5 >4
Ceftazidime/
clavulansyre
>2 (a) >0 >0.5 (a) >0
Ceftobiprole >1
Chloramphenicol >16 >8 >16 >8 >32 >0
Ciprofloxacin >0.064 >0.064 >0.064 >0.5 >4 >0 >0.5 >0.5 >1
Clindamycin >0.25(c) 
Colistin >2 (b) >2 >2 >2
Daptomycin >4 >0 >1
Ertapenem >0.064 >1 >0.064 >1
Erythromycin >4 >0 >4 >4 >1
Fusidic acid >0.5
Gentamicin >2 >4 >2 >4 >32 >0 >2 >0 >2
Imipenem >1 >8 >0.5 >8
Kanamycin >8
Linezolid >4 >4 >4
Meropenem >0.125 >8 >0.125 >8
Mupirocin >1
Nalidixic acid >16 >0 >16 >0 >16 >0
Norfloxacin >4
Penicillin >0.125
Quinupristin/
dalfopristin
>0
Rifampicin >0.03
Streptomycin >4 >0
Sulfamethoxazole/
Trimethoprim
>0.5
Sulfonamide >256 (a) >0 >64 >0
Teicoplanin >2 >2
Temocillin >32 (a) >0 >32 (a) >0
Tetracycline >8 >0 >8 >0 >4 >0.5 >1 >2 >1
Tigecycline >1 >2 >1 >2 >0.25 >0.25
Trimethoprim >2 >4 >2 >4
Vancomycin >4 >4 >2
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9.8 Data on antimicrobial consumption in humans
9.8.1 Data registration
Antimicrobial consumption at hospitals is reported to DANMAP 
once a year through the Register of Medicinal Product Statis-
tics at the Danish Health Data Authority. Before 2012, data 
from hospitals on certain infusion substances was obtained 
directly from the hospital pharmacies. From 2013 onwards, 
all data from hospitals are reported to and delivered by The 
Register of Medicinal Product Statistics at SSI.
Reporting is based on deliverances from the hospital pharma-
cies to the different clinical departments and includes all ge-
neric products that are supplied through general trade agree-
ments between the hospital and different medical suppliers. 
Detailed information is given on the different drugs delivered 
on ATC5 level. The reporting corresponds relatively well to the 
overall consumption at department level, but for many clinical 
departments it is difficult to establish the use of antimicrobi-
als dispersed on the different patient categories, since several 
clinical specialties are brought together within the same clini-
cal entity. Also, some clinical departments have close collabo-
ration with other specialties, which also may include helping 
each other out in situations of shortage of certain drugs. 
Finally, a clinical entity may be geographically spread across 
several hospital buildings and dispersing of deliverances of 
medicine will not always be announced to the pharmacy. 
In case of production failures and shortages in deliverance of 
specific products, the hospitals have to apply for special deliv-
erances through the Danish Medicines Agency. These special 
deliverances are reported separately to DANMAP through 
the Danish Health Authority. In 2017, there were shortages 
in deliverance of piperacillin with tazobactam and pivemecil-
linam as well as mecillinam. The shortage in piperacillin with 
tazobactam had significant impact on the amount used, while 
the shortage in (piv)mecillinam could not be clearly tracked in 
changes in consumption. 
Data on treatment at patient level is available at very few of 
the hospitals and has so far been used in local quality assur-
ance only but has not been available to the national surveil-
lance system. Improvement of patient monitoring has been 
included in the newest electronical patient journal systems 
but in several of the regions, this is not fully implemented yet, 
thus a national account of the prudence of use of antimicrobi-
als at hospitals has so far not been possible. 
Earlier reporting on human antimicrobial consumption in Den-
mark exist. These were performed through the Association of 
Medicine Importers (Medicinimportørforeningen, MEDIF) and 
the Association of Danish Medicinal Factories (Foreningen af 
danske Medicinfabrikker, MEFA) based on whole sales data to 
the pharmacies. This reporting became less reliable over time, 
since there was an increasing amount of parallel imported 
drugs from the late 1980´s, which were not covered by this 
registration.
In the primary sector, all antibacterial agents for human use 
are prescription-only medicines. Sales are reported through 
the pharmacies by a code relating to the defined package. The 
information from the code includes information on the active 
drug, the brand name of the product, formulation, size and 
number of packages. The sale also report the age, gender and 
regional residence of the patient. In 2017, clinical information 
on the indication to prescribe the drug, was available for 90% of 
prescriptions, (an increase from 86% in 2016). Yet some indica-
tion codes, like the term “infection”, suffer from being unspecific. 
Specific indications account for only 69%. Better and more 
precise indication codes will give the opportunity to register and 
evaluate on a more prudent use of antimicrobials in the future.
9.8.2 Method
Only somatic hospitals were included in the DANMAP reporting. Data 
from private hospitals and clinics, psychiatric hospitals, specialised 
non-acute care clinics, rehabilitation centres and hospices were 
excluded from DANMAP (representing approximately 3% of the anti-
microbial consumption at hospitals and of the number of bed-days).
The present report includes data on the consumption of “antibac-
terials for systemic use”, or group J01, of the 2017 update of the 
Anatomical Therapeutic Chemical (ATC) classification, in primary 
health care and in hospitals as well as consumption of per oral and 
rectal preparations of metronidazole (P01AB01) and oral prepara-
tions of vancomycin (A07AA09). As recommended by the World 
Health Organization (WHO), consumption of antibacterial agents in 
primary health care is expressed as DIDs, i.e. the number of DDDs 
per 1,000 inhabitants per day (DDD/1,000 inhabitant-days). 
The consumption in hospitals is expressed as DBDs, the number 
of DDDs per 100 occupied beds per day (DDD/100 occupied 
bed-days). Since reporting in DBD does not necessarily reflect 
changes in hospital activity and production, consumption at 
hospitals is also presented as DAD (the number of DDDs per 100 
admissions). Finally, the consumption of antibacterial agents at 
hospitals has also been calculated in DIDs, primarily for compari-
son with primary health care. These can be found in web annex. 
All consumption is provided with two decimal digits, if possible.
9.8.3 DBD
DDD/100 occupied bed-days. The number of occupied bed-
days are calculated as the date of discharge minus the date 
of admission and rounded up to the nearest whole day. Every 
new admission to a new hospital department counts as a new 
bed-day. These were extracted from the National Patient Reg-
istry at the National Board of Health [www.sst.dk].
9.8.4 DAD
DDD/100 admissions. One admission is registered whenever a 
patient is admitted to a specific ward (i.e. one patient can be 
registered as admitted multiple times if transferred between 
wards during the same hospital stay). The admissions were 
extracted from the National Patient Registry at the National 
Board of Health [www.sst.dk].
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9.9 Salmonella and Campylobacter in humans
9.9.1 Data source
Antimicrobial susceptibility was performed on human clinical 
isolates submitted to Statens Serum Institut (SSI). Salmo-
nella isolates were submitted from all clinical microbiology 
laboratories in Denmark and Campylobacter isolates were 
submitted from clinical microbiology laboratories repre-
senting the island of Zealand excluding the capital region, 
Funen, and Northern Jutland. Exact figures of the proportion 
tested and the sampling strategy for the different species 
can be found in Sections 6.1 and 6.2. As in previous years, 
SSI collected information on travel history from the patients. 
Cases were categorised as “domestically acquired” if the pa-
tients had not travelled within the week prior to the onset 
of disease.
9.9.2 Microbiological methods
Salmonella isolates were analysed by whole genome sequenc-
ing and the serotypes were derived from the DNA sequences. 
In a few cases, the DNA information was supplemented with 
slide agglutination according to the Kauffman-White Scheme. 
Campylobacter species identification was performed by the 
use of MALDI-TOFF.
9.9.3 Susceptibility testing
Antimicrobial susceptibility testing of Salmonella and Campy-
lobacter was performed as Minimum Inhibitory Concentration 
(MIC) determination using the Sensititre broth microdilution 
system (Trek Diagnostic Systems Ltd.). Inoculation and incuba-
tion procedures were in accordance with the CLSI guidelines 
[Clinical and Laboratory Standards Institute, USA] and the 
European standard ISO 20776-1:2006.  
9.9.4 Data handling
Data on Salmonella and Campylobacter infections are stored 
in the Danish Registry of Enteric Pathogens (SQL database) 
maintained by SSI. This register includes only one isolate per 
patient within a window of six months and includes data on 
susceptibility testing of gastrointestinal pathogens.
9.10 Staphylococcus aureus including MRSA  
in humans
9.10.1 Data source
Blood isolates are referred on a voluntary basis by all DCMs to 
the National reference laboratory for antimicrobial resistance 
at SSI. Detection of methicillin-resistant Staphylococcus aureus 
(MRSA) is a notifiable condition in Denmark and therefore all 
MRSA isolates from all sample types are sent to the reference 
laboratory.
9.10.2 Microbiological methods
At SSI, all isolates are initially tested using a multiplex PCR 
detecting the spa, mecA, hsd, scn and pvl (LukF-PV) genes 
[Larsen et al. 2008. Clin Microbiol Infect. 14: 611–614; Stegger 
et al. 2012. Clin Microbiol Infect. 18: 395–400]. Spa is used 
as S. aureus specific marker and for subsequent typing by 
Sanger sequencing [Harmsen et al. 2003. J Clin Microbiol. 41: 
5442–5448], mecA to determine MRSA status, and scn and hsd 
as markers for human adaptation and relation to CC398, re-
spectively. All bacteremia cases and mecA negative presumed 
MRSA are tested for presence of the mecC gene.
spa-negative isolates are confirmed as S. aureus by MALDI-
TOF. Based on the spa type and known association with MLST 
typing, each isolate is assigned to a clonal complex (CC).
9.10.3 Susceptibility testing
Antimicrobial susceptibility testing of Staphylococcus aureus 
was performed by Minimum Inhibitory Concentration (MIC) 
determination using a custom-made panel (DKSSP2, Trek 
Diagnostic Systems Ltd.). Inoculation and incubation procedures 
were in accordance with the CLSI guidelines [Clinical and Labora-
tory Standards Institute, USA] and the European standard ISO 
20776-1:2006. The isolates were tested for antimicrobial sus-
ceptibility in accordance with the Decision 2013/652/EU about 
the EU harmonized monitoring of antimicrobial resistance.
Staphylococcus aureus ATCC 29213 was included as quality 
control for each batch of resistance determination.
9.10.4 Data handling
For MRSA, data on the characteristics of the isolates and the 
clinical/epidemiological information were obtained from the 
Danish MRSA register at SSI (mandatory reportable). Patients 
were registered, regardless of colonisation or clinical infec-
tion, the first time they were diagnosed with MRSA or when 
a new subtype was demonstrated. Based on the reported 
information, MRSA cases were classified as colonisation/active 
screening (i.e. surveillance samples to detect nasal, throat, gut 
or skin colonization), imported infection (i.e. acquired outside 
Denmark), infection acquired in a Danish hospital, defined as 
diagnosed >48 hours after hospitalisation with no sign of 
infection at admittance (HA-MRSA) or infection diagnosed 
outside hospitals (community onset).
MRSA cases with community onset were further classified 
according to risk factors during the previous 6 months as 
either health-care associated with community onset (HACO) or 
community-acquired (CA). Health-care associated risk factors 
included prior hospitalizations, stay in long-term care facilities 
and being a health-care worker. Community risk factors includ-
ed known MRSA-positive household members or other close 
contacts. Due to the increasing numbers of cases belonging to 
CC398, this type was treated separately as both epidemiology 
and relevant exposure are different from other CA cases
9.11 Invasive Streptococcus pneumoniae in humans
9.11.1 Data source
Invasive pneumococcal disease is a notifiable disease in Den-
mark, and therefore all invasive isolates nationwide are sent to 
SSI for identification or confirmation as well as serotyping and 
susceptibility testing.
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9.11.2 Microbiological methods 
Identification or confirmation of the species S. pneumoniae is 
based on: visual evaluation of colonies, positive optochin test and 
test with either latex omni serum or Neufeld based Omni serum. 
If challenging results occur, are MALDI-TOF and bile solubility test 
perform to further confirm the correct species identification. 
Serotype identification of invasive S. pneumoniae are per-
formed by using latex agglutination (ImmuLex™ Pneumotest 
Kit, SSI Diagnostica, Hillerød, Denmark) and serotype specific 
antisera by the Quellung test (SSI Diagnostica, Hillerød, Den-
mark).
9.11.3 Susceptibility testing
Screening for penicillin- and erythromycin-resistant S. pneu-
moniae was performed with 1 μg oxacillin discs and 15 μg 
erythromycin discs (Oxoid, Roskilde, Denmark), respectively, on 
Müller-Hinton agar (Müller-Hinton plate, 5% blood, 20 mg beta-
NAD, SSI Diagnostica, Hillerød, Denmark). Penicillin and eryth-
romycin MICs were determined using STP6F plate, Sensititre 
(Trek Diagnostic Systems, Thermo Scientific) as recommended 
by the manufacturer. All breakpoints used were as defined 
by EUCAST. Both fully and intermediary resistant isolates are 
counted as non-susceptible.
9.11.4 Data handling
Data on susceptibility testing of isolates were stored as MICs 
in a Microsoft® Access database linked to a SQL server at SSI. 
Analysis including selection of isolates from blood and spinal 
fluid samples and removal of duplicate isolates was performed 
in Microsoft® Access.
9.12 Invasive Beta-haemolytic streptococci (Group A, 
B, C and G Streptococci) in humans
9.12.1 Data source
Isolates are submitted to SSI on a voluntary basis. Only isolates 
from blood and spinal fluid are included in the DANMAP report
9.12.2 Microbiological methods
Identification of streptococcal group is performed by latex ag-
glutination (Streptococcal Grouping Reagent, Oxoid, Roskilde, 
Denmark).
9.12.3 Susceptibility testing
Screening for penicillin, erythromycin and clindamycin re-
sistance was performed with 1 unit penicillin G discs, 15 μg 
erythromycin discs and 2 µg clindamycin discs (Oxoid, Roskilde, 
Denmark) on Müller-Hinton agar (Müller-Hinton plate, 5% 
blood, 20 mg beta-NAD, SSI Diagnostica, Hillerød, Denmark). 
Isolates were also tested for inducible clindamycin resistance. 
For non-susceptible streptococci the MIC was determined with 
E-test (Biomérieux), with either benzylpenicillin, erythromycin 
or clindamycin on Müller-Hinton agar. The breakpoints used 
were as defined by the EUCAST. Both fully and intermediary 
resistant isolates were categorized as resistant.
9.12.3 Data handling
Data on susceptibility testing of isolates were stored as inhibi-
tion zone diameters and if indicated also MICs in a Microsoft® 
Access database linked to a SQL server at SSI.
9.13 E. coli, K. pneumoniae, P. aeruginosa, Acinetobacter 
spp., E. faecium and E. faecalis in humans
9.13.1 Data source
Susceptibility data on all isolates are provided from all DCMs, 
this includes blood samples (E. coli, K. pneumoniae, P. aerugi-
nosa, Acinetobacter spp., E. faecium and E. faecalis) and urines 
samples (E. coli and K. pneumonia)
No samples were collected from healthy humans
9.13.2 Microbiological methods
All microbiological analysis, including susceptibility testing and 
interpretation of test results is being performed by the DCMs. 
Test results from susceptibility testing are reported to SSI 
based on S-I-R interpretation. Since November 2015, all Danish 
DCMs used the EUCAST terminology with the EUCAST break-
points and the EUCAST disk diffusion method for most species. 
Interpretation mainly follows EUCAST principles but for some 
DCMs local interpretation rules are applied on the susceptibility 
in specific species, primarily from invasive infections (e.g. sus-
ceptibility to mecillinam in E. coli obtained from blood samples).
9.13.3 Data handling
All DCMs in Denmark provided data on antimicrobial suscep-
tibility test results from all E. coli, K. pneumoniae, invasive P. 
aeruginosa, invasive Acinetobacter spp., invasive E. faecium 
and invasive E. faecalis isolates. Data were extracted from the 
following laboratory information systems:
ADBakt (Autonik AB, Skoldinge, Sweden) for the DCMs at Hvi-
dovre, Herlev and Aalborg Hospitals.
MADS (DCM Skejby Hospital, Aarhus, Denmark) for the DCMs at 
Rigshospitalet, Slagelse/Region Zealand, Odense University, Søn-
derborg, Esbjerg, Vejle and Aarhus University (Skejby) Hospitals. 
Resistance data on the first isolate per patient per sample 
material per year were included. Generally, resistance data on 
a specific antimicrobial agent were excluded if the DCM had 
only performed susceptibility tests on that agent on a limited 
number of isolates.
9.14 ESBL-producing bacteria in human patients
9.14.1 Data source
Since 2014, the Danish DCMs have on a voluntary basis 
submitted 3rd generation cephalosporin resistant Escherichia 
coli isolates from bloodstream infections for verification and 
genotyping at Statens Serum Institut. Since January 1st 2018, 
3rd generation cephalosporin resistant Klebsiella pneumoniae 
from bloodstream infections isolates have been included as 
well (data not available at this point). 
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9.14.2 Microbiological methods of isolates from patients
Since 2014, whole genome sequencing (WGS) and in silico 
bioinformatics analysis have been applied for characterization 
of the genetic background of the ESBL and AmpC phenotypes. 
Only one isolate from each patient was included if less than 12 
months were between isolation of the two isolates.
9.14.3 Data handling
The Bacterial Analysis Pipeline – Batch upload version 1.0 
from Center of Genomic Epidemiology (https://cge.cbs.dtu.dk/
services/cgs/) was used for the in silico detection of acquired 
ESBL genes, pAmpCs, carbapenemase genes and MLST from 
assembled WGS data. For isolates with no ESBL-, pAmpC-, or 
carbapenemase-encoding genes detected, the sequences were 
investigated for  promotor mutations presumed to up-regulate 
chromosomal AmpC by the use of myDb-Finder version 1.2 
(https://cge.cbs.dtu.dk/services/myDbFinder-1.2/).
9.15 CPO in human patients
9.15.1 Data source
The Danish DCMs have on a voluntary basis submitted car-
bapenem resistant isolates for verification and genotyping at 
Statens Serum Institut.
9.15.2 Microbiological methods
All submitted isolates (originating both from screening and 
clinical samples) predicted to carry a carbapenemase based 
on initial phenotypic tests were subjected to WGS. More than 
one isolate from the same patient were included, only if the 
isolates belonged to different bacterial species and/or if the 
isolates harboured different carbapenemases.
9.15.3 Data handling
The Bacterial Analysis Pipeline – Batch upload version 1.0 from 
Center of Genomic Epidemiology (https://cge.cbs.dtu.dk/ser-
vices/cgs/) was used for the in silico detection of acquired CPO 
genes and MLST from assembled WGS data. Possible clonal 
clusters were detected using the SeqSphere+ (Ridom) soft-
ware to call cgMLST types where such schemes are available 
(E. coli, Klebsiella pneumoniae and Acinetobacter baumannii).
9.16 VRE in human patients
9.16.1 Data source
The Danish DCMs have on a voluntary basis, submitted VRE 
for species identification, genotyping and surveillance to the 
Antimicrobial Resistance Reference Laboratory at Statens 
Serum Institut.
9.16.2 Microbiological methods
All Clinical VRE isolates have been whole-genome sequenced. 
Only one isolate from each patient was included if less than 12 
months were between isolation of the two isolates.
9.16.3 Data handling
The Bacterial Analysis Pipeline – Batch upload version 1.0 
from Center of Genomic Epidemiology (https://cge.cbs.dtu.dk/
services/cgs/) was used for the in silico detection of genes 
related to vancomycin resistance in enterococci and MLST from 
assembled WGS data. Possible clonal clusters were detected 
using the SeqSphere+ (Ridom) software to call cgMLST types.
9.17 Statistical tests for human data
Significance tests for trends in rates of resistance in human 
bacteria were performed by applying the Cochran-Armitage 
test. The significance levels were calculated using the 
DescTools v0.99.19 package in R version 3.5.0. A p-value of 
< 0.05 is generally considered significant. Presented in this 
report are results from trend analysis for five years- and ten 
years trend, respectively. 
The test was applied to several bacteria’s resistance to a broad 
range of antimicrobials. One-sided tests were chosen because 
of preliminary expected trend directions. Cochran-Armitage 
test calculates probability in binomial proportions across one 
single, levelled variable. In this report, the test has been per-
formed on susceptibility data from the past 10 years contain-
ing numbers of resistant/intermediate and susceptible cases, 
respectively. The resulting p-values are reported in chapter 
eight, supplied by an arrow indicating trend direction. Note 
that the significance levels serve to support the graphs and 
thus should be interpreted with caution.
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AGP  Antimicrobial growth promoter
AMU  Antimicrobial use
AMR  Antimicrobial resistance
ATC  Anatomical Therapeutic Chemical Classification System
ATCvet  Anatomical Therapeutic Chemical Classification System for veterinary medicines
CA  Community-acquired
CC  Clonal complex
CDI  Clostridium difficile infections
CHR  Central Husbandry Register
CPE  Carbapenemase producing Enterobactereales
CPO  Carbapenemase producing organisms
CPR  Danish Civil Registry, register for social security numbers
DAD  Defined Daily Doses per 100 admissions
DADD  Defined animal daily dose
DAPD  Defined animal daily dose per 1,000 animals per day
DBD  Defined Daily Doses per 100 occupied bed-days
DCM  Department of Clinical Microbiology
DDD  Defined Daily Dose
DID  Defined Daily Doses per 1,000 inhabitants per day (DDD/1000 inhabitant days)
DTU  Technical University of Denmark
DVFA  Danish Veterinary and Food Administration
EARS-Net  The European Antimicrobial Resistance Surveillance Network
ECDC  European Centre for Disease Prevention and Control
EFSA  European Food Safety Authority
ESBL  Extended spectrum beta-lactamase
GP  General Practitioner
HAI  Hospital-acquired infections
HCAI  Health care associated infections
HACO  Health care associated community onset
HAIBA  Hospital-acquired infections database
HLGR  High-level gentamicin resistance
MIC  Minimum inhibitory concentration
MRSA  Methicillin-resistant Staphylococcus aureus
OIE  World Organisation for Animal Health
RFCA  Regional Veterinary and Food Control Authorities
SEGES  Knowledge Centre for Agriculture
SSI  Statens Serum Institut
ST  Serotype/Sequence type
VASC  Veterinary advisory service contracts
VMP  Veterinary medicinal products
VetStat  Danish Register of Veterinary Medicines
VRE  Vancomycin resistant enterococci
WGS  Whole-genome sequencing
WHO  World Health Organization
List of abbreviations
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Glossary
Anatomical Therapeutic Chemical (ATC) classification. 
An international classification system for drug consumption 
studies. The ATC code identifies the therapeutic ingredient(s) 
of each drug for human use according to the organ or system 
on which it acts and its chemical, pharmacological and thera-
peutic properties. Antibacterials for systemic use are known 
as ATC group J01. The ATC classification is maintained by the 
WHO Collaborating Centre for Drug Statistics and Methodology 
(Oslo, Norway) (www.whocc.no/atcddd/indexdatabase/). The 
ATC classification for veterinary medicinal products, ATCvet, 
is based on the same main principles as the ATC classification 
system for medicines for human use and is also maintained by 
the WHO Collaborating Centre for Drug Statistics and Method-
ology (www.whocc.no/ atcvet/database/).
Antibacterial agents. Synthetic (chemotherapeutics) 
or natural (antibiotics) substances that destroy bacteria 
or suppress bacterial growth or reproduction [Source: 
Dorland’s Illustrated Medical Dictionary]. In the section on 
human consumption, ‘antibacterial agents’ are referred to as 
‘antimicrobial agents’ (see below).
Antimicrobial  agents. The term ‘antimicrobial agents’ 
covers antibacterial, antiviral, coccidiostatic and antimycotic 
agents. In the section on veterinary consumption, the 
broad term ‘antimicrobial agents’ is generally used because 
coccidiostats are included. Antiviral substances are not used 
in veterinary medicine, and antimycotics are only registered 
for topical veterinary use and used mainly in companion 
animals. Antimycobacterial agents are not included. The term 
’antibacterial agents’ is only used in the veterinary section 
for precision, to distinguish from use of coccidiostats as feed 
additives (poultry only). In the chapter on human consumption, 
the term ‘antimicrobial agents’ refers to all antibacterial 
agents for systemic use (J01 in the ATC system) including 
metronidazole and vancomycin, which are used for systemic 
treatment but registered under the ATC code P01AB01 and 
A07AA09, respectively.
Broiler. A type of chicken raised specifically for meat pro- 
duction. In Denmark, the average weight after slaughter is 
1.51 kg.
CentralHusbandryRegister (CHR). This is a register of all 
Danish farms defined as geographical sites housing production 
animals. It contains information concerning ownership, farm 
size, animal species, age groups, number of animals and 
production type. Each farm has a unique farm identity number 
(CHR-number).
Defined Daily Dose (DDD). This is the assumed average 
maintenance dose per day for a drug used for its main 
indication in adults. It should be emphasised that the 
Defined Daily Dose is a unit of measurement and does 
not necessarily reflect the recommended or prescribed 
daily dose. DDDs provide a fixed unit of measurement 
independent of price and formulation, enabling the 
assessment of trends in drug consumption and to perform 
comparisons between population groups. The DDDs are 
defined and revised yearly by the WHO Collaborating Centre 
for Drug Statistics and Methodology (www.whocc.no/
atcddd/ index database).
Defined Daily Dose per 100 admissions (DAD). DAD 
measures the amount of daily doses consumed per 100 
admitted patients at hospitals during a given timeframe (one 
year). It is used for benchmarking consumption related to 
the hospital activity and will typically be compared to the 
consumption measured in DBD (see below). DAD and DBD will 
generally be applied to comparing individual hospitals and 
consumption of individual drug classes over time. In DANMAP 
DAD cover all patients attended to at somatic hospitals only. 
Admission-days are extracted from the National Patient 
Registry (Landspatientregistret, LPR). Time of reporting differs 
between hospitals and closing time for reporting is later than 
extraction time for the DANMAP report. The current report is 
the first to update data 10 years back. 
Defined animal daily dose (DADD). DADD is the aver-
age maintenance dose per day for a drug used for its main 
indication in the appropriate animal species. DADD has 
been specifically defined for use in DANMAP and does not 
always completely match the “prescribed daily dose” or the 
recommended dosage in the Summaries of Product Char-
acteristics (SPC). In contrast to the ADD previously used in 
DANMAP, the DADD has not been defined for each antimi-
crobial agent, administration route and animal species but 
at product level. In DANMAP 2012, the DADD replaces the 
ADD (as defined in VetStat), which had been used since 
DANMAP 2003. For more details, see Chapter 9, Materi-
als and Methods. The DADDs used in DANMAP 2015 are 
presented the web annex.
DADD per 1,000 animals per day (DAPD). Trends in veteri-
nary consumption, both within and across species, are presented 
in DAPD, which allows for comparison between sectors and 
adjustment for changes in live biomass. The estimated live 
biomass is expressed as the number of standard animals with 
an estimated average weight and lifetime. This may also be re-
ferred to as the ‘standard-animals-at-risk’ and takes into account 
species differences in body-mass and life-span. DAPD is a statis-
tical measure, providing an estimate of the proportion of animals 
(in thousands) treated daily with a particular antimicrobial agent. 
For example, 10 DAPDs indicate that an estimated 1% of the 
population, on average, receives a certain treatment on a given 
day (Section 4.3 and Chapter 9, Materials and Methods).
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Defined Daily Doses per 100 occupied bed-days (DBD). 
DBD is the consumption calculated in defined daily doses at 
hospitals, divided through the number of bed-days. This al-
lows comparison of hospitals related to the length of patient 
stays. The number of bed-days is extracted from The National 
Patient Registry (Landspatientregistret, LPR). Time of report-
ing differs between hospitals and closing time for reporting is 
later than extraction time for the DANMAP report. The current 
report is the first to update data retrospectively for 10 years. 
Every patient admitted to hospital accounts for one bed-day, 
independent of the actual length of stay within every 24 
hours. This corresponds to the actual hours at hospital divided 
by 24 hours and rounded up to the next whole number. For 
patients transferred between wards each transfer will count as 
a new bed day. Non-ended hospital stays are not included. 
DDD per  1,000 inhabitants per day (DID). Consumption in 
both primary health care, hospital care and the overall total 
consumption is presented in DID, allowing for comparison 
between sectors and for illustration of the consumption in 
hospital care without taking hospital activity (discharges and 
length of stays) into account. Data presented in DID provide 
a rough estimate of the proportion of the population within 
a defined area treated daily with certain drugs. For example, 
10 DIDs indicate that 1% of the population on average gets 
a certain treatment daily. In figures presented as DDD/1,000 
inhabitant-days.
ESBL. In the DANMAP report, ‘ESBL’ describes the clinically 
important acquired beta-lactamases with activity against 
extended-spectrum cephalosporins; including the classical 
class A ESBLs (CTX-M, SHV, TEM), the plasmid-mediated AmpC 
and OXA-ESBLs  [Giske et al. 2009. J. Antimicrob. Chemother. 
63: 1-4].
Finishers. Pigs from 30-100 kg live weight from after the 
weaner stage to time of slaughter.
Fully sensitive. An isolate will be referred to as fully sensitive 
if susceptible to all antimicrobial agents included in the test 
panel for the specific bacteria.
Intramammaries. Antimicrobial agents for local application in 
the mammary gland (udder) to treat mastitis.
Layer. A hen raised to produce eggs for consumption.
Minimum inhibitory concentration (MIC). This is the lowest 
concentration of antimicrobial agent in a given culture medium, 
e.g. broth or agar, below which growth of the bacteria is not 
inhibited.
Multi-resistant. A Salmonella, Campylobacter, Enterococcus 
or E. coli isolate is assumed multi-resistant if it is resistant to 
three or more of the main antimicrobial classes. The number of 
antimicrobial classes and antimicrobial agents included in this 
definition depend on the test panel for each bacterium.
Pets or pet animals. Dogs, cats, birds, mice, Guinea pigs and 
more exotic species kept at home for pleasure, rather than one 
kept for work or food. Horses are not included as pet animals. 
The live biomasses of Danish pets used for estimating veteri-
nary consumption only include dogs and cat.
Piglet. The new-born pig is called a piglet from birth till they 
are permanently separated from the sow at 3-4 weeks of age. 
The weight of the piglet at weaning is approximately 7 kg.
Poultry. The major production species are fowl Gallus gallus 
(broilers, layers, including breeding and rearing) and turkey. 
Regarding antimicrobial consumption, ‘poultry’ also includes 
domesticated ducks, geese, game birds and pigeons.
Sow. Any breeding female pig on the farm.
Weaner. Any pig of 7–30 kg live weight after it has been 
weaned.
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